The molecular and serological detection of Chlamydia trachomatis in women with reproductive abnormalities. by Barlow, Rachael Emma Louise
The molecular and serological detection of 
Chlamydia trachomatis in women with reproductive 
abnormalities. 
Rachael Emma Louise Barlow 
B. Sc. (Hons. ) 
A thesis submitted for the degree of 
Doctor of Philosophy 
Section of Infection and Immunity, 
Division of Medical and Genetic Medicine 
April 1999 
Declaration: 
I hereby declare that no part of this thesis has previously been submitted in support of an 
application for any degree or qualification, of this or any other University or Institute of 
learning, unless otherwise acknowledged. 
Dedication: 
This thesis is dedicated to my family, especially my Granddad who has 
always been and will continue to be an inspiration to me. 
Contents 
Page 
Acknowledgements I 
Summary II 
List of Abbreviations III 
List of Figures VI 
List of Graphs IX 
List of Tables XII 
Web sites XIV 
1.0 General Introduction 1 
1.1 Historical perspective of Chlamydia 1 
1.2 Classification and taxonomy of Chlamydia 3 
1.2.1 Chlamydia pecorum 4 
1.2.2 Chlamydia pneumoniae 5 
1.2.3 Chlamydia psittaci 6 
1.2.4 Chlamydia trachomatis 7 
1.3 Biology of Chlamydia 8 
1.3.1 General characteristics 8 
1.3.2 Chlamydial developmental cycle 10 
1.3.2.1 Mechanisms of attachment and entry 10 
1.3.2.2 Growth and multiplication 11 
1.3.2.3 Release from host cell 11 
1.3.3 Chlamydial persistence 12 
1.3.4 Chlamydial genetics 13 
1.3.4.1 Chlamydial genome 13 
1.3.4.2 Plasmid 14 
1.3.4.3 Bacteriophage 14 
1.3.5 Chlamydial antigens 15 
1.3.5.1 Cysteine rich proteins 15 
1.3.5.2 Heat shock proteins 15 
1.3.5.3 Lipopolysaccharide 17 
1.3.5.4 Major outer membrane protein 17 
1.4 Pathogenicity 20 
1.4.1 Immune mechanisms 20 
1.4.1.1 Innate response 20 
Page 
1.4.1.2 Humoral response 21 
1.4.1.3 Cell mediated response 23 
1.4.1.4 Immunopathology 23 
1.4.2 Genetic susceptibility to chlamydial disease 24 
1.4.3 Chlamydia trachomatis : - 25 
1.4.3.1 Trachoma and inclusion conjunctivits 25 
1.4.3.2 Female genital tract infections 25 
1.4.3.2.1 Lower genital tract infections 25 
1.4.3.2.2 Pelvic inflammatory disease 26 
1.4.3.3 Male genital tract infections 28 
1.4.3.3.1 Epididymitis 28 
1.4.3.3.2 Non-gonococcal urethritis 28 
1.4.3.3.3 Post-gonococcal urethritis 29 
1.4.3.3.4 Proctitis 30 
1.4.3.3.5 Prostatitis 30 
1.4.3.4 Lymphogranuloma venereum 31 
1.4.3.5 Neonatal infections 31 
1.4.3.6 Sexually acquired reactive arthritis 32 
1.4.4 Chlamydia pneumoniae 32 
1.4.4.1 Acute respiratory disease 32 
1.4.4.2 Coronary heart disease 32 
1.4.5 Chlamydia psittaci 33 
1.5 Infertility 34 
1.5.1 Structure and function of the female genital tract 34 
1.5.2 Causes of infertilty 34 
1.5.2.1 Causes in the female 36 
1.5.2.2 Causes in the male 36 
1.5.3 Chlamydia trachomatis and female infertility 36 
1.5.3.1 Miscarriage/spontaneous abortion 36 
1.5.3.2 Ectopic pregnancy 37 
1.5.3.3 Tubal factor infertility 37 
1.5.4 Chlamydia trachomatis and male infertility 38 
1.5.5 Treatment of infertility 39 
1.5.5.1 In vitro fertilization 39 
1.5.5.2 Gamete intrafallopian tube transfer 39 
1.6 Diagnosis of chlamydial infections 40 
1.6.1 Specimens 40 
1.6.2 Tissue culture 41 
Page 
1.6.3 Direct sample analysis 42 
1.6.3.1 Enzyme-immunoassay 42 
1.6.3.2 Direct fluorescent antibody 43 
1.6.3.3 Nucleic acid detection 44 
1.6.3.3.1 DNA hybridization probes 44 
1.6.3.3.2 Polymerase chain reaction 44 
1.6.3.3.3 Ligase chain reaction 46 
1.6.3.4 Other molecular methods 46 
1.6.4 Serology 47 
1.6.4.1 Complement fixation test 47 
1.6.4.2 Enzyme immunoassay/ enzyme-linked immunoassay 48 
1.6.4.3 Microimmunofluorescence 48 
1.7 Treatment and prevention 49 
1.7.1 Chemotherapy 49 
1.7.2 Vaccine development 49 
2.0 Enzyme-linked immunoassay (ELISA) 51 
2.1 Aims of chapter 51 
2.2 Introduction 52 
2.3 Materials 54 
2.3.1 Reagents 54 
2.3.2 Cell culture 54 
2.3.3 Antigen preparation 56 
2.3.4 ELISA solutions 56 
2.3.5 Specimens 58 
2.4 Methods 60 
2.4.1 Cell culture 60 
2.4.2 Chlamydial staining 61 
2.4.3 Antigen preparation 62 
2.4.4 ELISA development 65 
2.4.5 ELISA of study samples 65 
2.4.6 IgG and IgM microimmunofluorescence 68 
2.4.7 Statistical analysis 70 
Page 
2.5 ELISA results 71 
2.5.1 Serology results for Sheffield/Bristol 71 
2.5.2 Serology results for Trinidad 72 
2.5.3 Validation of ELISA results 74 
2.6 IVF and anti-chlamydial IgG 75 
2.6.1 Definition of IVF groups 75 
2.6.2 IgG ELISA method 76 
2.6.3 Statistical analysis 76 
2.7 IVF serology results 77 
2.8 Conclusion 80 
2.8.1 Sheffield/Bristol and Trinidad study 80 
2.8.2 IVF study 86 
3.0 Polymerase chain reaction (PCR) 92 
3.1 Aims of chapter 92 
3.2 Introduction 93 
3.3 Materials 95 
3.3.1 Reagents 95 
3.3.2 DNA extraction 95 
3.3.3 Measurement of DNA concentration 96 
3.3.4 PCR 96 
3.3.5 PCR primers 97 
3.3.6 Gel electrophoresis 99 
3.3.7 Southern blotting 101 
3.3.8 ECL 3' hybridization solutions 102 
3.3.9 Patient specimens 104 
3.4 Methods 106 
3.4.1 DNA extraction 106 
3.4.2 Determination of DNA concentration 109 
3.4.3 PCR detection of human genomic DNA 110 
3.4.4 PCR detection of C. trachomatis DNA 113 
3.4.5 Confirmation of C. trachomatis PCR products 114 
3.4.6 Effect of human DNA on C. trachomatis PCR 117 
Page 
3.4.7 Major outer membrane protein PCR 118 
3.4.8 Determination of TNF gene polymorphisms 121 
3.4.9 Statistical analysis 124 
3.5 PCR and Southern blotting results 126 
3.5.1 Prevalence of C. trachomatis DNA in Sheffield/Bristol 126 
3.5.2 Prevalence of C. trachomatis DNA in Trinidad 128 
3.6 MOMP PCR results 130 
3.6.1 MOMP PCR results 130 
3.7 TNF polymorphism results 130 
3.7.1 TNF-a results 130 
3.7.2 TNF-ß results 131 
3.8 Conclusion 134 
3.8.1 Sheffield/Bristol and Trinidad study 134 
3.8.2 Polymorphism detection in the TNF gene 139 
4.0 In situ hybridization (ISH) 143 
4.1 Aims of chapter 143 
4.2 Introduction 14 4 
4.3 Materials 14 7 
4.3.1 Reagents 147 
4.3.2 EcoR 1 2.5kb probe preparation 147 
4.3.3 Polymerase chain reaction (PCR) 147 
4.3.4 PCR primers 148 
4.3.5 Isotopic in situ hyridization 149 
4.3.6 Dot blotting 151 
4.3.7 ECL direct hydridization solutions 152 
4.3.8 Non-isotopic in situ hybridization (NISH) 153 
4.3.9 Patient specimens 156 
4.4 Methods 157 
4.4.1 Histological processing 157 
4.4.2 Isotopic probe preparation 158 
4.4.3 Isotopic ISH 159 
Page 
4.4.4 NISH probe preparation 164 
4.4.5 Preparation of dot blots 164 
4.4.6 ECL direct nucleic acid labelling and detection 166 
4.4.7 NISH 167 
4.4.8 Statistical analysis 174 
4.5 NISH results 176 
4.5.1 Prevalence of C. trachomatis DNA in Sheffield/Bristol 176 
4.5.2 Prevalence of C. trachomatis DNA in Trinidad 178 
4.6 Conclusion 180 
4.6.1 Sheffield/Bristol and Trinidad study 180 
5.0 General Discussion 191 
6.0 Appendices 202 
6.1 Appendix 1. ELISA development 202 
6.1.1 IgG ELISA development 202 
6.1.2 IgM ELISA development 213 
6.2 Appendix 2. Appendices keys. 217 
6.2.1 Key for Appendices 3 and 4.217 
6.2.2 Key for Appendices 5.217 
6.3 Appendix 3. Individual patient results for SheffieldBristol 218 
6.3.1 Controls 218 
6.3.2 Ectopic Pregnancy 220 
6.3.3 Tubal factor infertility 221 
6.4 Appendix 4. Individual patient results for Trinidad 223 
6.4.1 Controls 223 
6.4.2 Miscarriage 225 
6.4.3 Ectopic pregnancy 227 
6.4.4 Tubal factor infertility 229 
6.5 Appendix 5. Comparison of ELISA and IF/CFT results 230 
7.0 References 231 
Acknowledgements 
Firstly I would like to acknowledge the hard work of all those involved in the 
establishment of the studies set up during this PhD, and the collection of patient samples. 
These include Prof. I. Cooke and Dr. 0. Odukoya (Dept. Obstetrics and Gynaecology, 
University of Sheffield); Dr. J. Jenkins and Dr. S. Keay (Dept. of Obstetrics and 
Gynaecology, University of Bristol); Dr. S. Ramsewak and associates (Trinidad); and 
Dr. M. Heatley (formerly of the Dept. Pathology, University of Sheffield). For the 
preparation of samples for histological investigation I would like to say thank you to 
Kevin Corke, and Orla Gallagher (Dept. Pathology, University of Sheffield). I would 
also like to acknowledge the help of Neil Cross in the TNF pilot study, and Prof. 
Cannings (Division of Molecular and Genetic Medicine, University of Sheffield) for his 
advice on the statistical handling of the data contained within this thesis. 
My thanks also go to my supervisor, Dr. Adrian Eley for his help and support during the 
long years of this PhD, my surrogate supervisor Kevin Oxley, and all the students and 
staff who work in the former Department of Medical Microbiology. I am also indebted to 
Dr. G. Kinghom (Dept. Genitourinary Medicine) for supporting the first year of my 
PhD, and WellBeing for funding the rest of my studies. 
My special thanks goes to Dr. Jon Shaw for his unerring friendship, support and 
wisdom, and most importantly the occasional kick up the arse when it looked like apathy 
was setting in. 
Penultimately I would like to thank my family and close friends (DS9, the Guy's, Will, 
Emmanuelle) who have suffered a great deal over the last couple of years. Finally my 
thanks go to my niece Jessica, who in the wisdom of youth managed to sum up five years 
of work in one sentence, "I bet you wish you were little again so you didn't have to work 
so hard? ". 
Summary 
The primary aim of this study was to evaluate the role of C. trachomatis in women with 
ectopic pregnancy (EP), miscarriage and tubal factor infertility (TFI) using PCR, non- 
isotopic in situ hybridization (NISH) and serology when compared to controls. Also, the 
influence of polymorphisms in the TNF gene were investigated in a pilot study to 
determine if there was an association between chlamydial infection and the development 
of tubal pathology. The primary study included patients from the UK and Trinidad. A 
secondary study was also conducted to assess the impact of anti-chlamydial IgG on 
ovarian response to gonadotropin stimulation prior to in vitro fertilization (IVF). 
Significant levels of anti-chlamydial IgG were found in the UK patients presenting with 
TFI, and a similar association was seen in the Trinidad EP group. In the case of 
miscarriage the detection of anti-chlamydial antibody was not significant. The IVF study 
showed that women undergoing IVF, who also had detectable levels of anti-chlamydial 
IgG were statistically more likely to respond poorly to gonadotropin ovarian stimulation 
prior to IVF. 
The presence of chlamydial DNA, as determined by both PCR and ISH was significant in 
the UK TFI group. There was an increased detection of chlamydial DNA in both EP 
groups, although this association was found not to be significant. Statistically the 
presence of chlamydial DNA in the Trinidad miscarriage group was not suggestive of a 
role for C. trachomatis in the development of this condition. 
Within the EP and TFI groups investigated, the presence of either anti-chlamydial IgG or 
chlamydial DNA was suggestive of tubal damage. In the case of the EP patients, a large 
number of patients had detectable levels of anti-chlamydial IgM and/or chlamydial DNA in 
serum and tissue samples respectively; whereas in the TFI group there was increased 
detection of anti-chlamydial IgG and/ or chlamydial DNA. From theses data it is 
proposed that EP is positively associated with a concurrent C. trachomatis infection of 
the genital tract as supported by both serological evidence, and the detection of chlamydial 
DNA in genital specimens. In the case of tubal damage found in TFI patients the presence 
of anti-chlamydial IgG and/ or chlamydial DNA suggests that this condition is associated 
with a repeated past/persistent C. trachomatis infection as opposed to a current genital 
II F 
chlamydial infection. 
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Chapter 1.0 
General Introduction 
1.1 Historical perspectives of Chlamydia 
In 1877, two years before the description of the gonococcus by Albert Neisser, Emil 
Noeggerath published findings that linked sexuality, genital infection and infertility 
suggesting that approximately 90% of sterile women were married to men who had 
suffered from gonorrhoea. During the latter part of the last century Neisseria 
gonorrhoeae was documented as a causative agent of urethritis, epididymitis, cervicitis 
and salpingitis. Post-infectious infertility was described as a result of both gonococcal 
salpingitis and bilateral gonococcal epididymitis (cit. Oriel, 1994) and during the turn of 
the century only 6% of women who had had gonococcal salpingitis conceived (Forssner, 
1907). 
The oculogenital association of ophthalmia neonatorum was initially confirmed by the 
work of Piringer in 1841, who showed that the gonococcus could infect the human eye 
(cit. Duke-Elder, 1965). In 1884, Kroner published a report on a non-gonococcal 
manifestation of ophthalmia neonatorum, it was suggested that the infective organism 
was transmitted from the genital tract of the neonate's mother. In 1907, the causative 
agent of trachoma (a long recognised eye disease) was identified by Halbertaedter and 
von Prowazek, who originally suggested the name Chlamydozoa, derived from the 
Greek chlamys meaning 'mantle' describing the halo effect observed surrounding Giemsa 
stained inclusions. 
Other investigators found similar inclusions in conjunctival scrapings from neonates, and 
from urogenital tract samples from their mothers suggesting a link between the cause of 
the inclusions and sexually transmitted disease (Halbertaedter and von Prowazek, 1909; 
Stargardt, 1909; Heymann, 1910; Lindner, 1910). Fritsch et al. (1910) in a series of 
experiments infected the conjunctivae of monkeys with cervical secretions from mothers 
and urethral secretions from the fathers of infected neonates. The monkeys went on to 
develop inclusion conjunctivitis irrespective of the original source of the inoculum. 
Due to the difficulty of culturing the causative agent of inclusion conjunctivitis there was 
an extended delay in the study of chlamydiae until the end of the 1930s with the 
identification of the agent of psittacosis (Bedson et al., 1930) and Lymphogranuloma 
venereum (Hellerstrom and Western, 1930). In 1932, Bedson and Bland described the 
two distinct forms of chlamydiae, the elementary body and the reticulate body, and 
demonstrated the chlamydial developmental cycle. 
In 1957 Tang and co-workers successfully isolated the causative agent of trachoma 
using the yolk sac of fertilized hens eggs. This was followed in 1965 with the 
introduction of tissue culture by Gordon and Quan using irradiated McCoy cells. 
Jones et al. (1959) isolated Chlamydia trachomatis from a neonate with inclusion 
conjunctivitis and from the cervix of the mother thus confirming the original findings of 
investigators at the beginning of the century. C. trachomatis was subsequently isolated 
from urethral secretions of men who had had previous sexual contact with women with 
inclusion conjunctivitis, and from women diagnosed as having non-gonococcal genital 
tract infection (Jones, 1964; Dunlop et al., 1964; Holt et al., 1967). But it was not until 
the 1970s that the importance of C. trachomatis as a cause of non-gonococcal urethritis 
(Hilton et al., 1974; Swanson et al. 1975; Oriel and Ridgway, 1982), and acute 
salpingitis and pelvic inflammatory disease (Mardh et al., 1977; Punnonen et al., 1979; 
Mardh et al., 1981) was established. 
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1.2 Classification and taxonomy of Chlamydia 
The taxonomic classification of the order Chlamydiales reflects their unique obligate 
intracellular biology. Chlamydiae have been placed in their own order, Chlamydiales, 
containing one family Chlamydiaceae and a single genus Chlamydia (Moulder et al., 
1984). Although chlamydia were originally thought to be protozoa, or viruses, they were 
later found to have properties that classified them as bacteria (Sarov and Becker, 1971). 
It was confirmed using rRNA analysis that Chlamydia were in fact eubacteria but with 
very little relatedness to other eubacterial orders (Weisburg et al., 1986). 
The genus Chlamydia presently consists of four species, Chlamydia trachomatis, 
Chlamydia psittaci, Chlamydia pneumoniae and the newest member of the genus 
Chlamydia pecorum. DNA homology between chlamydial species is reported to be less 
than 10% (Kingsbury and Weiss, 1968; Campbell et al., 1987; Fukushi et al., 1992), 
although structurally and biochemically they appear to be similar, with amino acid 
homology between analogous proteins being high. 
Studies of the phylogenetic structure of the genus Chlamydia by analysis of the 16S 
rRNA gene show a phylogenetic tree with a distinct line of descent within the family 
Chlamydiaceae (Pettersson et al., 1997). This descent being built around two main 
clusters, labelled the C. pneumoniae cluster (human C pneumoniae isolates and the 
equine strain N 16), and the C. psittaci cluster (C. psittaci, C. pecorum and C. 
trachomatis). 
Similar work by Pudjiatmoko et al. (1997) also using analysis of the 16S rRNA gene 
sequences gave two clusters comprising eight groups, each cluster corresponding to a 
phenotype as defined by inclusion morphology, glycogen content, sulfadiazine 
sensitivity, and the number of rRNA gene loci. One cluster coincided with C. 
trachomatis, which forms vacuolar inclusions, contains glycogen in its inclusions, is 
sulfadiazine sensitive and has two rRNA loci. The second cluster included C. psittaci, C. 
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pneumoniae and C. pecorum which form dense inclusions that do not contain glycogen, 
are sulfadiazine resistant and only have one rRNA locus. 
Gaydos et al. (1993) by the analysis of the 16S ribosomal DNA sequences of C. 
pneumoniae, C. trachomatis and C. psittaci showed that C. pneumoniae was more 
closely related to C. psittaci than C. trachomatis. From an evolutionary standpoint it has 
been suggested that N 16 and/or C. psittaci carry ancestral features of the original species, 
and that C. trachomatis although not newly described is the most recently evolved species 
within the genus. It may be that studies on the phlylogentic analysis of the 16S rRNA 
gene sequences may eventually re-define the structure of the family Chlamydiaceae 
(Adam et al., 1998). 
Many Chlamydia-like organisms have been described in the literature, including the 
Simkania sp. strain "Z" (Kahane et al., 1993; Kahane et al., 1995) which was originally 
described as a contaminant of laboratory cell cultures. By analysis of the 16S rRNA gene 
sequence Pudjiatmoko et al. (1997) have suggested that "Z" may belong to a second 
genus of the family Chlamydiaceae, and that it may cause/contribute to community 
acquired pneumonia (Lieberman et al., 1997). Amann and colleagues (1997) have also 
described a chlamydia-like organism (BN9) which is an endoparasite of Acanthamoebae. 
The 16S rRNA gene was shown to have between 86-87% sequence homology to 
chlamydial 16S rRNA. 
1.2.1 Chlamydia pecorum 
C. pecorum is the most recently described chlamydial species and consists of bovine, 
ovine and swine strains that have been previously classified as Chlamydia psittaci 
(Fukushi and Hirai, 1992; Fukushi and Hirai, 1993). Chlamydial strains belonging to C. 
pecorum have been isolated from cattle with encephalomyelitis, from synovial fluid 
samples from sheep and calves with polyarthritis, and also from conjunctival and 
intestinal samples of ruminants. C. pecorum can also cause inapparent enteric infection, 
and animals can become carriers after recovery from infection. 
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Known phenotypes of C. pecorum are indistinguishable from C. psittaci in that they form 
oval and dense inclusions in cell culture, do not deposit glycogen in inclusions, and are 
resistant to sulfadiazine. The percentage DNA homology between C. pecorum and other 
Chlamydia has been shown to be less than 30%, and between strains of C. pecorum 
greater than 88%. 
1.2.2 Chlamydia pneumoniae 
The first isolates of C. pneumoniae were obtained during the trachoma studies of the 
1960s; TW-183 was isolated from the eye of a child with suspected trachoma in Taiwan, 
and IOL-207 was isolated from the eye of a child with trachoma in Tehran; it was shown 
that IOL-207 and TW-183 were antigenically similar by the micro-immunofluorescence 
(MIF) test (Dwyer et al., 1972). During 1983 a similar isolate was recovered from a 
college student with pneumonia in Seattle and named AR-39. AR-39 was shown to be 
antigenically similar to TW-183 (Grayston et al., 1986). The acronym TWAR reflects 
the geographic site of the initial isolate (Taiwan-TW), and the clinical manifestation of the 
latter (acute respiratory disease-AR). 
Initially TWAR was thought to be a C. psittaci strain on the basis of inclusion 
morphology and staining characteristics, but subsequent analysis demonstrated that it was 
a distinct organism which has now been recognized as a separate chlamydial species 
(Grayston et al., 1989; Grayston et al., 1990). Restriction endonuclease pattern analysis 
and nucleic acid hybridization studies have shown that C. pneumoniae isolates have less 
than 10% homology with C. psittaci and C. trachomatis, and between C. pneumoniae 
isolates greater than 95% homology. 
Unlike C. trachomatis, different serovars of C. pneumoniae have not been identified, and 
it has been suggested that all C. pneumoniae organisms represent a single strain 
(Campbell et al., 1990; Grayston, 1992). To date the ompl gene of nine C. pneumoniae 
strains have been sequenced and have been found to be 100% identical, suggesting the 
gene is conserved (Carter et al., 1991; Melgosa et al., 1991; Jantos et al., 1997). 
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However, Jantos et al. (1997) showed that even though the ompl gene was identical in 
the C. pneumoniae isolates studied, antigenic diversity did exist possibly within a 65kDa 
protein. 
1.2.3 Chlamydia psittaci 
C. psittaci comprises a plethora of isolates from many different mammals, birds and 
amphibians. C. psittaci is an important pathogen of domestic ruminants, and can induce 
abortion in cattle, goats and sheep. It can also cause respiratory disease, enteritis, 
conjunctivitis, arthritis and reproductive disorders, but latent infections (eg. intestinal 
colonization) without clinical symptoms are a common feature. 
C. psittaci can also cause zoonotic disease in man, being responsible for respiratory 
infection where the host has had contact with infected birds (psittacosis). C. psittaci is 
spread via the inhalation of aerosols derived from animal faeces or other animal products 
and causes predominantly pneumonia in man. Disease in humans can vary from a mild 
flu-like to severe generalised illness with symptoms ranging from a fever, to anorexia, 
and photophobia. In severe cases nausea, vomiting, and diarrhoea may be seen. 
Pregnant women who come into contact with infected placental material from domestic 
animals can suffer abortion (Herring et al., 1987). 
Restriction endonuclease pattern analysis and DNA hybridization studies have shown that 
C. psittaci isolates have between 14-95% DNA homology within the species, between 1- 
8% with C. pneumoniae isolates and below 33% with C. trachomatis isolates. Sequence 
analysis of restriction enzyme profiles of DNA amplified from the MOMP gene of C. 
psittaci indicate that ruminant abortion strains, guinea pig inclusion conjunctivitis 
(GPIC), and feline isolates have relatively homogenous MOMP sequences when 
compared to C. pecorum isolates. 
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1.2.4 Chlamydia trachomatis 
C. trachomatis has been subdivided into three biovariants (biovars); trachoma, 
lymphogranuloma venereum (LGV) and murine pneumonitis agent. DNA homology 
studies of the genome of the three C. trachomatis biovariants, and direct comparison of 
the DNA sequences of specific genes have shown that trachoma and the LGV biovars are 
basically identical, and that the murine biovar is more distantly related (Weiss et al., 
1970; Peterson and de la Maza, 1988). The trachoma and LGV biovars have distinct 
clinical features, LGV biovars can cause systemic infection and proliferate in lymphatic 
tissue, compared to the trachoma biovars which primarily infect the columnar epithelial 
cells of the mucous membranes. 
Currently the trachoma biovar consists of 14 serovars designated by the letters A to K 
including serovariants Ba, Da, D*, Ga, Jv, Ia, and l- (Wang and Grayston, 1991; Dean 
et al., 1992; Lampe et al., 1993; Dean et al., 1994; Ossewaarde et al., 1994a; Morre et 
al., 1998). The LGV biovar consists of 4 serovars L1, L2, L2a, and L3 (Wang and 
Grayston, 1970; Wang et al., 1985). In addition three serogroups independent of biovar 
have also been described; the B complex (serovars B, Ba, D, Da, E, L1, L2, and L2a), 
the C complex (serovars A, C, H, I, Ia, J, K, and L3), and the intermediate complex 
(serovars F and G) (Caldwell et al., 1982a; Wang et al., 1985; Yuan et al., 1989). 
The major serovar, subspecies, and species specific antigens have been attributed to the 
major outer membrane protein (MOMP) (Caldwell et al., 1981; Stephens et al., 1982; 
Baehr et al., 1988; Stephens et al., 1988). The polymerase chain reaction (PCR) 
amplification of the MOMP gene (ompl) and restriction enzyme digestion of PCR 
products have been used to differentiate the C. trachomatis serovars on the basis of 
restriction fragment length polymorphism (Frost et al., 1991; Lan et al., 1993; Rodriquez 
et al., 1993; Lan et al., 1994). Serovars A to C predominate in ocular trachoma, whereas 
serovars D-K are responsible for oculogenital infections. 
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1.3 Biology of Chlamydia 
1.3.1 General characteristics 
Chlamydiae are obligate intracellular bacteria, characterized by a biphasic developmental 
cycle consisting of two developmental forms the elementary body (EB), and the reticulate 
body (RB) (Figure 1). The EB is extracellular, and an infectious form characterized by 
an osmotically resistant outer membrane and a highly condensed chromosome. 
Following attachment and entry into a host cell the EB transforms into the RB, this 
transition involving structural changes in the outer membrane organization and the 
relaxation of the condensed nucleoid. The RB is the intracellular, replicative form of 
chlamydiae. Chlamydiae have been termed energy parasites, and are incapable of 
generating a net gain of ATP and therefore rely on the host for ATP. Due to this, cell- 
free growth of chlamydia has not been achieved, and culture in cell culture systems or 
yolk sac are needed for their in vitro growth. 
Another unique feature of chlamydiae is the envelope structure which is Gram negative in 
that it includes an inner membrane and an lipopolysaccharide-containing outer membrane. 
The chlamydial envelope apparently lacks peptidoglycan although chlamydiae possess 
penicillin binding proteins (Barbour et al., 1982), and are sensitive to drugs that inhibit 
peptidoglycan synthesis such as penicillin G and D-cycloserine. 
Chlamydiae also have unique 18 to 22 regularly spaced dome shaped surface projections 
per elementary body that protrude approximately 20nm above the outer membrane 
(Matsumoto, 1981; Nichols et al., 1985). The projections are also found in a less 
ordered array in the reticulate body (Gregory et al., 1979; Matsumoto, 1988). Studies 
have suggested that the projections extend through the domes and possibly through the 
membrane within which the reticulate bodies divide (Matsumoto, 1981; Matsumoto, 
1982; Matsumoto, 1988; Chang et al., 1997). The question still remains as to the 
purpose of the projections, they may serve as an anchor within the inclusion to bring the 
chlamydiae into close contact with the host cytoplasm; or they may actively participate in 
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Figure 1. Schematic representation of the chlamydial developmental cycle. 
1) EB adherence/attachment to the host cell, followed by internalization. 
2) Inhibition of phagolysosomal fusion, and primary differentiation EB->RB. 
3) RB multiplication by binary fission. 
4) Asynchronous re-differentiation RB->EB. 
5) EB release from host cell. 
6) Continuation of chlamydial developmental cycle. 
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nutrient acquisition or be ion channels (Stephens, 1993). An alternative function of the 
surface projections has been proposed by Bavoil and Hsia (1998) based on the recent 
finding of type III (contact-dependent) genes in chlamydiae (Hsia et al., 1997). Bavoil 
and Hsia have postulated that the surface projections and the associated fimbrial 
projections represent chlamydial type III secretion machinery and the associated virulence 
effector proteins. 
1.3.2 Chlamydial developmental cycle 
1.3.2.1 Attachment and entry mechanisms 
The infectious process commences with the contact of the chlamydial elementary body 
(EB) to the mucosal epithelial cell surface of the host. The identity of chlamydial 
adhesins (ie. the determinants of the initial EB/cell interactions) is a matter of conjecture 
but a number of putative adhesins have been proposed which include the chlamydial outer 
membrane protein (MOMP) (Su et al., 1990; Su et al., 1996), chlamydial cytadhesin 
(CCA) (Joseph and Bose, 1991), a heparan sulphate-like glycosaminoglycan (GAG) 
(Zhang et al. 1992), chlamydial heat shock protein 70 (HSP70) or a HSP70-genetically 
linked product (Schmiel et al., 1991; Raulston et al., 1993; Raulston et al., 1998a), a 
28kDa grpE protein (Schmiel et al., 1996), and the cysteine-rich outer membrane protein 
OMP2 (Ting et al., 1995). The precise mechanism by which EB uptake is mediated is 
not clear but proposed mechanisms include receptor-mediated endocytosis in clathrin- 
coated pits, pinocytosis in non-coated pits, and parasite-specified phagocytosis. 
Zhang et al. (1992) and Stephens et al. (1994a, 1994b) using LGV demonstrated that 
chlamydial heparan sulphate attached to an undefined chlamydial surface ligand could 
bind the infecting EB to heparan sulphate receptors located in coated pits found on the 
surface of HeLa cells facilitating attachment and entry. Trachoma serovar infectivity has 
also been shown to use the same heparan sulphate-like mechanism (Chen and Stephens, 
1994). 
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Kuo et al. (1996) have identified a glycosylated component of MOMP which has been 
shown to bring the EB in close contact with the surface of HeLa cells. It has also been 
shown that after conformational changes in the EB envelope, the substrate binding 
domain of envelope-associated chlamydial heat shock protein 70 (CHSP70) becomes 
selectively exposed. The exposed CHSP70 can either directly interact with a host cell 
ligand or present a separate chlamydial ligand which may trigger entry into the cell by an 
energy dependent process (Raulston et al., 1998a). 
1.3.2.2 Growth and multiplication 
Once the chlamydiae have entered the host cell they remain within a vacuole termed the 
inclusion which does not fuse with lysosomes (Moulder, 1991) due to the early synthesis 
of chlamydial proteins (Scidmore et al., 1996). Primary differentiation of EB to RB 
involves the reductive cleavage of MOMP and the other outer membrane proteins, and the 
relaxation of the chlamydial chromosome. 
Sphingomyelin from the host's trans-Golgi network is specifically transported to the 
inclusion membrane, and it has even been detected in chlamydiae (Hackstadt et al., 
1995). Evidence has also suggested that chlamydiae re-model the inclusion membrane by 
the insertion of chlamydial proteins (Rockey et al., 1995; Taraska et al., 1996; 
Bannantine, 1998). 
The RB replicates by binary fission within the inclusion with the resulting progeny 
remaining closely associated with the inclusion membrane until later in the developmental 
cycle, suggesting that such an intimate interaction may be required for intracellular 
growth (Matsumoto, 1981). 
1.3.2.3 Release from host cell 
Between 48-72h post-infection the asynchronous process of RB to EB differentiation 
begins. It has been suggested by Hackstadt et al. (1997) that RB detachment from the 
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inclusion membrane may be a signal for differentiation. RB to EB differentiation 
involves the oxidation of the outer membrane cysteine containing proteins, and the 
recondensation of the chlamydial chromosome. 
The actual mechanism by which chlamydiae are released from the host cell, and the 
triggering mechanism remains unclear. It has been proposed that the chlamydial 
inclusion membrane fuses with the host cell membrane, releasing EBs, or that there may 
be a gradual disintegration of the inclusion releasing EBs into the host cytoplasm which 
then leave the cell. 
1.3.3 Chlamydial persistence 
The importance of re-infection in the development of chlamydial disease is well 
documented. In both ocular and genital tract infection progression to disease involves a 
stage of chronic immunopathology and scarring during which chlamydiae are rarely 
isolated. There has been indirect evidence in cases of genital tract and ocular infection 
that supports the existence of persistent chlamydial forms (Schachter et al., 1988; 
Holland et al., 1992; Campbell et al., 1993; Patton et al., 1994b). 
The concept of persistent chlamydial infection is not new (Meyer et al., 1933). 
Persistence in vitro has been induced via nutrient deficiency, antimicrobial agents and 
immunologically. Penicillin and ampicillin when added to chlamydial culture inhibit the 
redifferentiation of RB to EB by affecting the synthesis of the cysteine rich 60kDa outer 
membrane protein (Cevenini et al., 1988; Sardinia et al., 1988). 
In vitro chlamydial persistence induced by nutrient depletion is characterized by smaller 
inclusions, and a reduction in the number of infected cells (Coles et al., 1993). The 
specific depletion of cysteine results in the development of morphologically and 
metabolically abnormal chlamydiae (Allen et al., 1985), possibly due to the requirement 
of cysteine in the biosynthesis of MOMP and other cysteine rich outer membrane 
proteins. 
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Beatty et al. (1993) demonstrated interferon gamma (IFN-'y) mediated chlamydial 
persistence in vitro, characterized by enlarged morphologically abnormal developmental 
forms similar to those induced by penicillin and nutrient depletion (Matsumoto and 
Manire, 1970; Kramer et al., 1971; Coles et al., 1993). In persistently infected cells 
aberrant chlamydiae are non-infectious, however viability is maintained as shown by the 
recovery of infectious progeny following the removal of IFN-'y (Beatty et al., 1995). The 
development of persistence has been postulated to be related to the induction of host 
indoleamine 2,3-dioxygenase (IDO), and the subsequent depletion of cellular tryptophan 
coupled with reduced synthesis of MOMP, 60kDa outer membrane protein and 
lipopolysaccharide and the continued/up-regulated synthesis of chlamydial heat shock 
protein 60 (Beatty et al., 1994). 
1.3.4 Chlamydial genetics 
1.3.4.1 Chlamydial genome 
The genome of C. trachomatis has been measured at 1045kb , and as such 
is one of the 
smallest prokaryotic genomes being approximately a quarter the size of the E. coli genome 
(Birkelund and Stephens, 1992). The biochemical and/or physical events that trigger and 
mediate chlamydial differentiation from elementary body to reticulate body, and back 
again are unknown. 
The chlamydial elementary body displays a highly condensed genome (Costerton et al., 
1976) containing stage specific DNA binding proteins (Wager and Stephens, 1988) 
which have been shown to be analogous to eukaryotic histone protein H1 (Hackstadt et 
al., 1991; Perara et al., 1992; Brickman et al., 1993). 
Early in the transition from elementary body to reticulate body the supercoiled state of the 
DNA is relaxed which is then compatible for transcription and replication. RNA 
synthesis by chlamydial DNA-dependent RNA polymerase is an essential part of 
chlamydial differentiation (Sarov et al., 1971). Data suggest that the chlamydial DNA- 
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dependent RNA polymerase is activated within minutes after the elementary body enters 
the host cell. 
1.3.4.2 Plasmid 
Chlamydial plasmids have been isolated from nearly all chlamydial species and isolates 
except C. pneumoniae (Campbell et al., 1987). Many strains of C. psittaci carry 
plasmids ranging in size from 6.2-7.9kb. C. pecorum encephalomyelitis strains have 
been shown to contain a plasmid (Timms et al., 1988; Hugall et al., 1989) that differs 
from the plasmids of C. psittaci and C. pecorum. 
Lovett et al. (1980) were the first to describe the presence of a 7.5kb plasmid in three 
serovars of C. trachomatis. The 7.5kb plasmid of C. trachomatis is not essential for 
growth or disease, and three isolates have been described that lack the plasmid (Peterson 
et al., 1990; An et al., 1992; Farencena et al., 1997). 
Tam et al. (1994) used the 7.5kb plasmid of C. trachomatis to construct a chimeric 
plasmid for the introduction of recombinant DNA into C. trachomatis by electroporation, 
this method proved to be unsuccessful in that stable transformants were not produced. 
Recently O'Connell et al. (1998) described a successful method for the introduction of 
foreign DNA into C. psittaci using shuttle plasmids carrying chloramphenicol resistance. 
1.3.4.3 Bacteriophage 
To date, two bacteriophages have been described that infect chlamydiae. The first phage 
to be reported was from a C. psittaci duck isolate (Richmond et al., 1982) and was 
named Chp 1. Electron microscopy of cell sections infected with Chp1 showed that the 
phage was a regular polyhedron with a diameter of 22nm. The second phage, reported 
by Hsia et al. (1996) was also a C. psittaci GPIC phage. Recent work by Hsia et al. 
(1998) on the ultrastructure of phage (bCPG1)-infected C. psittaci RBs have shown that 
infected RBs have an altered developmental cycle giving rise to enlarged 'maxi' RBs. 
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1.3.5 Chlamydial antigens 
1.3.5.1 Cysteine rich proteins 
OMP2 and OMP3 are developmental stage specific cysteine rich proteins that have only 
been demonstrated in elementary bodies (Hackstadt et al., 1985; Hatch et al., 1986; 
Moulder, 1993). It is thought that MOMP, OMP2 and OMP3 are extensively di-sulfide 
cross-linked mediating the structural and osmotic resistance of the chlamydial elementary 
body. 
One biochemical difference between LGV and the trachoma biovars is that OMP2 has 
different pI values (Batteiger et al., 1985; Allen et al., 1990). OMP2 has been shown to 
be sensitive to trypsin treatment, and OMP2 in elementary body lysates selectively bind 
eukaryotic cells suggesting OMP2 may have a role in chlamydiae/host cell interactions 
(Ting et al., 1995). 
1.3.5.2 Heat shock proteins 
When cells infected with C. trachomatis are subjected to heat shock there is an increased 
synthesis of at least 20 heat shock proteins (HSP), the most extensively studied being 
HSP60 (approximate molecular weight 57kDa), and HSP70 (approximate molecular 
weight 75kDa). A recent study by Raulston (1998b) has shown that both HSP60 and 
HSP70 remain confined within the inclusion during the course of the chlamydial 
developmental cycle in vitro. 
Both chlamydial HSP60 and HSP70 are constitutively expressed, and HSP60 
transcription is upregulated under heat stress, in IFN-'y treated cells (Beatty et al., 1994), 
penicillin exposed cells (Morrison et al., 1989a), and under iron limiting conditions 
(Raulston et al., 1997). It has been suggested that the chlamydial dnaK (encoding 
HSP70) and groE (encoding HSP60) operons may be regulated by a mechanism similar 
to that described in Bacillus subtilis in which, when the transcription of HSP60 is turned 
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off the dnaK operon is activated, and if HSP60 is over produced there is decreased 
expression of the dnaK operon. (Tan et al., 1996; Raulston et al., 1998b). 
Chlamydial HSP70 is found in both elementary and reticulate bodies as a dithiothreitol 
extractable protein, and shares 46% amino acid sequence identity to the mammalian 
homologue. Schmiel et al. (1991) originally suggested the serovar E dnaK gene product 
as a potential chlamydial ligand, with recombinant E. coli expressing chlamydial HSP70 
on their surface specifically attaching to epithelial cells. Recent studies have suggested 
that membrane associated HSP70 may influence entry into host cells (Raulston et al., 
1998a). It has also been shown that polyclonal antibody to recombinant chlamydial 
HSP70 can neutralize chlamydial infectivity in vitro (Danilition et al., 1990). 
Chlamydial HSP60, like HSP70 is found in both developmental forms, and is extractable 
with sarkosyl or dithiothreitol from elementary bodies. Within the chlamydial genus 
HSP60 amino acid sequence homology is greater than 80%, but possibly more 
importantly the chlamydial HSP60 protein shares 48% homology to human HSP60 
(Morrison et al., 1990). 
Chlamydial heat shock proteins HSP60 and HSP70 have both been shown to be highly 
immunogenic during the course of natural infection (Brunham et al., 1994). In women 
the presence of anti-chlamydial HSP60 antibodies has been correlated with pelvic 
inflammatory disease (PID) (Chernesky et al., 1998), tubal factor infertility (Dieterle and 
Wollenhaupt, 1996) and ectopic pregnancy (Sziller et al., 1998). In a recent study by 
Witkin et al. (1998) immunity to a specific chlamydial HSP60 epitope was associated 
with autoimmunity to human HSP60, and with a history of two or more spontaneous 
abortions. Conversely, anti-chlamydial HSP70 antibodies have been associated with 
protective immunity in women against ascending infection and tubal disease (Brunham et 
al., 1987). 
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1.3.5.3 Lipopolysaccaride 
Chlamydial lipopolysaccharide (LPS) is a group specific antigen which has been shown 
to contain as an immunodominant group a 3-deoxy-2-keto sugar similar but not identical 
to 3-deoxy-octulosonic acid (Kdo) (Dhir et al., 1972; Brade et al., 1987). A unique 2.8 
linkage (coded by the gseA gene) joins the two terminal chlamydial Kdo units forming a 
chlamydial specific epitope. Data has suggested that chlamydiae produce a smooth LPS 
variant (Lukacova et al., 1994) in addition to a rough form (Nurminen et al., 1985). 
Originally it was thought that LPS was poorly exposed on the surface of chlamydial 
elementary bodies (Kuo et al., 1987; Collett et al., 1989), but chemical cross-linking has 
demonstrated that LPS and MOMP lie within IOA of one another on the bacterial cell 
surface (Birkelund et al., 1988). Studies have demonstrated that LPS can escape the 
inclusion during the chlamydial development cycle, and can be detected on the surface of 
infected epithelial cells (Richmond and Stirling, 1981; Karimi et al., 1989; Campbell et 
al., 1994; Wyrick et al., 1994). The early release of chlamydial LPS likely serves as one 
of the first signals for the influx of polymorphonuclear leukocytes observed in patients 
with cervicitis and endometritis (Paavonen et al., 1985). It has also been suggested that 
chlamydial LPS may alter the fluidity of the plasma membrane of the infected cell thereby 
helping prevent the destruction of the cell by cytotoxic T cells (Wilde et al., 1986). 
Antibody against chlamydial LPS is commonly elicited during natural infection (Brunham 
et al., 1987), however such antibodies have been shown not to be protective, do not elicit 
inflammation in animal models, and are not neutralizing in vitro (Caldwell et al., 1984; 
Watkins et al., 1986). 
1.3.5.4 Major outer membrane protein 
The major outer membrane protein (MOMP) makes up approximately 60% of the 
chlamydial outer membrane complex of elementary bodies (Caldwell et al., 1981). The 
gene for MOMP (ompl) which is found as a single copy gene (Stephens et al., 1985), 
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was initially sequenced from LGV2 and consisted of 1,182-bp, encoding 394 amino 
acids (Stephens et al., 1986). 
Comparisons of C. trachomatis serovars demonstrates that the ompl gene is between 84- 
97% identical at both the nucleotide and amino acid levels (Fitch et al., 1993; 
Kaltenboeck et al., 1993). Variation in the ompl gene is clustered into four variable 
domains (VD 1, VD2, VD3, and VD4) regularly interspersed with five conserved regions 
(Stephens et al., 1987; Baehr et al., 1988). The surface exposed variable domains of C. 
trachomatis MOMP gives rise to species-, subspecies-, serovar-, and serogroup-specific 
epitopes (Zhang et al., 1987; Conlan et al., 1988; Stephens et al., 1988; Zhang et al., 
1989; Batteiger et al., 1990; Zhong et al., 1990) which react with human immune sera 
(Zhang et al., 1987; Zhang et al., 1989a). VD 1, VD2 and the amino terminal segment of 
VD4 specify type-specific epitopes while VD3 and the C-terminal of VD4 specify 
species-, sub-species, and serogroup epitopes. Monoclonal antibodies directed against 
MOMP are neutralizing in cell culture and in some animal models (Peeling et al., 1984; 
Zhang et al., 1987; Baehr et al., 1988; Zhang et al. 1989a; Morrison et al. 1992). 
MOMP is a focus of C. trachomatis vaccine development even though protective 
immunity is serovar specific, and MOMP variants can escape in vitro neutralization by 
both monoclonal antibody and human immune sera (Lamp et al., 1997) 
Like chlamydial LPS, MOMP has been demonstrated to be surface exposed (Kuo and 
Chin, 1987; Collett et al., 1989) having trypsin sensitive antigenic epitopes (Baehr et al., 
1988); exhibits potential porin function (Bavoil et al., 1984); is post-translationally 
glycosylated (Baehr et al., 1988; Collett et al., 1989; Swanson and Kuo, 1991; Kuo et al. 
1996); and is thought to play a role in the structural integrity of the organism (Caldwell et 
al., 1981; Hatch et al., 1981; Caldwell et al., 1982c). 
It has been suggested that MOMP plays an electrostatic role in adherence following a 
conformational change in VD4, a nonapeptide sequence (previously located in a cryptic, 
immunoinaccessible cleft) which becomes immunoaccessible and promotes binding (Su 
et al., 1988; Su et al., 1990; Su et al., 1996). MOMP can contain between 7-10 
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cysteines which may form homo- or hetero-oligomers with itself and/or other outer 
membrane proteins (Newhall et al., 1983; Newhall et al., 1986). 
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1.4 Pathogenicity 
1.4.1 Immune mechanisms 
1.4.1.1 Innate response 
The importance of the host's innate response to chlamydial infection has only recently 
begun to be examined. Acute chlamydial infection is characterized by an early influx of 
neutrophils (possibly mediated by CD 18 which is involved in lipopolysaccharide 
binding) which have been shown to play an important role in controlling the early stages 
of infection (Bartaneva et al., 1996). 
An alternative explanation for the influx of neutrophils to the site of infection may be the 
action of pro-inflammatory cytokines. Chlamydial infection of epithelial cell lines, and of 
monocytic cells has been shown to elicit the production of pro-inflammatory cytokines 
including IL-la, IL-6, IL-8, TNF-a, growth regulated oncogene (GRO) a and 
granulocyte-macrophage colony stimulating factor (GM-CSF) independent of nascent 
LPS (Ault et al., 1996; Heinemann et al., 1996; Bianchi et al., 1997; Rasmussen et al., 
1997). The production of the pro-inflammatory cytokines is possibly important in the 
recruiting of neutrophils and other inflammatory cells to the site of infection before the 
recruitment of lymphocytes. 
After re-infection, or after the initiation of an immune response, the continued stimulation 
of epithelial cells may exaggerate the local inflammatory response, and IFN-y has been 
postulated to have such an effect during repeated infections. In chlamydial infected 
epithelial cell lines IFN-y has been shown to increase the production and secretion of IL-8 
(Rasmussen et al., 1996). The production of IFN-, y as part of a Th 1 response may thus 
contribute to increased inflammation. Such an enhanced cytokine response has been 
reported to occur in natural infection. For example, C. trachomatis infection stimulates 
local cytokines which promote a strong cell-mediated and pro-inflammatory response in 
both the early and late stages of trachoma (Bobo et al., 1996). IFN-'y has also been 
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detected in sera from women with PID (Grifo et al., 1989), and in endocervical 
secretions of women infected with C. trachomatis (Arno et al., 1990). 
Studies using gene knockout mice and neutralization with antibody have been used to 
study the importance of IFN-, y in the resolution of chlamydial infection (Rank et al., 
1992a; Williams et al., 1993; Cotter et al., 1997; Johansson et al., 1997; Perry et al., 
1997; Williams et al., 1997). Although these studies have given conflicting results, it 
appears that IFN-y is dispensable for the resolution of local infection and protection 
against challenge but it may play an important role in the prevention of chlamydial 
dissemination from the mucosal surface. It has been suggested that IFN-y induces the 
inducible nitric oxide synthase (iNOS) pathway, although recent studies have shown 
iNOS is not required for the elimination of C. trachomatis from epithelial cells of the 
female genital tract in mice, but may contribute to the control of dissemination of the 
infection by infected macrophages (Igietseme et al., 1998; Ramsey et al., 1998). 
TNF-a has also been shown to be secreted in the genital tract, as early as 3 days post- 
infection in the guinea pig model (Darville et al., 1995). While TNF-a most likely plays 
an important role in the pathogenesis of infection, and the potential role in the recruiting 
of various cells to the genital tract via its induction of ICAM-1, there is also evidence that 
it may have direct anti-chlamydial activity (Shemer-Avni et al., 1988; Williams et al., 
1990). 
1.4.1.2 Humoral response 
Studies using C. trachomatis MoPn in murine models have confirmed that antibody 
contributes to, but is not essential for protection (Perry et al., 1997; Su et al., 1997; 
Williams et al., 1997). However, it has been demonstrated that antibody is able to 
neutralize C. trachomatis infection in vitro (Banks et al., 1970; Howard et al., 1975; 
Byrne and Moulder, 1978; Caldwell et al., 1982b; Peeling et al., 1984; Lucero and Kuo, 
1985; Byrne et al., 1993). 
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Neutralization has been demonstrated with (Lucer and Kuo, 1985; Peterson et al., 1988), 
and without (Caldwell et al., 1982b; Su et al., 1990; Peterson et al., 1993) the presence 
of complement, and occurred by either preventing the attachment of chlamydial 
elementary bodies to the cell (Byrne et al., 1978; Su et al., 1991) or by allowing the 
internalization of the chlamydiae but preventing/inhibiting replication (Caldwell et al., 
1982b). Opsonization of C. psittaci has also been demonstrated, resulting in the fusion 
of phagosomes containing chlamydiae with lysosomes (Wyrick et al., 1978a; Wyrick et 
al., 1978b). 
The predominant molecule in the chlamydial outer membrane is MOMP. The C. 
trachomatis serovars display significant sequence variation in MOMP possibly due to 
immune pressure (MOMP is a predominant target for antibody). Lampe et al. (1997) 
showed that serovars that vary in MOMP variable regions can escape neutralization with 
both monoclonal antibodies and immune serum. It has also been shown that the in vitro 
neutralization of C. trachomatis serovars isolated from humans was serovar specific and 
dependent upon conformational epitopes (Fan et al., 1997). 
In the human there is a strong antibody response in both genital secretions and serum, but 
whether they play a protective role is unclear. An inverse relationship between the 
number of chlamydiae isolated from genital swabs and level of IgA has been documented 
(Brunham et al., 1983). Jones et al. (1994), reported that the presence of neutralizing 
antibody in patients did not correlate with the immune status of the patient. 
Little is known about antibody profiles during acute or chronic chlamydial genital tract 
infections in humans. Superficial infections (eg. cervicitis) are considered to provide a 
poor stimulus for antibody formation, whereas infiltrating disease (eg. salpingitis) is 
associated with seroconversion. IgG can persist for years, and can be used as a marker 
for a past infiltrating chlamydial disease (Ngeow, 1996). 
The specificity of circulating antibodies may change during the course of the immune 
response. In C. pneumoniae infections during the first 3 weeks after the primary 
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exposure, there is a systemic appearance of IgM, IgA and IgG against less specific 
epitopes (eg. LPS). Only after 4-8 weeks does more specific IgG against MOMP appear 
(Ekman et al., 1993). 
1.4.1.3 Cell mediated response 
Humans have been shown to develop cell mediated immune responses as measured by 
lymphocyte proliferative assays, against chlamydial genital tract infection. (Hanna et al., 
1979; Brunham et al., 1981; Hanna et al., 1982; Witkin et al., 1993a). Like humoral 
immunity, as yet there is no direct evidence that cell mediated immunity is protective in 
humans. Studies of both animals and humans have suggested that the protective 
response to chlamydial infection is predominantly Thl related (Bobo et al., 1996; Kelly et 
al., 1996; van Voorhis et al., 1996; Darville et al., 1997; Perry et al., 1997; Williams et 
al., 1997; van Voorhis et al., 1997). 
It has been proposed that in reference to scarring disease, individuals with weak cell 
mediated immune responses and strong antibody responses are those susceptible to re- 
infection, are slow to resolve infection, and have high levels of clinical inflammation and 
consequently disease (Bailey et al., 1993; Brunham and Peeling, 1994). Conversely 
individuals with a strong cell mediated immune response and a low antibody response are 
those resistant to infection and are less susceptible to disease. 
1.4.1.4 Immunopathology 
It is believed that immune pathogenesis is the underlying mechanism of chlamydial 
disease but it is still not clear if specific antigens coupled with cellular immune responses 
are directly responsible (eg. delayed-type hypersensitivity [DTH]), or if other 
inflammatory or immune regulatory processes contribute to disease. Chlamydial 
infection has been shown to evoke a DTH response, and that re-infection is required to 
induce disease (Grayston et al., 1985). Evidence suggests that chlamydial heat shock 
protein 60 (HSP60) may be the mediator of pathogenesis. Many studies have shown an 
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association between the detection of anti-chlamydial HSP60 antibodies and pelvic 
inflammatory disease (Eckert et al., 1997; Money et al., 1997; Peeling et al., 1997; 
Chernesky et al., 1998), tubal factor infertility (Toye et al., 1993; Clanman et al., 1997), 
ectopic pregnancy (Yi et al., 1993), and trachoma (Taylor et al., 1987; Morrison et al., 
1989b; Taylor et al., 1990). 
It has been suggested that increased levels of chlamydial HSP60 production may result in 
the induction of self anti-HSP60 antibodies inducing autoimmunity which ultimately 
results in tissue damage and scarring. 
1.4.2 Genetic susceptibility to chlamydial disease 
Studies have shown that some murine strains are more susceptible to chlamydial infection 
than others (Tuffrey et al., 1992a; Darville et al., 1996; Darville et al., 1997), and in 
humans not all those infected develop the scarring sequelae. It is believed that host 
genetic factors may play a role in the tissue damage associated with chlamydial disease. 
Conway et al. (1996) studied HLA linkage and disease outcome in patients with scarring 
trachoma and showed that the A*6802 allele of the HLA-A28 (class I) was significantly 
more common in study patients than controls. No particular HLA type was associated 
with protection from disease, and no class II alleles were associated with disease. 
Conway et al. (1997) also demonstrated that scarring trachoma was also associated with a 
polymorphism in the TNF-a promoter region, independent of HLA type. In a macaque 
model of PID the relative susceptibility or resistance to the development of tubal 
adhesions was correlated with specific MHC class I alleles (Lichtchenwalner et al., 
1997). 
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1.4.3 Chlamydia trachomatis 
1.4.3.1 Trachoma and inclusion conjunctivitis 
Trachoma is a chronic keratoconjunctivitis associated mainly with C. trachomatis 
serovars A, B, Ba, and C. Trachoma is hyperendemic in communities with poor hygiene 
and sanitation and of low economic resources. Active trachoma may range from a mild 
asymptomatic inflammation with collections of immune cells visible on the tarsal 
conjunctiva (follicular trachoma) to an intense inflammatory response in which most of 
the tarsal plate is obscured by capillary congestion (intense trachoma). Repeated ocular 
infections cause scarring of the conjunctiva (scarring trachoma), inversion of the eyelids 
and eyelashes (trichiasis), which ultimately can lead to blindness following damage to the 
cornea by inturned lashes. 
Inclusion conjunctivitis is caused by C. trachomatis serovars D to K and is mainly seen in 
the sexually active age groups. Transmission of the disease is usually by self-inoculation 
with infective genital discharge. Concomitant genital tract infection of patients with 
inclusion conjunctivitis is seen in 80-90% of females and approximately 50% of males. 
Clinical manifestations include swollen eyelids, mucopurulent discharge, papillary 
hypertrophy, and follicular hypertrophy; corneal scarring is rarely found. As in 
trachoma, repeated episodes lead to the development of more severe disease possibly by 
the same mechanisms. 
1.4.3.2 Female genital tract infections 
1.4.3.2.1 Lower genital tract infections 
In women C. trachomatis is one of the major causes of urethritis and urethral symptoms. 
Stamm et al. (1980) associated dysuria and/or frequency without significant bacteriuria 
with C. trachomatis infection, although Homer et al. (1995) in a recent study showed no 
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such association. There is little evidence of urethral inflammation and C. trachomatis 
infection, although mucopurulent cervicitis is suggestive of urethral syndrome. 
Chlamydial mucopurulent cervicitis is often asymptomatic, and if left untreated can 
ascend to the upper genital tract often leading to the development of PID. It has been 
reported that 64% of women with chlamydial mucopurulent cervicitis have subclinical 
PID (Paavonen et al., 1985a). Paavonen et al. (1992) introduced a simple set of 
diagnostic criteria which included the detection of eight or more polymorphonuclear 
leukocytes per high power field in a cervical smear, the presence of a yellow 
mucopurulent endocervical discharge, increased eyrthema, oedema, and induced mucosal 
bleeding in an area of ectopy and in the cervical transformation zone. 
Histological findings associated with chlamydial cervicitis include the presence of dense 
stromal inflammation (plasma cell infiltrations), intraepithelia and intraluminal 
inflammation, and well-formed lymphoid follicles comprising transformed lymphocytes 
(Kiviat et al., 1990). 
1.4.3.2.2 Pelvic inflammatory disease 
"Pelvic inflammatory disease (PID), or salpingitis, refers to infection of the uterus, 
Fallopian tubes and adjacent structures not associated with pregnancy or surgery. PID is 
almost always an ascending infection in which pathogenic microorganisms spread from 
the cervix and vagina to the upper genital tract" (McCormack, 1994). 
PID is one of the most important complications of sexually transmitted disease, and over 
half the reported cases are caused by C. trachomatis, N. gonorrhoeae or both. Each 
repeat episode of PID doubles the risk of tubal disease associated with possible 
permanent tubal damage and development of ectopic pregnancy (EP) or infertility 
(Westrom, 1975). As a consequence of tubal scarring approximately 20% of women 
with laparoscopically confirmed PID will become infertile, 18% will develop prolonged 
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pelvic pain and 9% will have ectopic pregnancies (Westrom, 1980; Westrom et al., 
1992). 
Manifestations of acute PID can include endometritis, salpingitis, pelvic peritonitis and 
ovarian abscesses. The ascending infection can also spread to the appendix 
(periappendicitis) and the liver capsule (perihepatitis). Diagnosis of PID is to say the 
least difficult. Minimum criteria for the diagnosis of PID include lower abdominal 
tenderness, bilateral adnexal tenderness, cervical motion tenderness and no evidence of a 
competing diagnosis. 
In many instances the condition is asymptomatic or silent as demonstrated by Cates and 
Wasserheit (1991) who showed a strong link between serum anti-chlamydial antibodies 
and tubal factor infertility or EP in patients with and without a history of PID. Women 
with PID often have damaged Fallopian tubes at the time of diagnosis, and studies in both 
primate and murine models suggest that antibiotic treatment with or without anti- 
inflammatory agents had little effect on tubal inflammation (Patton et al., 1997; Verhoest 
et al., 1997). 
The mechanism by which chlamydial PID mediates tubal damage is thought to be 
immunopathological. The deleterious sequelae of chlamydial infection appears to be 
caused by a DTH response to chlamydial heat-shock protein 60 (CHSP60) (Morrison et 
al., 1989b). Many studies have suggested a correlation between serum antibodies to 
CHSP60 and PID, tubal factor infertility (TFI) or ectopic pregnancy (EP) (Miettinen et 
al., 1990; Wager et al., 1990; Brunham et al., 1992; Toye et al., 1993; Paavonen and 
Lehtinen, 1994; Clanman et al., 1997; Eckert et al., 1997; Money et al., 1997; Peeling et 
al., 1997; Chernesky et al., 1998; Sziller et al., 1998). In women with chlamydial PID, 
a prior history of PID, cervicitis or chlamydial infection, laparoscopically verified tubal 
obstruction, the degree of tubal inflammation and the presence of adhesions have all been 
associated with the presence of HSP antibodies (Stamm et al., 1994). 
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The actual mechanism by which CHSP60 mediates damage is unclear, one hypothesis is 
that antibodies directed against CHSP60 cross react with human HSP60 resulting in 
autoimmunity and damage. It may also be that the presence of detectable levels of 
antibodies against CHSP60 may simply be a marker, for example of chlamydial 
persistence. 
1.4.3.3 Male genital tract infections 
1.4.3.3.1 Epididymitis 
Epididymitis is the most common intrascrotal inflammatory disorder, usually resulting 
from the spread of microorganisms from the prostatic urethra, prostate or seminal vesicle. 
Idiopathic epididymitis exhibits an acute or chronic inflammatory infiltration with or 
without abscess formation and ductal destruction. Chlamydial epididymitis has been 
characterized as being nondestructive and proliferative compared to epididymitis which is 
destructive and abscess forming often found associated with other bacteria (Hori and 
Tsutsumi, 1995). 
Studies in both the UK and USA have demonstrated that the microorganisms causing 
acute epididymitis vary with age and sexually activity. 30-60% of men with acute 
epididymitis under the age of 35 years show the presence of C. trachomatis in epididymal 
aspirates (Berger et al., 1978; Doble et al., 1989a; Robinson et al., 1990). 
1.4.3.3.2 Non-gonococcal urethritis 
Non-gonococcal urethritis (NGU) is defined as urethritis where N. gonorrhoeae is not 
the aetiological agent. Many studies have shown that C. trachomatis can be demonstrated 
in urethral specimens of up to 13%-50% of NGU cases (Oriel and Ridgway, 1982; Janier 
et al., 1995), the remaining cases have been attributed to several other organisms such as 
Trichomonas vaginalis, Herpes simplex virus (Swartz et al., 1978), and Mycoplasma 
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genitalium (Jensen et al., 1993; Taylor-Robinson, 1996). There is no clinical difference 
between chlamydial or non-chlamydial NGU. 
The average incubation period of NGU following sexual contact is between 1 and 3 
weeks, with many men complaining of dysuria and urethral irritation with a mucoid or 
mucopurulent discharge. Up to 25% of all cases of NGU clear spontaneously within 
three weeks and most will resolve within two months (Mardh et al., 1989), although 
many symptomatic cases become asymptomatic within three weeks (Shahmanesh, 1994). 
More than 10 polymorphonuclear leukocytes (PMNs) in the centrifuged sediment of first- 
catch urine per high-power field (x400), or more than 5 PMNs per high-power field 
(x1000) in the urethral smear is usually included in the definition of male urethritis 
(Swartz et al., 1978; Bowie et al., 1978; Desai et al., 1982). While asymptomatic 
urethritis in men is recognized (Swartz et al., 1978; Munday et al., 1985), NGU is more 
frequently associated with discharge and/or penile irritation. 
1.4.3.3.3 Post-gonococcal urethritis 
Post-gonococcal urethritis (PGU) has been defined as a persistent non-gonococcal 
urethritis following treatment for gonococcal urethritis. It occurs due to a dual infection 
with an organism which causes NGU, with up to 80% of cases being attributed to C. 
trachomatis (Stamm et al., 1984). Whether the two infections were acquired 
simultaneously, or whether C. trachomatis was acquired first remaining dormant until 
triggered by a gonococcal infection (Mardh et al., 1989) is unclear. PGU can be 
prevented by both treatment for gonorrhoea and an effective anti-chlamydial regimen. 
1.4.3.3.4 Proctitis 
C. trachomatis serovars D-K have been isolated from rectal samples from both hetero- 
and homosexual men (Munday et al., 1981; Bauwens et al., 1995). LGV can cause 
severe proctitis, with symptoms that include rectal pain and discharge (Bauwens et al., 
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1995). The other genital serovars of C. trachomatis have been recovered from 
homosexual men, but they have not been associated conclusively with any particular 
rectal symptoms (Munday et al., 1983). 
1.4.3.3.5 Prostatitis 
Weidner et al. (1991) suggested that nearly one third of cases of 'non-bacterial' prostatitis 
were of chlamydial origin. Chlamydial urethritis can be diagnosed by culture in 
approximately 10% of prostatitis cases (Mardh et al., 1978). Bruce et al. (1981) 
examined early morning urine specimens and/or prostatic fluid or semen of fifty patients 
with chronic prostatitis by tissue culture, 56% proved positive for C. trachomatis. 
However, Doble et al. (1989b) using transperineal prostate biopsies from 50 men with 
'non-bacterial' chronic prostatovesiculitis failed to identify C. trachomatis in prostatic 
tissue. Recently C. trachomatis has been identified by in situ hybridization in prostate 
tissue (Corradi et al., 1996; Krieger et al., 1996) and expressed prostatic secretions (Guo 
et al., 1997) by PCR. Symptoms of prostatitis can include discomfort, urethral 
discharge, dysuria, an increased frequency of urination, painful ejaculation and a reduced 
libido. 
1.4.3.4 Lymphogranuloma venereum 
Lymphogranuloma venereum (LGV) is a systemic, sexually transmitted disease caused 
by C. trachomatis serovars L1 to L3. The disease is endemic in East and West Africa, 
India, South-East Asia and South America. It is uncommon in the UK with a combined 
total of 91 reports of chancroid, granuloma inguinale or LGV from GUM clinics in 1995 
(Dept. Health, 1996). 
The primary lesion of LGV usually appears 3-12 days post-infection, classically the ulcer 
is transient commonly effecting the corona; suculus, frenulum or prepuce in men, and the 
posterior vaginal wall, fourchette or posterior cervical lip in women. Other symptoms 
during the primary stage may be urethritis, endometritis or salpingitis. The secondary 
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stage is characterized by inflammation and swelling or the regional lymph nodes, which 
may take up to 6 months post-infection. This secondary stage is also associated with the 
systemic spread of LGV. The tertiary stage is characterized by proctocolitis, perirectal 
abscesses, fistula formation and rectal stricture/stenosis. 
1.4.3.5 Neonatal infections 
C. trachomatis can cause conjunctivitis and pneumonitis in neonates born to genitally 
infected mothers (Claesson et al., 1989; Hammerschlag et al., 1989). Neonatal 
conjunctivitis is characterized by swelling of the eyelids, erythematous conjunctivae and a 
mucopurulent discharge. Neonatal pneumonitis symptoms include a pertussis-like 
cough, and infants with chlamydial pneumonia are at an increased risk for developing 
pulmonary dysfunction and possibly chronic respiratory disease at a later time (Weiss et 
al., 1991). 
1.4.3.6 Sexually acquired reactive arthritis 
Sexually acquired reactive arthritis (SARA) develops in between 1-3% cases of NGU, 
and approximately one third of patients with SARA also have Reiter's Syndrome 
(arthritis in association with uveitis and urethritis). Anti-chlamydial IgG titres in both 
serum and in synovial fluid have been reported to be elevated in patients with SARA 
when compared to controls (Bas et al., 1996; Wollenhaupt, 1996), although the organism 
itself has not been isolated. However, chlamydial DNA, rRNA and MOMP have all been 
detected in the affected joints of SARA patients (Keat et al., 1987; Hammer et al., 1992; 
Rahman et al., 1992; Taylor-Robinson et al., 1992). 
31 
1.4.4 Chlamydia pneumoniae 
1.4.4.1 Acute respiratory disease 
C. pneumoniae was first described as a major cause of mild, community-acquired human 
respiratory infection (Saikku et al., 1985; Kuo et al., 1986) resembling Mycoplasma 
pneumoniae pneumonia (Cotton et al., 1987) except for the frequent occurrence of 
pharyngitis, sinusitis (Hashigucci et al., 1992), and otitis media (Ogawa et al., 1990). 
Clinical and radiological evidence of consolidation can range from sub-segmental lesions 
to extensive bilateral pneumonitis. The onset of disease is prolonged with upper 
respiratory tract symptoms followed by increased coughing and other symptoms 
indicative of lower respiratory tract disease. Other diseases that have been linked to C. 
pneumoniae infection include encephalitis, the Guillain-Barre syndrome (Haidl et al., 
1992), arthritis, and erythema nodosum (Erntell et al., 1989). C. pneumoniae has also 
been associated with asthma in both children and adults (Hahn et al., 1991; Hahn et al., 
1992; Hahn et al. 1996; Cook et al. 1998; Cunningham et al., 1998; Magee, 1998; 
Miyashita et al., 1998). 
1.4.4.2 Coronary heart disease 
C. pneumoniae was first demonstrated in autopsy coronary atheroma specimens by 
electron microscopy (Shor et al., 1992), the results of which were later confirmed by 
immunohistochemistry and PCR (Kuo et al., 1993). The organism has been 
demonstrated in several vascular tissue types using a variety of techniques (Campbell et 
al., 1995; Kuo et al., 1995; Grayston et al., 1995). Using immunohistochemistry C. 
pneumoniae has been localised to macrophages and smooth muscle cells from aortic 
atherosclerotic lesions (Ong et al. 1996), and foam cells of carotid plaques (Grayston et 
al. 1995). 
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The question of whether C. pneumoniae is an 'innocent' bystander or the cause of 
endothelial damage, hypercoaguability, and macrophage activation still remains to be 
fully elucidated. It has been suggested that macrophages may act as a'Trojan horse' in 
that C. pneumoniae is ingested in the lung and taken to atheromatous lesions. 
Alternatively, C. pneumoniae may actively induce immune activation, cytokine release, 
endothelial damage, and thrombosis leading to atherogenesis. A recent study has shown 
that C. pneumoniae induces macrophage foam cell formation which may initiate or 
promote atheroma development (Kalayoglu and Byrne, 1998). Animal models have 
shown that C. pneumoniae does have a tropism for atherosclerotic lesions (Moazed et al., 
1997), and is capable is of inducing inflammatory atherosclerosis-like changes in the 
aorta (Laitinen et al., 1997). 
1.4.5 Chlamydia psittaci 
C. psittaci is spread via the inhalation of aerosols derived from animal faeces or other 
animal products and causes predominantly pneumonia in humans. Disease in humans can 
vary from a mild like flu to severe generalised illness with symptoms ranging from a 
fever, to anorexia, and photophobia. In severe cases, nausea, vomiting, and diarrhoea 
may be seen. Abortion in humans has been associated with C. psittaci , the 
infection 
being transmitted from infected placental/foetal material. C. psittaci has been shown to 
produce endocarditis in humans (Regan et al., 1979; Lamaury et al., 1993), myocarditis 
(Jannach, 1958; Dymock et al., 1971), pericarditis (Sutton et al., 1967), and major 
arterial embolism (Pesanti and Smith, 1979). 
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1.5 Infertility 
1.5.1 Structure and function of the female genital tract 
The female genital tract is composed of five main structures, the ovaries, the Fallopian 
tubes, the uterus, the cervix and the vagina (Figure 2). The morphology of the female 
genital tract is not static, undergoing repetitive cyclic changes which are a consequence of 
the re-occurring fluctuations in ovarian hormone production which are an important 
component of the 28 day ovulatory cycle (Figure 3). 
During the ovulatory cycle a single follicle develops into a mature ovum secreting large 
quantities of oestrogen, under the influence of rising follicle stimulating hormone (FSH). 
Ovulation occurs at approximately mid-cycle in response to a surge of luteinizing 
hormone (LH) which is provoked by a critical oestrogen level. The ovum is expelled 
from the follicle which then undergoes conversion in to a corpus luteum. Under the 
influence of LH the corpus luteum secretes large amounts of both oestrogens and 
progesterones but in the absence of pregnancy the corpus luteum degenerates 
accompanied by a decline in oestrogen and progesterone. The tissues of the female 
genital tract posses steroid hormone receptors and are therefore capable of responding to 
the cyclic hormonal changes, these changes representing a recurrent 'priming' for 
potential pregnancy. 
1.5.2 Causes of infertility 
Data from the USA suggest that less than 50% of infertile couples seek medical advice 
(Wilcox and Mosher, 1993). A 1982-1985 WHO multi-centred study found that in 20% 
of infertility cases the problem was predominantly male, in 38% the problem was 
attributed to the female, 27% had abnormalities in both partners, and the remaining 15% 
had no clearly defined cause of infertility (WHO, 1987). 
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1.5.2.1 Causes in the female 
Tubal disease includes an array or disorders including blockage, both distally and 
proximally, peritubal adhesions, salpingitis, and hydrosalpinx. PID, previous EP, 
previous sterilization or surgery, and a history of peritonitis which can cause such 
conditions leading to the development of TFI. Severe tubal disease, specifically distal 
tubal obstruction leading to hydrosalpinx has been associated with a poor fertility 
prognosis (Bahamondes et al., 1984; Marana et al., 1995; Nackley et al., 1998). 
1.5.2.2 Causes in the male 
To be fertile the male requires a normal spermatogenesis, successful epididymal 
maturation and storage of sperm, normal sperm transport and accessory gland function. 
Male infertility can be categorized as due to three aetiological factors, pre-testicular 
(altered endocrine function, coital disorders and ejaculatory failure), testicular (genetic, 
congenital, infective, effect of anti-spermatogenic agents, vascular, immunological and 
idiopathic), and post-testicular (obstructive, vasal, accessory gland infection, 
immunological, and epididymal hostility). 
1.5.3 Chlamydia trachomatis and female infertility 
1.5.3.1 Miscarriage/spontaneous abortion 
Serological studies investigating the possible role of C. trachomatis in miscarriage have 
given conflicting results (Witkin et al., 1992; Osser and Persson, 1996; Witkin et al., 
1998). When considering women undergoing in vitro fertilization (IVF), antibodies 
against C. trachomatis have been associated with spontaneous abortion (Licciardi et al., 
1992; Witkin et al., 1994; Neuer et al., 1997). 
C. psittaci can cause abortion in women by infection of the placenta, the question remains 
does this process take place in pregnant women infected with C. trachomatis ? C. 
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trachomatis DNA has been detected in the placenta of a stillborn foetus by in situ 
hybridization (Gencay et al., 1997) but the importance of C. trachomatis in 
miscarriage/abortion still remains to be elucidated. 
1.5.3.2 Ectopic pregnancy 
The incidence of ectopic pregnancy (EP) ranges from between 0.25%-1.4% of all 
pregnancies (ie. the sum of reported live births, legal abortions and EP) (Chow et al., 
1987; Coste et al., 1994b) . EP was responsible 
for 11 % of maternal mortality in the UK 
during 1988-1990. 
EP refers to the implantation of the fertilized ovum outside the uterine corpus. The basic 
cause of EP is the impediment of the passage of the fertilized ovum down the Fallopian 
tube. Approximately 92% of EPs occur in the ampulla where fertilization takes place and 
4% in the isthmus, but they may occur anywhere along the tube from the fimbriae to 
cornu as well as in extratubal sites such as the cervix, ovary and abdominal cavity. The 
commonest pathology is damage to the ciliated epithelium and peristaltic activity of the 
tube by a previous infection with such microorganisms as C. trachomatis, and N. 
gonorrhoeae. It has been suggested that chlamydial associated EP may be the result of 
infectious damage/loss of Fallopian tube function and ongoing infection 
1.5.3.3 Tubal factor infertility 
The Fallopian tubes act as a conduit for the sperm to reach the ovum, and for the fertilized 
ovum to reach the uterus. Tubal occlusion resulting from hydrosalpinx and peritubal 
adhesion formation and tubal scarring are the underlying pathological changes associated 
with TFI following acute salpingitis. 
The mechanism by which C. trachomatis induces adhesion formation and scarring may 
be immune mediated, and similar to that observed in scarring trachoma. Animal model 
studies have shown that repeated chlamydial infection of the Fallopian tubes resulted in 
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pathological changes associated with a delayed type hypersensitivity response (DTH) 
(Patton et al., 1982; Patton et al., 1987; Patton et al., 1989a; Tuffrey et al., 1990; Patton 
et al. 1994a; Rank et al., 1995a), and hydrosalpinx formation (Sweet et al., 1980; Patton 
et al., 1982; Schachter et al., 1982; Rank et al. 1992b; Rank et al. 1995a). Campbell et 
al. (1993) and Patton et al. (1994) demonstrated that chlamydial DNA could persist in 
human Fallopian tube tissue from TFI patients, and suggested that such persistence may 
stimulate immune-mediated tissue damage. 
There have been many serological studies that have linked exposure to C. trachomatis and 
the subsequent development of tubal pathology (Brunham et al., 1985; Campbell et al., 
1993; Patton et al., 1994b). Data has also associated the presence of anti-chlamydial 
HSP60 antibodies with TFI (Toye et al., 1993; Sziller et al., 1998). 
1.5.4 Chlamydia trachomatis and male infertility 
Asymptomatic infection of the reproductive tract of infertile men has been acknowledged 
for over two decades (Ulstein et al., 1976; Nikkanen et al., 1979). The impact of C. 
trachomatis infection on male infertility, and semen parameters is controversial. C. 
trachomatis has been shown to attach (Wolner-Hansen and Mardh, 1984) and enter into 
spermatozoa (Erbengi, 1993), it can be detected in cytoplasmic droplets of spermatozoa 
(Villegas et al., 1991), and chlamydial DNA has been demonstrated in prostate tissue 
specimens (Corradi et al., 1996). 
It has been suggested that C. trachomatis infection of the genital tract may stimulate the 
immune system inducing autoimmunity to spermatozoa (Witkin and Toth, 1983; 
Shamanesh et al., 1986; Soffer et al., 1990; Naz and Menge, 1994; Munoz and Witkin, 
1995; Witkin et al., 1995a). Anti-sperm antibodies can be directed against various sites 
of the spermatozoa (Peters and Coulam, 1992), attachment of antisperm antibodies can 
effect sperm motility (Zouari et al., 1993); head-directed antibody binding may prevent 
fertilization due to the occlusion of binding sites for the zone of pellucida (Bronson et al., 
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1984). The acrosome reaction, one of many crucial steps in sperm function may also be 
altered by anti-sperm antibodies (Lansford et al., 1990). 
1.5.5 Treatment of infertility 
1.5.5.1 In vitro fertilization 
The first baby conceived by in vitro fertilization (IVF) was born in 1978 (Steptoe and 
Edwards, 1978). IVF tends to be used in women with absent, damaged or blocked 
Fallopian tubes. The technique involves the use of ovulation-enhancing drugs so 
multiple oocytes mature, the retrieval of the oocytes followed by in vitro fertilization, and 
finally after approximately 48h the re-introduction of the developing embryo into the 
uterus. 
1.5.5.2 Gamete intrafallopian tube transfer 
Gamete intrafallopian tube transfer (GIFT) was first described by Asch et al. (1986) as an 
alternative to NF in situations where NF had been previously utilized, but where the 
Fallopian tubes were normal. The basic procedure involves the in vitro mixing of 
oocytes and sperm followed by the re-introduction of the mixture into the distal end of the 
Fallopian tube where fertilization may occur in vivo. 
39 
1.6 Diagnosis of chlamydial infections 
1.6.1 Specimens 
Specimen collection and transport is important in the diagnosis of chlamydial infections, 
both the sensitivity and specificity of many diagnostic tests have been related to the 
'quality' of the specimen (Phillips et al., 1987; Moncada et al., 1990; Schwebke et al., 
1990; Howard et al., 1991; Kellogg et al., 1991). Due to the intracellular nature of 
Chlamydia the main objective of sampling should be to collect host cells containing the 
microorganism. 
For culture, specimens should be collected in a medium specifically designed to maintain 
the host cell and chlamydial viability, for example 0.2M sucrose in phosphate buffered 
saline (2SP). Antibiotics which chlamydiae are not susceptible to are usually added to the 
transport medium to prevent the growth of other bacteria and fungi in the specimen. In 
women the most common site for the isolation of C. trachomatis is the endocervix; the 
type of swab used for collection has been shown to be of some importance due to toxicity 
to cell cultures, or the direct inhibition of chlamydial growth (Mahony et al., 1985). The 
pooling of a urethral and an endocervical swab has been reported to increase culture 
sensitivity by 23% (Jones et al., 1986a). In males, the preferred site of sample collection 
is the anterior urethra. 
Specimen storage can also effect chlamydial isolation, isolation is optimized if specimens 
are kept and transported at temperatures between 2-8°C immediately after collection. The 
time between specimen collection and processing should ideally be less than 48h, 
although freezing at -70°C is acceptable but can lead to a 20% loss of chlamydial viability 
after three days (Reeve et al., 1975; Mahony et al., 1985). 
For non-culture tests, specimens such as urine can be used for antigen tests, polymerase 
chain reaction (PCR) and ligase chain reaction (LCR). Culture of urine specimens has 
not always proved to be successful, with the best performance on urine from 
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symptomatic males (Chernesky et al., 1990; Chernesky et al., 1995). Tests such as PCR 
and LCR do not require intact chlamydial elementary bodies since only a few copies of 
target DNA are required for the generation of a positive signal; Kellogg et al. (1995) 
showed that the number of host cells and hence the number of chlamydiae present in a 
sample can affect the outcome of DNA amplification. 
Recently vaginal introitus and vulval specimens have been investigated using DNA 
amplification techniques. PCR testing of vaginal introitus specimens proved to be as 
sensitive as culture of cervical specimens (Wiesenfeld et al., 1995), and LCR testing of 
vulval specimens was as sensitive as cervical specimens (Stary et al., 1995). The 
importance of these sample types is that they are non-invasive, and in the case of the 
vaginal introitus sample can be taken by the patient. 
1.6.2 Tissue culture 
Cell culture for the in vitro growth of C. trachomatis was first described by Gordon and 
Quan (1965) using irradiated McCoy cells. Culture is performed by inoculating patient 
specimens onto cell monolayers. While the technique has a specificity reaching 100%, 
sensitivity is lower (70-85%) when compared to DNA amplification techniques 
(Chernesky et al., 1994a; Chernesky et al., 1994b; Lee et al., 1995). Many cell lines 
have been used for the propagation of C. trachomatis including McCoy cells (Yoder et 
al., 1981; Smith et al., 1982; Stamm et al., 1983), HeLa 229 (Rota et al., 1971; Kuo et 
al., 1995), and BGMK (Krech et al., 1989; Hosein et al., 1992). 
Ideally specimens should be sonicated prior to culture to disrupt cellular material which in 
turn liberates chlamydial elementary bodies (Watford et al., 1985). Before inoculation 
the maintenance medium should be removed from the cell monolayer, and replaced by the 
specimen. Centrifugation of the specimen onto the cell monolayer (2,500-3,000xg at 
35°C for lh) after inoculation has been shown to improve the recovery of viable 
chlamydiae (Rota et al., 1971). It has also been shown that the addition of polyethylene 
glycol before centrifugation increased the number of inclusions, improved the sensitivity 
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of the culture and decreased the possibility of missing weak positive specimens 
(Mohammed and Hillary, 1985; Gibson et al., 1993) 
After centrifugation the remaining sample is aspirated and replaced with fresh culture 
maintenance medium thus reducing the possibility of a cytotoxic effect. The culture 
should then be incubated at 37°C in 5% CO2 for between 48-72h. The blind passage of 
samples after an initial 48h incubation period has been reported to aid in the recovery of 
an additional 3-10% of isolates (Barnes, 1989). 
The maintenance medium routinely contains antibiotics to which chlamydiae are not 
susceptible, and a cytostatic agent. Generally cycloheximide (Ripa and Mardh, 1977), a 
eukaryotic protein synthesis inhibitor is added to the maintenance medium preventing 
cellular growth and multiplication. It is believed that the inhibition of cellular protein 
generation results in a pool of amino acids and ATP that the chlamydiae can then utilise 
for growth. 
The identification of chlamydial inclusions in cell culture is routinely accomplished using 
either genus specific anti-chlamydial lipopolysaccharide fluorescent antibodies, or species 
specific anti-C. trachomatis MOMP fluorescent antibodies. The direct visualization of 
fluorescent chlamydial inclusions with a distinctive morphology is deemed a positive 
culture result. Other stains have been used to determine the presence of chlamydial 
inclusions including Gram, Giemsa, and iodine but due to their lack of sensitivity and 
specificity, fluorescent antibody staining is the preferred method (Stephens et al., 1982; 
Stamm et al., 1983; Schoenwald et al., 1988). 
1.6.3 Direct sample analysis 
1.6.3.1 Enzyme immunoassay 
Enzyme immunoassays (EIA) for the detection of chlamydiae were originally developed 
in the 1980s, and based on the immunochemical detection of chiamydial genus-specific 
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lipopolysaccharide (LPS). Two basic types of EIA have been described, a direct and an 
indirect methodology. Direct EIA uses enzyme-labelled antibodies that recognise and 
bind chlamydial LPS on the surface of elementary bodies present in the clinical sample. 
Indirect EIA utilises a primary anti-chlamydial LPS antibody as a detector reagent 
followed by a the addition of a secondary enzyme-linked antibody. The enzyme 
component of both EIAs converts a colourless substrate to a coloured product which can 
then be detected using a spectrophotometer. Alternatively, the conjugated enzyme may be 
used to convert a fluorescence-generating substrate to a fluorescent signal. 
One of the main disadvantages of EIA is that antibodies to other bacterial LPS may cross- 
react with the chlamydial LPS, generating a false positive result (Stamm et al., 1988; 
Barnes, 1989; Centers for Disease Control, 1991; Kellogg et al., 1992). Another 
problem with EIA is the inability of the system to differentiate between chlamydial 
species. 
There are many commercially available EIAs including Chlamydiazyme (Abbott), IDEIA 
(Dako), and Clearview (Unipath). Many of the commercially available EIAs include a 
secondary blocking assay to verify positive EIA results; this uses a monoclonal antibody 
that competitively inhibits, or blocks the LPS epitope resulting in a reduced signal which 
is taken as verification of the initial EIA result. The use of blocking antibodies has 
improved the specificity of EIA (Newhall et al., 1994). 
1.6.3.2 Direct fluorescent antibody 
Direct fluorescent antibody (DFA) testing is based on the use of a fluorescein-conjugated 
monoclonal antibody to stain chlamydial elementary bodies in genital, ocular and other 
smears. DFA using monoclonal antibodies against chlamydial MOMP of C. trachomatis 
(MicroTrak, Syva, USA; Pathfinder, Kallestad, USA; Monofluor, Synbiotics, USA) 
produces brighter and less non-specific staining than do antibodies against chlamydial 
LPS (Imagen, Dako). 
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The reported sensitivity of DFA ranges from 70-100% for men and from 68-100% for 
women, and a specificity of 87-99% for men and 82%-100% for women (Taylor- 
Robinson, 1991a; Taylor-Robinson, 1991b). The major disadvantage of DFA is that is 
requires technical expertise, and discrimination between specific and non-specific 
staining. 
1.6.3.3 Nucleic acid detection 
1.6.3.3.1 DNA hybridization probes 
At present there is only one commercially available DNA probe for the detection of C. 
trachomatis (PACE 2, Gen-Probe, San Diego, CA). The test employs a 
chemiluminescent DNA probe that is designed to hybridize to a species specific 16S 
rRNA sequence. After the formation of the DNA probe/rRNA complex, it is adsorbed 
onto magnetic beads and the chemiluminescent response is detected and quantified using 
a luminometer. 
The system theoretically should be more sensitive (approximately 103 chlamydial 
elementary bodies) than antigen detection methods due to the fact that actively dividing 
chlamydiae contain at least 104 copies of 16S rRNA. The sensitivity and specificity of 
PACE 2 compared to culture and an expanded culture standard has been estimated to be 
between 85% and 98-99% respectively. Like EIA, a probe competition assay has been 
developed which has been reported to confirm the high number of PACE 2 positive 
results (Limberger et al., 1992; Stary et al., 1994; Beebe et al., 1997). 
1.6.3.3.2 Polymerase chain reaction (PCR) 
PCR is a method for the in vitro amplification of specific DNA sequences by the 
simultaneous primer extension of complementary strands. PCR involves three main 
steps; 1) denaturation of the double stranded DNA at high temperature, at 
temperatures between 90-95°C depending on the G+C content of the sample DNA; 2) 
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annealing of the primers to the single stranded DNA, 37-65°C; 3) and the primer 
extension reaction at 72°C which involves the formation of the desired PCR product 
flanked by both primers. 
There are five major reaction components for conducting PCR, a DNA polymerase; 
deoxynucleoside triphosphates (dNTPs); an appropriate reaction buffer; specifically 
designed primers that flank the target sequence; and the target DNA. 
The first FDA approved PCR for the detection of C. trachomatis in the USA was 
developed by Roche Diagnostics (Amplicor) (Loeffelholz et al., 1992). The Amplicor 
test targets a 207-bp fragment of the 7.5kb endogenous plasmid of C. trachomatis. 
Plasmid-free C. trachomatis isolates have been described (Peterson et al., 1990; An et al., 
1992; Farencena et al., 1997) but their abundance in the general population, and clinical 
significance is unknown. 
Detection of amplified products is by an immobilized oligonucleotide capture probe 
consisting of a sequence complimentary to the amplified target. An avidin-horse radish 
peroxidase conjugate is then added that binds to the biotinylated PCR product, after 
washing a peroxidase substrate is added giving rise to a colour change which is read in a 
spectrophotometer. 
Amplicor PCR has been widely evaluated for both urogenital and urine specimens, with 
an overall sensitivity of 90-99% and 100% specificity and has been approved for use 
with cervical, male urethral, and male urine specimens. In some studies with Amplicor 
PCR, a small number of false-negatives that become positive after storage and repeat 
testing have been reported (Loeffelholz et al., 1992; Bass et al., 1993; Bauwens et al., 
1993a; Mahony et al., 1994). It is believed that SDS in the Amplicor transport buffer 
was the problem, and tests using a 'universal' non-detergent transport buffer (Salmon et 
al., 1994) or 2SP (Verkooyen et al., 1995) have been shown to improve sensitivity. 
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MOMP PCR is not available as a diagnostic test commercially, and its sensitivity is below 
that of PCR based on the C. trachomatis plasmid. The reduced sensitivity of MOMP 
reflects the fact that the MOMP gene is a single copy gene (Stephens et al., 1985), 
compared to the C. trachomatis plasmid which can be present in 5-10 copies 
(Comanducci et al., 1990). MOMP PCR has been used by Roche Diagnostics for the 
discrepant analysis of the Amplicor PCR system (Lin et al., 1992; Bawens et al., 1993b). 
1.6.3.3.3 Ligase chain reaction 
The ligase chain reaction (LCR) was first described by Backman (1987), four 
oligonucleotide probes attached to two different haptens are used to recognise and bind 
the target sequence. If the target sequence is present the probes bind adjacently to each 
other and are enzymatically joined by a ligase to form the amplification product. The 
amplification product then serves as the target sequence during successive rounds of 
amplification. Finally the amplified target sequence is detected by hybridization utilising 
a microparticle enzyme assay. 
Abbott have introduced a commercial LCR named LCx. This system has been used to 
detect C. trachomatis in female endocervical swabs, male urethral swabs and in both male 
and female urine specimens; and has been shown to be highly sensitive in the detection in 
female chlamydial genital infections (Chernesky et al., 1994a; Chernesky et al., 1994b; 
Chernesky et al., 1994c; Lee et al., 1995). 
1.6.3.4 Other molecular methods 
Several new molecular amplification methods have been used to detect C. trachomatis 
DNA in clinical samples. These include the Q-beta replicase-amplified hybridization 
assay (Gene-Track) (Shah et al., 1994); Gen-Probe AMPLIFIED Chlamydia trachomatis 
Assay (AMP CT) which is based on transcription mediated amplification (TMA) 
technology (Chambers et al., 1995); and nucleic acid sequence based amplification 
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(NASBA) for the detection of C. trachomatis RNA in cervical and urine specimens 
(Morre et al., 1996). 
The Q-beta replicase-amplified hybridization assay requires an RNA-directed RNA 
polymerase and two different probes. The reporter probe consists of Q-beta replicase 
RNA synthetically linked to a C. trachomatis rRNA tail, and the capture probe consists of 
C. trachomatis DNA with a polyadenine tail. Both probes hybridize to adjacent regions 
of C. trachomatis 16S rRNA. The hybridization complex is captured by polythymidine 
coated beads, and the attached products are detected by a fluorimetric system. 
The TMA assay at present targets 16s rRNA, and works as an isothermal system that 
utilizes enzymatic target amplification followed by chemiluminescent detection. AMP CT 
has been shown to be highly sensitive and specific for the detection of C. trachomatis 
DNA in urine specimens from women and men (Pasternack et al., 1997; Crotchfelt, 
1998) and endocervical specimens (Crotchfelt, 1998). 
NASBA uses a system similar to that of TMA. One primer contains a T7 RNA 
polymerase promoter and a sequence homologous to a portion of C. trachomatis RNA. 
A reverse transcriptase extends the primer to make a DNA copy of the target sequence 
forming an RNA-DNA hybrid. The RNA strand is subsequently degraded by RNase H, 
and the remaining DNA strand forms the template for a second primer, the extension of 
which is accomplished by a reverse transcriptase forming a DNA-DNA hybrid. The 
double stranded DNA then forms a template for the production of further RNA transcripts 
by T7 RNA polymerase. 
1.6.4 Serology 
1.6.4.1 Complement fixation test 
The complement fixation test (CFT) is based on the detection of genus specific antibodies 
aimed at chlamydial LPS. The sensitivity of CFT is insufficient to detect uncomplicated 
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genital infections, but it can be used in the diagnosis LGV (Perine et al., 1990). While 
the test is still used for the presumptive diagnosis of C. psittaci infections based on a four 
fold rise in titre between acute and convalescent sera, it cannot differentiate between 
chlamydial species. 
1.6.4.2 Enzyme immunoassay/enzyme-linked immunoassay 
These tests are designed to detect antibody reactivity to genus-specific antigens such as 
LPS. As for other serological tests a single measurement of a patient's serum will not 
give any evidence whether the infection is a current or past infection. Although EIAs for 
the detection of anti-chlamydial antibodies are less sensitive than MIF, it has been shown 
that for the detection of IgM in children with chlamydial pneumonitis, EIA is comparable 
to MIF (Mahony et al., 1986). 
1.6.4.3 Micro-immunofluorescence 
Wang and Grayston (1970) developed the micro-immunofluorescence (MIF) test which 
is based on purified chlamydial elementary bodies spotted onto a glass slide. The test 
serum is diluted and applied to the glass slide spotted with chlamydial elementary bodies, 
and bound antibody is subsequently detected by the addition of a class specific anti- 
human fluorescein conjugated antibody. Single antigen types from a specific C. 
trachomatis serovar, or a pooled antigen can be used. C. psittaci and C. pneumoniae 
antigen can also be used, allowing species specific antibody to be distinguished. 
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1.7 Treatment and prevention 
1.7.1 Chemotherapy 
The current recommended treatment regime for C. trachomatis infections entail a 7-10 day 
course of tetracycline, doxycycline or erythromycin. The major problem associated with 
multi-dose therapies is the potential for patient non-compliance. The azalide antibiotic 
azithromycin has emerged as an effective alternative treatment for C. trachomatis 
infections. Azithromycin concentrates within cells, and has a tissue half life of up to 5 
days (Wyrick et al., 1993). It been shown to be an effective treatment of uncomplicated 
chlamydial urethritis, and cervicitis when given as a single 1g dose (Worm and Osterlind, 
1995; Ridgway, 1996; Thorpe et al., 1996). 
1.7.2 Vaccine development 
Antibiotic therapy can effectively eliminate chlamydial infection but can have little if any 
effect on established pathology, or immune-mediated damage. Prevention of infection 
rather than treatment could be potentially less costly than a screening program, and 
computer modelling has suggested that even a partially effective vaccination program 
may considerably reduce the prevalence of chlamydial genital tract infection (de la Maza et 
al., 1995). 
Early chlamydial vaccine attempts were not totally successful. In the 1960s, trachoma 
vaccine trials in both humans and other primates demonstrated that neutralizing antibodies 
could be produced and a degree of protection against conjunctival challenge could be 
elicited. However, it became apparent that some vaccinated individuals developed more 
severe disease (Woolridge et al., 1967; reviewed in Sowa et al., 1969; Schachter and 
Dawson, 1978), and that trachoma was an immune mediated disease. Subsequent 
challenge with different serovars led to more severe inflammation and it was suggested 
that a delayed type hypersensitivity response was the cause (Wang et al., 1967). More 
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recent studies have implicated chlamydial HSP60 in the pathogenesis of ocular 
inflammation (Morrison et al., 1989b). 
In animal models live vaccine have been shown to confer a degree of immunity, they 
have been used successfully in preventing abortion in sheep (McEwen et al., 1951; 
Rodolakis et al., 1984; Chalmers et al., 1997), and in murine MoPn induced infertility 
(Pal et al., 1996). In humans, whole-organism vaccines are unlikely to be used in the 
future due to the problems encountered with the early trachoma vaccine trials. 
Recent research has focused on the development of sub-unit vaccines based on the major 
outer membrane protein (MOMP) of C. trachomatis. Most of the MOMP-based vaccines 
have been designed to provoke protective antibody responses, and have been shown to 
elicit both mucosal and serum antibody responses (Tuffrey et al., 1992b; Batteiger et al., 
1993; Su et al., 1995), even though immunization with MOMP-derived peptide vaccines 
have given protection in the absence of antibody production (Campose et al., 1995). One 
of the problems associated with MOMP vaccines is that variation within the same serovar 
can be sufficient to evade neutralization by antibody (Lampe et al., 1997). 
50 
Chapter 2.0 
Enzyme-linked immunoassay (ELISA) 
2.1 Aims of chapter 
The initial aim of the work in this chapter was to develop and validate a C. trachomatis 
specific enzyme-linked immunoassay (ELISA) which could be used to detect both IgG 
and IgM in serum samples. 
Once established the ELISA system was used to determine the presence of antibodies 
against C. trachomatis (IgG and IgM) in two different studies. One study was designed 
to look at the prevalence of anti-chlamydial antibodies in women diagnosed with 
miscarriage, ectopic pregnancy, and tubal factor infertility in both the UK (Sheffield and 
Bristol) and Trinidad (Mount Hope and Port of Spain) compared to non-pregnant, and 
antenatal controls. 
The second study was used to determine the impact of anti-chlamydial IgG on the success 
of in vitro fertilization (IVF) with respect to the patient's response to gonadotropin 
stimulation prior to IVF. This study involved two IVF centres (Bristol and 
Southampton), with the patients from each divided into two groups, those who 
responded well to gonadotropin stimulation (good responders), and those who responded 
poorly to gonadotropin stimulation (poor responders). Non-pregnant, and antenatal 
controls were used to establish a baseline prevalence of anti-chlamydial IgG. 
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2.2 Introduction 
Tubal disease is one of the major causes of female infertility (Westrom et al., 1980) and 
includes a vast range of conditions including tubal blockage both proximally and distally, 
peritubal adhesions and hydrosalpinx formation. C. trachomatis has been associated with 
urethritis, endometritis, and more importantly salpingitis and pelvic inflammatory disease 
(PID) both of which have been shown to be risk factors for ectopic pregnancy (EP) and 
the development of tubal disease. Other risk factors of tubal disease include a previous 
EP, endometriosis, previous sterilisation, previous tubal surgery and a history of 
peritonitis. 
Serological studies have supported the role of C. trachomatis in the development of PID 
and its sequelae. In an early study Mardh et al. (1977) reported that 80% of sixty women 
with acute PID had antibodies to C. trachomatis. Studies by Punnonen et al. (1979), 
Moore et al. (1982), and Conway et al. (1984) looked at the detection rate of antibodies to 
C. trachomatis in women with infertility, all concluded that tubal disease was associated 
with the presence of anti-chlamydial antibodies. Many studies have also related EP to the 
detection of antibodies against C. trachomatis, Chrysostomou et al. (1992) found a 
significant rate of detection of anti-chlamydial IgG in women with EP compared to 
pregnant controls. 
Severe tubal disease, specifically distal tubal obstruction leading to the formation of 
hydrosalpinx has been reported to be associated with a poor fertility prognosis (Edwards 
et al., 1984, Marana et al., 1995). Englert et al. (1987) found that patients with infertility 
of tubal origin had lower in vitro fertilization (IVF) success rates than patients with 
partners diagnosed with male infertility, or idiopathic causes. 
Lewis et al. (1977) was the first to develop an enzyme-linked immunoassay (ELISA) 
technique for the detection of antibodies to chlamydiae using antigens derived from C. 
psittaci which involved the fixation of chlamydial elementary bodies to an EIA plate. 
Evans and Taylor-Robinson in 1982 described an ELISA system based on sodium 
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deoxycholate extracted C. trachomatis lipopolysaccharide (LPS) as antigen, and although 
this method was found to be more sensitive than both micro-immunofluorescence (MIF) 
and the complement fixation test (CFT), it was unable to distinguish between chlamydial 
species. 
In a study of a UK STD population it was reported that antibodies to C. pneumoniae and 
C. psittaci accounted for up to half of all the chlamydial specific IgG (Moss et al. 1993). 
In a recent paper by Chernesky et al. (1998) five serological assays were compared in the 
detection of antibodies to C. trachomatis in women with pelvic pain, with and without 
evidence of chlamydial infection. The best sensitivity and specificity was found with the 
whole inclusion fluorescence test (WIF), and even though a recombinant anti-LPS ELISA 
measured antibodies in the majority of the test patients the specificity was low. Due to the 
presence of genus cross reactive epitopes on the chlamydial surface it could be argued that 
for an ELISA with the highest specificity for antibodies against a particular chlamydial 
species, a purified species specific antigen should be used (Puolakkainen et al., 1984); or 
alternatively there should be the removal of genus cross reactive epitopes (eg. chlamydial 
LPS) from antigen preparations. 
In 1989 Ladney et al. described an ELISA method based on the pre-treatment of 
chlamydial elementary bodies to extract the LPS. This system showed a decreased cross 
reactivity which was able to distinguish antibodies against C. trachomatis and C 
pneumoniae. In the same year Ossewaarde et al. (1989) also published an ELISA method 
that used either a periodate or Triton X-100 pre-treatment, that could measure antibodies 
to C. trachomatis proteins or LPS. This method was validated against a standard ELISA 
and WIF (Ossewaarde et al., 1994b) the results of which concluded that oxidation of 
chlamydial LPS reduced the binding of genus cross reactive antibodies to C. trachomatis 
elementary bodies pre-treated with sodium periodate, enhancing ELISA specificity. 
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2.3 ELISA Materials 
2.3.1 Reagents 
Reagents were purchased from Sigma (Dorset, UK) unless otherwise stated. 
2.3.2 Cell culture 
McCoy cells (Cat. No. 90010305) were purchased from ECACC (Salisbury, UK), 
and were Mycoplasma free. The cell line was originally derived from the synovial fluid 
of a patient suffering from degenerative arthritis, but subsequent sublines have been 
shown to be of mouse origin. 
Glutamine (Gibco, Paisley, UK) was purchased as a 200mM solution and stored in 5m1 
aliquots at -20°C. 
McCoy cell growth medium 
RPMI 1640 445m1 
Foetal calf serum (Bioclear Ltd., Wilts, UK) 50m1 
200mM glutamine 5m1 
The pH growth medium was adjusted to 7.4 and stored at 4°C. 
Amphotericin B (Fungizone) was obtained from Gibco as a 250µg/ml sterile solution, 
it was aliquoted into 2m1 volumes and stored at -20°C. 
Cycloheximide was dissolved in sterile water to give a final concentration of 1mg/ml, 
aliquoted in 5O00 volumes and stored at -20°C. 
Gentamicin (Royal Hallamshire Hospital Pharmacy) was purchased as a 40mg/ml. 
sterile solution and was stored in 250µl amounts at -20°C. 
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Glucose was dissolved in sterile water to give a 20% (w/v) solution and was then 
sterilised through a 0.2µm Millipore filter and stored at 4°C. 
Streptomycin was obtained from Flow Laboratories, and dissolved in water to give a 
concentration of 40mg/ml, aliquoted in 1ml amounts and stored at -20°C. 
x10 trypsin (Gibco) was purchased as a sterile 2.5% solution and diluted to a 0.25% 
solution in PBS. 5m1 aliquots were stored at -20°C. 
Vancomycin hydrochloride was dissolved in sterile water to give a concentration of 
20mg/ml, aliquoted in 1 ml amounts and stored at -20°C. 
Versine (C10H14N2O5Na2.2H20) was purchased from BDH Chemicals (Poole, UK), 
dissolved in PBS to give a final concentration of 5mM and the pH adjusted to 7.2-7.4. 
The solution was then aliquoted into 5ml volumes, autoclaved and stored at -20°C. 
McCoy cell maintenance medium 
RPMI 1640 416. Om1 
Heat inactivated foetal calf serum (Bioclear Ltd. ) 50m1 
glutamine 5m1 
1% glucose 25ml of stock 
I pg/m1 amphotericin B 2m1 of stock 
20pg/m1 gentamicin 250µ1 of stock 
20pg/m1 vancomycin 500µ1 of stock 
20pg/m1 streptomycin 250µ1 of stock 
2pg/m1 cycloheximide 1 ml stock 
The pH of the maintenance medium was adjusted to 7.4 and stored at 4°C. 
Sterility checking of medium 
Before use, both types of medium were subjected to sterility checking. Briefly, iml of 
medium was inoculated in two bottles of thioglycolate broth and incubated at both 33°C or 
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37°C for 1 week. The medium was deemed sterile if no growth was visualised. 
2.3.3 Antigen preparation 
Urografin 150 was purchased from Schering Health Care Ltd (West Sussex, UK). 
The solution contained sodium diatrizoate (0.04g/ml) and meglumine diatrizoate 
(0.26g/ml), and was stored at 4°C. 
0.02% (v/v) formalin-PBS for the preservation of chlamydial antigen preparations 
was prepared by adding 20µ1 of formalin to 100m1 of PBS. 
Bradford dye solution 
Coomassie brilliant blue G-250 (BDH) 100mg 
95% ethanol 50ml 
85% orthophosphoric acid l00ml 
purified water 50m1 
The Coomassie brilliant blue was initially dissolved in the 95% ethanol and left for 15 
min. Finally the 100ml of 85% orthophosphoric acid was added and the total volume 
made up to 200ml with purified water. The dye was stored at 4°C, and used within 6 
months. 
2.3.4 ELISA solutions 
EIA/RIA plates were purchased from CoStar (Cambridge, USA). The plates were 
non-sterile, flat bottomed and high affinity binding. 
Sodium bicarbonate buffer (coating buffer) 
Na2CO3 0.795g 
NaHCO3 1.465g 
NaN3 O. lg 
purified water 500m1 
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The pH of the coating buffer was adjusted to 9.6 with 1M NaOH, and stored at 4°C. 
PBS-Tween 
Tween 20 (BDH) 0.5m1 
PBS 1L 
The solution was stored at room temperature. 
Serum diluent 
PBS 500m1 
0.3M NaCl 8.766g 
0.001M MgC12 0.0476g 
0.5% (w/v) BSA fraction V (Winlab, Middlesex, UK) 2.5g 
0.5% (w/v) gelatine 2.5g 
The diluent was aliquoted in 20m1 amounts and stored at -20°C. 
Citrate phosphate buffer 
0.1M citric acid 2. lg 
purified water 100ml 
0.2M Nat Hp04 12H20 7.3g 
purified water 100m] 
24.3m1 of the citrate solution and 25.7m1 of the phosphate solution were added to a final 
volume of 100ml. The pH was adjusted to 5.0 with either solution, and the buffer stored 
at 4°C. 
Substrate buffer 
10mg of ß-phenylenediamine dihydrochloride 1 tablet 
citrate phosphate buffer 25m1 
This was prepared fresh, followed by the addition of lOµ1 of 30% hydrogen peroxide 
(H202) immediately before use. 
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Antibody conjugates 
Goat anti-human IgG (whole molecule), conjugated with horseradish peroxidase and IgM 
conjugated with horseradish peroxidase were obtained from Sigma. The antibodies were 
aliquoted in 10µl amounts and stored at -70°C. 
2M sulphuric acid 
98% H2SO4 19.6m1 
water 90.2m1 
The acid was stored at room temperature. 
1% (w/v) sodium periodate-PBS 
sodium periodate log 
PBS 500m1 
The solution was stored at room temperature. 
1% Triton X-100 was prepared in PBS containing 5mM EDTA and stored at 4°C. 
Chlamydia MIF Kits for the detection of anti-chlamydial IgG and IgM were obtained 
from MRL Diagnostics (Cypress, CA, USA) and stored at 4°C. Before use the MIF 
slides and reagents were allowed to reach room temperature. 
2.3.5 Specimens 
Specimen preparation 
Patient samples were either delivered as non-heparinised whole blood or had been pre- 
separated to leave serum. Whole blood samples were centrifuged briefly to sediment out 
the red blood cells, and the serum removed. Finally each sample was coded blind and 
stored at -20°C. 
Serum samples from the West Indies were sent frozen in dry ice, and were immediately 
stored at -20°C on arrival. Samples from Bristol, and Southampton (IVF samples only) 
58 
were transported overnight in liquid nitrogen containers, and placed at -20°C on arrival in 
Sheffield. 
Control sera 
Human control sera with known MIF titres (IgG) for C. trachomatis, C. pneumoniae and 
C. psittaci were donated by Dr. Treharne (Institute of Ophthalmology, London). Each 
serum sample was aliquoted in 50µ1 volumes and stored at -20°C. In addition a selection 
of known IgG MIF titre samples from the Northern General Hospital (Sheffield) serum 
sample bank were collected and stored at -20°C. 
Also from the UK, serum samples from twenty eight pregnant women and from fifty 
three non-pregnant females (serum obtained during routine medical management) were 
collected and stored at -20°C. From Trinidad sixty four antenatal serum samples were 
collected, and stored at -20°C. These samples were used to determine a baseline 
prevalence of anti-chlamydial IgG and IgM for both geographic locations. 
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2.4 Methods 
2.4.1 Cell culture 
Growth of McCoy cells 
The McCoy cells were originally purchased from ECACC and were confirmed as being 
Mycoplasma free. Initially a frozen lml vial of trypsinised McCoy cells suspended in 
growth medium containing 10% DMSO was revived by washing once in fresh growth 
medium. The cells were then seeded into a 25cm2 culture flask (Bibby Sterilin Ltd., 
Staffordshire, UK) and incubated at 37°C in 5% CO2 for 4 days, or until confluent. 
Once a confluent cell monolayer was achieved the cells were passaged. The growth 
medium was removed and the cell monolayer was gently washed with PBS. The PBS 
was replaced with 2m1 of trypsin and 2ml of versine pre-warmed to 37°C, and the cell 
culture flask was incubated for 5 min at 37°C or until the monolayer had become detached 
from the flask surface. 10ml of growth medium was then added and the cellular 
suspension was divided equally between four 25cm2 culture flasks, each flask was 
topped up with growth medium to give a final volume of 25m1. The flasks were then 
incubated for up to 4 days at 37°C in 5% CO2 until confluent and either passaged into 
25cm2 or 75cm2 flasks, or infected with Chlamydia. 
Shell vial culture of McCoy cells 
A confluent 25cm2 flask of McCoy cells was gently washed with PBS after the removal 
of growth medium. The PBS was replaced with 2m1 of trypsin and 2m1 of versine pre- 
warmed to 37°C, and the cell culture flask incubated for 5 min at 37°C or until the cells 
had become separated from the flask surface. Growth medium was then added to give a 
final cell concentration of approximately 1-2 x 105 cells/ml of growth medium. iml of 
this suspension was then used to seed 5m1 Trac bottles containing a glass coverslip 
(Sterilin). The Trac bottles were then incubated for up to 4 days in 5% CO2 at 37°C until 
confluent and were then infected with Chlamydia. 
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Growth of Chlamydia trachomatis LGV1 
C. trachomatis serovar LGV 1 was obtained from Dr. Treharne (Institute of 
Ophthalmology, London) and after revival was confirmed as LGV 1 by MOMP PCR (Lan 
et al., 1994) and DNA restriction pattern analysis. 
Initially McCoy cells grown in Trac bottles were used to revive the LGV 1 serovar. The 
growth medium was removed and 5m1 of maintenance medium containing 1 pg/ml 
cycloheximide was added. The original egg culture was diluted 1: 200 in PBS and 100µ1 
was used to inoculate each Trac bottle. The cells were then incubated at 37°C in 5% CO2 
for 3 days. 3m1 of the maintenance medium was removed from each Trac bottle and the 
monolayer was scraped off the glass coverslip using the end of a sterile Iml syringe. 
l00µ1 of the resulting cellular suspension was then used to inoculate a new Trac bottle 
containing maintenance medium. The chlamydial culture was passaged three times before 
the presence of Chlamydia was confirmed using either iodine staining, or 
immunofluorescence (Syva MicroTrak Chlamydia trachomatis Culture Confirmation Test, 
Behring Diagnostics, France). 
Once the culture had been established in Trac bottles and there was an approximately 
100% infection of the McCoy cells, the culture was transferred firstly into 25cm2 flasks 
and finally 75cm2 flasks. Before the passage of a flask the cell monolayer was iodine 
stained to determine the percentage of infection When the percentage of infection reached 
approximately 80%, the cells were removed by agitation with sterile glass beads and the 
resulting cellular suspension was stored at 4°C until chlamydial elementary body 
purification. 
2.4.2 Chiamydial staining 
Iodine staining 
The maintenance medium was removed from either the Trac bottle or flask, and the cell 
monolayer was washed briefly in PBS. The McCoy cells were then fixed in lml of 
methanol for 10min, which was then replaced with lml of iodine for 10min. For Trac 
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bottles the glass coverslip was removed, mounted in glycerol on a glass microscope slide 
and examined under light microscopy at x 100 and x400 magnifications (Figure 4). The 
number of chlamydial inclusions (dark brown spheres within cells) were counted per 
coverslip. 
Immunofluorescent detection of C. trachomatis 
The immunofluorescent detection of C. trachomatis was achieved using the Syva 
MicroTrak Chlamydia trachomatis Culture Confirmation Test (Behring Diagnostics, 
France) as per the manufacturer's instructions. Briefly, the maintenance medium was 
aspirated from the Trac bottle, 1 ml of ethanol was added and the monolayer fixed for 
10min. The ethanol was poured away, the coverslip was removed with forceps and 
placed cell side up on a clean microscope slide. 30µl of reagent (supplied) was added to 
the monolayer and the cells incubated at 37°C in a moist chamber for 30min. The 
coverslip was then rinsed gently in PBS, mounted cells side down in the medium 
supplied and viewed under a fluorescence microscope (fitted with a F1TC filter system) at 
x100 and x400 magnification (Figure 5). Again, the number of elementary bodies 
(fluorescent apple green spheres within red counterstained cells) was determined. 
2.4.3 Antigen preparation 
Preparation of LGV1 elementary bodies 
The McCoy cell/Chlamydia suspension was disrupted by sonication at a 12 micron 
amplitude for 30sec, followed by a lmin interval to allow the dissipation of the heat 
generated during sonication into a surrounding ice cushion. The process was repeated 
three times before the suspension was centrifuged at 500xg for 15min at 4°C to remove 
cellular debris. The supernatant was kept for further purification. 
Purification of LGV1 elementary bodies 
The crude elementary body preparation was centrifuged at 30,000xg for Ih at 4°C to 
pellet the elementary bodies, each pellet was resuspended in 8ml of PBS and sonicated as 
previously described to give a homogeneous suspension. 15ml of the suspension was 
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Figure 4. McCoy cell monolayer infected with C. trachomatis LGV 1 (48h) 
after iodine staining (mag. x400). A- uninfected McCoy cell; B- LGV 1 
inclusion. 
.. 
Figure 5. McCoy cell monolayer infected with C. trachomatis LGV 1 (48h) 
after immunofluorescent staining (mag. x1000). A- uninfected McCoy cell; B- 
LGV 1 inclusion. 
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then layered onto 15m1 of Urografin and centrifuged at 4°C for lh at 30,000xg. The 
pellet was washed in PBS, sonicated and centrifuged as above. The final pellet 
containing the elementary bodies was resuspended in a small volume of 0.02% formalin- 
PBS, sonicated and the protein concentration measured. The antigen preparation was 
ultimately aliquoted into l00µ1 amounts and stored at -70°C. 
McCoy cell antigen preparation 
A negative control McCoy cell antigen preparation was prepared in the same manner from 
uninfected McCoy cells. 
Chlamydia pneumoniae and HL cell antigen preparations 
C. pneumoniae strain IOL-207 and HL cell antigen preparations of known protein 
concentrations were kindly donated by Dr. M. Khan (formally of the Department of 
Medical Microbiology, University of Sheffield). The method of elementary body 
preparation of C. pneumoniae was the same as that for C. trachomatis. 
Measurement of protein concentration (Bradford method) 
The protein concentration of both the LGV 1 and McCoy cell antigen preparations was 
measured using the Bradford dye binding assay (Bradford, 1976). 
A series of BSA solutions containing 6.25µg/ml to 1000pg/ml of protein were examined 
by the Bradford method to establish a standard protein curve (Table 1, Graph 1. ). The 
Bradford dye was diluted 1: 5 with purified water in a plastic disposable cuvette and l00pl 
of each standard protein solution was added. The protein standards were left for 15min 
for colour to develop, and then the absorbance of each was measured twice at 600nm. A 
standard curve was constructed relating protein concentration to OD, the standard curve 
being linear between 20-150µg of protein in 100µl. 
Each antigen preparation was diluted to 1: 7 and the absorbance measured as previously 
described. The absorbance value was compared to the standard protein curve and the 
protein concentration of each antigen preparation was determined (BSA gives an OD two 
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fold higher than its weight). The LGV 1 antigen preparation was found to give an 
approximate protein concentration of 357pg/m1, and the McCoy antigen 110µg/m1. 
Table 1. Absorbance values (OD) at different protein concentrations using the Bradford 
method. 
protein conc. mean OD standard 
ml at 600nm deviation 
1000 1.245 0.008 
400 1.1065 0.0025 
200 0.706 0.004 
100 0.4365 0.0035 
50 0.235 0.002 
25 0.1035 0.0005 
12.5 0.043 0 
6.25 0.0095 0.0005 
antigen prep. mean OD standard 
(1: 7 dilution) at 600nm deviation 
LGV 1 0.45 0.002 
McCoy cell 0.16 0.01 
2.4.4 ELISA development 
The development of both the IgG and IgM ELISA methodologies can be found in 
Appendix 1. 
2.4.5 ELISA of study samples 
IgG ELISA specific for C. trachomatis 
The C. trachomatis LGV 1 antigen preparation was diluted to 20pg/ml in coating buffer, 
and 50µl was dispensed into each well of an EIA plate. The plate was left overnight at 
4°C in a moist chamber, was then washed once in PBS-Tween and 5Oµ1 of 1% sodium 
periodate was added to each well and the plate incubated at 37°C for 10min. The plate 
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Graph 1. Protein (BSA) standard curve using the Bradford 
method for the determination of antigen protein concentration 
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was then washed twice in PBS-Tween before the addition of the diluted serum. 
Each study sample was diluted 1: 200 in serum diluent, and 50µl was placed into three 
wells; the plate was then incubated for lh at 37°C in a moist chamber. The plate was then 
washed three times in PBS-Tween, 50µI of HRP-conjugated anti-human IgG pre-diluted 
1: 4000 in serum diluent was then added to each well and the plate incubated again at 37°C 
for Ih. Following incubation the plate was washed three times to remove unbound 
antibody that could contribute to the generation of a background signal, and excess liquid 
removed by inverting the plate on tissue paper. 50µl of substrate buffer was placed in 
each well and the plate left to develop at room temperature for 15min. The enzyme 
reaction was stopped by the addition of 50pl of 2M H2SO4 to each well, and the 
absorbance was read immediately at 492nm in an ELISA reader. 
Control samples (IgG) 
Control sera of known MIF titres for C. trachomatis and C. pneumoniae were used on 
each EIA plate to ascertain the success of the ELISA and to determine the presence of C. 
trachomatis IgG. Due to the possibility of plate to plate variation, samples were 
compared only to the controls from the plate on which they were tested. An EIA plate 
was repeated if negative control sera and positive control sera did not give the appropriate 
results. 
For the IgG ELISA, five control sera were included on each plate; an MIF 1: 512 C. 
trachomatis positive serum; two MIF 1: 16 C. trachomatis positive serum samples; two 
serum samples negative for C. trachomatis by MIF; and a dual species Chlamydia serum 
containing chlamydial IgG against both C. trachomatis and C. pneumoniae (MIF 1: 16 
against C. trachomatis, and MIF 1: 256 against C. pneumoniae). Samples were 
considered negative for C. trachomatis IgG if the mean OD value was below that of the 
mean negative control OD value plus three standard deviations (+3SD). A sample was 
considered positive if the mean OD was greater then the mean OD of the MIF 1: 16 
samples +3SD. Samples with a mean OD between that of the mean negative control OD 
value +3SD, and the mean OD of the MIF 1: 16 samples +3SD were tested by MIF (MRL 
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Diagnostics, USA) as per the manufacturer's instructions. 
IgM ELISA specific for C. trachomatis 
Study sera were tested in triplicate at a serum dilution of 1: 200, against 20µg/ml of the 
LGV 1 antigen preparations using a sodium periodate pre-treatment, and an IgM conjugate 
dilution of 1: 2000. The method of EIA plate coating of the antigens and the actual 
ELISA methodology were as previously described for the IgG ELISA (p. 65) with one 
exception; the substrate buffer was left to develop at room temperature for 35min. 
Control samples (IgM) 
Again, due to the possibility of plate to plate experimental variation, test samples were 
only compared to the controls found on the same plate. 
For the IgM ELISA, four control sera were included on each plate; an MIF >1: 40 C. 
trachomatis positive serum; an MIF 1: 10 C. trachomatis positive serum ; and two serum 
samples negative for C. trachomatis by MIF. Samples were considered negative for C. 
trachomatis IgM if the mean OD value was below that of the mean negative control OD 
value +3SD. A sample was considered positive if the mean OD was greater then the mean 
OD of the MIF 1: 10 sample +3SD. Samples with a mean OD between that of the mean 
negative control OD value +3SD, and the mean OD of the MIF 1: 10 sample +3SD were 
considered 'query' positive. Due to problems with circulating rheumatoid factor giving 
rise to false positive results, all samples deemed positive for anti-chlamydial IgM were 
tested by an IgM MIF (MRL Diagnostics, USA) as per the manufacturer's instructions. 
2.4.6 IgG and IgM micro-immunofluorescence 
Both micro-immunofluorescence (MIF) systems used were based on the fluorescent 
detection of anti-chlamydial antibodies against purified elementary bodies which allowed 
the semi-quantification and speciation of human serum IgG and IgM antibodies. The test 
utilised purified elementary body preparations of C. psittaci, C. trachomatis and C. 
pneumoniae diluted in yolk sac. All three antigen preparations were spotted within a 
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single well on a slide, each slide contained twelve such wells. Yolk sac was used as a 
negative antigen control. Patient samples were screened at a single dilution (1: 16 for IgG 
and 1: 10 for IgM) to determine the presence/absence of anti-chlamydial antibodies. 
For the IgG MIF, slides were allowed to reach room temperature before being opened to 
prevent condensation developing on the slides. The serum samples were pre-diluted in 
PBS at a factor of 1: 16 and 25µl was added to the appropriate well. Each slide also 
contained a positive and negative control serum (supplied). The test slide was then 
incubated at 37°C for 30 min in a moist container, rinsed gently in PBS for 10 min, 
dipped in distilled water and left to air dry. 25µl of the fluorescein-labelled goat anti- 
human anti-mouse IgG (supplied) was added to each slide well and the slide incubated for 
30 min at 37°C in a moist container. The slide was washed again in PBS for 10 min, left 
to air dry and finally mounted with a coverslip. The slide was then viewed using a 
fluorescence microscope at a magnification of x400. 
Each serum sample was scored according to fluorescent intensity of the elementary bodies 
for each chlamydial species. A score of ++ to ++++ was given if moderate to intense 
apple-green fluorescence was seen, + if a definite but dim fluorescence was observed and 
a negative score if no fluorescence or fluorescence equal to that of the corresponding yolk 
sac control or negative control was seen. The positive control serum was expected to 
exhibit ++ to ++++ fluorescence for all three chlamydial antigen preparations, and the 
negative no fluorescence. A score of + for a study sample was considered as positive 
evidence of antibodies against the appropriate chlamydial species. 
The IgM MIF was similar to the IgG test with one exception. Each serum sample was 
initially diluted (1: 10) in an IgM pre-treatment diluent (supplied), which contained 
monospecific goat antiserum to human IgG in PBS. The IgG was removed since IgG 
may compete with IgM giving rise to false negative results, and complexed IgG 
(rheumatoid factor) may give rise to the generation of a false positive result. 
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2.4.7 Statistical analysis 
The results for each patient group were compared to the appropriate study control group 
using the Fisher Exact Probability Test (2 tailed). The Bonferroni correction was used 
for multiple comparisons. A probability (P) value of <0.05 was considered to be 
statistically significant. 
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2.5 ELISA results 
2.5.1 Serology results for Sheffield/Bristol 
The serological results from all the Sheffield/Bristol groups are shown in Table 2, and 
Graph 2. The results for individual patients can be found in Appendix 3. 
Table 2. Serology results (IgG and IgM) for Sheffield/Bristol. 
Patient Group Prevalence of anti- Prevalence of anti- 
_______________________ 
chlam dialIgG chlam diallgM 
Antenatal controls 
mean age= 27yr 14%(4/28) 7%(2/28) 
SD= 5.3 
age range= 18-42yr 
Study controls 
mean age= 40yr 15%(3/20) 10%(2/20) 
SD= 6.2 
age range= 33-57yr 
Ectopic pregnancy (EP) 
mean age= 30.5yr 67%(6/9) 22% (2/9) 
SD= 5.7 
age range= 24-40yr 
Tubal factor infertility 
(TFI) 
mean age= 30yr 75%(9/12) 8%(1/12) 
SD= 3.7 
age range= 24-36yr 
Study control group vs. EP IgG 
Study control group vs. EP IgM 
Study control group vs. TFI IgG 
Study control group vs. TFI IgM 
P<0.05 significant difference 
P>O. 1 no significant difference 
P<0.05 significant difference 
P>O. 1 no significant difference 
Of the twenty study controls anti-chlamydial IgG was detected in three patients, and IgM 
in two. For the twenty eight antenatal controls, anti-chlamydial IgG was found in four 
patients, and IgM in two. There was no significant difference found between the two 
control groups in the detection of antibodies against C. trachomatis (IgG P>0.5; IgM 
P>0.5). 
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2.5.2 Serology results for Trinidad 
The serological results from all the Trinidad groups are shown in Table 3, and Graph 3. 
The results for individual patients can be found in Appendix 4. 
Table 3. Serology results (IG and IgM) for Trinidad (Mount Hope and Port of Spain). 
Patient Group Prevalence of anti- Prevalence of anti- 
_______________________ 
chlam dialIgG chlam diallgM 
Antenatal controls 
mean age= 25.3yr 23%(15/64) 8%(5/64) 
SD= 6.5 
age range= 15-43yr 
Study controls 
mean age= 31.7yr 36%(10/28) 11%(3/28) 
SD= 5.3 
age range= 22-44yr 
Ectopic pregnancy (EP) 
mean age= 30yr 62%(13/21) 38%(8/21) 
SD= 6.3 
age range=16-40yr 
Miscarriage (Msc) 
mean age= 33yr 39%(7/18) 11%(2/18) 
SD= 1.0 
age range= 24-41yr 
Tubal factor infertility 100% (2/2) 0% (0/2) 
(TFI) 
Study controls vs. EP IgG P>O. 1 no difference 
Study controls vs. EP IgM P>0.05 no difference 
Study controls vs. Msc IgG P>0.5 no significant difference 
Study controls vs. Msc IgM P>0.5 no significant difference 
Of the twenty eight study controls anti-chlamydial IgG was detected in ten patients, and 
IgM in three. Of the sixty four antenatal controls anti-C. trachomatis IgG was found in 
fifteen patients, and IgM in five. No significant difference in the detection of antibodies 
against C. trachomatis was found in the two control groups (IgG P>O. 1; IgM P>0.5). 
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Graph 2. Percentage detection of IgG and IgM in Sheffield/ 
Bristol by enzyme-linked immunoassay (with sodium periodate 
pre-treatment). 
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Graph 3. Percentage detection of IgG and IgM in Trinidad 
by enzyme-linked immunoassay (with sodium periodate 
pre-treatment). 
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2.5.3 Validation of ELISA results 
All of the Sheffield/Bristol serum samples were sent to the lab of Dr. Owen Caul (Bristol 
PHLS Laboratory, UK) for an independent assessment of the IgG ELISA results. The 
samples were re-coded, and tested by both inclusion immunofluorescence (IF) and the 
complement fixation test (CFI') to determine the presence of anti-chlamydial IgG. 
Sixty serum samples were sent to be tested (Appendix 5), with some samples represented 
more than once. Two serum samples were found to be negative by ELISA (IgG) and 
positive by IF/CFT; four samples were positive by ELISA (IgG) and negative by IF/CFT 
(two of these samples were from the same patient); and one sample which was tested in 
duplicate was both positive and negative by IF/CFT. 
All the samples with discrepant serological results were re-tested by ELISA for the 
presence of anti-chlamydial IgG, all but one of the samples gave the same results as when 
previously tested by ELISA. Of the re-tested samples, two samples previously ELISA 
positive were only weakly positive, but IF/CFT negative. It may be that these samples 
were in fact weak positives missed by IF/CFT, or that defrosting/freezing had facilitated 
the 'integrity' of the serum ultimately giving discrepant IF/CFT serological results. The 
ELISA negative, but IF/CFI' positive samples may be a reflection of the non-specific 
nature of IF/CFT; and the ELISA positive, IF/CFT negative samples may be due to 
'sticky sera' giving a false positive ELISA reading. The percentage correlation between 
ELISA and IF/CFI' results was calculated to be 85%. 
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2.6 In vitro fertilization and anti-chlamydial IgG 
2.6.1 Definition of IVF groups 
The purpose of this retrospective study was to investigate the relationship between IgG 
antibodies against C. trachomatis and poor ovarian response to gonadotropin stimulation 
prior to in vitro fertilization (IVF) (Keay et al., 1998). Although there is no standard 
definition of poor response to gonadotropin stimulation, it may be defined as the failure to 
develop sufficient mature follicles to proceed to oocyte retrieval after ovarian stimulation 
(Keay et al., 1997). 
Two IVF groups were studied, Group A consisted of serum samples previously collected 
from patients (n=97) on the University of Southampton IVF programme between March 
1992 and June 1993; and Group B comprised of serum samples (n=145) from the IVF 
programme at the University of Bristol, collected between January 1993 and December 
1994. 
For Group A, pituitary down-regulation was achieved using nasal buserelin (200µg) 
three times daily, commenced in the luteal phase of the menstrual cycle prior to the start of 
IVF. From day four of the ensuing menses four ampoules of human gonadotropin 
(hMG) were administered daily (each ampoule containing 751U of follicle stimulating 
hormone [FSH] and 751U of luteinizing hormone [LH] [Pergonal, Serono, UK]). Blood 
samples were taken on days 4,7 and 9 of the IVF cycle, the serum was separated for 
oestradiol assay and the remainder was stored at -20°C. 
For Group B, the stimulation protocol for IVF has been previously described by Hull et 
al. (1992). Briefly, suppression of pituitary gonadotropin with buserelin was started 
mid-luteal phase of the proceeding ovarian cycle. After 10-14 days of buserelin 
treatment, ovarian stimulation was initiated by subcutaneous injection of 1501U purified 
FSH (Metrodin HP Serono, UK). Ovarian follicular development was monitored by 
vaginal ultrasonography and the measurement of serum oestradiol. Serum was obtained 
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during the stimulation attempt and was separated for oestradiol assay, the remaining 
serum was stored at -20°C. 
Both groups were further sub-divided into poor, and good responders of gonoadotropin 
stimulation. In Group A, patients were classified as poor responders if fewer than four 
follicles developed after six days of hMG stimulation (Jenkins et al., 1991). By this 
definition 49 patients were identified as poor responders. Each poor responder was age 
matched (within two years) to 48 patients receiving IVF treatment exhibiting a good 
response to the standard regime (ie. sufficient to reach oocyte retrieval). For Group B, 
poor responders were classified as patients who failed to reach oocyte retrieval despite 
3001U FSH daily (n=45), and good responders as those who reached oocyte retrieval 
(three or more follicles) on no more than 150IU FSH daily (n=100). 
Control sera from non-IVF patients were also tested, these included sera from 28 
pregnant patients, and from 53 non-pregnant females taken in the course of routine 
medical management. 
2.6.2 IgG ELISA method 
The ELISA used has been previously described (p. 65), in summary each serum sample 
was tested in triplicate at a dilution of 1: 200 in PBS against 20pg/ml LGV 1 antigen and 
20pg/ml of negative McCoy cell antigen. The presence of anti-chlamydial IgG was 
determined using a goat anti-human IgG HRP conjugate diluted 1: 4000 in serum diluent. 
The determination of the serological status of each test sample was achieved using the 
appropriate controls as previously described by IgG ELISA and IgG MIF (p. 68). 
2.6.3 Statistical analysis 
The Chi squared (x2) test and Student t test were used for comparisons between groups 
where appropriate, using the statistical package ARCUS Protstat (Medical Computers, 
Aughton, UK). AP value of <0.05 was considered to be statistically significant. 
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2.7 IVF ELISA results 
There were no significant differences in age between the good and poor responders in 
both Group A and Group B (Table 4). The incidence of detectable levels of anti- 
chlamydial IgG was significantly higher in all the IVF patients (Group A plus Group B) 
when compared to the control patients (P<0.0001). When the response to gonadotropin 
stimulation was considered, both poor and good responders in both groups had 
significantly higher detection rates of IgG antibodies against C. trachomatis than the 
combined control group (Table 4). 
A significantly higher incidence of serum IgG against C. trachomatis was observed in the 
poor responders in comparison to the age matched good responders in Group A 
(P<0.05). A similar association was seen in Group B between poor and good responders 
(Table 5, Graph 4), but it was found not to be statistically significant. Combining the 
results for both groups of poor responders and good responders, the incidence of anti- 
chlamydial IgG was significantly higher in those patients that responded poorly to 
gonadotropin stimulation than those who responded well (P<0.05). 
The patients in Group A were subdivided on the basis of the infertility diagnosis (Table 6) 
to determine whether those patients with tubal infertility had a higher incidence of anti- 
chlamydial IgG than those with infertility of a non-tubal nature. Some patients had more 
than one infertility diagnosis and were included in all the appropriate infertility diagnosis 
groups. The corresponding information for Group B was unavailable. 
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Table 4. Comparison of the incidence of serum IgG against C. trachomatis between in 
vitro fertilization (IVFI patients compared to controls. 
Percentage of patients seropositive for 
anti-chlamydial IgG 
Poor responders 45%(42/94) 
Good responders 30% (45/148) 
All IVF patients 36% (87/242) 
Pregnant controls 14%(4/28) 
Non-STD female controls 11%(6/53) 
All controls 13% (10/81) 
All IVF poor responders vs. all controls P<0.0001 
All IVF good responders vs. all controls P<0.0005 
All IVF vs. all controls P<0.0001 
Group A poor responders mean age= 34yr SD 3.9 
good responder mean age= 33yr SD 3.8 
Group B poor responders mean age= 39yr SD 4.8 
good responder mean age= 37yr SD 4.1 
significant difference 
significant difference 
significant difference 
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Graph 4. The detection of IgG against C. trachomatis by enzyme-linked 
immunoassay (sodium periodate antigen pre-treatment) in poor and good 
responders in two in vitro fertilization (IVF) populations (Groups A and B). 
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Group A Group B All IVF 
Seropositive for anti-chlamydial IgG 
Group A 
(n=97) 
Group B 
(n=145) 
Groups A+B 
(n=242) 
Poor responders 49% 40% 45% 
(24/49) (18/45) (42/94) 
Good responders 27% 32% 30% 
(13/48) (32/100) (45/148) 
Group A 
poor responders vs. good responders 
Group A+B 
poor responders vs. good responders 
P<0.05 significant difference 
P<0.05 significant difference 
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Group A Group A 
diagnosis of infertility prevalence of anti- 
chlamydial IgG 
poor response good response poor response good response 
(n=49) (n=48) (n=49) (n=48) 
Tubal 47% 33% 52% 44% 
(23/49) (16/48) (12/23) (7/16) 
Endometriosis 14% 8% 14% 50% 
(7/49) (4/48) (1/7) (2/4) 
Male factor 22% 35% 55% 18% 
(11/49) (17/48) (6/11) (3/17) 
Unexplained 16% 25% 38% 8% 
(8/49) (12/48) (3/8) (1/12) 
Other 8% 12% 50% 33% 
(4/49) (6/48) (2/4) (2/6) 
Tubal infertility diagnosis 
poor responders vs. good responders P>0.5 no significant difference 
Male factor infertility diagnosis 
poor responders vs. good responders P<0.05 significant difference 
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2.8 Conclusion 
2.8.1 Sheffield/Bristol and Trinidad study 
The reported prevalence of C. trachomatis in women from Bristol in 1980 in a GUM 
clinical setting was 19% by culture (Richmond et al., 1980). In other areas of the UK 
figures ranged from 3.6-9.1 % of women attending gynaecology/antenatal or family 
planning clinics (Fish et al., 1989; Hopwood et al., 1990). When considering only IgG 
the prevalence of antibodies against C. trachomatis in the Sheffield/Bristol control groups 
is comparable to those previously reported in the UK. 
In Trinidad the prevalence of anti-chlamydial IgG was higher in the study control group, 
when compared to the antenatal group (P>0.1). Although this was not statistically 
significant it may be accounted for by differences in the actual patient populations 
sampled. The IgM results (P>0.5) for the two groups were found to be similar to each 
other, and the UK control groups. 
The results for the Trinidad control groups raise some important questions about the 
prevalence of chlamydial disease in the West Indies. The apparent difference in the 
detection of IgG may simply be age related (Chout et al., 1995), the mean age of the 
study controls being approximately six years greater than the antenatal patients. A recent 
study by Dowe et al. (1998) showed that the incidence of C. trachomatis infection of the 
endocervix of pregnant Jamaican women by DIF was 16%. This value is lower than that 
seen in the Trinidad antenatal group, but the Dowe et al. results reflect the actual detection 
of C. trachomatis , and not the prevalence of past/present or persistent chlamydial 
infection as determined by the detection of circulating IgG or IgM. In Martinique the 
reported prevalence of C. trachomatis by culture of the cervix and urethra in pregnant 
women was reported to be 27% (Chout et al., 1995). This value is comparable to the 
IgG serology data for the Trinidad control groups. 
Comparisons of the Trinidad and Sheffield/Bristol study controls groups and antenatal 
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controls reveal a very different picture for the prevalence of C. trachomatis. It is an 
important consideration when comparing the UK control groups with the Trinidad control 
groups to take into account factors such as ethnicity and its impact on differing risk 
factors for EP (eg. vaginal douching [Chow et al., 1990; Kendrick et al., 1997]) and 
STD (Coste et al., 1994a). In a recent study by Scholes et al. (1998) a relationship 
between vaginal douching and the risk of cervical chlamydial infection was found. The 
results of this study support the hypothesis that douching predisposes to the acquisition 
of cervical infection by C. trachomatis, which could further lead to the sequelae of upper 
genital tract chlamydial infection. 
Few studies have looked at the possible role of C. trachomatis and miscarriage, and those 
that have been conducted have reported conflicting results. Witkin et al. (1992) was the 
first to report a link between C. trachomatis and spontaneous abortion, showing a high 
titre of anti-chlamydial IgG in those women who miscarried. 
A recent study by Witkin et al. (1998) evaluated the relationship between immunity to 
specific regions of C. trachomatis HSP60 (CHSP60) and infertility. The results showed 
that humoral immunity to a particular CHSP60 epitope was associated with sensitization 
to human HSP60 and with a history of two or more spontaneous abortions, and may be 
an immunological marker for spontaneous abortion. 
In the Trinidad miscarriage group anti-chlamydial IgG was detected in 39% of the 
patients, and IgM in 11%. Although not statistically significant (P>0.5) when compared 
to the Trinidad study control group, there was still a 12% difference in the detection of 
IgG. IgM levels in the miscarriage group were approximately the same as the combined 
control group. The results of the Trinidad miscarriage group are similar to a recent study 
in Sweden (Osser et al., 1996) where the frequency of IgG antibodies against C. 
trachomatis was 39% in women surgically treated for spontaneous pregnancy loss, 
compared to 33% of pregnant controls. This study, like the Trinidad miscarriage data, 
found no association serologically between evidence of chlamydial infection and 
miscarriage. 
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There have been many studies over the last two decades which have looked at the 
association between antibodies against C. trachomatis, and ectopic pregnancy (EP) or 
tubal factor infertility (TFI). The significance of C. trachomatis in tubal infertility was 
originally supported by the work of Jones et al. (1982) and Moore et al. (1982), who 
both showed a correlation between TFI and the presence of serum anti-chlamydial 
antibodies. Gump et al. (1983) linked chlamydial salpingitis to EP through serological 
evidence, patients with elevated anti-chlamydial IgG titres found during an initial 
infertility evaluation had an increased incidence of EP. 
Within the Sheffield/Bristol ectopic pregnancy (EP) group, 67% of the patients had 
detectable IgG, and 22% had detectable IgM. It is interesting to note that when individual 
EP patients were considered, all patients with IgM also had anti-chlamydial IgG. The 
prevalence of anti-chlamydial IgG was statistically significant (P<0.05) when compared 
to the UK control group, but the detection of IgM although double that of the study 
control group was not statistically significant (P>O. 1). 
In the Trinidad EP group 62% of the patients had detectable anti-chlamydial IgG, and 
38% had detectable IgM. The prevalence of neither IgG and IgM were statistically 
significant when compared to the Trinidad study control group (IgG P>0.05; IgM P> 
0.1). The increased detection of IgM in the Trinidad EP group, compared to the UK EP 
group, may be explained by the comparatively larger number of patients tested from 
Trinidad. Interestingly at a significance level of P<0.1 the Trinidad IgM results would 
become significant warranting further investigation. 
Chrysostomou et al. (1992) reported similar findings in a study conducted in Greece, 
where a statistically significant detection of anti-chlamydial IgG by IF was found in 
women with EP, when compared to pregnant controls (75% vs. 46%, P<0.001). In this 
Greek study none of the women in the EP group had detectable IgM, it was suggested 
that this was due to the conventional IgM to IgG switch in response to chlamydial 
infection. This study concluded that there was a positive relationship between a prior C. 
trachomatis infection and the risk of tubal pregnancy. 
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Sziller et al. (1998) evaluated the serological responses to 13 synthetic peptides 
corresponding to major epitopes of the chlamydial HSP60, and against an elementary 
body preparation of LGV2 in 67 women with EP and 45 pregnant controls. This study 
found that EP patients were more likely to have anti-chlamydial IgG than the pregnant 
controls. In the EP group, when antibodies against both C. trachomatis and the HSP60 
epitopes were detected there was an increased incidence of salpingitis, pelvic adhesions 
and/or a history of PID compared to EP patients negative for antibodies against HSP60 
and LGV2. Sziller et al. suggested that a prior or prolonged C. trachomatis infection may 
be necessary for the induction of HSP60-related immunopathology that could result in 
tubal damage predisposing to EP. 
In the Sheffield/Bristol TFI group the detection of IgG was higher than that of the UK 
study control group (P<0.05), and the Sheffield/Bristol EP group. What is interesting is 
that the IgM levels (8%) were the same as the UK study control group (8%), unlike the 
UK EP group (22%) and the Trinidad EP group (38%). It may be that the increased 
prevalence of anti-chlamydial IgG is an indicator of damage/loss of tubal function 
resulting in TFI from a previous/persistent chlamydial infection; whereas chlamydial 
associated EP may be the result of damage and ongoing infection suggested by detectable 
levels of IgM. Brade et al. (1994) suggested that IgM may be an indicator of acute 
infection, this was further supported by the high frequency of anti-chlamydial IgM in 
female patients who were found to be C. trachomatis culture positive in the genital tract. 
Claman et al. (1997) using MIF for IgG and IgM found no significant difference between 
the prevalence of anti-chlamydial antibodies in women with infertility of tubal, and non- 
tubal origin (63% vs. 46%), whereas Brunham et al (1985) did find a significant 
difference (72% vs. 9%, P <0.0001). Patton et al. (1994b) also detected anti-chlamydial 
IgG in 71 % of TFI patients studied. In our study we also saw a significant difference in 
the detection of anti-chlamydial IgG in the TFI group when compared to the control 
group. We did not find a significant difference in the detection of anti-chlamydial IgM, 
neither did Campbell et al. (1993) in a study of sixteen women with distal tubal 
occlusion. 
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A possible explanation of our results may be since TFI is supposedly the result of damage 
caused by a past infection, circulating IgM levels may havedeclined below the positive 
threshold value for our ELISA. It is also possible that in patients with evidence of 
having/or having had a C. trachomatis infection, and who have no detectable anti- 
chlamydial antibodies, an inadequate antibody response was originally mounted during 
infection resulting in tubal damage due to non-clearance/persistence of the organism. Or 
it may simply infer that the tubal pathology associated with TFI was the result of 
repeated, past chlamydial infection. 
From the results of both the UK, and Trinidad studies it can be seen that C. trachomatis is 
an important aetiological agent in the development of both EP and TFI. The question 
remains whether chlamydial serology can be used as a screening method for conditions 
such as asymptomatic PID (Chernesky et al., 1998) and salpingitis, that could predispose 
to EP or TFI? Many studies have supported the use of chlamydial serology in the 
diagnosis of tubal pathology, suggesting that chlamydial antibody titres are comparable to 
the use of hysterosalpingography in the diagnosis of tubal occlusion (Dabekausen et al., 
1994; Henry-Suchet et al., 1994; Tanikaw et al., 1996; Mol et al., 1997). However 
although serology is a'non-invasive' technique the limitations of the procedure have to be 
recognized, for example circulating levels of antibody may have declined over time 
generating false negative results. 
The serology data from Sheffield/Bristol and Trinidad suggest that the presence of IgG 
against C. trachomatis appears to be a good indicator of tubal pathology with respect to 
EP, and TFI. As for the Trinidad miscarriage patients, neither IgG nor IgM was 
suggestive of chlamydial involvement in the aetiology of miscarriage. 
2.8.2 IVF study 
There are many factors that affect embryo implantation rates and therefore the success of 
IVF, one important factor that is not fully understood is the intrauterine environment and 
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the mechanism by which hydrosalpinx alters the uterine receptive capacity. It has been 
proposed that connections between the hydrosalpinx and the uterine cavity allow the 
direct flow of hydrosalpingeal fluid into the uterus exposing the endometrium and embryo 
to a potentially 'toxic' fluid which has been postulated to contain microorganisms, debris, 
lymphocytes, cytokines, prostaglandins and leukotrienes which could all interfere with 
normal endometrial function or be embryotoxic (Strandell et al., 1994; Anderson et al., 
1994; Schenk et al., 1996). It has also been suggested that a reflux of hydrosalpingeal 
fluid into the uterus may also alter integrin expression potentially affecting endometrial 
receptivity (Lesley et al., 1994). It has been shown that the surgical removal of 
hydrosalpinx can improve the IVF sucess rate (Nackley et al., 1998), suggesting that the 
presence of hydrosalpinx may be a major factor in embryo rejection. 
Hydrosalpinx can form as a result of C. trachomatis infection. Previous infection with C. 
trachomatis as determined by the presence of anti-chlamydial IgG is more prevalent in 
patients with tubal disease than in women with infertility of non-tubal origin (Rowland et 
al., 1985; Sharara et al., 1996). Rowland et al. (1985) reported that a past C. trachomatis 
infection halved the success rate of IVF (30% vs. 65.5%), although Driscoll et al. (1991) 
showed that a prior chlamydial infection had no effect on IVF outcome. 
The question of whether elevated C. trachomatis antibodies adversely effect IVF outcome 
has been the subject of many studies. Rowland et al. (1985) found a significantly lower 
pregnancy rate in patients with antibodies to C. trachomatis whereas Torode et al. (1987) 
found no significant difference. 
Licciardi et al. (1992) found an association between previous exposure to C. trachomatis 
and spontaneous abortion after IVF. The study looked at chlamydial endocervical culture 
and the presence of antibodies to C. trachomatis in 145 women undergoing IVF. None 
of the women were found to have a positive endocervical culture, however 48% of those 
with tubal disease had detectable anti-chlamydial IgG compared to 18% with infertility of 
a non-chlamydial aetiology. The rate of spontaneous abortion within the NF population 
was 20%, of those 69% had IgG antibodies against C. trachomatis, compared to 24% of 
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the women who achieved a successful pregnancy after IVF. 
A similar study by Neuer et al. (1997) looked at the prevalence of antibodies against C 
trachomatis (IgG and IgA) with respect to chlamydial MOMP, and recombinant 
chlamydial LPS (rLPS) in paired follicular fluid and sera of 149 women undergoing IVF. 
The study also investigated the expression of human HSP60 in follicular fluid. IgA 
antibodies to both MOMP, and rLPS in follicular fluid were associated with failure to 
become pregnant after embryo transfer. Anti-chlamydial IgG in sera and follicular fluid, 
and anti-chlamydial IgA in sera were found to be unrelated to IVF outcome. The 
expression of human HSP60 in follicular fluid correlated with the presence of both anti- 
MOMP and anti-rLPS in follicular fluid. The association between anti-chlamydial IgA 
against two chlamydial antigens in follicular fluid, and the expression of human HSP60 
may support the possibility that a persistent upper genital tract chlamydial infection could 
contribute to IVF failure. 
Witkin et al. (1994) studied women with previous C. trachomatis infection diagnosed by 
the presence of IgA in cervical mucus by ELISA, and compared their IVF outcomes. 
Increased levels of chlamydial HSP60 (CHSP60) IgA were observed. CHSP60 is 
thought to induce a local immune response that may lead to an inflammatory reaction 
impairing implantation and facilitating immune rejection after embryo transfer, but the 
actual mechanism remains unknown. Conversely, Claman et al. (1996) showed that IVF 
patients with tubal infertility and with anti-CHSP60 antibodies had a significantly higher 
pregnancy rate when compared to TFI patients who were seronegative for CHSP60 (42% 
vs. 7%). 
An impaired ovarian response to gonadotropin stimulation signifies a reduced likelihood 
of pregnancy following IVF, possibly through a reduction in the quality and quantity of 
oocyte production (Keay et al., 1997). The capacity of the ovary to respond to such 
stimulation is an indirect measure of ovarian reserve. The results of our study with the 
combined results from two IVF centres (Group A and Group B) showed a significant 
number of poor responders to IVF gonadotropin stimulation have had previous exposure 
88 
to C. trachomatis. This suggest that prior genital tract infection with Chlamydia may 
affect the ovary in an as yet undefined way. 
When infertility diagnosis was considered, a greater proportion of the poor responders 
classified as having male factor infertility also had detectable anti-chlamydial IgG 
(P<0.05). It would have been interesting to have tested the male partners of these 
patients for the presence of anti-chlamydial IgG and/or anti-sperm antibodies. There is 
evidence that C. trachomatis infection can cause morphological alterations in the 
epididymis decreasing sperm maturation and sperm motility (Villegas et al., 1991). Many 
studies have also shown an association between the presence of C. trachomatis (as 
demonstrated by either the detection of chlamydial DNA, or the presence of anti- 
chlamydial antibodies) and the production in the male of anti-sperm antibodies (Witkin et 
al., 1993; Munoz et al., 1995; Witkin et al., 1995; Weidner et al., 1996; Munoz et al.; 
1996). 
Witkin et al. (1993b) also showed an association between the detection of C. trachomatis 
in semen, and the presence of circulating anti-sperm antibodies in female partners of 
couples diagnosed with unexplained infertility. It was suggested that C. trachomatis may 
provoke an immune response to sperm in women, and that the infertility in these couples 
may have resulted from a direct inflammatory response in the cervix or endometrium to 
repeated chlamydial infection from their partner, or the ability of C. trachomatis to evoke 
an immune response to sperm. 
It is possible that the ELISA system developed in this study simply detected more patients 
with severe adnexal adhesions and post-infective pelvic damage due to C. trachomatis 
(Tanikawa et al., 1996). Patients with tubal infertility produce fewer oocytes, have a 
lower peak oestradiol and require more gonadotropin when compared to patients with 
prolonged unexplained infertility. This demonstrates a subtle but significant impaired 
ovarian response in women with tubal infertility (FIVNAT, 1992). If the results of our 
study simply indicate that the ELISA system detected more intense pelvic damage in 
patients with severe adnexal damage, the underlying mechanism by which the ovary has 
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been compromised, its relationship to gonadotropin response and hence the poor 
prognosis for IVF is unknown. It may be that ovarian reserve is influenced by ovarian 
infection with a microorganism such as C. trachomatis, or it may be possible that ovarian 
function is indirectly affected by the formation of post-infection adhesions. 
There is indirect evidence that has linked pelvic infection to adhesion formation and 
reduced ovarian response (Madehevan et al., 1985; Molloy et al., 1987; Bowman et al., 
1993; Cszemichy, 1996), which has been supported by experiments in rabbits (McComb 
and Delbeke, 1984). Hamilton et al. (1986) found apparent altered ovarian function in 
spontaneous cycles in a small study of patients with pelvic adhesions following PID. 
These studies suggest a link to the sequelae of PID and a reduction in the capacity of the 
ovaries to respond to gonadotropin stimulation. 
In their study of the effect of hydrosalpinx and IVF, Sharara et al. (1996) tested each 
patient for C. trachomatis cervical infection, and determined the levels of anti-chlamydial 
IgG. The study was designed to evaluate the role of a previous chlamydial infection and 
hydrosalpinx in the success of IVF. Patients with elevated levels of IgG antibodies to C. 
trachomatis were treated with antibiotics prior to IVF. Of the thirty-four women who 
were seropositive for C. trachomatis, and received treatment, 21 % became pregnant after 
IVF compared to 12% of the women who did not receive treatment (found not to be 
statistically significant). This study also found that the pre-treatment with antibiotics of 
those patients with hydrosalpinx and positive chlamydial serology had no effect on IVF 
outcome, suggesting that a current chlamydial infection was not directly linked to IVF 
success. 
The detection of IgG against C. trachomatis in the Southampton and Bristol IVF 
populations suggests that a chlamydial infection can, in some as yet defined way, 
influence the success of IVF. Witkin et al. (1995) using PCR detected C. trachomatis 
DNA in the cervices of culture negative women undergoing IVF which correlated with 
adverse IVF outcome. This study suggested that an undetected chlamydial infection 
(silent/persistent) may be responsible for IVF implantation failure or spontaneous 
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abortion. It may be useful in the future to include chlamydial serology in the initial 
routine infertility work-up prior to IVF in order to help identify those patients who may 
respond 'poorly' to gonadotropin treatment. In this way, different treatment regimes, 
such as increased gonadotropin stimulation or hydrosalpinx investigation/removal, could 
be included in the IVF treatment. 
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Chapter 3.0 
Polymerase chain reaction (PCR) 
3.1 Aims of chapter 
The work described in this chapter had two distinct aims. The first aim was to utilise the 
polymerase chain reaction (PCR) to determine the prevalence of C trachomatis DNA in 
two study populations (Sheffield/Bristol and Trinidad). Patients from both study 
populations included women presenting with ectopic pregnancy (EP), miscarriage, tubal 
factor infertility (TFT), and controls undergoing either hysterectomy, or tubal sterilization. 
Three tissue samples from each patient (endometrial, ovarian and Fallopian tube) were 
examined for the presence of C. trachomatis DNA. 
The second aim of this chapter was to investigate the distribution of polymorphisms in the 
human TNF gene in a pilot. Tumor necrosis factor alpha (TNF-(X) has been implicated in 
the pathogenesis of chlamydial disease. TNF-a, and TNF-ß gene polymorphisms have 
been previously linked with functional differences of TNF-a levels, so the possible link 
between regulatory polymorphisms effecting TNF-a production and the risk of the 
inflammatory sequelae of C. trachomatis infection were investigated. TNF-a -308A, and 
TNF-ß TNFB* 1 Ncol polymorphisms were studied by PCR and restriction enzyme 
digestion of the appropriate PCR product in all patient groups, from both 
Sheffield/Bristol, and Trinidad. 
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3.2 Introduction 
Chlamydia trachomatis is a major cause of infection of the female genital tract often 
resulting in pelvic inflammatory disease (PID), tubal occlusion which can predispose to 
ectopic pregnancy, and infertility. One of the major problems associated with genital 
chlamydial infection, especially PID, is that in many cases the infection is asymptomatic 
or silent. Cates et al. (1993) showed that of 283 infertile women with tubal occlusion, 
84% had never had any notable symptoms indicative of upper genital tract infection. 
Therefore detection of chlamydial infection is of paramount importance in the prevention 
of the sequelae of chlamydial infection. 
Griffais and Thibon (1989) were the first to describe a PCR for the detection of C. 
trachomatis DNA in clinical samples using primers aimed at the endogenous 7.5kb 
plasmid. In the same year Pollard et al. (1989), and Duthil et al. (1989) also published 
primers for the detection of C. trachomatis, the former described primers aimed at the 
chlamydial 16S rRNA gene and the latter targeted the MOMP gene. Claas et al. (1990) 
utilised PCR with primers aimed at both the C. trachomatis plasmid, and 16S rRNA 
gene, to compare culture and PCR with product confirmation by oligonucleotide 
hybridization. The plasmid primers were found to be specific for C. trachomatis, and 
more sensitive than culture. 
The C. trachomatis 7.5kb plasmid has been estimated to be present in upto 10 copies per 
elementary body (Palmer and Falkow, 1986), and as such provides a multiple copy 
template for PCR increasing sensitivity, compared to for example chlamydial MOMP 
(single copy gene [Stephens et al., 1985]). Mahony et al. (1992) described a C. 
trachomatis plasmid based PCR using a second set of confirmatory primers which were 
shown to improve specificity and increased sensitivity. This nested PCR, which used a 
second set of primers aimed at an internal region of the primary PCR product produced 
by the first set of primers. Although nested PCR can improve sensitivity, contamination 
problems may arise with the generation of false-positive results. 
TNF-a may play a central role in the disease pathogenesis associated with C. trachomatis 
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infection. Conway et al. (1997) showed that scarring trachoma was associated with 
polymorphism in the TNF-a gene promoter, and with elevated TNF-a levels in tear 
fluid. Persistent or repeated infection of the epithelia with C. trachomatis can trigger a 
chronic inflammatory response causing tissue damage (Taylor et al., 1987), leading to 
fibrosis and scar formation. In trachoma scarring of the upper eyelid causes inversion 
and trichiasis which can lead to blindness, and in genital chlamydial infection scarring of 
the Fallopian tube can cause tubal occlusion and predispose to tubal factor infertility (TFI) 
or ectopic pregnancy (EP). 
The family of tumour necrosis factors comprises three members; TNF-a ; TNF-ß (also 
known as lymphotoxin a, LT-a); and LT-ß. The genes encoding TNF-a and TNF-ß are 
tandemly arranged within a 7kb region of the major histocompatibility complex (MHC) 
(Nedwin et al., 1985; Browning et al., 1993). Both cytokines encoded by the TNF 
genes are potent immunomodulators, and are essential mediators of the inflammatory 
response (Beutler et al., 1988; Paul et al., 1988; Fiers et al., 1991; Vilcek et al., 1991). 
The location of TNF within the MHC region has prompted much speculation about the 
role of TNF genes in the aetiology of MHC-linked disease, in particular those diseases 
with an inflammatory or autoimmune component. 
Two polymorphisms in the TNF genes have been described, one at position -308 in the 
promoter region of the TNF-a gene (Wilson et al., 1993) for which allele 2 is associated 
with higher constitutive and inducible levels of TNF-a (Wilson et al., 1994); the second 
polymorphism was located in the TNF-ß gene at intron 2/exon 3 (Messer et al., 1991). 
Both TNF polymorphisms have been associated with both increased, and decreased 
TNF-a secretion by mononuclear cells, depending on the population studied (Spengler et 
al., 1992; Abraham et al., 1993; Pociot et al., 1993). The mechanism(s) by which these 
polymorphisms influence TNF-a secretion is not known, and the effect of these 
polymorphisms with respect to C. trachomatis infection of the genital tract and the 
development of tubal disease remains to be elucidated. 
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3.3 Materials 
3.3.1 Reagents 
Reagents were purchased from Sigma (Dorset, UK) unless otherwise stated. 
3.3.2 DNA extraction 
Pestle and mortars were soaked in O. 1M HCl overnight before being autoclaved. 
Lysis buffer 
x 10 KC1 PCR buffer (Bioline, London, UK) IOml 
1% Triton X-100 (v/v) (BioRad, Herts, UK) lml 
500pg/ml proteinase K 0.05g 
sterile purified water 89m1 
The lysis buffer was stored at -20°C in Iml aliquots in a DNA-free freezer. 
Phenol: chloroform: isoamyl alcohol was purchased as a pre-mixed solution at a 
ratio of 25: 24: 1. 
Glycogen was obtained from Boehringer Mannheim (Diagnostics and Biochemicals 
Ltd., East Sussex, UK) at a concentration of 20mg/ml. 
Sodium acetate 
3M sodium acetate 24.6g 
purified water 100m1 
The solution was adjusted to pH 4.8, autoclaved and stored at 4°C. 
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3.3.3 Measurement of DNA concentration 
Fluorescent measurement of DNA concentration 
Hoechst 33258 dye, for use with the TKO 100 mini-fluorometer (Hoefer Scientific 
Instruments, San Francisco, USA), was prepared as a stock solution of 1mg/ml in water, 
and stored in a dark container at 4°C for 6 months. 
THE buffer 
I OOmM Tris-OH 12. l g 
1 OmM EDTA 3.7g 
IM NaC1 58.4g 
water l000ml 
The THE buffer was adjusted to pH 7.4, autoclaved and stored at 4°C. 
Working dye solution 
O. lpg/ml Hoechst 33258 dye 10µl of stock 
1OxTNE lOml 
water 90m1 
The dye solution was pre-filtered through a sterile 0.2µm Millipore filter before use, and 
was prepared fresh daily. 
3.3.4 PCR 
OmniGene PCR machine (Hybaid Ltd., Middlesex, UK) with heated lid, was used for 
all PCR applications. 
Sterile aeroguard tips and positive displacement tips were purchased from Alpha 
Laboratories Ltd. (Hampshire, UK). 
0.5 ml PCR tubes were obtained from GeneMate (Kaysville, UT, USA) and were 
DNase and RNase free. Before use the tubes were autoclaved. 
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Stock nucleotides containing dATP, dCTP, dGTP, and dTTP were purchased as a 
polymerisation mix (Bioline). The DNA polymerisation mix contained 10mM of each 
nucleotide in solution and was stored at -20°C in a designated DNA-free freezer. 
Stock nucleotides containing dUTP, dATP, dCTP, and dGTP were puchased as 
separate solutions from Perkin Elmer (Langen, Germany). Each nucleotide was supplied 
as a stock solution of 10mM, except dUTP which was supplied as 20mM. A working 
dNTP solution (1.25mM of each dATP, dCTP, dGTP and 2.5mM of dUTP) was made 
by adding 125µl of each nucleotide to 500pl of sterile purified water, this was stored at 
-20°C in a designated DNA-free freezer. In a 50pl PCR reaction mix, 8µl of the stock 
nucleotides containing dUTP will yield 200pM of dATP, dCTP, dGTP and 400µM of 
dUTP. 
AmpEraseTM Uracil N-glycosylase (UNG) was purchased as a 1U/pl solution 
from Perkin Elmer and kept at -20°C in a designated DNA-free freezer. 
Magnesium chloride (MgC12) was purchased from Bioline as a 50mM stock 
solution and stored at -20°C in a designated DNA-free freezer. 
x10 PCR reaction buffers NH4 and KCI were purchased from Bioline. The NH4 
buffer contained 160mM (NH4)2SO4,670mM Tris-HC1 and 0.1% (v/v) Tween-20; the 
KCI buffer contained 500mM KC1,100mM Tris-HCI, 15mM MgC12 and 1% (v/v) Triton 
X-100. 
BioTaq DNA polymerase was obtained from Bioline at a concentration of 5U/µl. 
The polymerase was stored -20°C in a designated DNA-free freezer. 
3.3.5 PCR primers 
PCR primers were purchased from R&D Systems Ltd. at 0.2mM with no further 
purification, and diluted to IOOpmolpl. Aliquots of 100 µl were stored at -20°C, one 
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aliquot was stored at 4°C for routine day to day use. 
Chlamydia trachomatis single plasmid primers (Claas et at., 1990) 
binding position 
(nucleotide [nt]) 
Ti Forward (F) 5' ggA CAA ATC gTA TCT Cgg 3' 2464-2481nt 
T2 Reverse (R) 5' gAA ACC AAC TCT ACg CTg 3' 2980-2963nt 
Oligonucleotide probe for Southern blot analysis (Claas et al., 1990) 
binding position 
5' CgC AgC gCT AgA ggC Cgg TCT ATT TAT gAT 3' 2705-2734nt 
The binding positions of primers Ti and T2, and the oligonucleotide probe were based on 
the published sequence of the Chlamydia trachomatis cryptic plasmid pLGV440 (Hatt et 
al., 1988. Accession number X06707). 
Chlamydia trachomatis MOMP primers (Lan et at., 1994) 
binding position 
NRO F 5' CTC AAC TgT AAC TgC gTA TTT 3' 5632-5653nt 
NLO R 5' ATg AAA AAA CTC TTg AAA TCg 3' 6759-6739nt 
SERO2A F 5' TTT CTA gA(T/C) TTC AT(CTT) TTg TT 3' 5696-5715nt 
PCTM3 R 5' TCC TTg CAA gCT CTg CCT gTg ggg AAT CCT 3' 6705-6676nt 
The relative binding positions of the MOMP primers were based on the published 
sequence of the C. trachomatis complete genome, section 65 (Stephens et al., 1998. 
Accession number AE001338). 
Human ß-globin primers (Saiki et al., 1985; Lan et al., 1995) 
binding position 
PC03 F 5' ACA CAA CTg TgT TCA CTA gC 3' 62150-62169nt 
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PCO6 R 5' CAT CAg gag Tgg ACA gAT CC 3' 62476-62457nt 
The binding positions of the two human ß-globin primers were based on the published 
sequence of the human ß-globin region on chromosome 11 (Marotta et al., 1974. 
Accession number U01317). 
Tumour necrosis factor alpha (TNFa) primers (Cabrera et at., 1995) 
binding position 
TNFa1 F 5' Agg CAA TAg gTT TTg Agg gCC AT 3' 284-302nt 
TNFa2 R 5' TCC TCC CTg CTC CgA TTC Cg 3' 390-371nt 
The binding position of the TNFa primers were based on the sequence of the human 
gene for tumor necrosis factor alpha ( Nedwin et al., 1985. Accession number X02910). 
Tumour necrosis factor beta (TNFO) primers (Messer et al., 1991) 
binding position 
TNFß 1F 5' CCg TgC TTC gTg CTT Tgg ACT A 3' 129-150nt 
TNF02 R 5' AgA gCT ggT ggg ACA TgT CTg 3' 869-848nt 
The binding position of the TNFß primers were based on the human tumor necrosis 
factor beta sequence (accession number M55913) published by Abraham et al. (1991). 
3.3.6 Gel electrophoresis 
Agarose gel electrophoresis 
Electrophoresis grade agarose was obtained from Gibco Life Technologies Ltd. 
(Paisley, UK). Gel solutions were prepared in 0.5xTBE and heated in a microwave. 
Ethidium bromide was prepared as a working stock solution of 10mg/ml in water and 
stored in a dark container at room temperature. 
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Gel loading dye 
0.25% bromophenol blue (BDH Chemicals, Poole, UK) 0.025g 
0.25% xylene cyanol (BDH) 0.025g 
30% glycerol 3ml 
water lOml 
5xTBE buffer 
Tris-OH 54g 
boric acid 27.5g 
EDTA 4.65g 
water 1000ml 
The buffer was adjusted to pH 8.3, autoclaved and stored at room temperature. A 0.5x 
TBE solution was prepared for electrophoresis. 
Polyacrylamide gel electrophoresis 
10% ammonium persulphate 
ammonium persulphate 0.5g 
purified water 5ml 
The solution was prepared fresh each time a polyacrylamide gel was prepared. 
Resolving gel 
xl TBE 2m1 of of stock 
acrylamide/bis acrylamide 30% (w/v) [29: 1] soln. 2.34ml 
glycerol 9Oµ1 
10% ammonium persulphate 5Oµ1 
purified water 5.51 ml 
l0µ1 of TEMED was added to the resolving gel solution immediately before the gel was 
poured. 
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Stacking gel 
xl TBE 2m1 of of stock 
acrylamide/bis acrylamide 30% (w/v) [29: 1] soln. 1.3m1 
glycerol 9Oµ1 
10% ammonium persulphate 50µl 
purified water 6.55ml 
10µl of TEMED was added to the stacking gel solution immediately before the gel was 
poured. 
Silver staining of polyacrylamide gels was achieved using the BioRad silver staining 
kit. All reagents were made up as per the manufacturers instructions with purified water. 
3.3.7 Southern blotting 
HybondTM-N+ positively charged membrane was purchased from Amersham Life 
Sciences Ltd. (Buckinghamshire, UK) 
Denaturation solution 
1.5M NaCl 87.66g 
0.5M NaOH 20. Og 
purified water 1000ml 
Neutralization solution 
1.5M NaC1 87.66g 
0.5M Tris-HC1 78.8g 
purified water 1000ml 
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20xSSC stock solution 
0.3M Na3C6H5O7.2H20 88.2g 
3M NaCI 175.3g 
purified water 1000ml 
The pH was adjusted to 7.0 and the solution autoclaved. 
3.3.8 ECL 3' hybridization solutions 
The ECL 3'-oligolabelling and detection kit was purchased from Amersham (Bucks, 
UK), the anti-fluorescein-horseradish peroxidase (HRP) conjugate, blocking solution and 
the ECL detection reagents were stored at 4°C. The remaining kit components were 
stored at -20°C. 
Hybridization buffer 
5xSSC 95m1 
0.1 % (w/v) hybridization buffer component (supplied) 0.1 g 
0.02% (w/v) SDS 0.02g 
Blocking solution (as supplied) (1: 20 dilution) 5ml 
The hybridization buffer was warmed to dissolve the hybridization buffer component, 
aliquoted in 20m1 amounts and stored at -20°C for up to 3 months. 
Primary wash solution 
20xSSC (1 x SSC) 250m1 
0.1% (w/v) SDS lg 
water 750m1 
The wash buffer was stored at room temperature. 
Secondary wash solution 
20xSSC (0.5xSSC) 50m1 
0.1% (w/v) SDS Ig 
water 950m1 
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The wash buffer was stored at room temperature. 
Buffer 1 
0.15M NaC1 8.77g 
0.1M Tris-OH 12.1g 
water 1000ml 
The pH of the buffer was adjusted to pH 7.5 with concentrated HCI, autoclaved and 
stored at room temperature. 
Buffer 2 
0.4M NaCl 23.4g 
O. 1 M Tris-OH 12. lg 
water 1000ml 
The pH of the buffer was adjusted to pH 7.5 with concentrated HCI, autoclaved and 
stored at room temperature. 
Block solution 
buffer 2 475m1 
liquid block (supplied) 25ml 
The block solution was aliquoted in 20m1 volumes and stored at -20°C. 
Antibody solution 
buffer 2 500m1 
0.5% (w/v) BSA fraction V (Winlab, Middlesex, UK) 2.5g 
The buffer was aliquoted in 15m1 amounts and stored at -20°C. Prior to use, 15µl of anti- 
fluorescein HRP conjugate (supplied) was added. 
ECL detection reagents (supplied) were mixed in equal volumes under safe light 
conditions and used immediately. 
Hyperfilm ECL autoradiography paper was obtained from Amersham and stored in the 
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dark at room temperature. 
Ilford PQ universal developer was purchased from Ilford Ltd. (Cheshire, UK) and 
diluted 1: 10 with water before use. 
Ilford Ilforspeed fixer was purchased from Ilford Ltd. and diluted 1: 5 with water 
before use. 
3.3.9 Patient specimens 
Specimens were collected from Sheffield (Jessop Hospital for Women), Bristol (St. 
Michael's Hospital) and Trinidad (Mount Hope Women's Hospital, St. Augustine; and 
the General Hospital, Port of Spain). From Sheffield/Bristol, three study groups were 
examined, women presenting with ectopic pregnancy (EP), women undergoing surgery 
for tubal factor infertility (TFI), and control patients. From Trinidad, four study groups 
were considered, women presenting with EP, women with a history of miscarriage, 
women undergoing surgery for tubal factor infertility, and control patients. The 
specimens taken from the miscarriage group were taken retrospectively. The study 
controls from Sheffield/Bristol were hysterectomy patients and controls from Trinidad 
were patients undergoing sterilization. 
Three tissue samples were collected from each patient in the study; an endometrial sample; 
a sample of the Fallopian tube (ampulla, isthmus or fimbriae); and an ovarian core 
biopsy. For the patients belonging to the EP groups, tissue samples were taken at the 
time of surgery, and Fallopian tube samples were taken from the site of the EP. Each set 
of tissue samples were collected in duplicate, one set was frozen and used for DNA 
extraction, and the other fixed immediately in buffered formalin for histological 
examination and in situ hybridization. Samples were coded with a patient reference 
number and the sample type. The study had Ethics Committee approval at all 
geographical sites. 
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Specimens for PCR from Trinidad were sent frozen in dry ice, and upon arrival in 
Sheffield were stored at -20°C. Samples from Bristol were delivered after overnight 
transport in liquid nitrogen and stored at -20°C. Tissue samples from Sheffield were 
collected fresh and stored immediately at -20°C. 
For the TNF study, the DNA extracted from a single tissue specimen from all patients 
(Sheffield/Bristol and Trinidad) was tested by PCR. 
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3.4 Methods 
3.4.1 DNA extraction 
DNA extraction development 
A small amount of tissue was removed from each defrosted tissue sample, and ground to 
a fine powder in liquid nitrogen. Iml of lysis buffer (containing 200pg/ml proteinase K) 
was then added to resuspend the cells, and the suspension transferred to a sterile tube and 
incubated at 37° for lh. Each tube was then boiled for 10min to denature the proteinase 
K, centrifuged at 10,000xg for 5min, and the resulting supernatant divided equally into 
three tubes. One tube was purified with 200µ1 of Insta Gene Purification Matrix; one 
tube was subjected to routine phenol/chloroform DNA extraction followed by ethanol 
precipitation; and the final tube was not purified further. 
The concentration of DNA liberated by each method varied. The lysis buffer extraction 
procedure yielded the highest yield of DNA and the Instagene Purification the least. The 
phenol/chloroform extraction method gave marginally less DNA than the lysis buffer 
method (as determined using a TKO fluorometer), probably due to loss of DNA during 
the phenol/chloroform extraction procedure. 
It became apparent that a problem with contamination may arise from using liquid 
nitrogen. Once the samples had been covered in liquid nitrogen, small pieces of tissue 
were observed to become airborne when the tissue was ground. DNA extraction by 
grinding the sample in the absence of liquid nitrogen and extraction in a lysis buffer 
containing 500pg/ml proteinase K, was found to be as efficient as DNA extraction with 
liquid nitrogen and lysis buffer containing 200pg/ml proteinase K. 
The effect of varying the incubation time on the recovery of DNA with a 500pg/ml 
proteinase K lysis buffer was also investigated using a TKO fluorometer. A small 
amount of tissue (either endometrial, Fallopian tube, or ovarian) was crushed in a pestle 
and mortar with lml of 500pg/ml proteinase K lysis buffer. 250µ1 of the resulting 
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cellular suspension was aliquoted into three tubes, and the tubes incubated at 37°C for lh, 
2h, 3h respectively, centrifuged at 10,000xg for 5min and then subjected to conventional 
phenol/chloroform DNA extraction followed by ethanol precipitation. A steady increase 
in the DNA concentration recovered was observed over time (Graph 5), with the 3h 
incubation giving the highest DNA yield. Overnight incubation of samples, at 37°C, was 
found not to significantly increase the final concentration of extracted DNA. 
DNA extraction of study samples 
Tissue samples were thawed and a measured amount (depending on sample size) was 
homogenized with a sterile pestle and mortar in Iml of lysis buffer (containing 500µg/ml 
proteinase K). The cellular suspension was incubated at 37°C overnight, boiled for 
10min, and then centrifuged at xlO, 000g for 2min to sediment cellular debris. The 
resulting supernatant was subjected to phenol: chloroform: isoamyl alcohol DNA extraction 
followed by ethanol precipitation with 50µ13M sodium acetate and 5µl glycogen at 
-70°C overnight. The DNA was pelleted by centrifugation at xlO, 000g for 30min at 4°C, 
washed twice with 70% ice cold ethanol, air dried and finally resuspended in l00µ1 of 
sterile water. Appropriate extraction controls were set up throughout the procedure to 
detect contamination between samples and from equipment/material and the environment. 
Extraction of LGV1 DNA 
C. trachomatis serovar LGV 1 DNA was extracted from cell culture. LGV 1 was grown in 
Trac bottles containing a McCoy cell monolayer, as previously described (p. 61). After 
two days of growth, the cell monolayer was removed with the end of a sterile lml 
syringe. The resulting cellular suspension was pelleted at xIO, 000g for 5min, lml of 
lysis buffer (containing 500µg/ml proteinase K) was added to the pellet and sample 
incubated at 37°C for lh. The sample was then boiled for 10min, and centrifuged at 
xlO, 000g for 2min. The resulting supernatant was subjected to phenol: chloroform 
: isoamyl alcohol DNA extraction followed by ethanol precipitation with 50µl 3M sodium 
acetate and 5µl glycogen at -80°C overnight. The DNA was pelleted by centrifugation at 
xlO, 000g for 30min at 4°C, washed twice with 70% ice cold ethanol, air dried and finally 
resuspended in 100µl of sterile water. The extracted LGV 1 DNA was used as a positive 
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Graph 5. The effect of varying incubation time on the 
concentration of DNA recovered (µg/ml) from female 
genital tract specimens using a 500pg/ml proteinase K 
lysis buffer. 
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control for C. trachomatis plasmid PCR. 
3.4.2 Determination of DNA concentration 
TKO 100 fluorometer 
The TKO fluorometer was used to determine the presence of human genomic DNA after 
sample extraction. The system depends on the preferential binding of a bis benzimidizole 
dye (Hoechst 33258) to A-T rich regions of DNA. In the absence of DNA, the emission 
spectrum of Hoechst 33258 peaks at 492nm, when DNA is present the emission 
spectrum of the dye peaks at 458nm. The fluorescent characteristics of the dye bound to 
DNA closely match the emission and detection peaks of the TK100 fluorometer. 
Initially the machine was allowed to stabilize for at least 15min before use and was first 
calibrated with calf thymus DNA (Hoefer) standard of known DNA concentration in 
1xTNE buffer. 2m1 of the freshly prepared working dye solution was placed in a TKO 
105 glass cuvette (supplied) and 2µl of standard was added. After gentle mixing, the 
cuvette was placed in the fluorometer and the instrument calibrated to the appropriate 
concentration of DNA (taking into account the 1: 1000 dilution of the standard in the 
working dye solution). The DNA concentration of each sample was measured in the 
same way, in units of ng/ml. The cuvette was washed with working dye solution 
between samples, and the fluorometer was blanked between each sample. 
Spectrophotometer determination of DNA concentration 
The DNA concentration of a random selection of extracted study samples was assessed to 
determine the average DNA content. Briefly, 2µl of each study sample was diluted in 
998µl of sterile water and the optical density (OD) measured in a spectrophotometer at 
260nm and 280nm. lml of sterile water was used to zero the spectrophotometer, and the 
microcuvette (quartz) was washed in sterile water between samples. 
The OD at 260nm allowed the calculation of the DNA content of the sample, an OD of 1 
is equivalent to 50µg/ml of double stranded DNA. The average recovery of DNA 
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(assuming a 100% extraction, and recovery rate) was calculated to be 13µg DNA/pg (SD 
7.4) of wet weight tissue initially extracted in lml of lysis buffer. For PCR, l0µ1 of 
sample was used routinely which equated to an average of 4.68µg of DNA in a 50µl PCR 
reaction mix. 
Pure preparations of DNA should have a 260nm/280nm ratio of 2.0 (double stranded 
DNA), protein contamination of the DNA sample would have the effect of lowering this 
value. None of the study samples tested showed evidence of protein contamination. 
3.4.3 PCR detection of human genomic DNA 
Titration of human (3-globin PCR 
The detection of the human ß-globin gene by PCR was subjected to magnesium (Mg2+) 
titration to determine the optimal Mg2+ concentration. MgC12 concentrations tested 
ranged from 0.5mM to 2.5mM, in 0.5mM increments. 
The PCR was performed on 1µg of human placental DNA in a final reaction mix of 50µ1, 
using primers PCO3 (Saiki et al. 1985), and PCO6 (Lan et al. 1995). The final reaction 
mix contained the appropriate concentration of MgC12; xl NH4 PCR buffer; 200µM of 
dNTP; 50pmol of each primer (PC03, PC06); and 1U Taq DNA polymerase. The PCR 
consisted of 40 cycles of amplification, comprising denaturation at 94°C for 1min, primer 
annealing at 55°C for 40sec and primer extension at 72°C for 40sec. Pre-PCR the tubes 
were incubated at 94°C for 4min, and post-PCR at 72°C for 8min. 
The PCR product (326-bp) was visualised on a 0.8% agarose gel after ethidium bromide 
staining (Figure 6). The optimal MgCl2 concentration was determined to be 1.0mM, and 
was therefore used in all subsequent human ß-globin PCR experiments. 
Human ß-globin PCR sensitivity 
The average amount of extracted DNA used in each PCR was approximately 4.68µg in a 
50µ1 reaction mix. The sensitivity of the human ß-globin PCR was determined to ensure 
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that the PCR detection threshold was greater than the average DNA concentration 
extracted per sample. 
Human placental DNA (Sigma) was serially diluted from 1 pg/pl to 0.06ng/µl in purified 
sterile water. 2µl of each DNA concentration was added to 48µl of reaction mix. The 
final reaction mix contained 1.0mM MgC12; xl NH4 PCR buffer; 200µM of dNTP; 
50pmol of each primer; and 1U Taq DNA polymerase. The PCR consisted of 40 cycles 
of amplification, comprising denaturation at 94°C for 1min, primer annealing at 55°C for 
40sec and primer extension at 72°C for 40sec. Pre-PCR the tubes were incubated at 94°C 
for 4min, and post-PCR at 72°C for 8min. The expected PCR product of 326-bp was 
visualised on a 0.8% agarose gel after ethidium bromide staining. The human ß-globin 
PCR was able to detect below 1 ng of human DNA in a final reaction volume of 50µ1. 
Human (3-globin PCR of study samples 
Detection of human genomic DNA was performed by PCR using primers PCO3 (Saiki et 
al. 1985), and PCO6 (Lan et al. 1995) aimed at the human ß-globin gene. This PCR was 
not only used to show the presence of human DNA and the success of DNA extraction, 
but was also used to show the absence of PCR inhibitors. Only samples positive for the 
presence of human DNA were subsequently tested for the presence of C. trachomatis 
DNA. 
The PCR was performed on IOµ1 of the extracted DNA sample in a final reaction mix of 
50µl. The final 50pl PCR reaction mix contained 1.0mM MgC12; x1 NH4 PCR buffer; 
200pM of dNTP; 50pmol of each primer; and IU Taq DNA polymerase. Prior to PCR, 
the reaction tubes minus template DNA were subjected to UV irradiation. The PCR 
consisted of a total of 40 cycles of amplification, comprising denaturation at 94°C for 
lmin, primer annealing at 55°C for 40sec and primer extension at 72°C for 40sec. Prior 
to the commencement of PCR cycling the tubes were incubated at 94°C for 4min, and 
post-PCR at 72°C for 8min. The expected PCR product of 326-bp was visualised on a 
0.8% agarose gel after ethidium bromide staining (Figure 6). Human placental DNA was 
used as a positive control, and purified water as a negative control. 
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Figure 6. A representative 0.8% agarose gel showing lane 1,1 kb 
ladder; lane 2,326-bp human ß-globin polymerase chain reaction product; 
lane 3,517-bp single plasmid C. trachomatis polymerase chain reaction 
product; and lane 4,1 kb ladder. 
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3.4.4 PCR detection of C. trachomatis DNA 
The production of a false positive PCR result due to the amplification of exogenous 
template from a previous PCR is an important consideration when interpreting the results 
of PCR. Methods such as the physical separation of pre- and post-amplification steps 
(Kwok and Higuchi, 1989), the use of designated pipettes, the use of positive 
displacement tips and filter barrier tips, and UV irradiation of reagents and reaction tubes 
(Sarker and Summer, 1990) have been employed to reduce the risk of amplicon 
contamination. 
Another method for reducing the possibility of a false positive PCR result is the 
GeneAmp Carry Over Prevention System (Perkin Elmer). This system uses the 
enzymatic, and chemical reactions analogous to the restriction-modification and excision- 
repair systems of cells to specifically degrade PCR products from a previous PCR and 
mis-matched or mis-primed products produced prior to PCR, but not native DNA. dUTP 
is substituted for dTTP in the PCR reaction mix, so amplicons containing dUTP are 
produced. In subsequent PCR reactions, uracil N-glycosylase (UNG), in the presence of 
alkaline pH and heat, is used to degrade contaminating dU-containing DNA. 0.5U of 
UNG in a final volume of 5Oµ1 and a 10min incubation at room temperature has been 
shown to prevent the amplification of 1x 106 copies of dU-containing PCR product. One 
of the limitations of the UNG system is that it is incompatible with a nested PCR. If 
UNG were present in the secondary PCR reaction mixture it would facilitate the 
degradation of the template (primary PCR product containing dU) leading to a false 
negative result. 
Samples found positive for human genomic DNA were tested for the presence of C. 
trachomatis DNA using primers Ti and T2 homologous to specific regions of the 
chlamydial 7.5kb plasmid (Claas et al., 1990). The PCR (using the GeneAmp Carry 
Over Prevention System), including the other anti-contamination methods previously 
described was performed on 10µl of the extracted DNA sample in a final reaction mix of 
50pl. 
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The final reaction mix contained 2.5mM MgC12; xl KCl PCR buffer; 200µM of dATP, 
dCTP, and dGTP; 400mM dUTP; 100pmol of each primer; 0.5U UNG; and 1U Taq 
DNA polymerase. Prior to PCR, the reaction tubes minus template DNA were subjected 
to UV irradiation (9.9xlO5pJ/cm2). The PCR consisted of 40 cycles of amplification, 
comprising denaturation at 95°C for 30sec, primer annealing at 55°C for 30sec and primer 
extension at 72°C for 30sec. Pre-PCR the tubes were incubated at 28°C for 10min to 
allow the digestion of any contaminating dUTP PCR product, followed by 10min at 95°C 
to denature the UNG. LGV 1 DNA was used as a positive PCR control and sterile water 
was used as a negative control. 
Post-PCR the tubes were held at 72°C and chloroform was added to denature any residual 
UNG. The expected product, a 517-bp amplicon, was analysed through a 0.8% agarose 
gel by standard protocols and visualised under UV light after ethidium bromide staining 
(Figure 6, and Figure 7). 
3.4.5 Confirmation of C. trachomatis PCR products 
Southern blot 
The DNA from the agarose gel was transferred to a nylon membrane by Southern 
blotting. Briefly, after ethidium bromide staining the gel was washed for 10min in 
purified water, followed by 15min in denaturation solution and 15min in neutralisation 
solution. A electrophoresis tank was rinsed, and a wick made from filter paper soaked in 
20xSSC was laid over the platform and the tank partially filled with 20xSSC. The gel 
was laid on the wick and a piece of Hybond-N+ membrane (pre-soaked in purified water) 
was placed on top. Air bubbles were carefully removed. Three sheets of filter paper, cut 
to size and wetted with 20xSSC were placed on top of the membrane followed by 
absorbent towels and a weight. 
Capillary blotting was allowed to proceed overnight. Finally, the blotting apparatus was 
dismantled, the membrane marked for orientation and left to air dry before being UV 
cross-linked at 12xIO4jJ/cm2. The agarose gel was re-stained with ethidium bromide to 
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determine whether DNA transfer had been successful. 
Oligonucleotide labelling 
The 3' labelling of the oligonucleotide probe with fluorescein was achieved using the 
Amersham 3'-oligolabelling and detection system. 
The required labelling components were allowed to defrost on ice. 10µl of fluorescein- 
11-dUTP was added to Iµd of the oligonucleotide probe (100 x 10-2pm/ml) followed by 
l6µ1 of cacodylate buffer, 117µl of water and 16µ1 of terminal transferase. The mixture 
was then incubated at 37°C for Ih and stored at -20°C in the dark. 
Hybridization 
The membrane was wetted in 2xSSC, placed in a clean sterile hybridisation tube with 
10m] of hybridisation buffer and left to pre-hybridize for lh at 55°C in a hybridization 
oven. 2ml of hybridization buffer was then removed from the tube and the probe added 
to give a final concentration of IOng/ml. The hybridization buffer containing the probe 
was returned and the membrane was then left for 2h at 55°C in the hybridization oven. 
The blot was then removed from the hybridization solution, placed in a clean container 
and covered with an excess of wash buffer 1 for 5min with constant agitation. This was 
repeated. The blot was then placed in a clean hybridization tube and covered with an 
excess of wash 2 which had been pre-warmed to 55°C, and returned to the hybridization 
oven for 15min at 55°C. This again was repeated. 
The blot was then placed in a clean container and rinsed with buffer 1 for 1min, which 
was then discarded and replaced with an excess of blocking solution for lh. The 
membrane was then washed briefly with buffer 1, incubated with the antibody solution 
for 30min and then rinsed in an excess of buffer 2 for 5min. This was repeated a further 
three times to ensure the complete removal of non-specifically bound antibody. 
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Figure 7. A 0.8% agarose gel of C. trachomatis single plasmid polymerase 
chain reaction products. MW -l kb ladder; A- LGV 1 positive control; B- 
positive endometrial sample; C- positive endometrial sample; MW - lkb 
ladder. 
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Figure 8. Southern blot of gel shown in Figure 7. A- LGV I positive control; 
B- positive endometrial sample; C- positive endometrial sample; D- positive 
ovarian sample not seen on gel. 
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Signal generation and detection 
Under safe-light conditions in a darkroom, the two ECL detection reagents were mixed in 
equal volumes, the membrane was drained and placed on an acetate in a developing 
cassette and covered with another acetate. Hyper film, cut to the appropriate size was 
placed over the acetate covered membrane and the cassette locked and left for 10 min. 
The film was then developed, fixed and washed and finally left to air dry. Depending on 
the strength of the signal, another piece of film was placed over the membrane and left for 
a maximum of 12h (Figure 8). 
3.4.6 Effect of human DNA on C. trachomatis PCR 
The effect of high concentrations of human genomic DNA on the single plasmid PCR 
was investigated to ensure that C. trachomatis DNA could be detected in samples with a 
high 'background' of human genomic DNA. 
Human placental DNA (Sigma) was diluted in sterile purified water, and 5µl of each 
dilution was added to a 50µl reaction mix to give final concentrations of 0.1 µg/Nl, 
0.02µg/µl, 0.01 pg/µl, 5ng/µl, 2.5ng/µl, and 1.25ng/µl. A duplicate set of samples was 
made to which 100ng of extracted C. trachomatis DNA was added. 
The final reaction mix contained 2.5mM MgC12; xl KCl PCR buffer; 200pM of dATP, 
dCTP, and dGTP; 400mM dUTP; 100pmol of each primer; 0.5U UNG; and lU Taq 
DNA polymerase. Prior to PCR, the reaction tubes minus template DNA were subjected 
to UV irradiation (9.9x105VJ/cm2). The PCR consisted of 40 cycles of amplification, 
comprising denaturation at 95°C for 30sec, primer annealing at 55°C for 30sec, and 
primer extension at 72°C for 30sec. Pre-PCR the tubes were incubated at 28°C for 10min 
to allow the digestion of any contaminating dU PCR product, followed by 10min at 95°C 
to denature the UNG. Post-PCR 50µl of chloroform was added to each sample to 
prevent degradation of dU PCR product by any residual UNG. LGV 1 DNA was used as 
a positive PCR control, and sterile water was used as a negative control. 
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The presence of high concentrations (0.1 µg/µ1) of human genomic DNA was shown to 
interfere with the amplification of chlamydial plasmid DNA (Figure 9). 
3.4.7 Major outer membrane protein PCR 
MOMP PCR of study samples 
Lan et al. (1994) published a series of primers, for single and nested PCR, targeted at the 
four variable domains of the chlamydial OMP1 gene. The nested set of primers with the 
highest reported sensitivity were NLO and NRO, followed by PCTM3 and SERO2A. 
Both the primary and secondary nested product were suitable for RFLP genotyping. 
Study samples that were found to be C. trachomatis DNA by plasmid PCR were tested by 
MOMP PCR. 
For the primary MOMP PCR the final reaction mix contained 1.5mM MgC12; xl KCl 
PCR buffer; 200µM of dNTP; 50pmol of each primer (NLO and NRO); 1U Taq DNA 
polymerase; and 10µ1 of extracted study DNA. The PCR consisted of 49 cycles of 
amplification, comprising denaturation at 94°C for 1min, primer annealing at 45°C for 
3min and primer extension at 72°C for 3min. Pre-PCR the tubes were incubated at 94°C 
for 6min, and post-PCR at 72°C for 8min. LGV 1 DNA was used as a positive PCR 
control, and sterile water was used as a negative control. The primary PCR product of 
1149-bp was visualised on a 0.8% agarose gel after ethidium bromide staining and UV 
transillumination. 
The secondary MOMP PCR was only used on samples that tested negative by the primary 
PCR. The secondary PCR final reaction mix contained 1.5mM MgC12; xl KCl PCR 
buffer; 200µM of dNTP; 50pmol of each primer (PCTM3 and SERO2A); IU Taq DNA 
polymerase; and 3µl of the primary MOMP PCR product. The PCR cycling parameters 
were the same as in primary MOMP PCR. 3µl of the primary product generated from the 
LGV 1 DNA control was used as a positive control for the second round of amplification. 
Sterile water was used as a negative control. The primary PCR product of 1013-bp was 
visualised on a 0.8% agarose gel after ethidium bromide staining and UV 
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Figure 9.0.8% agarose gel of C. trachomatis single plasmid polymerase 
chain reaction products with varying concentrations of human DNA. Lane 1, 
negative control; lane 2,0.1µg/µl of human DNA; lane 3,0.02µg/µi of 
human DNA; lane 4,0.01 pg/µl of human DNA; lane 5,5ng/µl of human 
DNA; lane 6,2.5ng/µl of human DNA; lane 7,1.25ng/µl of human DNA. 
Lanes 8-13 are duplicates of lanes 2-7, with the addition of 100ng of LGV I 
DNA. Lanes 14, and 15 contained 100ng, and 300ng of LGV 1 DNA. Lane 
16, negative control. Lanes A and B-1 kb ladder. 
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transillumination. 
RFLP genotyping 
RFLP genotyping was performed on either the primary or secondary MOMP PCR 
product. lOµ1 of PCR product was initially digested with 2.5U of Alul (Gibco) and 2µl 
of the appropriate enzyme buffer in a total reaction volume of 20µl in a waterbath 
overnight at 37°C. The samples were then analysed through a 7% polyacrylamide gel, 
and the gel was then silver stained. The resulting fragment patterns were compared 
against the RFLP patterns of fifteen reference strains (serovars A to LGV3). Samples that 
were thought to be of genotypes A, C, H, I, J, and LGV3 were further analysed by a 
second round of enzyme digestions. For genotypes C and J, IOµ1 of MOMP PCR 
product was digested with 2.5U of Hinfl; genotypes H, I, and LGV3 were digested with 
2.5U of both EcoRl and Ddell. All enzyme digestions were carried out overnight at 37°C 
in a waterbath. 
Polyacrylamide gel electrophoresis 
Polyacrylamide gels were prepared and run using a Mini-Protean II electrophoresis 
system (Bio-Rad). Before use the glass plates were washed, dried and wiped with 40% 
methanol. The resolving gel was poured first, and water saturated butanol was pipetted 
over the top to give a perfectly flat top surface to the gel. After the gel had set, the 
butanol was removed using 3MM blotting paper, and the stacking gel was laid over the 
resolving gel and the comb added. The gel was left to polymerise at room temperature for 
30min before the comb was removed, and excess liquid removed from the wells using 
fine strips of filter paper. 
The prepared gel was assembled in the Mini Protean gel tank, and the tank was filled with 
1xTBE in both chambers. 10µl of digested MOMP PCR product was added to 2µl of 
loading buffer, and the mixture loaded into one of the gel wells. A 1kb ladder (Gibco) 
diluted 1: 10 was also pre-mixed with loading buffer and loaded onto the gel. Finally the 
gel was run at 200V for approximately 45min, or until the leading dye front had reached 
the bottom of the gel. 
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Silver staining of polyacrylamide gels 
The polyacrylamide gel was carefully removed from the glass plates by immersion in 
200ml of 40% methanol, once detached the gel was left for 30min. The methanol was 
replaced with 200ml of 10% ethanol, and the gel gently shaken for 15min, the ethanol 
was replaced and 200ml of fresh 10% ethanol was added for a further 15n-dn. 
The ethanol was decanted and replaced with 50ml of oxidiser (supplied), and the gel 
shaken gently for 5min. The gel was then washed up to four times in purified water until 
the orange colour of the oxidizer was removed. 50ml of silver reagent (supplied) was 
then added to the gel, the gel shaken for 20min and then finally the gel was rinsed in 
purified water for 1min. The DNA bands were eventually visualized upon the addition of 
50ml developing solution (supplied) pre-warmed to 37°C. The developing solution was 
replaced after 15-20sec with 50ml of fresh developer. 5% acetic acid was used to stop 
the developing reaction. 
3.4.8 Determination of TNF gene polymorphisms 
TNF-a PCR 
Detection of the human TNF-a gene was achieved using the primers TNF-al and TNF- 
a2 (Cabrera et al., 1995). These primers were originally designed to incorporate a 
polymorphic site at position -308 of the TNF-a promoter region. The optimal Mg2+ 
concentration was determined by an Mg2+ titration PCR assay. 
The PCR was performed on 5µl of the extracted DNA sample in a final reaction mix of 
50pl. The final reaction mix contained 1.5 mM MgC12; xl NH4 PCR buffer; 200µM of 
each dNTP; 100pmol of each primer; and IU Taq DNA polymerase. The PCR consisted 
of 35 cycles of amplification, comprising denaturation at 94°C for lmin, primer annealing 
at 60°C for lmin, and primer extension at 72°C for l5sec. Pre-PCR the tubes were 
incubated at 95°C for 3min, 60°C for 35sec and 72°C for lmin. Post-PCR the tubes 
were held at 72°C for 5min. The expected PCR product of 107-bp was visualised under 
UV light on a 2% Nu Seive (FMC Bioproducts) gel under UV after ethidium bromide 
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staining. 
TNF-ß PCR 
Detection of the human TNF-ß gene was achieved using the primers TNF-(31 and TNF- 
ß2 (Messer et al., 1991), which amplify a 740bp fragment from exon 1 to intron 3 of the 
TNF-(3 gene, and also incorporates a polymorphic Ncol site. The optimal Mg2+ 
concentration for PCR was determined by an Mg2+ titration assay. 
The PCR was performed on 5µl of the extracted DNA sample in a final reaction mix of 
50µl. The final reaction mix contained 1.0 mM MgC12; x1 NH4 PCR buffer; 200µM of 
each dNTP; 50pmol of each primer; and 1U Taq DNA polymerase. The PCR consisted 
of 35 cycles of amplification, comprising denaturation at 95°C for lmin, primer annealing 
at 65°C for 45sec, and primer extension at 72°C for 30sec. Pre-PCR the tubes were 
incubated at 95°C for 6min, and post-PCR the tubes were held at 72°C for 5min. The 
expected PCR product of 740-bp was visualised under UV light on a 0.6% agarose gel 
after ethidium bromide staining. 
TNF-a and TNF-ß PCR digests 
For both Ncol digestions, IOpl of the appropriate PCR product was digested overnight at 
37°C, with 6U of Ncol (Gibco) and 30 of the appropriate buffer in a final volume of 
30µl. The TNF-a digests were separated on a 2% Nu Seive gel, and the TNF-ß digests 
on a 0.8% agarose gel before being ethidium bromide stained. The allele distribution for 
both the TNF-a, and TNF-(3 genes was determined under UV light. 
TNF-a wild type homozygotes (TNF-(x-308G/TNF-a-308G) gave two bands after Ncol 
digestion and gel electrophoresis; one band at 87-bp and the other at 20-bp. TNF-a 
heterozygotes (TNF-a-308G/TNF-(x-308A) gave three bands, one band at 107-bp, one 
at 87-bp and the final band at 20-bp. TNF-a -308A homozygotes (TNF-(x-308A/TNF- 
a-308A) gave only a single band at 107-bp due to the loss of the Ncol restriction site on 
both alleles. See Figures 10 and 11. 
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Figure 10. A representative 7.5% polyacrylamide gel of tu nor necrosis 
factor-a polymerase chain reaction products after Nco I digestion. Lane I 
I kb ladder; lane 2, uncut tumor necrosis factor-a polymerase chain reaction 
product; lane 3,308G/308G; lane 4,308G/308A; lane 5,308A/308A. The 
20-bp product was observed faintly on actual gel. 
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Figure 11.2% Nu Seive gel of tumor necrosis factor-(x polymerase chain 
reaction product Nco I digests of actual patient samples. Lane 1,1 kb ladder; 
lanes 2-6,308G/308G; lane 7,308G/308A; lanes 8 and 10,308G/308G; lane 
9,1 kb ladder; lane 11, unusual tumor necrosis factor-a Nco I polymorphism; 
lane 12,308G/308G; lane 13,308G/308A; lane 12,308G/308G, lane 13, 
308G/308A; lane 14,308G/308G; lane 15,308G/308A; lane 16, uncut tumor 
necrosis factor-a polymerase chain reaction product. 
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TNF-ß wild type homozygotes (TNFB*2ITNFB*2) gave a single band of 740-bp after 
Ncol digestion, and gel electrophoresis. TNF-(3 heterozygotes (TNFB*2/TNFB*1) gave 
three bands, one band at 740-bp, one at 555-bp and the final band at 185-bp. TNF-ß 
homozygotes for the Ncol polymorphism (TNFB*1/TNFB*1) gave two bands, one at 
555-bp and the other at 185-bp. See Figures 12 and 13. 
3.4.9 Statistical analysis 
The prevalence rate of C. trachomatis DNA for each study group was compared to the 
appropriate control group using the Fisher Exact Probability Test (2 tailed). A probability 
(P) value of <0.05 was considered to be statistically significant. 
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Figure 12. A representative 1% agarose gel of tumor necrosis factor-(3 
polymerase chain reaction products after Nco I digestion. Lane 1,100-bp 
ladder; lane 2, uncut tumor necrosis factor-F3 polymerase chain reaction 
product; lane 3, TNFB*2/TNFB*2; lane 4, TNFB*2/TNFB* 1; lane 5, 
TNFB* 1/TNFB* 1. The 185-bp product was observed faintly on actual gel. 
Figure 13. A 0.6'; < agarose gel of tumor necrosis factor-(3 polymerase chain 
reaction product Nco 1 digests of actual patient samples. Lanes 1 and 2, 
TNFB*2/TNFB* 1, lane 3, TNFB* l /TNFB* 1; lane 4, TNFB*2/TNFB*2; 
lane 5, TNFB*2/TNFB* l; lane 6, TNFB* 1/TNFB* 1; lanes 7-9, 
TNFB*2/TNFB*2; lane 10, TNFB*2/TNFB* l; lanes 11 and 12, 
TNFB*l/TNFB*l; lane 13,1kb ladder. 
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3.5 PCR and Southern blotting results 
3.5.1 Prevalence of C. trachomatis DNA in Sheffield/Bristol 
The detection of C. trachomatis plasmid DNA by polymerase chain reaction and 
Southern blotting are shown in Table 7, and Graphs 6 and 7. The results for individual 
patients can be found in Appendix 3. 
Sheffield/Bristol. 
% of patients 
Patient group positive for C. Tissue sample breakdown of positive samples 
trachomatis 
DNA. Endometrium Ovary Fallopian 
tube 
Study controls 
mean age= 40yr 15 % 0% 5% 10% 
SD= 6.2 (3/20) (0/19) (1/20) (2/20) 
age range= 33-57yr 
Ectopic pregnancy 
(EP) 56% 22% 22% 33% 
mean age= 31yr (5/9) (2/9) (2/9) (3/9) 
SD= 5.7 
age range= 24-40yr 
Tubal factor 
infertility (TFI) 71% 58% 38% 42% 
mean age= 30yr (10/14) (7/12) (5/13) (5/12) 
SD= 3.7 
age range= 24-36yr 
Control group vs. EP 
Control group vs. TFI 
P>0.05 
P<0.05 
no significant difference 
significant difference 
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Graph 6. Percentage detection of C. trachomatis 
DNA by polymerase chain reaction/Southern blotting 
in the Sheffield/Bristol groups. 
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Graph 7. Percentage detection of C. trachomatis 
DNA by polymerase chain reaction/Southern blotting 
in the individual tissuesites, Sheffield/Bristol. 
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3.5.2 Prevalence of C. trachomatis DNA in Trinidad 
The detection of C. trachomatis plasmid DNA by polymerase chain reaction and Southern 
blotting are shown in Table 8, Graphs 8 and 9. The results for individual patients can be 
found in Appendix 4. 
Trinidad (Mount Hope and Port of Spain). 
% of patients 
Patient group positive for C. Tissue sample breakdown of positive samples 
trachomatis 
DNA. Endometrium Ovary Fallopian 
tube 
Study controls 
mean age= 31.7yr 40% 6% 32% 24% 
SD= 5.3 (12/30) (1/17) (9/28) (7/29) 
age range= 22-44yr 
Ectopic pregnancy 
(EP) 66% 42% 62% 50% 
mean age= 30yr (19/29) (8/19) (13/21) (14/28) 
SD= 6.3 
age range= 16-40yr 
Miscarriage (Msc) 
mean age= 33yr 62% 38 % 45% 33% 
SD= 1.0 (13/21) (3/8) (9/20) (7/21) 
age range= 24-41yr 
Tubal factor 50% 0% 0% 50% 
infertility (TFI) (1/2) (0/2) (0/2) (1/2) 
Control group vs. EP 
Control group vs. Msc 
P>0.05 
P>0.1 
no significant difference 
no significant difference 
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Graph 8. Percentage detection of C. trachomatis 
DNA by polymerase chain reaction/Southern blotting 
in Trinidad. 
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Graph 9. Percentage detection ofC. trachomatis 
DNA by polymerase chain reaction/Southern blotting 
in the individual tissue sites sampled in Trinidad. 
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3.6 MOMP PCR results 
3.6.1 MOMP PCR results 
The results for the determination of the C. trachomatis serovar of MOMP positive 
samples can be found for individual patients in Appendices 3 and 4. 
3.7 TNF polymorphism results 
3.7.1 TNF-a results 
The distribution of the TNF-a polymorphism -308A (P), as determined by PCR and 
Ncol digestion of the PCR product for Sheffield/Bristol can be found in Tables 9 and 10. 
The comparable results for Trinidad can be found in Tables 11 and 12. The frequency (fl 
of the TNF-a 308A polymorphism is expressed as the proportion of P alleles within each 
patient group. The individual TNF-a results for each patient can be found in Appendices 
3 and 4. 
Table 9. The detection of TNF-a-308G (N) and TNF-a-308A (P alleles in 
patients. 
Patient Group N: N N: P P: P number 
(n) 
frequency 
(f) of P 
Study Controls 10 3 0 13 0.115 
EP 6 2 1 9 0.222 
TFI 6 6 1 13 0.308 
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Table 10. The detection of TNF-a-308G (N) and TNF-a-308A (P) alleles in all the 
Sheffield/Bristol study controls compared to ectopic pregnancy (EP) and tubal factor 
infertility (TFI) patients. 
Patient Group N: N N: P P: P number 
(n) 
frequency 
(f) of P 
Study Controls 16 4 0 20 0.100 
EP 6 2 1 9 0.222 
TFI 7 6 1 14 0.286 
Table 11. The detection of TNF-a-308G (N) and TNF-a-308A (P) alleles in Trinidad 
Patient Group N: N N: P P: P number 
(n) 
frequency 
(f) of P 
Study Controls 11 0 0 11 0.000 
EP+TFI 22 4 0 26 0.077 
Miscarriage (Msc) 14 2 0 16 0.063 
Table 12. The detection of TNF-a-308G (N) and TNF-a-308A (P) alleles in all the 
Trinidad study controls compared to ectopic pregnancy (EP). tubal factor infertility (TFI) 
and miscarriage patients. 
Patient Group N: N N: P P: P number 
(n) 
frequency 
(f) of P 
Study Controls 26 3 0 29 0.052 
EP+TFI 25 5 0 30 0.083 
Miscarriage (Msc) 16 3 1 20 0.125 
3.7.2 TNF-ß results 
The distribution of the TNF-ß polymorphism TNFB* 1 (P), as determined by PCR and 
Ncol digestion of the PCR product, for Sheffield/Bristol can be found in Tables 13 and 
14. The comparable results for Trinidad can be found in Tables 15 and 16. The 
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frequency (f) of the TNFB *1 is expressed as the proportion of P alleles within each 
patient group. The individual TNF-ß results for each patient can be found in Appendices 
3 and 4. 
Table 13. The detection of TNFB*2 (N) and TNFB* 1 (P) alleles in Sheffield/Bristol 
Patient Group N: N N: P P: P number 
(n) 
frequency 
(f) of P 
Study Controls 9 4 0 13 0.154 
EP 1 6 2 9 0.556 
TEL 5 6 2 13 0.385 
Table 14. The detection of TNFB*2 (N) and TNFB*1 (P) alleles in all the 
Sheffield/Bristol study controls compared to ectopic pregnancy (EP). and tubal factor 
infertility (TFI) patients. 
Patient Group N: N N: P P: P number 
(n) 
frequency 
(f) of P 
Study Controls 11 9 0 20 0.225 
EP 1 6 2 9 0.556 
TFI 5 7 2 14 0.393 
Table 15. The detection of TNFB*2 (N) and TNFB*1 (P) alleles in Trinidad study 
Patient Group N: N N: P P: P number 
(n) 
frequency 
(f) of P 
Study Controls 6 4 1 11 0.273 
EP+TFI 12 9 5 26 0.365 
Miscarriage (Msc) 8 5 3 16 0.344 
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Table 16. The detection of TNFB*2 (N) and TNFB* 1 (P) alleles in all the Trinidad study 
controls compared to ectopic pregnancy (EP). tubal factor infertility (TFI) and miscarriage 
patients. 
Patient Group N: N N: P P: P number 
(n) 
frequency 
(f) of P 
Study Controls 13 14 2 29 0.310 
EP+TFI 14 9 7 30 0.383 
Miscarriage (Msc) 9 6 5 20 0.400 
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3.8 Conclusion 
3.8.1 Sheffield/Bristol and Trinidad study 
There have been several studies over the past decade that have looked at the prevalence of 
C. trachomatis DNA by PCR in women with ectopic pregnancy (EP), tubal factor 
infertility (TFI) and controls. The type of specimen used for PCR has varied, with 
studies investigating the presence of chlamydial DNA in cervical and urethral swabs 
(Osser et al., 1992), archival cervical smears (Lan et al., 1995), paraffin embedded tubal 
specimens (Lan et al., 1995), and fresh endometrial biopsies (Lan et al., 1995; 
Chernesky et al., 1998). To the best of our knowledge there have been no studies 
reported in the literature that have used fresh endometrial, ovarian and Fallopian tube 
samples taken at the time EP, at the time of surgery for TFI, or from patients with a 
recorded history of miscarriage for PCR. 
This study showed that PCR could successfully be applied to the detection of C. 
trachomatis DNA from fresh tissue specimens. The incorporation of the human ß-globin 
PCR proved to be a reliable method for showing the successful extraction of human 
genomic DNA and the absence of PCR inhibitors. The use of multiple controls set up 
throughout the extraction procedure, and pre-PCR, the use of the GeneAmp Carry Over 
Prevention System coupled with standard PCR anti-contamination methods; and the use 
of a specific oligonucleotide to confirm and detect weak positive PCR products, have 
together given a reliable method for studying the prevalence of C. trachomatis DNA by 
PCR. 
An important consideration in the interpretation of the PCR results discussed in the 
present study is the possibility of sampling error. There is no guarantee that tissue 
samples taken from patients were taken at the site of chlamydial infection, or that 
chlamydial DNA was not lost/diluted beyond the threshold sensitivity of the PCR 
employed giving rise to false negative results. In retrospect perhaps multiple samples of 
the same tissue site should have been taken to help overcome the potential problem of 
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sampling error. 
The discovery of clinical C. trachomatis isolates that lack the 7.5-kb plasmid (Peterson et 
al., 1990: An et al., 1992; Farencena et al., 1997) has prompted much speculation about 
the prevalence of such isolates in the general population. The effect these isolates may 
have on the prevalence rate of C. trachomatis if investigated by plasmid PCR alone is 
unclear, but since only three isolates have been described in the last eight years it may be 
their presence in the population is rare. 
MOMP PCR failed to pick up the majority of plasmid positive samples. While it could be 
argued that those plasmid positive samples which were MOMP PCR negative were false 
positives, it is unlikely due to the anti-contamination methods and controls used. It is 
likely that the amount of chlamydial DNA was very small in extracted samples, since 
most of the plasmid positive samples tested positive only after Southern blotting. 
Plasmid PCR is renowned for its sensitivity due to the presence of multiple copies of the 
plasmid in C. trachomatis. Although nested MOMP PCR as described by Lan et al. 
(1994) is reported to have a sensitivity rivalling that of a single PCR and Southern 
blotting, or nested plasmid PCR, it has in our hands a sensitivity of approximately 100 
times less. Alternately, the presence of high background levels of human genomic DNA 
may have interfered with the amplification of the MOMP PCR product as was shown for 
the chlamydial single plasmid PCR. 
Chlamydial DNA was detected in 15% of the control Sheffield/ Bristol control patients. 
The reported prevalence of C. trachomatis in the UK has ranged from 3.6-9.1 % of 
women attending gynaecology/antenatal or family planning clinics (Fish eta!., 1989; 
Hopwood et al., 1990). It is important to remember that the majority of chlamydial 
epidemiological data is based on either culture or serology which could give a prevalence 
rate that may not truly reflect the carriage of C. trachomatis in the general population. 
To date there have been no studies conducted that have determined the prevalence of C. 
trachomatis DNA in Trinidad by PCR. The only data available have been based on 
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culture (Chout et al., 1995), and DIF (Dowe et al., 1998) in other West Indian countries. 
The former giving a prevalence of C. trachomatis in the cervix of women in Martinique of 
27%, and the latter detected C. trachomatis in the endocervix in 16% of pregnant 
Jamaican women studied. In our study chlamydial DNA was detected in 40% of the 
Trinidad control patients suggesting either a reservoir of persistent C. trachomatis in the 
population, or a very high incidence of asymptomatic/silent chlamydial genital infection.. 
Studies relating C. trachomatis infection and a possible role in miscarriage have given 
conflicting results. None of the studies investigating the possible role of C. trachomatis 
in miscarriage used DNA detection by PCR. Chlamydial DNA was detected in 62% of 
the patients in the miscarriage group, and although this was found not to be statistically 
significant when compared to the control group, it was over 20% greater. Interestingly a 
substantial proportion of the miscarriage patients tested positive in the endometrium 
(P<0.05). 
The mechanism by which C. trachomatis infection of the endometrium could induce 
miscarriage is unclear, it is possible that the presence of the organism facilitates the 
immune rejection of the foetus due to the production of TNF-a and IFN-y. Alternately, 
TNF-a may damage the placenta directly (Clark and Chaouat, 1989; Hill, 1991), or cause 
foetal expulsion due to uterine contraction or the necrosis of implanted embryos; or it 
could act by thrombosing the blood supply to the developing foetus. 
Normal pregnancy is characterized by a lack of a strong maternal cell mediated anti-foetal 
immunity and a dominant humoral immune response (Wegmann et al., 1993; Voisin et 
al., 1995). Some cytokines are beneficial to the success of pregnancy, whereas certain 
cytokines may lead to adverse effects on the conceptus either by direct embryotoxic 
activity or by damaging the placental trophoblast (Hill, 1991): IFN-y inhibits trophoblast 
outgrowth in vitro, IFN-y and TNF-a inhibit embryonic and foetal development as well 
as the proliferation of human trophoblast cell lines in vitro (Haimovici et al., 1991). IFN- 
y in combination with TNF-a is cytotoxic to rodent embryonic fibroblast-like cells 
(Suffrys et al., 1989), and TNF-a mediates apoptotic death of trophoblast cells (Yui et 
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al., 1994). The inflammatory cytokines TNF-a, IFN-y, and IL-2 have all been shown to 
terminate normal pregnancy when injected into pregnant mice (Chaouat eta!., 1990). 
The prevalence of C. trachomatis DNA in the Sheffield/Bristol EP group was 
significantly higher than the appropriate control group (P<0.05). Out of the 29 Trinidad 
EP patients studied many had one or more tissue sites missing and these were therefore 
unavailable for PCR analysis. Of these patients, 66% had detectable C. trachomatis DNA 
in one or more tissue specimens. This was not statistically significant when compared to 
the Trinidad control group (P>0.05) but at a significance level of 10% would have been 
considered significant. 
Within both EP groups, chlamydial DNA was detected in all the sample types by PCR, 
thus stressing the importance of ascending infection in the development of tubal damage 
that can predispose to tubal pregnancy. Osser et al. (1992) studied 33 EP cases for the 
presence of chlamydial DNA by PCR of DNA extracted from paraffin embedded tubal 
material removed at the time of salpingectomy. This study did not detect chlamydial DNA 
in any of the samples and concluded that there was no evidence of a persistent chlamydial 
infection. Conversely this study did demonstrate an association between the presence of 
anti-chlamydial IgG and ectopic pregnancy, suggesting a past and not a current 
chlamydial infection may have been responsible for the development of the EP. 
Lan et al. (1995) reported similar findings in a retrospective study of forty-eight archival 
paraffin embedded salpingectomy specimens from thirty-seven women with EP. This 
study detected chlamydial DNA by PCR in only one patient. However, C. trachomatis 
DNA was detected in genital specimens (cervical smears and/or endometrial biopsies) that 
had been taken up to six years before the ectopic pregnancy. It is interesting to note that 
chlamydial DNA was not detected in endometrial, or cervical specimens taken at the time 
of surgery for EP, implying that a current genital tract C. trachomatis infection was not 
responsible for the EP. It was suggested, that in the cases studied, the EP was a late 
post-inflammatory complication of an ascending C. trachomatis resulting in 
damage/scarring of the Fallopian tube. 
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In Sheffield/Bristol and Trinidad, C. trachomatis DNA was detected in tissue samples 
taken at the time of EP. This apparent difference in the detection rate of chlamydial DNA 
may be due to the use of archival material for DNA extraction, or the amount of paraffin 
embedded material used for extraction. The presence of chlamydial DNA in a high 
proportion of both the Trinidad and Sheffield/Bristol EP groups from all sample types 
may indicate ongoing/persistent infection of C. trachomatis. The question of whether on 
going/persistent chlamydial infection plays a role in the development of tubal damage 
needs to be addressed using such methods as RT-PCR to determine whether the DNA 
detected was from an actively replicating organism/persistent infection, or from the 
persistence of DNA after the clearance of infection, although this is thought to last for 
only a few weeks. 
The detection of chlamydial DNA was significantly higher in the Sheffield/Bristol TFI 
group (P<0.05). Again, like both EP groups, chlamydial DNA was detected in all three 
sample types. 42% of the Sheffield/Bristol TH patients had chlamydial DNA in the 
Fallopian tube implying that at some point the Fallopian tube had been/or was still 
infected with C. trachomatis inducing tubal damage; and 38% of the patients had positive 
ovarian samples which could indicate silent PID. 58% of patients had chlamydial DNA in 
the endometrium, this could indicate an active chlamydial infection. Cleary et al. (1985), 
using culture, recovered C. trachomatis from the endometrium in 25% of TFI patients 
studied with serological evidence of C. trachomatis. It is possible that the 
Sheffield/Bristol TFI group still have an active C. trachomatis infection, and the question 
of the role of active infection and inflammatory damage in women with tubal infertility 
needs to be investigated. 
The importance of a positive ovarian sample by PCR is controversial. It may be that the 
C. trachomatis DNA detected in these patients was a contaminant of the peritoneal cavity, 
as described by Marana et al. (1990) who found by culture, 8/34 infertile women tested 
positive for C. trachomatis with two patients testing positive in the peritoneal fluid. If 
chlamydial contamination of the peritoneal cavity is the answer, it may indicate that those 
patients with a positive ovarian sample may in fact be suffering from silent/asymptomatic 
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chlamydial PID. This would imply that a proportion of patients from both the UK and 
Trinidad in all study groups may have silent/asymptomatic chlamydial PID. 
The question of possible chlamydial infection of the ovarian epithelia is intriguing, it may 
be that such an infection could potentially affect ovarian function/reserve. Positive 
chlamydial serology has been associated with a poor ovarian response to gonadotropin 
stimulation during IVF (Keay et al., 1998). Since IVF can be used in the treatment of 
TFI, TFI patients that have a positive ovarian sample may require alternative NF 
management. 
Within the EP, TFI groups in both the UK and Trinidad, and in the Trinidad miscarriage 
group chlamydial DNA was detected in more than one tissue specimen belonging to a 
particular patient (see Appendices 3 and 4). More importantly the detection of C- 
trachomatis DNA in endometrial samples appears to be suggestive of EP, TFI, or 
miscarriage although many studies have failed to culture C. trachomatis from endometrial 
samples from significant numbers of patients in comparative groups ( Jones et al., 1986b; 
Henry-Suchet et al., 1987; Shepard et al., 1989). Perhaps multiple sampling of the 
endometrium by biopsy may provide a screening method for the presence of C. 
trachomatis, whether an active or persistent infection? 
3.7.2 Polymorphism detection in the TNF gene 
It has been suggested that genetic factors influence susceptibility to the inflammatory 
sequelae of C. trachomatis infection, which has been supported by studies of ocular and 
genital chlamydial infections in humans (Mabey et al., 1992; Turner et al., 1993; Conway 
et al., 1996; Conway et al., 1997). It has been shown that C. trachomatis induced PID is 
associated with the expression of HLA A31, C2, and C3 (Kimani et al., 1996); and the 
expression of major histocompatibility complex (MHC) class II allele DR has been linked 
to the antibody response to chlamydial heat shock protein 60 (CHSP60) in patients with 
trachoma (Peeling et al., 1998). In a macaque model of chlamydial PID, Lichtenwalner et 
al. (1997) concluded that susceptibility or the relative risk to the formation of tubal 
139 
adhesions was correlated to the expression of MHC class I alleles, consistent with similar 
reports of chlamydial immunopathology in humans (Kimani et al., 1996). 
TNF-a has also been shown to be an important mediator of the inflammation process 
induced by chlamydial LPS (Ingails et al., 1995), and TNF-a mRNA has been associated 
with trachomatous inflammation (Bobo et al., 1996), and has been suggested to play a 
role in chlamydial persistence. TNF-a is also known to be involved in the process of 
fibrogenesis and tissue remodelling, including the stimulation of prostaglandin E2, 
glycosaminoglycan and collagenase production by fibroblasts (Dayer et al., 1985; Elias et 
al., 1988; Vassalli et al., 1992). 
TNF-a may also be protective against active C. trachomatis infection, it has been shown 
to have an anti-chlamydial effect both in vitro (Shemer-Avani et al., 1988; Shemer-Avani 
et al., 1989) and in vivo in the C. trachomatis mouse pneumonitis model (Williams et al., 
1990) TNF-a has also been shown to be secreted at the genital site of C. psittaci 
infection in guinea pigs (Darville et al., 1995), and in women with salpingitis (Toth et al., 
1992) 
In cases of salpingitis, which can lead to tubal damage predisposing to ectopic pregnancy 
and tubal factor infertility, an immune mechanism may also contribute to damage of the 
Fallopian tube. Toth et al. (1992) examined fluids from the reproductive tract of seven 
women with salpingitis, and five controls for the presence of TNF-a. Three women with 
salpingitis, who were also culture positive for C. trachomatis showed TNF-a only in 
Fallopian tubes showing actual signs of disease. All control patients had negative 
findings at all genital tract sites. Only one patient had detectable levels of serum TNF-a, 
suggesting a localized cell-mediated immune activation in response to salpingitis. 
In the UK, homozygous TNF-a-308A and TNFB* 1 were not identified in the control 
group. The presence of the TNF-a-308A Ncol polymorphism was found to be 
associated with TFI, as was the presence of the TNFB* 1 Ncol polymorphism in patients 
with evidence of having/or having had a chlamydial infection. In the EP group the TNF- 
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a-308A Ncol polymorphism did not appear to be associated with the development of EP, 
but the presence of the TNFB *1 Nco 1 was associated with the EP group (with anti- 
chlamydial, or without anti-chlamydial antibodies). 
Polymorphisms in the TNF gene have been shown to affect transcriptional regulation, 
and in women with TFI increased levels of TNF-a production may induce immune 
mediated tissue destruction. In trachoma increased levels of TNF-a have been associated 
with high chlamydial loads and severe follicular inflammation (Bobo et al., 1996) 
Conversely, if TNF-a production is reduced the infection may be not be cleared, or 
become persistent which could also lead to immune mediated tubal damage. 
In Trinidad homozygous TNF-a-308A patients were not detected in the control group, 
although TNFB*1 homozygotes were. In Trinidad the presence of either Ncol 
polymorphism in the TNF gene was found not to be associated with either EP or 
miscarriage. 
The data collected in this pilot study suggests in the UK that the TNF-a-308A 
polymorphism may be linked to TFI, independent of the detection of anti-chlamydial 
antibody. The TNFB*1 polymorphism, in the same group, appears to be linked to the 
detection of anti-chlamydial antibody. For the UK EP group, only the TNFB* 1 
polymorphism appeared to be detected in patients with antibodies against C. trachomatis. 
In the UK, in the small number of patients investigated the TNFB* 1 polymorphism may 
be associated with the development of tubal pathology in response to a chlamydial 
infection. In Trinidad there appeared to be no association in the detection of TNF gene 
polymorphisms in any of the study groups, irrespective of anti-chlamydial antibody 
status. 
Although it would be advantageous to be able to identify those women at risk from the 
adverse sequelae of chlamydial genital tract infection, it may be difficult to pin down a 
single genetic marker found exclusively in patients with tubal damage. It may be that a 
much larger genetic study encompassing HLA typing as well as the detection of 
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polymorphisms in genes of the TNF locus may hold some insight into the possible 
genetic deposition of some individuals to the deleterious effects of a chlamydial infection. 
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Chapter 4.0 
In situ hybridization (ISH) 
4.1 Aims of chapter 
The aim of work contained in this chapter was to develop an in situ hybridization (ISH) 
protocol that could be used to determine the prevalence of C. trachomatis in paraffin 
embedded genital tract tissue specimens from women with EP, TFI or miscarriage. 
Patients from both Sheffield/Bristol and Trinidad included women presenting with ectopic 
pregnancy (EP), miscarriage, tubal factor infertility (TFI), and controls undergoing either 
hysterectomy, or tubal sterilization. Three formalin fixed paraffin embedded tissue 
samples from each patient (endometrial, ovarian and Fallopian tube) were examined for 
the presence of C. trachomatis by ISH. 
Also histological evidence of inflammation in the tissue specimens was investigated to 
determine whether inflammation correlated with the presence of C. trachomatis infection 
as assessed by the detection of chlamydial DNA. 
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4.2 Introduction 
Serological studies on women with both ectopic pregnancy (EP) and tubal factor 
infertility (TFI) have demonstrated a strong association with chlamydial infection and 
tubal damage. However in these patient groups C. trachomatis has rarely been cultured 
from the reproductive tract (Henry-Suchet et al., 1981; Cleary et al., 1985; Thejls et al., 
1991; Patton et al., 1994b; Radouani et al., 1997), and the question of chlamydial 
persistence within genital tract tissues still remains somewhat of an enigma. 
Obstruction of the Fallopian tubes resulting in infertility has been associated with 
chlamydial genital tract infection, but the actual mechanism by which the pathological 
changes develop is not fully understood. Acute salpingitis caused by C. trachomatis 
infection is associated with acute inflammation in the adjacent perisalpinx and 
parametrium, resulting in tubal damage, oedema and congestion. Microscopically there is 
an infiltrate of neutrophil polymorphs which may be followed by the loss of cilia. 
Chronic salpingitis, which consists of a plasma cell and mononuclear leukocyte infiltrate 
is not uncommon. In other cases the end result of tubal inflammation may be the 
formation of a hydrosalpinx, in which the tubes become distended with watery fluid due 
to the failure of the drainage of excess tubal fluid. 
It has been suggested that one of the main mechanisms that may be involved in the 
immune mediated damage of the Fallopian tubes may be a delayed type hypersensitivity 
response (DTH) similar to that seen with repeated exposure to C. trachomatis in scarring 
trachoma. It is thereby possible that repeated chlamydial infection of the upper female 
genital tract, or the persistence of C. trachomatis within such tissues is central to the 
development of DTH. It has been noted that the incidence of tubal obstruction increases 
with the number of episodes of chlamydial pelvic inflammatory disease (PID) (Svensson 
et al., 1983). 
One of the first investigations into the presence of C. trachomatis in Fallopian tubes of 
women with acute salpingitis was published in 1979 by Moller et al. This study did not 
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find any chlamydial inclusions by electron microscopy and noted that ciliated cells did not 
show any notable structural changes although the nucleus of ciliated cells did show 
degenerative alterations with a distorted morphology. Non-ciliated secretory cells 
showed protrusions with plenty of microvilli indicating an increased luminal surface. In 
non-ciliated epithelial cells, an increased number of lysosomes were seen suggesting 
increased secretory activity. 
In animal model studies it has been shown that repeated chlamydial infection of the 
Fallopian tubes with Chlamydia resulted in the characteristic pathological changes 
associated with DTH, when compared against controls infected only once (Patton et al., 
1987; Patton et al., 1989a; Tuffrey et al., 1990; Patton et al., 1994a). Although in these 
studies the route of infection was by direct inoculation into the uterine horns, Rank et al. 
(1995a) demonstrated the same phenomenon with repeated chlamydial infection via the 
natural vaginal route. 
In the guinea pig model of repeated chlamydial infection (Rank et al., 1995a) tubal 
blockage was associated with mesosalpingeal fibrosis. Scanning electron microscopy, 30 
days post-infection confirmed significant alterations in the ciliated and secretory epithelial 
cells of the tubal mucosa suggestive of tubal dysfunction. Similar observation of tubal 
damage associated with hydrosalpinx induced by chlamydial infection have been seen in 
mice (Patton et al., 1989b), rabbits (Patton et al., 1982), and guinea pigs (Sweet et al., 
1980; Schachter et al., 1982; Rank et al., 1992; Rank et al., 1995a) 
In situ hybridization (ISH) may be defined as the direct detection/ localisation of specific 
nucleic acid sequences in intact cellular material. The technique of ISH was originally 
described simultaneously by two research groups working both in the United Kingdom 
(John et al., 1969), and in the USA (Gall and Pardue, 1969). In clinical situations, ISH 
has been used to provide cytological information on the location/mutation of genomic 
sequences in metaphase spreads as well as the direct detection of nucleic acid sequences 
of microbial origin in paraffin embedded, and frozen material. 
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The basic principle of ISH involves the pre-treatment of the cellular/tissue preparation to 
unmask the target nucleic acid; the hybridization of a nucleic acid probe to a 
complementary region of the target sequence; and finally the detection of the labelled 
probe followed by the subsequent visualization of the target/probe complex. 
In situ hybridization can be performed using probes that have been isotopically labelled, 
followed by autoradiography for the detection of hybridized duplexes; or by using probes 
labelled non-istopically, with for example biotin coupled with a streptavidin detection 
system. However the use of isotopic probes is time consuming, and quicker and safer 
approaches using non-isotopic probe labels have been developed. The disadvantage of 
using biotinylated probes is that biotin has a widespread endogenous tissue distribution 
contributing to high back ground/non-specific staining. Other labels such as digoxigenin 
and fluorescein in conjunction with a Fab fragment antibody conjugate system have been 
found to exhibit equal or superior sensitivity to biotin with lower non-specific 
background staining. 
ISH has been used in the detection of chlamydial DNA in a variety of studies using many 
different sample types including rectal biopsies (Horn et al., 1988); culture (Horn et al., 
1986; Naher et al., 1988); cervical specimens (Horn et al., 1986; Ghirardini et al., 1991); 
synovial tissue from patients with Reiter's syndrome (Beutler et al., 1995); semen 
specimens (Yoshida et al., 1994); and prostate biopsies (Corradi et al., 1996). 
C. trachomatis DNA was first demonstrated by ISH in Fallopian tube tissue from patients 
with tubal infertility by Campbell et al. (1993) who showed chlamydial DNA in 44% of 
the TFI patients studied. This was later confirmed in a study by Patton et al. (1994) who 
concluded that chlamydial infection of the salpinx tended to be chronic and asymptomatic. 
In the monkey model of chlamydial salpingitis and tubal infertility, chlamydial DNA was 
detected at the sites of inflammation and tissue damage by ISH (Cappuccio et al., 1994). 
It was suggested that C. trachomatis could persist in Fallopian tube specimens, and may 
be directly involved in the stimulation of the immune-mediated tissue destruction. 
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4.3 Materials 
4.3.1 Reagents 
Reagents were purchased from Sigma (Dorset, UK) unless otherwise stated. 
4.3.2 EcoRl 2.5kb probe preparation 
Ampicillin was prepared in sterile water as a stock solution of 50mg/ml, and stored at 
4°C. Ampicillin was added to cooled nutrient broth or agar to give a final concentration of 
50µg/m1. 
E. coli JM83 carrying the recombinant plasmid pCTL12A was originally acquired from 
Prof. Ian Clarke, University of Southampton, UK. 
Nutrient broth and agar were purchased from Oxoid Ltd. (Hants, UK), and prepared 
as per the manufacturer's instructions. 
Restriction endonucleases and the relevant buffer system were purchased from 
Gibco Life Technologies Ltd. (Paisley, UK) and stored at -20°C. 
4.3.3 Polymerase Chain Reaction (PCR) 
OmniGene PCR machine (Hybaid Ltd., Middlesex, UK) with a heated lid was used 
for all PCR applications. An Omni Gene flat block satellite module was used for non- 
isotopic in situ hybridization. 
Sterile aeroguard tips and positive displacement tips were purchased from Alpha 
Laboratories Ltd., Hampshire, UK. 
0.5m1 PCR tubes were purchased from GeneMate (Kaysville, UT, USA), and were 
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validated as being DNase and RNase free. They were autoclaved prior to use. 
Stock nucleotides containing dATP, dCTP, dGTP, and dTTP were purchased as a 
polymerisation mix (Bioline, London, UK). The DNA polymerisation mix contained 
20mM of each nucleotide in solution, and was stored at -20°C in a designated DNA-free 
freezer. 
Cloned Pfu DNA polymerase was obtained from Stratagene Ltd. (Cambridge, UK), 
at a concentration of 2.5U/µ1. The polymerase was stored at -20°C in a designated DNA- 
free freezer. 
x10 Pfu PCR reaction buffer was supplied by Stratagene and contained 200mM 
Tris-HCI, 20mM MgSO4,100mM KC1,100mM (NH4)2SO4,1% Triton X-100 and 
1mg/ml nuclease-free BSA. 
4.3.4 PCR primers 
PCR primers were purchased from R&D Systems Ltd. at 0.2mM with no further 
purification, diluted to 100pmol/pl and aliquots of 100 pl were stored at -20°C. One 
aliquot was stored at 4°C for routine day to day use. 
Nested Chlamydia trachomatis PCR primers 
The primary PCR primers, Ti and T2, have been previously described (p. 98). 
binding position 
(nucleotide [nt]) 
T3 Forward 5' ATC CAT TgC gTA gAT CTC Cg 3' 2622-2641nt 
T4 Reverse 5' gCC ATg TCT ATA gCT AAA gC 3' 2940-2921nt 
The binding position of primers T3 and T4 were based on the published sequence of the 
C. trachomatis 7.5kb plasmid (Hatt et al., 1988). Ti and T2 were originally designed by 
Claas et al. (1990), T3 and T4 were in-house primers. 
148 
Human (3-globin primers (Saiki et al., 1985; Lan et at., 1995) 
The PCR primers PC03 and PCO6 used for the detection of human genomic DNA were 
as previously described (p. 98). 
4.3.5 Isotopic in situ hybridization 
[a_35S]dCTPaS was purchased from Amersham Life Sciences (Bucks, UK) with a 
specific activity of >1000Ci/mmol (product code SJ 1305). The storage and handling of 
the radiolabelled nucleotide was as per the manufacturer's guidelines. 
Proteinase K stock solution of 20mg/ml was made in sterile water, and 50µ1 
aliquots were stored at -20°C. 
1M DTT stock solution was made in sterile water and stored in lml aliquots at -20°C. 
100% de-ionized formamide was made using AG501-X8 resin (BioRad Ltd., 
Herts, UK). 20g of resin was initially washed with 20m1 of formamide, the liquid was 
discarded. 400m1 of formamide was then added to the resin, and the mixture stirred for 
lh. Finally the deionized formamide was filtered twice through filter paper to remove the 
resin and aliquoted in 50xlml volumes and stored at -20°C. The remaining 350m1 was 
used to make 95% deionized formamide. 
95 % deionized formamide 
100% deionized formamide 332.5m1 
O. 1xSSC 17.5ml 
The solution was placed in a glass bottle, and the bottle covered in foil due to the light- 
sensitive nature of the solution. 
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x10 ISH buffer 
20mM sodium acetate 0.164g 
3M NaCl 17.532g 
10mM EDTA 0.372g 
sterile purified water loon-1 
The sodium acetate was initially added to the 100ml of sterile water, and the pH of the 
solution was adjusted to 5.0 before the addition of the rest of the buffer components. The 
ISH buffer was stored at -20°C. 
Proteinase K digestion buffer 
100mM Tris-base 12.118 
50mM EDTA 18.61g 
sterile purified water 1L 
350ml volumes were stored at -20°C. The digestion buffer was pre-warmed to 65°C and 
10mM of DTT and 5pg/ml of proteinase K was added before use. 
50 % dextran sulphate was made by the addition of 5g of dextran sulphate to I Oml of 
sterile purified water. The solution was heated to facilitate the dissolving of the dextran 
sulphate before the solution was aliquoted in 350µl volumes and stored at -20°C. 
Blocking buffer 
100% deionized formamide 500µl 
50% dextran sulphate 2O0µ1 
xlO ISH buffer 100µI 
50xDenhardt's solution (Amersham) 40µl 
10mg/ml ssDNA 10µ1 
purified water l30pl 
The blocking buffer was prepared fresh for each ISH run. 
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Hybridization buffer 
100% deionized formamide 25Oµ1 
50% dextran sulphate l00µ1 
x10 ISH buffer 50µ1 
50xDenhardt's solution (Amersham) 20µl 
10mg/ml ssDNA 5µl 
The amount of probe used was calculated to give 1x105cpm/10µd of hybridization 
solution (taking into account 35S has a half life of 87.4 days), the final volume of the 
hybridization solution was made up to 495µl with purified water. 
NTB-2 emulsion was purchased from Kodak (IBI Ltd., Cambridge, UK) and stored 
in a light-tight container at 4°C away from any radioactive sources. 
D-19 developer and Rapid Fix were purchased from Kodak, and prepared as per 
the manufacturer's instructions. Both solutions once prepared were stored at 4°C and 
used cold. 
4.3.6 Dot blotting 
HybondTM-N+ positively charged membrane was purchased from Amersham. 
Denaturation solution 
1.5M NaCl 87.66g 
0.5M NaOH 20. Og 
purified water 1000ml 
Neutralization solution 
1.5M NaCl 87.66g 
0.5M Tris-HC1 78.8g 
purified water 1000ml 
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4.3.7 ECL direct hybridization solutions 
The ECL direct hybridization kit was purchased from Amersham and stored at 4°C. 
ECL direct hybridization buffer 
hybridization buffer (supplied) 475m1 
liquid block (supplied) 25m1 
0.5M NaCl 14.6g 
The hydridization buffer and liquid block were warmed to 40°C, the NaCl added and the 
buffer stirred until all the salt had dissolved. The buffer was aliquoted in 10ml amounts 
and stored at -20°C for a maximum of 3 months. 
20xSSC stock solution 
0.3M Na3C6H5O7.2H20 88.2g 
3M NaC1 175.3g 
purified water 1000ml 
The pH was adjusted to 7.0, autoclaved and the solution stored at room temperature. 
Primary wash buffer 
6M urea 360g 
0.4% (w/v) SDS 4g 
20xSSC 25m1 
purified water 975m1 
The buffer was stored at 4°C. 
Secondary wash buffer 
20xSSC l00m1 
water 900m1 
The buffer was stored at 4°C. 
ECL detection reagents (supplied) were mixed in equal volumes in safe-light 
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conditions and used immediately. 
Hyperfilm ECL autoradiography paper was obtained from Amersham and stored in the 
dark at room temperature. 
Ilford PQ universal developer was purchased from Ilford Ltd. (Cheshire, UK), and 
diluted 1: 10 with water before use. 
Ilford Ilforspeed fixer was purchased from Ilford Ltd. and diluted 1: 4 with water 
before use. 
4.3.8 Non-isotopic in situ hybridization (NISH) 
The Amersham DNA colour Kit was used for NISH. The anti-fluorescein alkaline 
phosphatase (AP) conjugate and blocking component were stored at 4°C, and the 
remainder of the kit at -20°C. 
Glassware was cleaned in 7x detergent (ICN Biomedical, Oxfordshire, UK), rinsed in 
tap water followed by sterile purified water and finally dried at 80°C for a minimum of 
24h. 
Phosphate buffered saline (PBS) was prepared by dissolving a PBS tablet (Oxoid) 
in 100ml of water, which was then autoclaved and stored at room temperature. 
TBS buffer 
10mM Tris-HC1 15.76g 
400mM NaCl 23.38g 
purified water l000ml 
The pH was adjusted to 7.5, the solution was then autoclaved and stored at room 
temperature. 
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Pepsin digestion buffer 
0.2M HCl 350m1 
pepsin (500gg/m1) 0.7m1 
The pepsin (activity of 3200-4500U/mg protein)was prepared as a stock solution of 
500pg/ml in purified water and stored in lml aliquots at -20°C. The pepsin digestion 
buffer containing 1 µg/ml pepsin was prepared fresh for each ISH run. 
ISH hybridization buffer 
As supplied in Amersham DNA Colour Kit. 
4xSSC 
2x Denhardt's solution 
600pghnl herring testes DNA 
rate enhancing compound 
The hybridization buffer was supplied as a 2x concentrate, for ISH it was diluted 1: 1 with 
deionized formamide. The working ISH buffer was aliquoted in lml amounts and stored 
at -20°C. 
ISH wash 1 
20xSSC 25m1 
0.1% (w/v) SDS 0.5g 
purified water 475m1 
The buffer was stored at room temperature. 
ISH wash 2 
20xSSC 12.5ml 
0.1% (w/v) SDS 0.5g 
purified water 475m1 
The buffer was stored at room temperature. 
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ISH Blocking solution 
TBS 500m1 
0.5% (w/v) blocking component (supplied) 2.5g 
The blocking solution was gently warmed until the blocking component had fully 
dissolved and was then stored at 4°C. Before use the blocking solution was pre-warmed 
to 37°C. 
Antibody solution 
TBS 500ml 
0.5% (w/v) BSA fraction V (Winlab) 2.5g 
The solution was stored at 4°C. Prior to use the anti-fluorescein alkaline phosphatase 
conjugate (supplied in the Amersham DNA Colour Kit) was diluted to 1: 500 in the 
antibody solution. 
Detection buffer 
I OOmM Tris-HC1 15.8g 
100mM NaCl 5.8g 
50mM MgC12 4.8g 
purified water 1000ml 
The Tris-HC1 and NaC1 were pre-mixed with water and the pH adjusted to 9.5, finally the 
MgCl2 was added and the solution stored at 4°C. 
Substrate Solution 
detection buffer 10ml 
nitroblue tetrazolium (NBT, supplied) 45µ1 
5-bromo-4-chloro-3-indolyl phosphate (BCIP, supplied) 35µl 
The substrate solution was prepared fresh for each NISH run. 
1% (w/v) Methyl green counterstain was prepared by washing the appropriate 
amount of methyl green (BDH) in chloroform to remove impurities, and was finally 
diluted to the correct concentration in water. 
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4.3.9 Patient specimens 
Specimens were collected from Sheffield (Jessop Hospital for Women), Bristol (St. 
Michael's Hospital) and Trinidad (Mount Hope Women's Hospital; St. Augustine and the 
General Hospital, Port of Spain). From Sheffield/Bristol, three study groups were 
examined, women presenting with ectopic pregnancy (EP), women undergoing surgery 
for tubal factor infertility (TFI), and control patients. From Trinidad, four study groups 
were considered, women presenting with EP, women with a history of miscarriage, 
women undergoing surgery for tubal factor infertility, and control patients. The 
specimens taken from the miscarriage group were taken retrospectively. The study 
controls from Sheffield/Bristol were hysterectomy patients and controls from Trinidad 
were patients undergoing sterilization. The study had Ethics Committee approval at all 
sites (UK and Trinidad). 
Three tissue samples were collected from each patient in the study; an endometrial sample; 
a sample of the Fallopian tube (ampulla, isthmus or fimbriae); and an ovarian core 
biopsy. For the patients belonging to the EP groups, tissue samples were taken at the 
time of surgery, and Fallopian tube samples were taken from the site of the EP. Tissue 
samples were fixed immediately in 10% clear neutral buffered formalin for a maximum 
of 24h and a minimum of 2h for histological examination, and in situ hybridization. 
Samples were coded with a patient reference number and the sample type. 
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4.4 Methods 
4.4.1 Histological processing 
Histology Processing Schedule 
Samples were fixed for a maximum of 24h in clear neutral buffered formalin. Samples 
were then removed to a Shandon Citadel 2000 automatic processor for the following: - 2h 
in 70% alcohol x3; 2h in 95% alcohol x3; 2h in absolute alcohol x2; 2h in xylene x2; the 
samples were then immersed in paraffin wax for 2h and then in paraffin wax under 
vacuum for a further 2h. Samples were finally orientated and embedded in paraffin wax 
prior to sectioning 
APES coating of slides 
This was as previously described by van Prooijen-Knegt et al. (1983). Briefly, clean 
glass microscope slides (BDH Chemicals, Poole, UK) were immersed in 1% (v/v) lipsol 
for 30min, washed under running tap water for a further 30min, rinsed twice in distilled 
water and finally dried overnight at 37°C. The slides were then coated in a freshly 
prepared 1% (v/v) 3-aminopropyltriethoxysilane (APES) in acetone, rinsed twice in 
acetone followed by washing twice in distilled water. Finally the slides were dried 
overnight at 37°C, and stored in a dust free environment at room temperature. 
Sectioning 5µm sections were cut onto APES coated slides and dried at 37°C. Coated 
slides were finally stored in foil and used within 1 month. 
Haematoxylin and Eosin staining 
5µm sections were also cut onto glass slides for haematoxylin and Eosin staining (H&E 
staining). The sections were initially dewaxed in xylene twice for 2min, rehydrated 
through graded ethanol (100% x2,95% x2,70% x2) and finally rinsed in water for 
1min. Slides were then dipped in Gill's Haematoxylin (BDH) for 2min, washed in tap 
water, placed in Scott's tap water substitute and then washed again in tap water. Slides 
were then placed in 1% Eosin (w/v) for 5min, rinsed briefly in water, dehydrated through 
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graded ethanol (2x70%, 2x95%, 2x100%) before being placed in xylene. Finally the 
sections were mounted in picolyte (Phase Separation Ltd., Clywd, UK) and dried at 
room temperature. 
4.4.2 Isotopic probe preparation 
326-bp human ß-globin probe preparation 
The double stranded DNA probe for the detection of human ß-globin DNA was 
generated via PCR using primers PCO3 (Saiki et al., 1985), and PCO6 (Lan et al., 
1995). 
The PCR was performed on 1 µl of human placental DNA diluted to 1 pg/pl in a final 
reaction mix of 50µl. The final reaction mix contained 1.0mM MgC12; X1 Pfu PCR 
buffer; 200pM of dNTP; 50pmol of each primer; and 2.5U Pfu DNA polymerase. The 
PCR consisted of 25 cycles of amplification, comprising denaturation at 94°C for 40sec, 
primer annealing at 55°C for 40sec, and primer extension at 72°C for lmin. Pre-PCR the 
tubes were incubated at 95°C for 4min, and post PCR at 72°C for 8min. The expected 
PCR product of 326-bp was visualised under UV light on a 0.8% agarose gel after 
ethidium bromide staining. The remaining PCR product was purified through a 
QlAquick column (Qiagen Ltd., Crawley, UK) as per the manufacturer's instructions to 
remove primers, Pfu and dNTP's. Finally, the probe concentration was measured at 
260nm, aliquoted in l0µ1 amounts and stored at -20°C. 
EcoRl 2.5kb probe preparation 
The recombinant plasmid pCTL12A containing pUC18 and Pstl digested pLGV440 
(originally from C. trachomatis L1/440/LN) in E. coli JM83 was initially grown on 
ampicillin nutrient agar (Hatt et al., 1988). A single colony was inoculated into 5m1 
nutrient broth and the culture shaken at 37°C overnight. The recombinant plasmid 
pCTL12A was recovered from 3m1 of the resulting cellular suspension using the Wizard 
Plus Miniprep DNA purification system (Promega, Southampton, UK) as per the 
manufacturer's instructions. 
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The final purity of the plasmid preparation, and confirmation of the plasmid size was 
achieved by overnight digestion with Pstl. The digest was run on a 0.6% agarose gel, 
two fragments were observed, one fragment measured approximately 2.7kb (linearized 
pUC18) the other 7.5kb (linearized chlamydial plasmid). The 7.5kb fragment was 
extracted from the gel and the DNA purified using the Qiagen QlAquick gel extraction kit 
as per the manufacturer's protocol. The purified 7.5kb fragment was then digested with 
EcoRl overnight and the digest run on a 0.6% agarose gel. Two fragments were 
visualized after ethidium bromide staining and UV transillumination, one fragment was 
found to be approximately 5kb, the remaining fragment was 2.5kb. The 2.5kb fragment 
was removed from the gel and purified as previously discussed. 
Finally the DNA concentration of the 2.5kb EcoR 1 fragment was measured using a 
spectrophotometer, and stored at -20°C. 
4.4.3 Isotopic ISH 
ISH probe labelling 
The manufacture and storage of the radioactive probes was carried out in a designated 
radioactive area. Each probe was diluted in sterile purified water to a final concentration 
of 25ng in 10µl, denatured by boiling for 10min, and snap cooled on ice. The labelling 
reagents (Amersham Multiprime DNA labelling system) were thawed on ice prior to use. 
To 25ng of probe the following were added; lOpl of buffer (supplied); 2µl of primer 
containing random hexanucleotides; 2 i1 of Klenow fragment (2U/µ1); 2.5µl of 
radiolabelled dCTP; and the total volume was made up to 5O0 with sterile purified water. 
The labelling reaction was left to proceed at room temperature overnight. 
The initial specific activity of the labelled probes was calculated as per the manufacturers 
instructions to be approximately 8xlO8dpm/ug of DNA. Finally the radioactively labelled 
probes were stored at -20°C for a maximum of 5 weeks. 
159 
Isotopic ISH methodology 
The isotopic methodology was based on the work of Campbell et al. (1993) and Patton et 
A (1994). 
Pre-hybridization 
The sections were de-waxed in xylene for 15min, rehydrated through graded ethanol 
(3x100%; 2x95%; 1x70%; lxwater) and then soaked in 0.2N HCl for 15min at room 
temperature. The sections were then rinsed in water and washed gently in approximately 
1L of 2xSSC for 30min at room temperature. Sections were then lightly digested with 
the proteinase K digestion buffer for 5min and rinsed in water before being post-fixed in 
10% formalin for 5min. The slides were then washed in water and left for lmin in 0.1M 
triethanolamine (pH 8.0), excess buffer was removed carefully by blotting. Acetic 
anhydride (final concentration of 0.25% in 0.1M triethanolamine) was added to a clean 
staining dish, the sections left to soak for 10min and then rinsed in water. Slides were 
then washed in 2xSSC for 30min at room temperature and rinsed in water before being 
dehydrated through graded ethanol (1x70%; 2x95%; 3x100%). Sections were then 
soaked in 95% formamide at 65°C for 15min, followed by 10min in ice cold 0.1xSSC for 
10min and rinsed in water. Finally the slides were dehydrated through graded ethanol 
and left to drain. 
Blocking of non-specific hybridization was achieved using a blocking buffer (I ml) which 
was boiled for 10min, and then chilled on ice for 5min before the addition of 2Oµ1 of 1M 
DTT. The final blocking buffer was then vortexed, 10-30VI (depending in the section 
size) was applied over each section and a glass coverslip placed over the top. Sections 
were then placed in a box containing a moist paper towel and incubated at 42°C for 2h. 
After incubation the coverslips were floated off in 2xSSC (2min), rinsed in water and 
dehydrated through graded ethanol. The sections were then ready for hybridization with 
the isotopic probe. 
Hybridization 
All the steps proceeding the pre-hybridization steps were carried out in a designated radio- 
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isotope lab, radioactive waste was disposed of as per the University of Sheffield's 
guidelines. Appropriate shielding, safety precautions and monitoring were used at all 
times. The hybridization buffer containing the radioactively labelled probe was boiled for 
10min, and chilled immediately on ice for 10min before the addition of DTT to a final 
concentration of 20mM. An appropriate volume of hybridization buffer to cover each 
section was applied over the dehydrated tissues using an ISH EasiSeal (Hybaid). The 
EasiSeal was sealed and the slides left to hybridize overnight at 42°C in a moist chamber. 
Post-hybridization 
The EasiSeal was carefully removed, and the slides subjected to stringency washing in 
three changes of 4xSSC containing 10mM DTT (first wash, 15min; second wash, 15min; 
final wash, 30min). The slides were then washed in 1L of 2xSSC containing 10mM 
DTT for 30min at 37°C, followed by 1L of O. 1xSSC containing 10mM DTT for 30min at 
42°C. Finally the slides were washed in 0.1xSSC containing 10mM DTT for 30min at 
37°C, rinsed in water and dehydrated through graded ethanol containing 300mM 
ammonium acetate and left to air dry. 
Under the appropriate safe-light conditions in a dark room the NTB-2 emulsion (Kodak) 
was melted in a beaker of hot water. 10ml of emulsion was diluted 1: 1 with 600mM 
sodium acetate in a dipping chamber and the mixture allowed to aerate for 20min. The 
mixture was not shaken as this could introduce air bubbles into the emulsion which 
affects slide coating. Before the commencement of slide dipping a plain glass slide was 
dipped into the diluted emulsion to remove any air bubbles. Sections were dipped into 
the emulsion smoothly and evenly twice. The slides were allowed to dry vertically in a 
light-tight box for 3h before being transferred to a slide box containing a desiccant. The 
slide box was wrapped in multiple layers of foil followed by a black plastic bag and left to 
develop for 3 days at 4°C. 
Developing hybridization signal 
Under safe-light conditions the slides were removed from the box to slide carriers. The 
slides were developed for 3min in Kodak D-19 developer, rinsed in 2% acetic acid for 
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30sec to stop the developing reaction, and finally fixed for 5min in Kodak Rapid Fix. The 
sections were then washed in running water for 5min and then left to air dry if H&E 
counterstaining was not to be done the same day. After counterstaining the sections were 
examined by light microscopy. 
One major problem encounted with the isotopic ISH procedure was the development of 
high levels of non-specific background staining. This occurred both on positive and 
negative control slides and tissue sections making the discernment of a true C. 
trachomatis or (3-globin positive signal impossible. Both probes were tested for 
specificity using the Amersham ECL direct kit. Each probe was labelled using the kit 
and then used to hybridize to dot blots containing C. trachomatis DNA, purified C. 
trachomatis 7.5kb plasmid DNA, pUC18 DNA and human DNA. The EcoR12.5kb C. 
trachomatis probe was shown to hybridize against only the C. trachomatis DNA and 
purified C. trachomatis plasmid DNA (Figure 14). The human (3-globin probe was 
found to hybridize only to human DNA (Figure 15). 
Stringency washes and temperatures were increased, as was the concentration of acetic 
anhydride used in the pre-hybridization step, all of which had little effect on reducing the 
levels of background signal. 
Finally the emulsion itself was investigated. As previously described the emulsion was 
prepared using 600mM ammonium acetate in complete darkness. Three plain glass slides 
were dipped in the diluted emulsion one was placed immediately in a light-tight box, one 
was exposed under safe-light conditions before storing in a light-tight box, the last slide 
was exposed to white light. All three slides were developed in total darkness. All the 
slides showed the development of a background signal. It was concluded from this that 
either the emulsion had been exposed to an unknown radioactive source, or that the 
darkroom conditions were inadequate. The same effect was observed with a new batch 
of emulsion that had been stored in a different location. 
Due to the problems encounted with the radioactive ISH, a non-radioactive in situ 
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Figure 14. Dot blot using the 2.5kb EcoRl C. trachoinatis probe. 
A-pUC 18 DNA; B-LGV I DNA; C-human DNA; D-pCTL 12A; 
E, 7.5kb C. trachomatis plasmid fragment; F, 2.5kb EcoR 1 
C. trachomatis fragment. 
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Figure 15. Dot blot using the 326-bp human-(3 globin specific probe. 
A-pUC 18 DNA; B-LGV 1 DNA; C-human DNA; D-pCTL 12A; 
E, 7.5kb C. trachomatis plasmid fragment; F, 326-bp human-(3 globin 
polymerase chain reaction product. 
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hybridization protocol (NISH) was developed. 
4.4.4 NISH probe preparation 
326-bp human ß-globin probe preparation 
The human ß-globin PCR product as previously described was also used for NISH 
320-bp C. trachomatis probe preparation 
The DNA probe for the detection C. trachomatis was a double stranded 320-bp DNA 
PCR product produced via a nested PCR. The primary PCR used the Claas et al. 
primers, Ti and T2 with Pfu DNA polymerase and Pfu reaction buffer (Stratagene). The 
secondary PCR used in-house primers (T3 and T4) internal to the primary 517-bp PCR 
product. 
The primary PCR reaction mix contained 2.5mM MgC12; Xl Pfu PCR buffer; 200µM of 
dATP, dCTP, dGTP; and dTTP; 100pmol of each primer; 2.5U Pfu DNA polymerase 
and 50ng of LGV1 DNA (p. 107) in a final volume of 50pl. The primary PCR consisted 
of 25 cycles of amplification, comprising denaturation at 94°C for 30sec, primer 
annealing at 55°C for 30sec, and primer extension at 72°C for 80sec. The PCR product 
was purified through a QIAquick column (Qiagen). 
The secondary PCR was identical to the primary, except primers T3 and T4 were used, 
and 3µl of primary PCR product was used as template. Finally, the secondary PCR 
product of 320-bp was vizualised on a 0.8% agarose gel under UV light to verify product 
size (Figure 16), and the remaining PCR product was purified through a QIAquick 
column. The DNA concentration of the probe was measured at 260nm, and stored at 
-20°C. 
4.4.5 Preparation of dot blots 
The sensitivity of both NISH probes was initially investigated by solution phase 
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Figure 16. A representative 0.8% agarose gel showing Lane 1,1 kb 
ladder; Lane 2,326-bp human P-globin polymerase chain reaction product; 
Lane 3,320-bp C. trachomatis secondary polymerase chain reaction product; 
Lane 4,1kb ladder. 
165 
hybridization. Human placental DNA was initially diluted from 1 µg/µ1 to 0.03ng/pl in 
purified sterile water. 2µ1 of each dilution was dotted onto a piece of Hybond-N+ 
membrane and the membrane left to air dry. The membrane was then placed on a piece of 
filter paper pre-soaked in denaturation solution for 5min, followed by 5min on a filter 
paper pre-soaked in neutralization solution. The membrane was then left to air dry. Prior 
to hybridization the membrane was UV cross-linked. 
The 320-bp C. trachomatis secondary PCR product was diluted in a similar manner 
(3.9ng/pl to 0.007ng/pl), and a dot blot prepared as above. 
4.4.6 ECL direct nucleic acid labelling and detection 
ECL direct labelling of probes 
Each probe was diluted in sterile purified water to give 25ng DNA in lOµ1, denatured by 
boiling for 5min, and snap cooled on ice. 10µl of DNA labelling reagent (supplied) was 
added to l Opl of probe, and mixed thoroughly. An equivalent volume (l Oµ1) of 
glutaraldehyde solution (supplied) was then added, the mixture vortexed briefly, 
centrifuged and then incubated for 10min at 37°C. The labelled probe was either used 
immediately or stored at -20°C in 50% (v/v) glycerol. 
ECL direct hybridization 
10ml of hybridization buffer was pre-warmed to 42°C for lh in a clean hybridization 
tube, the membrane was then added and left to pre-hybridize for a further Ih. A small 
volume of hybridization buffer was withdrawn to which 10µl (70ng) of probe was 
added, the hybridization buffer plus probe was then returned and left to hybridize 
overnight at 42°C in a hybridization oven. 
The blot was removed from the hybridization buffer, placed in a clean hybridization tube 
with 20m1 of pre-warmed primary wash buffer and left at 42°C for 10min. The primary 
wash buffer was discarded and 20m1 of fresh primary one buffer added and left at 42°C 
for a further 10min. The blot was removed and placed in a clean container, covered in an 
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excess of secondary wash buffer and incubated at room temperature with agitation for 
5min. The wash buffer was discarded, fresh secondary buffer added and the blot 
incubated for a final5min. 
Signal generation and detection 
Under safe-light conditions in a dark room the two ECL detection reagents were mixed in 
equal volumes, the membrane drained of excess wash buffer and covered in the detection 
solution and left for Imin. The membrane was drained again, placed on an acetate in an 
X-ray developing cassette and covered with another acetate. An equivalent sized piece of 
ECL Hyperfilm was placed over the acetate-covered membrane and the cassette locked 
and left for a minimum of 5min. The film was then developed, fixed and washed and left 
to air dry. Depending on the signal strength another piece of film was placed over the 
membrane and left for a maximum of 24h. 
Probe sensitivity by solution phase hybridization 
The 326-bp human (3-globin probe could detect down to 0.9ng of human DNA (Figure 
17), and the 320-bp C. trachomatis probe 0.4ng of C. trachomatis DNA by solution 
phase hybridization (Figure 18). The detection threshold for NISH would be less than 
solution phase hybridization due to steric hindrance. 
4.4.7 NISH 
NISH probe labelling 
Each probe was diluted in sterile purified water to a final concentration of 25ng/µl, 
denatured by boiling for 10min, and snap cooled on ice. The labelling reagents 
(Amersham DNA Colour Kit) were thawed on ice. To 2µl of probe (50ng) the following 
were added; l0µ1 of nucleotide mix containing fluorescein-1 1-dUTP; 5µl of nonamer 
primers; lµ1 of Klenow fragment (40µ1); and 42µl sterile purified water. The labelling 
reaction was left to proceed at 37°C for lh. Finally the fluorescein labelled probes were 
stored at -20°C in the dark for a maximum of 6 months. 
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Figure 17. The determination of the 
detection threshold of the 326-bp 
human 
(3-globin probe after solution phase 
hybridization. 
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ISH positive control slides 
C. trachomatis positive control slides were prepared by growing LGV 1 on coverslips as 
previously described (p. 61). The presence of LGV1 was confirmed by 
immunofluorescence. Coverslips were then drained of maintenance media, washed 
briefly in PBS and fixed in acetone for Imin. The acetone was removed and the 
coverslips mounted on glass sides (cells facing upwards) with glue. The slides were then 
stored at 4°C. 
Determination of digestion time 
Formalin fixation prevents DNA and RNA degradation by endogenous nuclease activity 
and retains tissue/cellular morphology. Unfortunately cross-linking fixatives such as 
formalin used prior to paraffin embedding effectively mask nucleic acid sequences. To 
unmask nucleic acid sequences a proteolytic digestion step is necessary, but control of 
this process is essential as over-digestion can weaken protein structures that localise the 
target sequence leading to the diffusion/loss of a positive signal. If the digestion is 
inadequate the target sequences will not be unmasked and no signal will be evident. 
To investigate the effect of digestion time, duplicate sections of an ovarian and Fallopian 
tube sample were de-waxed in xylene for 15min. The sections were then re-hydrated 
through graded ethanol (2x100%, 2x95%, 2x70%) and washed in PBS for 5min. One 
ovarian and one endometrial section were then digested for 15min in the pepsin digestion 
buffer at 37°C, the remaining two section were digested for 30min. All the sections were 
then rinsed in sterile water to prevent over-digestion and immersed in 20% (v/v) acetic 
acid for l5sec to remove endogenous alkaline phosphatase activity from within the 
sections. All sections were gently washed for 5min in PBS, dehydrated through graded 
ethanol (2x70%, 2x95%, 2x100%) and left to air dry. 
The human ß-globin specific probe was boiled for 5min, snap cooled on ice for 10min 
and diluted to 100ng/ml in ISH hybridization buffer. 65µl of the resulting mixture was 
placed over each section using an ISH EasiSeal (Hybaid), air bubbles were carefully 
removed, and the chamber sealed. The slides were then heated to 95°C for 10min using 
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an OmniGene flat block satellite module. 
The slides were left to hybridize overnight at 42°C, the EasiSeal was removed and the 
slides subjected to stringency washing (ISH wash 1 for 2x5 min; ISH wash 2 for 2x10 
min at 42°C) to remove non-specifically bound probe. The slides were then washed for 
5min in TBS to remove any residual SDS, blocked for lh in ISH blocking solution at 
37°C, rinsed in TBS for lmin and then drained. The area surrounding each section was 
carefully dried and the section traced with a Pap Pen (Binding Site, Birmingham, UK) to 
provide a hydrophobic barrier to keep the antibody solution over the section. 70µl of 
antibody solution was placed over each section and the slides incubated in a humidified 
box at 37°C for lh. The slides were then washed in TBS for 3x5min and left to drain. 
Finally 150µl of substrate solution was placed over each section and the slides left to 
develop in the dark for 4h at room temperature. The reaction was terminated using water, 
and the slides were left to air dry prior to counterstaining. Figures 19 and 21 illustrate 
the effect of sufficient pepsin digestion leading to the development of a positive signal in 
the nucleus of the cells. Figures 20 and 22 show both the loss of cellular architecture, 
and a positive signal localized to the nucleus due to the over-digestion of the tissue 
sections. A digestion time of 15min was finally decided upon for further ISH runs. 
NISH methodology 
Study slides were de-waxed and pre-treated as described above. The C. trachomatis 
labelled probe was boiled for 5min, snap cooled on ice for 10min and diluted to 400ng/ml 
in ISH hybridization buffer. 65µl of the resulting mixture was placed over each section 
using an ISH EasiSeal, air bubbles were carefully removed and the chamber sealed. The 
slides were then heated to 95°C for 10min. The human ß-globin specific probe was 
diluted to 100ng/ml in the same manner and used as a positive digestion control. Other 
controls included a C. trachomatis positive control slide probed with the C. trachomatis 
specific probe (Figure 23); a negative McCoy cell control slide probed with the C. 
trachomatis specific probe (Figure 24); a negative control slide (tissue section with neither 
probe) to determine the presence of non-specific background staining (Figure 25); a tissue 
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Figure 19. Eosin counterstained Fallopian tube section (mag. x400) after 
15min pepsin digestion, probed with human (3-globin specific probe. Section 
showing retention of morphology, and a localized non-isotopic in situ 
hybridization signal in the nucleus. 
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Figure 20. Eosin counterstained Fallopian tube section (mag. x400) after 
30min pepsin digestion, probed with human (3-globin specific probe. Section 
showing loss of cellular morphology, and non-isotopic in situ hybridization 
signal. 
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Figure 22. Eosin counterstained ovarian section (mag. x400) after 30min 
pepsin digestion, probed with human ß-globin specific probe. Section 
showing loss of cellular architecture, and non-isotopic in situ hybridization 
signal. 
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Figure 21. Eosin counterstained ovarian section (mag. x400) after 15min 
pepsin digestion, probed with human (3-globin specific probe. Section 
showing retention of cellular architecture, and a localized non-isotopic in situ 
hybridization signal in the nucleus. 
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Figure 23. Methyl green counterstained McCoy cells infected with LGV I 
and probed with the 320-bp C. trachomatis specific probe (mag. xl000). A- 
positive non-isotopic in situ hybridization signal identifying a chlamydial 
inclusion; B-uninfected McCoy cell showing no non-isotopic in situ 
hybridization signal. 
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Figure 24. Methyl green counterstained uninfected McCoy cells 
probed with the 320-bp C. trachomatis specific probe (mag. x1000) 
after non isotopic in situ hybridization. 
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section of a lymph node biopsy of a patient with confirmed LGV (Kellock et al., 1997) 
(Figure 26). 
The slides were left to hybridize overnight at 42°C, the EasiSeal was removed and the 
slides subjected to stringency washing (ISH wash 1 for 2x5 min; ISH wash 2 for 2x10 
min at 42°C) to remove non-specifically bound probe. The slides were then washed for 
5min in TBS to remove any residual SDS, blocked for Ih in ISH blocking solution at 
37°C, rinsed in TBS for 1min and then drained. The area surrounding each section was 
carefully dried and the section traced with a Pap Pen. 70µl of antibody solution was 
placed over each section and the slides incubated in a humidified box at 37°C for Ih. The 
slides were then washed in TBS for 3x5min and left to drain. 
Finally 150µl of substrate solution was placed over each section and the slides left to 
develop in the dark for 4h at room temperature. The reaction was terminated using water, 
and the slides were left to air dry prior to counterstaining. 
Methyl green counterstaining 
After NISH the sections were rehydrated through graded ethanol (100%x2,95%x2, 
70%x2) and finally rinsed in water for 1min. Slides were immersed in 1% methyl green 
for lmin, rinsed briefly in water, dehydrated through graded ethanol (2x70%, 2x95%, 
2x100%) before being placed in xylene. Finally the sections were mounted in picolyte 
and allowed to dry at room temperature. A positive signal was observed as a blue/purple 
/black precipitate within a cell as viewed under light microscopy. 
4.4.8 Statistical analysis 
The prevalence rate of C. trachomatis DNA by non-isotopic in situ hybridization for each 
study group was compared to the appropriate control group using the Fisher Exact 
Probability Test (2 tailed). A probability (P) value of <0.05 was considered to be 
statistically significant. 
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Figure 25. Methyl green counterstained endometrial section (mag. x 1000) 
with neither probe after non-isotopic in situ hybridization. 
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Figure 26. Methyl green counterstained section of a human lymph node 
biopsy from a patient diagnosed with LGV after non-isotopic in situ 
hybridization with the 320-bp C. trachomatis specific probe (mag. xl000). A- 
positive non-isotopic in situ hybridization signal demonstrating a chlamydial 
inclusion. 
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4.5 NISH results 
4.5.1 Prevalence of C. trachomatis DNA in Sheffield/Bristol 
The detection of C. trachomatis DNA by non-isotopic in situ hybridization (NISH) is 
shown in Table 17, and in Graphs 10 and 11. NISH results, and histological findings 
for individual patients can be found in Appendix 3. 
Table 17. Breakdown of the number of patients and tissue sites sampled positive for C. 
trachomatis DNA by non-isotopic in situ hybridization for Sheffield/Bristol. 
% of patients 
Patient group positive for C. Tissue sample breakdown of positive samples 
trachomatis 
DNA. Endometrium Ovary Fallopian 
tube 
Study controls 5% 0% 0% 7% 
mean age= 40yr (1/19) (0/17) (0/14) (1/15) 
SD= 6.2 
age range= 33-57yr 
Ectopic pregnancy 18% 18% 0% 13% 
(EP) (2/11) (2/11) (0/9) (1/8) 
mean age= 31yr 
SD= 5.7 
age range= 24-40yr 
Tubal factor 43% 15% 0% 45% 
infertility (TFI) (6/14) (2/13) (0/12) (5/11) 
mean age= 30yr 
SD= 3.7 
age range= 24-36yr 
Study group vs. EP P>O. 1 
Study group vs. TFI P<0.05 
no significant difference 
significant difference 
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Graph 10. Percentage detection of C. trachomatis DNA 
by non-isotopic in situ hybridization in Sheffield/Bristol. 
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Graph 11. Percentage detection of C. trachomatis DNA 
by non-isotopic in situ hybridization in the individual tissue 
sites sampled from Sheffield/Bristol. 
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4.5.2 Prevalence of C. trachomatis DNA in Trinidad 
The detection of C. trachomatis DNA by non-isotopic in situ hybridization (NISH) is 
shown in Table 18, and in Graphs 12 and 13. NISH results, and histological findings 
for individual patients can be found in Appendix 4. 
Table 18. Breakdown of the number of patients and tissue sites sampled positive for C. 
trachomatis DNA by non-isotopic in situ hybridization for Trinidad. 
% of patients 
Patient group positive for C. Tissue sample breakdown of positive samples 
trachomatis 
DNA. Endometrium Ovary Fallopian 
tube 
Study controls 12% 0% 0% 13% 
mean age= 31.7yr (2/17) (0/14) (0/13) (2/15) 
SD= 5.3 
age range= 22-44yr 
Ectopic pregnancy 41% 30% 0% 29% 
(EP) (7/17) (3/10) (0/13) (5/17) 
mean age= 30yr 
SD= 6.3 
age range= 16-40yr 
Miscarriage (Msc) 29% 20% 0% 14% 
mean age= 33yr (2/7) (2/7) (0/5) (1/7) 
SD= 1.0 
age range= 24-41yr 
Tubal factor 50% 0% 0% 50% 
infertility (TFI) (0/1) (0/1) (0/1) (1/1) 
Study group vs. EP P>O. 1 
Study group vs. Msc P>0.5 
no significant difference 
no significant difference 
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Graph 12. Percentage detection of C. trachomatis 
DNA by non-isotopic in situ hybridization in Trinidad. 
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Graph 13. Percentage detection of C. trachomatis 
DNA by non-isotopic in situ hybridization in the 
individual tissue sites sampled in Trinidad. 
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4.6 Conclusion 
4.6.1 Sheffield/Bristol and Trinidad study 
Multiple episodes of PID are more likely to cause tubal scarring, and the histopathological 
changes associated with infertility and ectopic pregnancy, than a single episode of PID 
(Westrom et al., 1992). Tubal damage may occur as a result of an acute inflammatory 
response to a C. trachomatis infection of the Fallopian tube. It has been suggested that a 
mechanism by which tubal damage is mediated may be a delayed-type hypersensitivity 
response (DTH), analogous to the immune response to trachoma in which repeated 
chlamydial infection leads to conjunctival scarring. 
In the primate model of chlamydial infection a single inoculation of C. trachomatis has 
been shown to produce a self-limited infection of the lower reproductive tract. Repeated 
chlamydial genital infection in both guinea pig and primate models has been reported to 
induce local tissue destruction, adhesion formation and tubal occlusion (Patton et al., 
1987; Cappuccio et al., 1994; Rank et al., 1995a; van Voorhis et al., 1997). These 
findings are similar to those found in human salpingitis. 
Studies by Patton et al. (1994b) showed that distally occluded Fallopian tubes in infertile 
women were strongly associated with previous chlamydial infection as assessed by 
serology and histopatholgical findings, even in the absence of culturable C. trachomatis. 
The same group reported similar findings in women with post-infectious tubal infertility 
who had also been treated with antibiotics regarded as being effective against C. 
trachomatis. C. trachomatis was detected in tubal specimens from 22/25 of these women 
by culture, immunohistochemistry or ISH. The result of this study suggested that C. 
trachomatis, or chlamydial antigens may persist in genital tract tissues despite 
antimicrobial treatment, thereby stimulating tubal inflammation and prompting tubal 
fibrosis and scarring. 
Chlamydial DNA was detected by NISH in 5% of the Sheffield/Bristol controls and 12% 
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of the Trinidad controls. In the Trinidad miscarriage group the number of patients with 
detectable chlamydial DNA was found not to be statistically significant (P>0.5). In the 
EP group from Sheffield/Bristol C. trachomatis DNA was detected in 18% of the patients 
from Sheffield/Bristol (P>O. 1) and 41% of EP patients from Trinidad (P>O. 1), although 
the detection of chlamydial DNA was not statistically significant at either site. Finally, in 
the Sheffield/Bristol TFI group there was a statistically significant detection of chlamydial 
DNA by NISH (P<0.05). 
Infection of the endometrium is less common than elsewhere in the female genital tract, 
this being attributed mainly to regular endometrial shedding. The endometrium, or 
uterine mucosa consists of an epithelial lining and an endometrial stroma. The epithelial 
lining consisting of a simple columnar epithelia through which the uterine glands extend. 
Once the structural changes associated with the endometrial secretory phase become 
evident three endometrial zones can be identified, the compact and the spongy layers 
(both of which are lost during menstruation), and the basal layer (which is not lost during 
menstruation) containing the blind ends of the endometrial glands. Chlamydia infecting 
the endometrial epithelia would therefore be subjected to the regular menstrual shedding 
of the compact and spongy layers. 
In all of the study groups NISH localized chlamydial DNA mainly to the secretory cells of 
the endometrial glands (Figure 27), but due to the orientation of the sections it was 
impossible to determine through which endometrial layer the chlamydial DNA was 
observed. If the chlamydial infection was localised to the compact and spongy layers it is 
likely that chlamydia are lost with menstrual shedding, but if the infection had already 
ascended to the Fallopian tubes there is a possibility that the endometrium could be re- 
infected form chlamydia carried in tubal fluids. 
On the other hand if the chlamydia infected the blind ends of the endometrial glands in the 
basal layer they would remain throughout the menstrual cycle, and therefore may have the 
opportunity to infect deeper tissues such as the connective tissue stroma found 
immediately under the basal layer or the myometrium. It is also possible that a chlamydial 
181 
7 
-dL 10 
Ilk 
EG 
y, 4 ge, 1 
1Uý 
iW IN 'ü".. 
EG .ý __. 
I 
ZIA W, 
-W, 411 
uR"t 
K'L' M 
i. r 2i. "YF t rý.. 16 
%Aqq 
' 
Nh, ý 'API". '! 
ý 
Figure 27. Methyl green counterstained endometrial section (mag. x400) with 
320-bp C. trachomatis probe after non-isotopic in situ hybridization. Arrow 
heads indicate the location of chlamydial DNA. EG-endometrial gland. 
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infection of the endometrial glands may effect the production of protein components 
needed for egg implantation thus leading to infertility in women with possibly no evident 
tubal damage. 
In the Trinidad miscarriage group chlamydial DNA was detected in 20% of the patients in 
the endometrium. How chlamydial infection, whether current or persistent, could 
possibly mediate miscarriage remains uncertain, but an immune component elicited by C. 
trachomatis may be an underlying cause. In a recent study by Gencay et al. (1997) 
chlamydial DNA was demonstrated by in situ hybridization in paraffin embedded 
placental material from a stillborn foetus in the 36th week of gestation. The mother was 
shown to have anti-chlamydial antibodies and had been culture positive three years 
previous. It is possible that chlamydial infection of the placenta of the developing foetus 
contributes to immune rejection and hence miscarriage. 
Chlamydial DNA was not detected in any endometrial tissue section by NISH in any of 
the controls groups. However, it has to be noted that many of the Trinidad patients either 
did not have endometrial tissue samples taken at the time of surgery, or the samples were 
unsuitable for NISH due to inadequate fixation /processing (Figures 28 and 29). 
The cellular constituents of the Fallopian tube include the tubal columnar epithelia 
(consisting of ciliated and non-ciliated secretory cells) which rests upon a cellular lamina 
propria. The Fallopian tube is also part of the secretory immune system with the 
preferential secretion of IgA from normally present IgA plasma cells in the lamina 
propria. The epithelium also contains IgA receptors and secretory components (Kutteh et 
al., 1990). 
Chlamydial DNA found in the Fallopian tubes in the both the UK (13%) and Trinidad 
(29%) EP groups, was generally localized to the ciliated epithelium (Figure 30). 
Infection of the ciliated cells of the Fallopian tube may effect the wave-like motion of the 
cilia which are responsible for the movement of the fertilized ovum towards the 
endometrium. This could predispose to the tubal implantation of the fertilized ovum due 
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Figure 28. Haematoxylin and eosin stained endometrial section (UK sample) 
showing good formalin fixation and histological processing (mag. x400). 
Figure 29. Haematoxylin and eosin stained endometrial section (Trinidad 
sample) showing loss of tissue morphology due to inadequate formalin fixation 
and histological processing (mag. x400). 
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Figure 30. Methyl green counterstained Fallopian tube section from an ectopic 
pregnancy patient after non-isotopic in situ hybridization with the 320-bp C. 
trachomatis probe (mag. x400). Arrow heads indicate the localization of 
chlamydial DNA (purple). E- tubal epithelium; TL-tubal lumen; LP-lamina 
propria. 
- 
3K 
'0' 
14 1 
=r 
Qý 
TL 
061 
E 
00 LP 
1 fý 
ý'ä aw' -^K 
ir. 
4, 
al: c' 
'I ýr° w: wllt .. 
Figure 31. Methyl green counterstained Fallopian tube section from a tubal 
factor infertility patient after non-isotopic in situ hybridization with the 320-bp 
C. trachomatis probe (mag. x400). Arrow heads indicate the localization of 
chlamydial DNA (purple). E- tubal epithelium; TL-tubal lumen; LP-lamina 
propria. 
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to the mechanical failure of the cilia. 
The majority of the TFI patients tested positive in the Fallopian tube (45%), mainly in the 
epithelia and occasionally in the lamina propria of the mucosal folds and sub-mucosa 
(Figures 31). The presence of chlamydial DNA in the tubal epithelia and sub-mucosa has 
also been shown in the primate model of chlamydial salpingitis after a single inoculation, 
and in deeper tissues after repeated infection (Cappuccio et al., 1994). 
The localization of chlamydial DNA to the Fallopian tube epithelia is not surprising since 
epithelial cells are natural targets of chlamydial infection. Using NISH chlamydial DNA 
was rarely detected in the deeper tissue of the Fallopian tubes. Patton et al. (1994b) using 
isotopic ISH showed that C. trachomatis DNA was found in the sub-mucosa or 
adhesions in women with post-infectious tubal infertility. The inability of NISH to detect 
chlamydial DNA in deeper Fallopian tube tissues may be due to the relative insensitivity 
of the non-isotopic method when compared to the method of Campbell et al. (1993), and 
Patton et al. (1994b). 
Infection of the tubal epithelium could potentially damage normal tubal function by 
damaging ciliated cells. Scanning electron and transmission electron microscopy of 
Fallopian tube material from repeatedly C. trachomatis infected monkeys has shown 
enlarged non-ciliated cells, bald patches devoid of microvilli, the formation of connective 
bridges between non-ciliated cells, the presence of club tipped ciliated cells on the 
mucosal surface and intracellular epithelia damage to both secretory and ciliated cells 
(Patton et al. 1987). Also evidence of organized fibrous adhesions forming bridges 
between mucosal folds were observed in the monkey model, a phenomenon which is also 
seen in study TFI patients who showed a decreased tubal lumen. 
In the guinea pig model of PD with intravaginal inoculation of C. psittaci GPIC, only 
40% of animals that had chlamydia present in the oviducts developed tubal pathology 
(Rank et al. 1992b). Stacey et al. (1990) showed that chlamydial elementary bodies 
could be detected in apparently healthy Fallopian tubes. Both studies suggest that C. 
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trachomatis in the upper genital tract does not always correlate with active clinical disease. 
Histological examination of H&E stained Fallopian tube sections from TFI patients 
showed that in nearly all patients there was evidence of tubal fibrosis, and the loss of 
mucosal folds and a reduced tubal lumen (Figures 32 and 33). In some patients the folds 
of the Fallopian tube had been lost, coupled with the total lack of ciliated epithelial cells 
and damaged, flattened non-ciliated secretory epithelial cells (Figure 34). Such damage 
could potentially affect the secretion of tubal fluid, the importance of which is unknown 
but which may create a specialized microenvironment for fertilization and early embryonic 
development. 
The localization of chlamydial DNA to the tubal epithelium brings into question the role of 
active vs. persistent infection in the long term development of tubal damage. It has been 
suggested that a persistent infection, or the persistence of chlamydial antigens contributes 
to tissue damage due to immune stimulation. The NISH and histology results suggest 
that active chlamydial infection (as determined by the presence of chlamydial DNA in the 
tubal epithelia and the of absence of chlamydial DNA in deeper Fallopian tube tissues) in 
the TFI patients studied may be in part responsible for the observed tubal disease. 
None of the patients from either the Sheffield/Bristol or Trinidad groups had detectable 
chlamydial DNA in the ovarian tissue sections. It has been shown that positive 
chlamydial serology is associated with a poor ovarian response to gonadotropin 
stimulation during IVF (Keay et al., 1998). How a chlamydial infection could potentially 
affect ovarian reserve/function is unknown. C. trachomatis infects epithelial cells and it 
may be that it is able to infect the ovarian epithelia. The inability to localize chlamydial 
DNA in the ovarian samples may have simply been a reflection of the small size of the 
sample and the insensitivity of the NISH employed. 
Histological examination of H&E stained tissue specimens for the presence of 
inflammation was inconclusive. Out of all the samples examined only 9% (19/212) 
showed evidence of significant inflammation, but only three samples had inflammation 
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Figure 32. Haematoxylin and eosin stained normal Fallopian tube cross- 
section (mag. x25) showing a marked tubal epithelium (E) and mucosal folds. 
TL-tubal lumen. 
Figure 33. Haematoxylin and eosin stained Fallopian tube cross-section from 
a tubal factor infertility patient (JHW34-anti-chlamydial IgG positive) showing 
loss of mucosal folds, damaged epithelium (E) and reduced tubal lumen 
(mag. x 160). TL-tubal lumen. 
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Figure 34. Fallopian tube section from a tubal factor infertility patient (BR09- 
anti-chlamydial IgG positive and chlamydial DNA positive in endometrial, 
Fallopian tube and ovarian samples by polymerase chain reaction) after 
haematoxylin and eosin staining (mag. x400) showing lack of ciliated 
epithelium, and flattened damaged secretory epithelial cells. TL-tubal lumen; 
E- tubal epithelium. 
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and detectable chlamydial DNA by NISH. Two of the inflammation and chlamydial DNA 
positive samples were Fallopian tube samples from patients presenting with EP and both 
samples showed mild chronic inflammation. 
NISH proved to be a reliable method for the detection of C. trachomatis DNA in paraffin 
embedded biopsy material from women with EP, miscarriage and TFI although sampling 
error may have generated false negative results. Although ISH has many advantages in 
that it allows the direct localization of chlamydial DNA to particular cells types, the 
method itself can be very labour intensive and insensitive when compared to other 
molecular techniques such as PCR and LCR. 
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Chapter 5.0 
General discussion 
5.0 Discussion 
There have been many studies over the past two decades in which the relationship 
between C. trachomatis infection and the incidence of ectopic pregnancy (EP), 
miscarriage, and tubal factor infertility (TFI) have been investigated. Methods of 
investigation have included the polymerase chain reaction (PCR), in situ hybridization, 
and serology, but to date no single study has utilized all three methods to investigate the 
prevalence of C. trachomatis infection in women with reproductive abnormalities. 
The primary aim of this study was to evaluate the role of C. trachomatis in women with 
EP, miscarriage and TFI using PCR, non-isotopic in situ hybridization (NISH) and 
serology when compared to controls. Also, the influence of polymorphisms in the TNF 
gene were investigated to establish if there was an association between chlamydial 
infection and the development of tubal pathology that could predispose to EP and TFI. 
An important feature of this study was the use of three fresh tissue specimens from each 
patient (endometrial, Fallopian tube and ovarian) for PCR and NISH. These tissue 
samples were obtained at the time of surgery for EP, or at the time of tubal reconstruction 
in the case of TFI patients. In conjunction with the collection of fresh tissue specimens 
from each patient, a blood sample was also taken and the serum used for serology. The 
individual patient results (serology, PCR, NISH, histology) and their clinical details can 
be found in Appendix 3 (Sheffield/Bristol) and Appendix 4 (Trinidad). 
There were four study centres enrolled, two in the UK (Jessop Hospital for Women, 
Sheffield; St. Michael's Hospital, Bristol), and two in Trinidad (Mount Hope Women's 
Hospital, St. Augustine; and the General Hospital, Port of Spain). Ethical committee 
approval was granted at each individual study site. In total 130 patients were recruited, 
these included 50 study controls, 43 EP patients, 21 miscarriage patients, and 16 TFI 
patients. The study controls from the UK were hysterectomy patients, and the study 
controls from Trinidad were women undergoing sterilization. Serum samples from 
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antenatal patients were also collected from both the UK (n=28), and Trinidad (n=64) in 
order to establish a baseline prevalence of anti-chlamydial IgG and IgM in both areas. 
A secondary study was designed to investigate the role of C. trachomatis (as determined 
by the presence of anti-chlamydial IgG) in women who responded poorly to 
gonadotropin stimulation prior to in vitro fertilization (IVF). Two IVF centres were 
enrolled, one at the University of Bristol (UK) and the other at the University of 
Southampton (UK). In total 242 IVF patients were investigated for the presence of anti- 
chlamydial IgG. The IVF patients were further sub-divided into those patients that 
responded 'well' to gonadotropin stimulation prior to IVF (n=148), and those who 
responded 'poorly' (n=94). 
For the primary study, two distinct geographic areas were studied (UK and Trinidad), 
each with different socio-economic climates, and with differing risk factors for the 
acquisition of a sexually transmitted disease (STD). To date, in Trinidad there have been 
no studies that have evaluated the presence of C. trachomatis in the general population. 
The only information that is available in the West Indies has been from Jamaica and 
Martinique where the reported prevalence of C. trachomatis has been reported as being 
16% by DIF (Dowe et al., 1998) and 27% by culture of the cervix and urethra (Chout et 
al., 1995) respectively. In the UK, the reported prevalence of C. trachomatis ranges 
from 3.6-9.1% (Fish et al., 1989; Hopwood et al., 1990; cit. CMO's Expert Advisory 
Group, 1998). 
In the Sheffield/Bristol study control group, 15% (3/20) had detectable anti-chlamydial 
IgG, and 10% (2/20) had anti-chlamydial IgM. Similar serology results were found in 
the antenatal controls with 14% (4/28) having detectable IgG against C. trachomatis and 
7% (2/28) with IgM. What is interesting is that even though the study controls were 
approximately 13 years older (which should in effect add an element of negative bias in 
the acquisition of a C. trachomatis infection) than the antenatal controls, the prevalence of 
anti-chlamydial IgG and IgM were almost identical. The IgG results are comparable to 
those previously reported in the UK. However, the prevalence of anti-chlamydial IgM in 
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our study is approximately three times greater than has been previously reported in the 
UK (Moore et al., 1993). 
The detection of chlamydial DNA in the Sheffield/Bristol study control group was 15% 
(3/20) by PCR and 5% (1/19) by NISH. Overall, the prevalence of C. trachomatis by 
PCR was the same as the detection of anti-chlamydial IgG, but no control patients had 
both chlamydial DNA detected by PCR and anti-chlamydial antibody. One patient 
(JHW20) had detectable chlamydial DNA (by NISH in the Fallopian tube) and anti- 
chlamydial IgG, plus histological evidence of chronic inflammation at the site of DNA 
localization. It is possible that this particular patient was suffering from asymptomatic 
PID. 
Four patients had detectable anti-chlamydial antibody, but no chlamydial DNA in any of 
the tissue sites available for testing. The question therefore remains whether these 
patients had a cervical chlamydial infection, a site not investigated in this present study. 
Two of the four antibody positive/chlamydial DNA negative patients, only had detectable 
anti-chlamydial IgM, which may represent a newly acquired chlamydial infection in the 
lower genital tract and or the loss of chlamydial DNA during sampling or DNA 
extraction. 
In the Trinidad study control group, 36% (10/28) had detectable anti-chlamydial IgG, and 
11 % (3/28) IgM. In the Trinidad antenatal control group the prevalence of anti- 
chlamydial IgG was 23% (15/64), and 8% (5/64) for IgM. The prevalence of anti- 
chlamydial IgG was higher in the study controls, although this was found not to be 
statistically significant (P>O. 1). The difference in the detection of anti-chlamydial IgG in 
the two Trinidad control groups may simply be a reflection of the differing mean ages (the 
study controls being approximately seven years older than the antenatal controls), or due 
to differences in the populations sampled. 
The detection of chlamydial DNA by PCR was 40% (12/30) and 41% (7/17) by NISH. 
However, only seven control patients (25%) had both detectable antibody against C. 
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trachomatis, and chlamydial DNA. Six patients had only antibody alone, which could 
possibly indicate asymptomatic chlamydial infection of the lower genital tract. 
The detection of C. trachomatis in the Trinidad study control group was higher than the 
reported prevalence of C. trachomatis in other West Indian countries. In Martinique, the 
reported prevalence rate was 27% by culture (Chout et al., 1995), which may in fact 
represent an underestimation of the carriage of C. trachomatis in the female population, 
due to the relative insensitivity of the technique when compared to molecular techniques 
such as PCR. Culture of the lower genital tract would not indicate a past exposure to C. 
trachomatis, or persistent or active upper genital tract infection. 
In both the Sheffield/Bristol and Trinidad control groups the detection of antibody (either 
IgG and IgM) did not correlate well with the detection of chlamydial DNA. It may be that 
in those patients with detectable chlamydial DNA but no detectable antibody against C. 
trachomatis, an inadequate antibody response could have contributed to the establishment 
of an upper genital tract infection, or the persistence of C. trachomatis or DNA in genital 
tissue specimens. Alternatively, antibody levels may have fallen below the threshold 
value of the ELISA system developed. 
The Trinidad control group data suggest a population with an increased rate of silent/ 
asymptomatic or persistent chlamydial infection. Does Trinidad therefore have higher EP 
compared to the UK? The first report of ectopic pregnancies in the Caribbean was in 
1963 (Douglas, 1963) which revealed an incidence of 1 in 28 live births for the Jamaican 
population studied. The high EP rate was associated at the time with the high incidence 
of PID in Jamaica. To our knowledge there have been no similar studies reported from 
Trinidad. 
The incidence of EP in the UK (1988-1993) has been reported as being 10.8 per 1000 
total conceptions (cit. CMO's Expert Advisory Group, 1998). In France the incidence of 
EP has been reported as being 20.2 per 1000 live births (Coste et al., 1994b), in Finland 
28 per 1000 live births (Makinen, 1993), and 22 per 1000 live births in the USA (CDC, 
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1992). The 1963 EP rate in Jamaica equated to 35.7 EPs per 1000 live births, 
approximately three times greater than the UK. 
Within the Sheffield/Bristol EP group, anti-chlamydial IgG was detected in 67% (6/9) of 
the patients, and IgM in 22% (2/9). C. trachomatis DNA was detected in 56% (5/9) of 
the EP patients by PCR and in 18% (2/11) by NISH. When individual patients were 
considered, only two patients had both antibody against C. trachomatis and detectable 
chlamydial DNA, four patients had detectable antibody alone and three had demonstrable 
chlamydial DNA only. Again the detection of anti-chlamydial antibody did not correlate 
well the detection of chlamydial DNA by either PCR or NISH. 
Of the 11 EP patients examined from the UK all had evidence of having/or having had a 
chlamydial infection. Five of the EP patients had had at least one previous EP, of which 
three also had a history of PID. In the five women with a previous EP, the current EP 
may be a direct result of tubal damage elicited by a previous chlamydial infection. Of the 
remaining six EP patients, all had evidence (either by the presence of chlamydial DNA or 
anti-chlamydial antibody) of having had or still having a C. trachomatis infection, which 
may have been responsible for the development of the current EP. Only two EP patients 
had anti-chlamydial IgM, but neither patient had detectable chlamydial DNA and it is 
possible that in these women the current EP was not due to tubal damage caused by C. 
trachomatis. However, they may have had a chlamydial infection of the lower genital 
tract, as determined by the detection of anti-chlamydial IgM. 
In Trinidad, anti-chlamydial IgG was detected in 62% (13/21), IgM in 38% (8/21), and 
chlamydial DNA in 66% (19/29) by PCR and 41% (7/17) by NISH. It must be noted 
that many of the Trinidad EP patients had incomplete sample sets. Of the 30 Trinidad EP 
patients, 16 had both detectable antibody against C. trachomatis and detectable chlamydial 
DNA. Of the 22 EP patients with clinical details available, nine had a recorded history of 
PID, and two had pelvic adhesions at the time of surgery suggestive of PID. Of the 
women with a history of PID, who had serum samples available for testing, six had 
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detectable IgG and two had anti-chlamydial IgM. These results suggest that C. 
trachomatis might have been responsible for the reported episodes of PID. 
What is interesting in the Trinidad EP group is the relatively high incidence of IgM (38%) 
when compared to the Trinidad study controls (8%), and the antenatal controls (11%). 
Although this difference was found not to be statistically significant at the 5% level 
(P>0.05). A similar association was also seen in the UK EP group (P>O. 1), but the 
incidence of anti-chlamydial IgM was again found not to be statistically significant, 
possibly due to the limited number of patients studied in the UK. Within the two EP 
groups the detection of IgM in a large proportion of individuals tested warrants further 
study. 
The high incidence of IgM in this group, in women with evidence of having or having 
had a chlamydial infection suggests that in these women an active chlamydial infection 
may be in part responsible for the EP. NISH identified chlamydial DNA in the ciliated 
epithelium of the Fallopian tube of three EP patients with anti-chlamydial IgM, suggesting 
that active chlamydial infection may have been responsible for damaging the cilia resulting 
in the implantation of the fertilized ovum in the tube. 
In both the UK and Trinidad EP groups, chlamydial DNA was detected in all the sample 
types studied (ovarian sample by PCR only). From both the UK and Trinidad EP 
groups, of the total number of patients with ovarian samples available for testing by PCR 
(n=30), 57% (17/30) were positive for the presence of C. trachomatis DNA. Since no 
direct experimental evidence of chlamydial infection could be found using NISH, it can 
only be assumed that the detected chlamydial DNA by PCR was a contaminant of the 
pelvic cavity. Conversely it may reflect the insensitivity of NISH when compared to 
PCR. The discovery of such a high proportion of EP patients with detected chlamydial 
DNA in the pelvic cavity underlines the importance of ascending infection in the possible 
development of EP. 
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In the Trinidad miscarriage group anti-chlamydial IgG was detected in 39% (7/18) and 
IgM in 11% (2/18), both of which were found not to be statistically significant when 
compared to the appropriate control groups. Conversely in the miscarriage group the 
detection of chlamydial DNA was 62% (13/21) by PCR and 29% (2/7) by NISH, and 
although neither were statistically significant, there was an increased detection of C. 
trachomatis DNA. 
Of the 21 miscarriage patients, 24% (5/21) had a recorded history of PID, of these five 
patients, four had evidence of having or having had a chlamydial infection. All four 
patients had either/or positive Fallopian tube samples (by PCR or NISH) or ovarian 
samples (by PCR only) suggestive of an upper genital tract chlamydial infection. It is 
well documented that chlamydial PID tends to be asymptomatic in nature, and although 
many of the patients in all the Trinidad groups have had reported episodes of PID, it 
remains to be determined how many others have suffered from chlamydial PID without 
the appropriate treatment. If evidence of chlamydial PID is the detection of chlamydial 
DNA in the Fallopian tubes (PCR and NISH) or ovarian samples (PCR only) it would 
indicate that a large proportion (54%) of the Trinidad patients (with no recorded history of 
PID) irrespective of group may have chlamydial PID. 
Considering only the Trinidad miscarriage serological data, the incidence of anti- 
chlamydial IgG and IgM were found not to be statistically significant. Although the 
detection of chlamydial DNA was not statistically significant it was certainly higher than 
the control group (PCR 62% vs. 40%, P >0.1; and NISH 29% vs. 12%, P>0.5). These 
results suggest that in the case of miscarriage the detection of a presumed chlamydial 
infection (as determined by the detection of chlamydial DNA) may be an important factor. 
Of the eight endometrial samples available for testing by PCR and NISH from the 
miscarriage group, 50% (4/8) were positive for chlamydial DNA. It is possible that 
chlamydial infection, especially of the endometrium may contribute to miscarriage in as 
yet unknown way, possibly by triggering an adverse immune response detrimental to the 
developing foetus. A recent study by Gencay et al. (1998) showed the detection of C. 
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trachomatis DNA in the placenta of a miscarried stillborn foetus. Whether C. trachomatis 
infection of the placenta actually resulted in the miscarriage remains uncertain, but C. 
psittaci infection of the placenta has been shown to cause natural abortion in animals. The 
detection of chlamydial DNA in miscarried foetal material may shed light on the possible 
role of C. trachomatis in miscarriage. 
In the Sheffield/Bristol TH group, of the ten PCR positive patients, seven had positive 
endometrial samples, five had positive ovarian samples and five positive Fallopian tube 
samples. Two patients (BRO8, BR09) had all three sites positive by PCR, and detectable 
anti-chlamydial IgG but no IgM indicating that the damage associated with TFI may be 
from a previous infection. 
Of the 23 Fallopian tube samples from TFI patients available for PCR and NISH, 43% 
(10/23) were positive for chlamydial DNA. Histology revealed that many of the TFI 
patients had evidence of tubal fibrosis indicative of a past infection coupled with the lack 
of tubal epithelia and a reduced tubal lumen. Tubal occlusion resulting from hydrosalpinx 
and peritubal adhesion formation and tubal scarring are the underlying pathological 
changes associated with TFI following acute salpingitis. 
Of the nine chlamydial DNA positive patients who had serum samples available for 
testing, seven had detectable IgG, and none had anti-chlamydial IgM. Patient BR07 was 
histologically diagnosed as having salpingitis isthmic nodosa, the development of which 
has been attributed to inflammation due to an infection. This patient had anti-chlamydial 
IgG, and a positive ovarian sample by PCR suggestive of ascending infection and 
possibly Fallopian tube infection. The question of whether C. trachomatis was 
responsible for the development of this condition remains uncertain. 
Only two out of the nine TFI patients with detectable chlamydial DNA and serum sample 
available for testing, had no demonstrable anti-chlamydial antibodies. Campbell et al. 
(1993) also found two out of 16 TFI patients who were positive for chlamydial DNA by 
immunoperoxidase staining to be negative for anti-chlamydial IgG by MIF. The 
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Campbell et al. study failed to detect anti-chlamydial IgM in any of the 16 women 
examined with distal tubal occlusion. 
A possible explanation of the Campbell et al. results and the results of the 
Sheffield/Bristol TFI group is that tubal damage is associated with repeated past 
chlamydial infection, and circulating antibody levels may have declined below the 
threshold value of the serological tests used. It may also be that in the TFI patients with 
detectable chlamydial DNA but no detectable antibody response against C. trachomatis, 
an inadequate antibody response may have been elicited during infection resulting in tubal 
damage from prolonged chlamydial infection/persistence. 
Of the 13 ovarian samples tested by PCR, five (38%) were positive for chlamydial DNA. 
No evidence of chlamydial infection could be demonstrated by NISH indicating that the 
chlamydia detected was a contaminant from the pelvic cavity. However, it has to be 
stressed that our study did show that PCR was a more sensitive method for the detection 
of chlamydial DNA than NISH, and the failure of NISH to detected chlamydial DNA in 
ovarian samples may be a reflection of this apparent lack of sensitivity. 
Since chlamydial DNA could not be localized in the ovarian epithelium by NISH, but was 
detected by PCR in some patients it could only assume that due to ascending infection C. 
trachomatis had found its way into the fluid of the pelvic cavity surrounding the ovary 
and as such was a contaminant of the ovarian sample; or it could be argued that 
chlamydial DNA was not detected in ovarian samples due to the relative insensitivity of 
NISH when compared to PCR. 
The effect of a chlamydial infection in the pelvic cavity, and its possible effect on the 
ovary and ovarian function remains to be elucidated. Experimental evidence has 
indirectly suggested that pelvic infection and adhesion formation can effect ovarian 
response (Madehaven et al., 1985; Molloy et al., 1987; Bowman et al., 1993; 
Cszemichy, 1996), but the actual mechanism is unknown. Further work on the 
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possibility of C. trachomatis infection of the ovary using primary tissue culture, and in 
situ-PCR may help resolve this conundrum. 
The results of our study suggest that C. trachomatis does play an important role in the 
development of both TFI and EP. In the case of miscarriage the role of chlamydia is less 
clearly defined and may be related to the induction of maternal immune rejection of the 
foetus facilitated by a chlamydial infection. The IVF study showed that women 
undergoing IVF, who also had detectable levels of anti-chlamydial IgG were statistically 
more likely to respond poorly to gonadotropin ovarian stimulation prior to IVF, 
producing fewer follicles. This may be due to the presence of pelvic adhesions or 
hydrosalpinx, both of which have been shown to affect ovarian reserve in animal models. 
It is possible that due to the less invasive nature of serology, the detection of anti- 
chlamydial IgG could be used as an indicator of adverse tubal pathology of chlamydial 
aetiology. However, it is important that further work on the comparison between the 
molecular and serological detection of C. trachomatis in TFI and EP patients be 
completed. 
The identification of genes that make humans more susceptible to certain infectious 
diseases is difficult due to such factors as genetic heterogeneity and the effect of 
environmental factors. The TNF polymorphism data as determined by our study suggest 
that in the UK a polymorphism in the TNF-(3 gene may be associated with the 
development of tubal damage in women with evidence of having/or having had a 
chlamydial infection (as determined by the presence of anti-chlamydial IgG). In Trinidad 
neither of the Ncol polymorphisms in the TNF gene were found to be associated with 
either EP or miscarriage in patients with or without anti-chlamydial antibody. This may 
be due to environmental factors and the actual populations studied. Due to the limited 
number of patients studied in both the UK and Trinidad, a larger and more 
comprehensive genetic study on the role of polymorphisms in the TNF gene and the 
development of tubal damage due to C. trachomatis needs to be undertaken. 
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The importance of persistent chlamydial infection also needs to be addressed, our study 
showed the presence of chlamydial DNA in tissue samples from women without a 
detectable antibody response against C. trachomatis. The question of whether the DNA 
detected was from a past infection and the antibody levels had declined below the 
threshold value of the serological tests employed, or whether the DNA was from a 
persistently infecting chlamydia needs clarification. Methods such as reverse 
transcriptase (RT) PCR, RT-ISH or RT-in situ PCR may be useful in determining the 
presence of metabolically active chlamydia, although RT-ISH and RT-in situ PCR may be 
of more use by identifying and localizing persistently infecting chlamydia within tissue 
sections. Also of importance would be the continued investigation of the role of C. 
trachonwtis in miscarriage by evaluating the maternal immune/foetal immune response in 
pregnant women with chlamydial infections. 
What has been established in this present study is that C. trachomatis plays an important 
role in diseases of the upper female genital tract, and the subsequent development of tubal 
pathology that could predispose to both EP and TFI. However, even when different 
modem molecular methods were employed together, many questions still remain 
unanswered allowing plenty of scope and opportunity for further research. 
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Chapter 6.0 
Appendices 
6.1 Appendix 1. ELISA development 
6.1.1 IgG ELISA development 
Titration of LGV1 antigen 
A basic chequerboard ELISA was used to establish the optimal antigen concentration for 
the developmental detection of chlamydial IgG from both study patients and from sera of 
known chlamydial titres. 
The C. trachomatis antigen preparation was diluted from 40pg/ml to 0.625pg/ml in 
coating buffer by doubling dilutions, and 50µ1 of each dilution was dispensed into eight 
wells on an EIA plate. The plate was left overnight at 4°C in a moist chamber, and was 
then washed three times in PBS-Tween. A serum sample with a known MIF titre of 
1: 512 for C. trachomatis was diluted from 1: 10 to 1: 1280 by doubling dilutions in serum 
diluent; 50µ1 of each dilution was placed into each of the wells containing the different 
antigen concentrations, and the plate incubated for 1h at 37°C in a moist chamber. The 
plate was then washed three times in PBS-Tween, S0pl of HRP-conjugated anti-human 
IgG pre-diluted 1: 2000 in serum diluent was then added to each well and the plate 
incubated again at 37°C for Ih. Following incubation the plates were washed three times 
to remove unbound antibody that could contribute to the generation of a background 
signal, and excess liquid removed by inverting the plate on tissue paper. 50µ1 of 
substrate buffer was placed in each well and the plate left to develop at room temperature 
for 15min. The enzyme reaction was stopped by the addition of 50µl of 2M H2S04 to 
each well, and the absorbance was read immediately at 492nm in an ELISA reader. 
A decreasing absorbance (OD) with increasing serum dilution, and decreasing antigen 
concentration was seen (Graph 14). A final antigen concentration of IOpg/ml and a 
serum dilution of 1: 80 was initially chosen to develop the ELISA methodology. 
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Graph 14. IgG enzyme-linked immunoassay with a C. trachomatis 
specific serum (IgG microimmunofluorescence titre 1: 512) with 
1: 2000 IgG conjugate. 
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Effect of different detergents 
Ossewaarde et al. (1994b) reported an ELISA with an enhanced specificity for the 
detection of antibodies to C. trachomatis. The system involved the pre-treatment of C. 
trachomatis L2 elementary bodies with either sodium periodate (which oxidises LPS) or 
Triton X-100 (which extracts LPS) and measured the end-point titres of serum samples 
from patients with culture proven C. trachomatis infection, patients with symptoms 
suggestive of C. trachomatis infection, and patients with C. psittaci infection. The same 
methods were investigated. 
Three EIA plates were coated with 10µg/ml of LGV 1 antigen, and another three plates 
with 10µg/ml of C. pneumoniae antigen. The plates were left overnight at 4°C in a moist 
chamber, and were then washed once with PBS-Tween. 50µl of 1% sodium periodate 
was added to the wells of one set of plates (one coated with LGV 1 antigen the other C. 
pneumoniae antigen), 50µl of 1% Triton X-100 was added to the wells of the second set 
of plates; the final set of plates were not pre-treated. All the plates were then incubated at 
37°C for 10min, and washed twice with PBS-Tween. 
A selection of serum samples with known MIF titres against both C. trachomatis and C. 
pneumoniae were serially diluted in serum diluent. The samples tested included a C. 
trachomatis specific (CT SP) serum (IgG MIF serovar A-C 1: 64, D-K 1: 128, LGV1- 
LGV3 1: 128); a Chlamydia dual species (C DS1) serum containing chlamydial IgG 
against both C. trachomatis and C. pneumoniae (IgG MIF serovar A-C 1: 256, D-K 
1: 256, LGV 1-LGV3 1: 256; C. pneumoniae 1: 64); C. pneumoniae specific (CPN SP) 
serum (IgG MIF C. pneumoniae 1: 512 ); a Chlamydia dual species (C DS2) serum 
containing chlamydial IgG against both C. pneumoniae and C. trachomatis (IgG MIF C. 
pneumoniae 1: 256; serovar A-C 1: 16, D-K 1: 16, LGV 1-LGV3 1: 16); and a negative 
serum with no detectable antibodies against any chlamydial species as determined by 
MIF. - 
50µl of each serum dilution was placed into two wells on each plate, and the plate 
incubated for Ih at 37°C in a moist chamber. Each plate was then washed three times in 
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PBS-Tween, 50µl of HRP-conjugated anti-human IgG pre-diluted 1: 2000 in serum 
diluent was then added to each well and the plate incubated again at 37°C for lh. 
Following incubation the plates were washed three times to remove unbound antibody 
that could contribute to the generation of a background signal, and excess liquid removed 
by inverting the plate on tissue paper. 50µl of substrate buffer was placed in each well 
and the plate left to develop at room temperature for 15min. The enzyme reaction was 
stopped by the addition of 50µl of 2M H2SO4 to each well, and the absorbance was read 
immediately at 492nm in an ELISA reader. 
The C. pneumoniae and HL cell antigen preparations were used to show the effect of 
both antigen pre-treatments on the end-point titres of the different test serum samples 
(data not shown); and to confirm the absence/presence of antibodies to C. pneumoniae in 
the test samples . All the serum samples with detectable levels of anti-C. pneumoniae 
IgG by MIF had detectable IgG by the C. pneumoniae ELISA. 
The mean OD values for each serum sample against both antigen preparations and all the 
pre-treatments were calculated and plotted against reciprocal serum dilution (x10-1) to 
determine end-point titres (Graphs 15-17). The effect of each pre-treatment on the end- 
point titres of the different serum samples is shown in Graph 18. 
For the untreated LGV 1 antigen preparation it can be seen that both the C. pneumoniae 
specific and dual species serum would have given OD values that could have been 
interpreted as borderline negative/low positive for C. trachomatis IgG. This underlines 
the importance of the removal of genus cross reactive epitopes to give a more'reliable', 
species specific serological result. 
The C. trachomatis specific serum had a reduced end-point titre after LGV 1 antigen pre- 
treatment with sodium periodate (from log10 3.0-2.8), but the Triton X-100 pre-treatment 
had no effect on the end-point titre when compared against the untreated LGV 1 antigen. 
The same effect was observed with the C. trachomatis dual species sample and sodium 
periodate, as you would expect after the oxidation of LPS. The Triton X-100 gave a 
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Graph 15. The determination of end point titres of known micro- 
immunofluorescence (MIF) titre sera against LGV 1 antigen with 
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Graph 17. The determination of end point titres of known micro- 
immunofluorescence (MIF) titre sera against LGV 1 antigen with 
Triton X- 100 pre-treatment. 
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Graph 18. The effect of different enzyme-linked immunoassay 
pre-treatments on the end point titres of Chlamydia specific and 
dual species (IgG) serum samples. 
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higher end-point titre as compared to the untreated and the sodium periodate treated 
antigen preparations. In this instance, the Triton X-100 pre-treatment enhanced the effect 
of having both antibodies against C. pneuminae and C. trachomatis in the same serum 
sample. 
The effect of both pre-treatments on the LGV 1 antigen preparation was more marked with 
the C. pneumoniae specific and dual species samples. Both sodium periodate, and Triton 
X- 100 reduced the ELISA OD values to below that of the chlamydia negative sample at 
all serum dilutions, suggesting that both pre-treatments work equally as well in reducing 
cross reactivity. Ossewaarde et al. (1994b) recommended the use of sodium periodate 
over Triton X-100, as detergents like Triton X-100 can remove proteins from chlamydial 
elementary body preparations (Caldwell et al., 1981 ) which could possibly reduce the 
sensitivity of the ELISA. For all subsequent ELISA runs, the sodium periodate pre- 
treatment of antigen was used routinely. 
Titration of LGV1 antigen with sodium periodate 
Due to the fact that sodium periodate pre-treatment reduced the mean OD and end-point 
titres of all the test samples examined previously, the antigen was re-titrated against a C. 
trachomatis specific serum (IgG MIF 1: 512). The titration method was the same as 
previously described with a few minor alterations; after the overnight incubation of the 
antigen at 4°C, the plate was washed once in PBS-Tween and 50µl of 1% sodium 
periodate was added to each well and the plate incubated at 37°C for 10min. The plate 
was then washed twice in PBS-Tween before the addition of the diluted serum. 
A decreasing OD with increasing serum dilution, and decreasing antigen concentration 
was observed (Graph 19). For the sodium periodate treated LGV 1 antigen preparation a 
final antigen concentration of 20pg/ml, and a serum dilution of 1: 100 was finally decided 
upon for all further developmental ELISA experiments. 
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Graph 19. IgG enzyme-linked immunoassay standardization with 
a C. trachomatis specific serum (IgG micro-immunofluorescence 
titre 1: 512) with sodium periodate pre-treatment of LGV 1 antigen, 
at a IgG conjugate dilution of 1: 2000. 
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1: 2000 vs. 1: 4000 IgG conjugate titration 
It was observed that some serum samples showed a small degree of cross reactivity 
against the McCoy cell antigen preparation, although it must be noted that the OD of cross 
reactive samples was below that of the negative cut off value. In an attempt to reduce this 
effect the conjugate dilution was altered from 1: 2000 to 1: 4000. 
A standard ELISA was run using 20pg/ml of both LGV 1 and McCoy cell antigen 
preparations, sodium periodate pre-treatment and a selection of known MIF serum 
samples diluted 1: 100 (one C. trachomatis MIF 1: 2048, two C. trachomatis MIF 1: 512, 
and five chlamydia negative samples), using an IgG conjugate dilution of both 1: 2000 
and 1: 4000 (Graph 20 and Graph 21). 
There was little reduction in the degree of cross reactivity between some of the serum 
samples and the LGV1 and McCoy cell antigen preparations. There was a reduced OD 
against the LGV 1 antigen, at an IgG conjugate dilution 1: 4000, when compared to the 
same serum sample at 1: 2000 IgG conjugate dilution. The cross reactivity may simply 
have been due to the relatively low serum dilution, with this in mind the LGV 1 antigen 
was re-titrated with the IgG conjugate diluted 1: 4000. 
Titration of LGV1 antigen with 1: 4000 IgG conjugate dilution 
The LGV 1 antigen was titrated as formerly described at antigen concentrations ranging 
from 40pg/ml to 5pg/ml and at serum dilutions from 1: 50 to 1: 800 (C. trachomatis IgG 
MIF specific 1: 512). The results are shown in Graph 22. From the data obtained from 
this experiment, for all ELISA of actual study samples the antigen concentration was left 
at 20µg/ml with sodium periodate treatment, and the serum dilution altered to 1: 200. 
Validation of ELISA with known titre MIF samples 
Using the established ELISA method, with a sodium periodate pre-treatment of the 
antigen, a selection of MIF samples with known IgG titres were tested to see how the 
mean OD of samples varied with differing levels ofC. trachomatis IgG. 
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Graph 20. Comparison of mean OD values of a panel of sera (diluted 1: 100) 
against both LGV, and McCoy cell antigen preparations (20µg/ml), after 
sodium periodate treatment at adgG conjugate dilution of 1: 2000. 
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Graph 21. Comparison of mean OD values of a panel of sera (diluted 1: 100) 
against both LGV 1 and McCoy cell antigen preparations (20µg/ml), after 
sodium periodate treatment at an IgG conjugate dilution of 1: 4000. 
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Graph 22. IgG ELISA standardization with a C. trachomatis 
specific serum (IgG micro-immunofluorescence titre 1: 512) 
with sodium periodate antigen pre-treatment, at an IgG 
conjugate dilution of 1: 4000. 
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The MIF samples (Northern General Hospital) were tested in triplicate at a serum dilution 
of 1: 100 against 20pg/ml of the LGV 1, and at an IgG conjugate dilution of 1: 4000. The 
mean ODs of a series of C. trachomatis IgG positive samples were compared to the mean 
OD of two chlamydia negative samples (Graph 23); and the mean OD of a selection of 
chlamydia negative samples (labelled A through to T) were compared to a high titre C. 
trachomatis positive (IgG MIF 1: 512) serum sample (Graph 24). 
The high 1: 512 titre MIF samples (Graph 23) gave a range of mean OD values (0.7-1.4) 
and the 1: 128 samples ranged from 0.7-0.85. When compared to the appropriate 
negative controls all the samples would have been considered positive. The negative 
serum samples (Graph 24) also had a range of OD values (0.058-0.36), and by 
calculating the mean OD of the negative samples with addition of three times the mean 
standard deviation (SD), all the negative samples would have been considered negative if 
tested by ELISA alone. 
This experiment highlighted one of the problems associated with MIF, the subjectivity of 
the reader. It is highly likely that the serum samples tested were tested by different 
operators, which could give variability in MIF titres accounting for the range of optical 
densities seen by ELISA. Generally speaking, the designated MIF titres of the samples 
were reflected in the mean optical densities after ELISA, in that negative MIF sera OD 
values fell below the negative cut off value; and positive MIF samples gave OD results 
that ranged above the negative experimental cut off. A similar study by Ben-Ahmeida et 
al. (1990) using a panel of human sera, determined the presence of IgG antibody against 
chlamydia by three serological assays; CFT, IF, and ELISA. This study showed that 
there was a strong correlation between IF titre and ELISA readings. 
6.1.2 IgM ELISA development 
IgM titration 
As previously described, the IgM conjugate was titrated against the LGV 1 antigen 
preparation, after sodium periodate treatment. Briefly, the LGV 1 antigen was diluted to 
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give a range of concentrations (40µg/ml to 5pg/ml). Two serum samples were tested, a 
low IgM MIF C. trachomatis specific serum (IgM MIF 1: 20), and a high IgM MIF C. 
trachomatis specific serum (IgM MIF>1: 40). Both sera were diluted from 1: 40 to 
1: 1280, and titrated against the LGV 1 antigen at all antigen concentrations. The basic 
ELISA methodology was the same as previously stated for IgG ELISA, except the 
substrate buffer was left to develop at room temperature for 35min. 
The results for both samples are shown in Graph 25, and Graph 26. From the data 
obtained in this experiment the optimal antigen concentration for IgM ELISA was 
20µg/ml, with a conjugate dilution of 1: 2000, and a serum dilution of 1: 200. 
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Graph 25. IgM standardization with sodium periodate 
LGV 1 treatment with a C. trachomatis specific serum 
(IgM micro-immunofuorescence titre >1: 40), at an IgM 
conjugate dilution of 1: 2000. 
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Graph 26. IgM standardization with sodium periodate 
LGV 1 treatment with a C. trachomatis specific serum 
(IgM micro-immunofuorescence titre >1: 20), at an IgM 
conjugate dilution of 1: 2000. 
1.6 antigen concentration 
1.5 
1.4- --t-- 40yg/ml 
1.3 " 
1.2 ....... 20yýg/ml 
1.1 "-" 
1 ý\ 
"'ý, ' ----ý--- lOjsg/ml 
0.9 '" . S. 
0. g ý". ---- A---- 5yc g/ml 
0. % 
0.6 
0.5- 
0.4- 
0.3 
0.2 
0.1 _-"_ 
216 
et 0C 
.. r 
serum dilution factor 
uv oow r. 
n 
cow M 
Nä 
.ýd rd N. 
"d 
0 
b 
O 
Cli 
a) 
A 
p 
0 >b Z (L) 
a :. n 19 
.o 124 
m 
"Ci 
ý+ 
E 
0 
5- 
u 
ö 
0 
4-4 
Ü 
b U 
U 
0 
> 
" ""U" 
c 
-ci 
ý+ E 
o c2.4 Z E 
'° 
u 
C 
" 
O 
o 
C 
`e 
a 
>, 
ä 
ca 
ä 
_ 
ö 
,0 
0 
E 
cu 
"Ö `ý 12 
ä z 
b A E 
W ;c 
-d 
.., 
r. 
0 
"F- 
b 
ýe 
0 
Ici 
2 
o 
' 
o 
+ 
(a 
P. 
aý o ä 
... c2 
w 
o 
p 
Q 
z 
., 
10 
4ý 
> 
o a 
v 
NW ö 
., 
"0 
ý? 
:, 
0 
Ci. 
o 
.m 
u o 0 
ä x vý H H 
Vi 
"O 
C 
aý 
Oý 
a 
L. w 
N 
N 
'C () 
U 
4) 
r. + N 
b 
r. + O 
Q 
«i 
... 
.ý 
b 
aý 
aý 
aý 
b 
+ 
217 
MC 
"ý 
Ü 
b .. cö 
a 
M' M 
Z 
p 
r. 
y 
v 
w 
0 
O 
W 
Q 
N 
Z 
Ö 
0 
Z 
Cl 
a 
O 
w 
fý 
0 
'. 
- 
1u 
a 
O 
w 
Ö 
'Z 
- 
cu 
r. 
O 
w 
a 
G 
C 
y 
w 
O 
Cl 
° 
z 
0 
w 
O 
a 
= 
.ä 
C 
° 
.C 
-+F 
Z= 
V 
w° 
oQ 
v 
° 
r. 
Co 
°' 
r_ v2 
m 
r. 
cli 
° 
Z 
M 
C 
° 
_ 
CL 
° 
u2 
Ü 
5 
° 
ri, 
'. " ¢ ¢ Cl) ¢ z ¢ Cl) ¢ ¢ Cl) ¢ ¢ ¢ 
aý ý ý ý V V U cn 
V 
rA 
U 
rn 
V 
cn c02 
V 
Ln 
V 
Gn 
U 
cn 
V 
v2 
CL) 
00 
== 
0 
w 
o 
w 
w 
o 
w w 
w 
o 
w 
z W W W w o 
w 
w 
0 
w 
w 
o 
w w 
ö w O 
w 
--ý U w 
o 
u" 
O 
w 
O 
w 
o 
w 
0 
w 
0 
w 
o 
w 
O 
w 
o 
w 
0 
w 
o 
w 
o 
w 
O 
w 
o 
0w w w w w w w w w w w w w w w 
ýC 
M 
00 
M 
'ýf 
M 
lý 
V) 
M 
M 
V1 
M a.. 
Gý 
M 
00 
M 
ýO 
ýt 
ON 
rt 
M 
<T ý. ý.. 
1 
V1 \D t- 00 11 
, 
L29 
x x 
x - U M 
218 
aý u 
u 
ý 
0 
U 
10 -0 CA 
. 
0 
- 
ai 
~ U N `u tu 
b 
+ý ýbD ö ö 
Ö env E 
cE 
-"i r. .Z "r, U Ua 
.r U 
U O 
U cd 
:2 
U cl 
"C 
> 
Z z o o w w 
wV 
+ 
V ^ý 
+ > > > + 
Q+ ö ¢ w ¢ ¢ ¢ 0 
E 
°-ý' x 
w 
w 
w 
w 
w 
w 
w  w 
0ö 
ö ö ö ö ö ö 
w w w w w w 
ce ý 
«e e m 
eý 
t}' 
M M 
r. + 
ö N N 
4 
cn 
E A rq 
219 
u 
C 
bA 
Lr 
0 
ca. 
ö 
0 
N 
M 
U, 
Pzi gý 
0 0 c 
c2. 
0 
10 
(2 0 
O 
ü Gn 
.. r 
." V 
ö 
w 
U 'b 
,; 
¢ 
as 
b< ICJ 
cu ý 
ýb 
w 
U, O 
o "r 
a0 .b x 
9) 
Wä 
w 
; 
0 
a 
Wä 
'0 
u 
"a 
äu 
> 
i. 4 W W 
0 
b 
Ic 
C 
W 
w 
Wo 
C 
O- 
aa 
W 
'Q 
0 
y 
O 
a 
W W 
aý b 
N 
y 
W 
+ + + U + + . . + 
Cm- F -++ ý, <Z- ýe 
ji. j 
C) 
> 
U 
> 
0 
> 
0 
> 
U 
> 
4) 
> 
4) 
> 
U 
> 
; 
+ + 
y 
> 
V w' 
aö 
°' w 
+ö 
wN vý rA ¢ 
> 
+ 
o 
+ö 
wy 
> 
UD ¢ 
Z Z 
> 
w 
w 
o 
w 
vý 
¢ 
äý 
cö 
o 
w 
w 
w 
w 
0 o w 
o 
w 
w 
w w w 
w 
w 
w 
w 
w 
w 
w 
w 
a ä 
ý- U a 
ý 
w 
o 
w 
w 
o 
w 
w 
o 
w 
w 
0 
w 
w 
o 
w 
w 
0 
w 
ö 
ý 
ö 
ý 
w 
0 
w 
w 
0 
w 
w 
0 
w 
N M 
N N 
M ý' 
N M N M 
r+ 6ý 
ßr 
Oý N M 
iti 
ti 
W 
º-i 
W 
b" ý-y -. º1 º-l ti º-ý 
220 
Aý 
"Ay 
w 
u 
cC W 
eý 
.a Z 
H 
cý 
0 
M 
M 
C 
s,. 
rA 
C 
0 
N 
V1 
. - 
,A U aQ~. CA 
O 
e 
y 2 ucä 
J5 
5 
Q 
0 
'° 
a4 
F 
,d 
4> 
cu 
Ei 
cu 
V 
ä 
y 
;g 
C 
e 
ýC 
~ 
... 
ri.. ý 
plp 
o 
w 
+ 
"a 
o 
0 ä 
>r, 
,% 9. 
=- 
> 
0 
*c ä 
.r 
2. 
app 
Eý 
cn 
-o 
Q 
ö 
r+ýi 
>, 
co 
e 
id 
.C 
e 
. 
im 
V". 
ä 
.c 
ö 
b 
Iii 
;ä 
b ä 
w 
to 
00 
>, 
oo o 
y 
-2 
,ý 
" ö 
v 
_ 
-E 
ä 
cu y 
ö 
ö 
E 
ö 
cri = 
7E w 
`ý 2 
> C 
O 
0 C 
GA "r 
.. 
w 
° 
0 
o 
w 
E 
0 
o 
rA 
t7 
w 
° 
0 
0 
i"' 
w 
0V 
Q 'C 
r. 
412 
O 
cL 
w 
`E 
w 
O 
, EL aý 
+ 
< 
+ + + S + + + 
1 
C + ¢ ¢ + w ¢ +w W w+ ¢ Q 
c > ¢ > ¢ 8 >> + ¢ +> w + W > w > + +> O + w O 
w 
> + w o 
w 
°' 
ö 
o 
w 
o 
w 
w 
w 
w 
w 
w 
w o w 
w 
w 
w 
w w O o w 
0 
w 
ä 
E 
U 
Q+ 
w 
Ow 
w 
0 
w 
w 
w o 
w 
w 
0 
w 
0 
w 
w 
o 
w 
w 
O 
w 
w 
0 
w 
0 
w 
w 
0 
w 
cu 't 
(`1 
N 
M 
M r" M 
M 
m 
N N N M 
P. 9 
ö '' 
º-S 
N 
-l 
M 
Ga0 
ý 
= 
r- 0 
cc 
c= 
221 
b 
Ö C 
ö0 
Ü t) 
Kg 
10 U 
5 42 
.s 
42 
s 
42 
0 
V 
0 
+ z + 
n.. 
Q Q + 
a ä c + o 
w 
+ o 
w 
> + cl 
y 
E 
cl 
- w 
C) 
w 
w 
0 
w 
w 
0 
w 
c 
z 
U 
ö w w w W 
Cl 
M 
m N 
C d 
b 
0 ä 
222 
E Z I N. 34 Z 9.9 
O - 
" U 
a 0 
e 
'd 
rA 
.ýb 
" 
'd o 
"ý :c 
"ý :c 
-ý 4- 4- 4- -. - . 3- 4- 
x 
rA 
C) 
ö 
0 
0) 
"d 
X 
ö 
0 
0) 
X 
ö 
0 
0) 
x 
S 
0 
0 
ö 
0 
-0) aý 
> > >> + > z > z > >> 
äo 
++ 
> > >+ > > 
+ 
> 
+ z 
G 
> 
, 
(U 
> 
" 
- 
z 
> 
+ 
I 
>> 
w ý+ ý + ' + " + 
10 
+ + 
++ + + ++ + + + + + + 
00 
N 
V) 
0N 
rA En 
V 
cn 
Q) 
V) 
4) 
w 
N 4) 
V) 
4) 
V) 
N 
Ln En 
zz 
U 
ao 
vý 
>> 
vý vý 
a¢ 
> 
vý 
a 
> 
+ 
o 
>> 
cn vý 
¢¢ 
> 
+ 
o 
> 
vý 
a 
> 
vý 
a 
> 
vý 
¢ 
> 
vý 
¢ 
> 
vý 
¢ 
> 
vý 
¢ 
>w 
Li ö 
wy 
> 
V) 
¢ 
> 
ci vn 
o 
>4 >4 0 
°--' 
E 0-4 
cm w 
w V. 
o0 
ww 
w 
o 
w 
w ww o0 
ww 
w 
0 
w 
0 
w 
o 
w 
w 
O 
w LT. 
V. 
O 
w 
w 
o 
w 
l W zz 
-- U a' a+ ýý 
w 
ww 
OO 
ww 
w 
O 
w 
w 
o 
w 
ww 
oo 
ww 
w 
o 
w 
w 
o 
w 
O 
w 
w 
w 
w 
w 
w 
O 
w 
w 
O 
w 
w 
O 
w 
w 
O 
w 
w 
Ow 
wo 
pýA 
cl 
M et 
m 
`tt 
en 
N 
en 
gN 
N 'It 
ON 
N 
N 
M 
en 
M 
N 
M 
N 
N 
tý 
N 
\O 
en 
ON 
en 
O\ 
en 
MO 
NN 
w v 
".. 
Ö 
ä 
-M 
SS 
ý/'1 
S 
00 
S 
M 
ö ö 
00 
ö 
M 
ö 
V'f 
ö 
110 
ö 
00 
ö 
en 
O O 
223 
NW 
0 
b 
"° 
0 
10 
0 
Ici 
0 
"0 
0 
"U 
0 
"0 
u "0 10 "Ci "Ci "C 
M 
t- 
M N 
-F- N 4-- .ý -F- -i- i- -! - 4- 
> > > > > > > > > 
CZ- 
ý 
' t t t t t t t f t + ý f 
t 
t 
t 
f t t 
t 
t f 
f 
f 
f 
f 
t 
f t t 
t 
f 
+ 
t '} 
f 
ýF 
'z z z z z z ¢ z' z z 'z w 
U r-' ö ýn ¢ O 
w ý, ¢ 
+ + 
O 
+> 
U. ¢ ¢ 
t 
o 
t 
o ¢ +' O 
+ 
O 
E 
(X 
ö z z z z z z w z z O z z w 142 C. 
ä 
ö,, U a 
C 
w 
O 
w 
o 
w 
O 
w 
o 
w 
o 
w 
o 
w 
O 
w 
o 
w 
O 
w 
o 
w 
O 
w 
o 
ö 
w 
M N M 
ýt M M 
M M M M M N 
w y 
^+ 
.. r 
V 
N 
N M M M M N O O 
'n 
N 
- 
224 
bA 
i, 
Gn 
Ö 
C) Vl 
110 
C 
<D 
U cu ce 
U 
C 
"Ci 
ce 
U 
m 
U 
m 
U 
+ 
ýy 
E 
m 
U 
U 
ö rA 
0 
m 
CE 
p 
in 
° 
Cý 
m}''ý 
U 
m 
U 
o 
ce 
U 
o 
(n 
U 
m 
U 
In 
C 
.ý 
VI 
0 
' 
m 
U 
>X 
"--4 
X 
M 
>< 
"-r 
iG 
. -r 
i< 
-q e. 
>< 
-4 
,, ý 
Mc 
A 
i^i 
p., 
i< 
- 
x 
- 
it 
. -r 
i< 
. --d 
x 
. --i -e 1 rar 
> > > > > > > > > > > > 
> > 
t 
> 
t 
> 
+ 
> 
+ 
C) > C) > u > u > >aý C > a " 
+l 
Cam. 
z {' 'ý' f f f 
ö 10 
ºý Q 
w 
¢ 
+ Q z z z z z z z z ¢ z z 
ý. ý Z. 4 Gn d 
> + 
iz 
+ W + O + W > Q Q ; + W > t w o 
> + w 0 
> + w 0 ; + ° 
> t w o > ä ; < < GA 
E 
äý 
ýö 
w 
W 
w 
W 
w 
W 
w 
w w ¢ z ¢ z ¢ z Q z d z d z ¢ z ¢ z w o 
¢ 
z ¢ z 
zw 
aä 
ö 
Cl) w 
Ö 
W 
Ö 
W 
Ö 
W 
Ö 
W 
Ö 
W 
w 
O 
p 
W 
w 
W 
w 
O 
w 
0 
w 
0 
w 
0 
w 
0 
w 
0 
w 
0 
w 
0 
(2 u V) 
N el. - nt M 
N N O 
M 
Oý 
N 
V1 
en 
O 
M 
°ý 
M 
e 
M 
°ý 
N 
N 
M 
V1 
M 
O 
M 
N 
M 
w 
U 
PCJ 
p 
O 
O N en 
N 
- 
:Z 
~ N 
. 
~. 
00 
- 
N 
M 
M 00 
en et 
N 
225 
'C 
C 
ÖC 
ý 
+ bA 
... 
;ý " E C Ü Ü 
Cl 
Ü Ü 
u Gn eI, CA (A (A 
X X X x x 
z z z 
+ z z l < 
el el 
z z z ¢ Co 
9. d 
pes,,, ö > cý' ¢ > u. > O > 
ö ö ö 
y c c a 
x 
EW z z z w 
w 
o 
,A p4 V 
z 
w 
o 
w 
0 
w 
0 
w 
o 
w 
äo 
C 
00 
M 
rm 
M M 
N 
y zt 
^" 
v 
- 
226 
u 
bA 
u 
cý. 
c°. 
L7 
M 
114 
"d r 
e 
Z 
'o 
.ý 2 
~ 
rin 
o .ý 
.C 
a w 
'b 
Ei 
w 
° 
a+ 
Ö 
cd 
o 
v 
ai 
q 
2 
w 
.b 
ca 
bQ 
v`ý, 
r_ 
cl 
r4.1 
U 
U 
Lý 
Q 
a+ 
O 
O 
E 
E 
U 
ýO 
O 
O 
O 
. 
a 
U 
L 
cd 
`a 
.n 
: 
0 
tu 
C 
- ö 
b 
. -, 
1ý 
p 
.a 
a 
U 
to 
,, 
C 
ý+7 
ä 
ai 
11 
:ý 
"0 
[ 
I 
ä 
v^, 
p 
5 
ai 
:g 
eý 
r. 
Ö 
y 
O w 
ýä 
ä 
cji 
ä ä ä Z= 
.5 
0 
1'521 . 
ä 
w 9 
ä 
w 
U 
b 
E 
ä 
w 
ä 
w 
ä 
w 
r 
w 
ä 
w 
ý., z z z + 
U 
' 
; 
+ 
; 
+ 
¢ 
z 
¢ 
z 
¢ 
z 
; 
+ 
U U N 
+ 
y 
' 
U 
+ 
re, ý 
+ + + 
10 
w z z z 
¢ w z Cl) Q 
yýj U 
d 
; 
+ 
4) 
Q 
U 
> Q 
y 
+ w 
6) 
Q z z > + 
U U 
Q w 
C q q 
ä ý 
c 
w 
w 
ý' 
w w ¢ z ¢ z ¢ 'z w O 
w 
o 
¢ 'z ¢ 'z w O 
w w 
°' 
ll- U CL4 
w 
0 
w 
w 
o 
w 
w w w w 
0 0 o w O 
w 
-4 
en 
YD 
- 
N C M 
N 
M M M 
> 
N Qý O 
N N 
> 
- 
> 
1 91 
227 
C 
cam, C 
r. + 
b 
bC~,, 
n.. i 
'., p 
O 
v 
V 
W 
y 
n" 
lF 
a 
w 
~ 
"' 
A 
° > 
q 
,ýt 0 
Lir 
3t 
a 
w "., 
> 
a 0 
0 
12- 
Z. 
ýE 
a 
w 
"° 
U 
ý' 
ai b 
ý 
cUi 
e 
ýE cý 
a 
w .a 
> 
c 0 
0 
ýr 
iF 
a 
w 
61 
> 
c 0 
0 
Zi 
1E 
a 
w 
Cl 
dE 
a 
w 
w 
0 
ý "ý 
ö 
>Q 
a 0 
p 
öö 
ý, tu '> 
ýE .d .b a0o 
wEE 
N 
> 
c 0 
0 
i 
9E 
a 
w 
0 
`ý 
Ü 
v° 
K 
U 
9F 
a 
w 
V 
-Iz 
> 
a o 
0 
7 
9E 
a. 
w 
N 
-g3 
> 
0 
0 
i 
ýE 
a 
w 
0 
Ow 
if 
a 
w 
aý+ 
öÖ 
V y 
ts' 
_ 
0 
° 
cu 
N 
iF ° 
a 
wu 
° 
P 
ä 
to 
N 
9E 
P. 
w 
z z z z z z z z 
ý/ 
S. -9 + 
l 
Id 
V 
+ 
V 
> 
¢ 
z 
¢ 
z 
¢ 
'z 
¢ 
z 
¢ 
zz 
¢ 
zz 
¢ 
zz 
¢ 
z 
V 
+ 
N 
+ 
V 
+ 
Gn (A w ä ¢ ¢ W z 
äö 
ý 
¢ 
> 
o 
> 
¢ 
> 
¢ 
> 
¢ 
> + 
W 
> + 
w 
; 
¢ 
> 
+ 
> 
w 
> 
+ 
> 
o 
> 
ý' 
o 
z 
> 
o 
w 
c a c 
V 
a 
u 
a 
9 
a c 
u 
a 
Cö w o o W W z z W W z o z w z 
a ä 
U 
a 
ý- zw 
w 
o 
w 
ö ö w 0 
w 
w 
0 
w 
w 
0 
w 
w 
0 
w 
w 
o 
w 
w W 
w 
o 
w 
ö w 0 
w 
V ö 
C 
w 
0 
w 
4) 
4) M CD 
'fit 
C le) 
N " 
0% 't 
N c, " M M 
%0 
en 
oo 
N 
v1 
M 
v) 
N 
y 
wA Vy m_ tt V1 e 00 
ä 
ON 
ä ä 2 ä 
- 
ä 
N 
228 
öý 
r.. l V 
°' 
ä 
fA 
ä 
V1 
'" v ä 
º'd ý'n 
JA 
"ý ý 
rýýý+++ 
to 
N 
tV/1 
Rýr7 
tß/1 
CO 
fVA 
CC 
fUA 
cý +e ie ie i< 
M 
w w w w w 
F4 
+ 
y 
I 
d 
+ 
O 
+ 
O 
FBI + 
I 
+ + 
' H 1 2 _ - + + + + H 
x Q Q Q Q 
w z 'z z 'z 
I.. 
U- 
a 
" 
+ 
° 
' + 
o 
+w 
wö 
0y 
> 
w 
o 
+ 
w 
W 
E 
.=x Eý 
w om 
w 
° z z z z 
v , 
a ä 
-ý U w w w w w a o 
w 
0 
w 
0 
w 
0 
w 
0 
w 
OA M N M N M 
b 
O 
e 
Ö 
ä 
ý} 
O 
ä 
ýO 
ä 
ýp 
ä 
o 
ä 
a 
t 
161.1 
C 
0-4 
LO 
V 
W 
.G D 
H 
D 
0 
It 
kg C 12 
.M= 
JD 
po 
.=Ü 
u .- , rA 
o\ - 
u 
++ 
CCL 
E-+ 
Qz 
r4 
aZ>> .Z1 äQw 
2 
`ö 
wz 
aä öö ý ý" ww w 
ýMM 
r. + 
Qa 00 
O 
229 
U + + 
I I + I I . -4- I . I . . + 
~ + + " I + I . + + . ý I + + + . , + 
'$ 
u 
(N 
3 
Z 
3 3 3 
Z 
cal 
3 
z 
M, 
3 
I 
N 
3 
T 
N 
3 
T 
- 
3 
I 
3 
= 
3 
2 
c+', 
3 
I 
M 
3 
I 
O 
3 
T oý 
C 
3 
2 
0 
° 
cA 
M 
3 
x 
C 
3 
X 
M 
3 
x 
^C w c 'C 
O 
N M 
ýt 
V1 ýG 
ý7 
I- 00 
ýi 
Qý C 
ýn 
- 
vý 
N 
ýn 
M 
vý Vn 
- 
v) 
`p 
W) 
r- 
tn 
00 
v) 
Qý 
vý 
O 
ýO 
U 
. I . I I i I . I . I . + I I I + . -f" 
4. 
r 
tý a v) r, x z C -- C -- v) oc N -t z v1 ON C J C C N - - - C, M, - m N M N N -- N N 
^ 
ö 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 u Z Z Z Z 2 Z T T x x x Z x = x x x x x x 
'a 4w C C= N M V) ýc N oc O' O N M If ýp N V f1 N N N N N N N N M c r, M M M M M 
00 ON O 
M M M 't 
aý L 
a 
0 
"r 
L 
F 
w 
U 
U 
I I + T 
+ + I + + + I + I 1 T I I + 1 
FZI 
VJ 
I + + + + + + + + + I + 1 + I I I 
"'d - -- O O 
^ 
O O O C 
2 r r1 O 
M 
cn O N O 
z z cý cý x x x c 3 3 3 3 3 3 3 u rý cn w m oa as as as co as m x x x x x x x 
ti ý, ti ti .1 ti ti 
'o Qý Ö N M ý! 1 ýO Iý OC N M ýp [ý 00 Qý O pý 
ºri 
IV 
In 
230 
Chapter 7.0 
References 
Abraham, L., Du, D., Zahedi, K. et al. (1991), " Halotypic polymorphisms of the 
TNFß gene. " Immunogenetics 33: 50-53. 
Abraham, L., French, M., and Dawkins, R. (1993), " Polymorphic MHC ancestral 
haloptypes affect the activity of tumor necrosis factor-alpha. " Clin. Exp. Immunol. 92: 
14-18. 
Adam, M., and Ossewaarde, J. (1998), " Broad range chlamydial PCR detects 
previously unrecognized chlamydia sequences: a new genus in the family 
Chlamydiaceae. " In Chlamydia Infections. Stephens, R., Byrne, G. et al. (Eds. ). 
International Chlamydia Symposium, San Francisco, CA. 
Allen, I., Hatch, T., and Pearce, J. (1985), " Influence of cysteine deprivation on 
chlamydial differentiation from reproductive to infective life-cycle forms. " J. Gen. 
Microbiol. 131: 3171-3177. 
Allen, J., Cerrone, M., Beatty, P. et al. (1990), " Cysteine-rich outer membrane proteins 
of Chlamydia trachomatis display compensatory sequence changes between biovariants. " 
Mol. Microbiol. 4: 1543-1550. 
Amann, R., Springer, N., Schonhuber, W. et al. (1997), " Coccoid obligate intracellular 
parasites of Acanthamoebae are distantly related to the genus Chlamydia. " Endocytobiosis 
Cell Res. 12: 99-101. 
An, Q., Radcliffe, G., Vassallo, R. et al. (1992), " Infection with a plasmid-free variant 
chlamydia related to Chlamydia trachomatis identified by using multiple assays for nucleic 
acid detection. " J. Clin. Microbiol. 30: 2814-2821. 
Anderson, A., Yue, Z., Meng, F. et al. (1994), " Low implantation rate after in-vitro 
fertilization in patients with hydrosalpinges diagnosed by ultrasonography. " Hum. 
Reprod. 2: 1935-1938. 
Arno, J., Ricker, V., Batteiger, B. et al. (1990), " Interferon-? in endocervical secretions 
of women infected with Chlamydia trachomatis. " J. Infect. Dis. 162: 1385-1389. 
Asch, R., Balmaceda, J., and Elsworth, L. (1986), " Preliminary experiences with 
gamete intrafallopian tube transfer (GIFT). " Fertil. Steril. 45: 366-371. 
Ault, K., Tawfik, 0., Smith-King, M. et al. (1996), " Tumor necrosis factor-cc response 
to infection with Chlamydia trachomatis in human fallopian tube organ culture. " Am. J. 
Obstet. Gynecol. 175: 1242-1245. 
Backman, K. (1987), " Method for detecting a target nucleic acid sequence. " European 
Patent Office 320,308. 
Badenhoop, K., Schwarz, J., Trowsdale, V et al. (1989), " TNF-a polymorphisms in 
type 1 (insulin-dependent) diabetes mellitus. " Diabetologia. 32: 445-460. 
Baehr, W., Zhang, Y., Joseph, T. et al. (1988), " Mapping antigenic domains expressed 
by Chlamydia trachomatis major outer membrane protein gene. " Proc. Natl. Acad. Sci. 
USA 85: 4000-4004. 
Bahamondes, L, Bueno, J., Hardy, E. et al. (1984), " Identification of main risk factors 
for tubal infertility. " Fertil. Steril. 61: 478-482. 
Bailey, R., Kajbaf, M., Whittle, H. et al. (1993), " The influence of local antichlamydal 
antibodies on the aquisition and persistence of human ocular chlamydial infection: IgG 
antibodies are not protective. " Epidemiol. Infect. 111: 315-324. 
231 
Banks, J., Eddie, B., Sung, M. et al. (1970), " Plaque reduction technique for 
demonstrating neutralizing aantibodies for Chlamydia. " Infect. Immun. 2: 443-447. 
Bannantine, J., Rockey, D., and Hackstadt, T. (1998), Tandem genes of Chlamydia 
psittaci that encode proteins localized to the inclusion membrane. " Mol. Microbiol. 28: 
1017-1026. 
Barbour, A., Amano, K., Hackstadt, T. et al. (1982), " Chlamydia trachomatis has 
penicillin-binding proteins but not detectable muramic acid. " J. Bacteriol. 151: 420-428. 
Barnes, R. (1989), " Laboratory diagnosis of human chlamydial infections. " Clin. 
Microbiol. Rev. 2: 119-136. 
Bartaneva, N., Theodor, I., Peterson, E. et al. (1996), " Role of neutrophils in 
controlling early stages of a Chlamydia trachomatis infection. " Infect. Immun. 64: 4830- 
4833. 
Bas, S., Cunningham, T., Kvien, T. et al. (1996), " Synovial fluid and serum antibodies 
against Chlamydia in different forms of arthritis: intra-articular IgA production in 
Chlamydia sexually aquired arthritis. " Br. J. Rheumatol. 35: 548-552. 
Bass, C., Jungkind, D., Silverman, N. et al. (1993), " Clinical evaluation of a new 
polymerase chain reaction assay for detection of Chlamydia trachomatis in endocervical 
specimens. " J. Clin. Microbiol. 31: 2648-2653. 
Batteiger, B., Newhall, W., and Jones, R. (1985), " Differences in outer membrane 
proteins of the lymphogranuloma venereum and trachoma biovars of Chlamydia 
trachomatis. " Infect. Immun. 50: 488-494. 
Batteiger, B., Newhall, W., Terho, P. et al. (1986), " Antigenic analysis of the major 
outer membrane protein of Chlamydia trachomatis with murine monoclonal antibodies. " 
Infect. Immun. 53: 505-510. 
Batteiger, B., Rank, R., Bavoil, P. et al. (1993), " Partial protection against genital 
reinfection by immunization of guinea-pig inclusion conjunctivitis. " J. Gen. Microbiol. 
139: 2965-2972. 
Bauwens, J., Clark, A., and Stamm, W. (1993b), " Diagnosis of Chlamydia trachomatis 
endocervical infections by a commercial polymerase chain reaction. " J. Clin. Microbiol. 
31: 3023-3027. 
Bauwens, J., Clark, A., Loeffelholz, M et al. (1993a), " Diagnosis of Chlamydia 
trachomatis urethritis in men by polymerase chain reaction assay of first-catch urine. " J. 
Clin. Microbiol. 31: 3013-3016. 
Bauwens, J., Lampe, M., Suchland, R. et al. (1995), " Infection with Chlamydia 
trachomatis lymphogranuloma venereum serovar L1 in homosexual men with proctitis- 
molecular analysis of an unusual case cluster. " Clin. Infect. Dis. 20: 576-581. 
Bavoil, P, and Hsai, R. (1998), " Type III secretion in Chlamydia: a case of deja vu? " 
Mol. Microbiol. 28: 860-862. 
Bavoil, P., Ohlin, A., and Schachter, J. (1984), " Role of disulfide bonding in outer- 
membrane structure and permeability in Chlamydia trachomatis. " Infect. Immun. 44: 479- 
488. 
Beatty, W., Byrne, G., Morrison, R. et al. (1993), " Morphological and antigenic 
characterization of interferon gamma-mediated persistent Chlamydia trachomatis infection 
in vitro. " Proc. Natl. Acad. Sci. USA 20: 3998-4002. 
232 
Beatty, W., Morrison, R., and Byrne, G. (1994), " Immunoelectron-microscopic 
quantitation of differential levels of chlamydial proteins in a cell culture model of 
persistent Chlamydia trachomatis infection. " Infect. Immun. 62: 4059-4062. 
Beatty, W., Morrison, R., and Byrne, G. (1995), " Reactivation of persistent Chlamydia 
trachomatis infection in cell culture. " Infect. Immun. 63: 199-205. 
Bedson, S., and Bland, J. (1932), " Morphological study of psittacosis virus with a 
description of the developmental cycle. " Exp. Pathol. 13: 461-466. 
Bedson, S., Western, G., and Simpson, S. (1930), " Observations on the aetiology of 
psittacosis. " Lancet.!: 235-236. 
Beebe, J., Sharpton, T., Zanto, S. et al. (1997), " Performance characteristics of the 
Gen-Probe competition assay used as a supplementary test for the Gen-Probe PACE2 and 
2C assays for the detection of Chlamydia trachomatis. " J. Clin. Microbiol. 'i5: 477-478. 
Ben-Ahmeida, T., Smith, T., Hicks, D. et al. (1990), " Incidence of chlamydial 
antibody in patient groups, as measured by the ELISA technique. " Int. J. STD AIDS 1: 
114-121. 
Berger, R. (1990), " Acute epididymitis. " In Sexually Transmitted Disease. 2nd edition, 
McGraw-Hill, New York. Holmes, K., Mardh, P., Sparling, P et al. (Eds. ). pp. 641- 
652. 
Berger, R., Alexander, E., Monda, G. et al. (1978), " Chlamydia trachomatis as a cause 
of acute 'idiopathic' epididymitis. " N. Eng. J. Med. 228: 301-304. 
Beutler, B., and Cerami, A. (1988), " The common mediator of shock, cachexia, and 
tumor necrosis. " Adv. Immunol. 42: 213-231. 
Beutler, J., Schumacher, R., Whittum-Hudson, J. et al. (1995), " Case report: in situ 
hybridization for the detection of inapparent infection with Chlamydia trachomatis in 
synovial tissue of a patient with Reiter's syndrome. " Am. J. Med. 310: 206-213. 
Bianchi, A., Dosquet, C., Henry, S. et al. (1997), " Chlamydia trachomatis growth 
stimulates interleukin 8 production by human monocytic U-937 cells. " Infect. Immun. 
65: 2434-2436. 
Birkelund, S., and Stephens, R. (1992), " Construction of physical and genetic maps of 
Chlamydia trachomatis serovar L2 by pulsed-field gel electrophoresis. " J. Bacteriol. 174: 
2742-2747. 
Birkelund, S., Lundemose, A., and Christiansen, G. (1988), " Chemical cross-linking of 
Chlamydia trachomatis. " Infect. Immun. 56: 654-659. 
Bobo, L., Novak, H., Mkocha, S. et al. (1996), " Evidence for a predominant 
proinflammatory conjunctival cytokine response in individuals with trachoma. " Infect. 
Immun. 64: 3273-3279. 
Bowie, W. (1978), " Comparison of Gram-stain and first void urine sediment in the 
diagnosis of urethritis. ' Sex. Trans. Dis. 139-42. 
Bowman, M., Cooke, I., Lenton, E. et al. (1993), " Investigation of imparied ovarian 
function as a contributing factor to infertility in women with pelvic adhesions. Hum. 
Reprod. 8: 1654-1656. 
Brade, H., Brade, L., and Nano, F. (1987), " Chemical and serological investigations on 
the genus-specific lipopolysaccharide epitope of Chlamydia. " Proc. Natl. Acad. Sci. 
USA. 84: 2508-2512. 
233 
Brade, L., Brunnemann, H., Ernst, M. et al. (1994), " Occurance of antibodies against 
chlamydial lipopolysaccaride in human sera as measured by ELISA using an artificial 
glycoconjugate antigen. " FEMS Immunol. Med. Microbiol. 8: 27-42. 
Bradford, M. (1976) A rapid and sensitive method for the detection of microgram 
quantities of protein utilising the principle of protein dye binding. Anal. Biochem. 72: 
1419-1426 
Brickman, T., Barry, I., and Hackstadt, T. (1993), " Molecular cloning and expression 
of hctB encoding a strain-variant chlamydial histone-like protein with DNA-binding 
activity. " J. Bacteriol. 175: 4274-4281. 
Bronson, P., Cooper, G., and Rosenfeld, D. (1984), " Sperm antibodies: their role in 
infertility. " Fertil. Steril. 42: 171-183. 
Browning, J., Ngamek, A., Lawton, P. et al. (1993), " Lymphotoxin (3, a novel member 
of the TNF family that forms a heteromeric complex with lymphotoxin on the cell 
surface. " Cell Z2,: 847-856. 
Bruce, A., Chadwick, P., Willett, W et al. (1981), Case control study of men with 
suspected chonic idiopathic prosatitis. " J. Urol. 126: 625-629. 
Brunham, R., and Peeling, R. (1994), " Chlamydia trachomatis antigens: role in 
immunity and pathogenesis. " Infect. Agents Dis. 3: 218-233. 
Brunham, R., Kuo, C., Cles, L. et al. (1983), " Correlation of host immune response 
with quantitative recovary of Chlamydia trachomatis from the human endocervix. " Infect. 
Immun. 39: 1491-1494. 
Brunham, R., Maclean, I., Binns, B. et al. (1985), " Chlamydia trachomatis: its role in 
tubal infertility. J. Infect. Dis. 152: 1275-1282. 
Brunham, R., Martin, D., Kuo, C. et al. (1981), " Cellular immune response during 
uncomplicated genital infection with Chlamydia trachomatis in humans. Infect. Immun. 
34: 98-104. 
Brunham, R., Peeling, R., Maclean, I. et al. (1987), " Postabortal Chlamydia 
trachomatis salpingitis: correlating risk with antigen-specific serological responses and 
with neutralization. " J. Infect. Dis. 155: 749-755. 
Brunham, R., Peeling, R., Maclean, I. et al. (1992), " Chlamydia trachomatis-associated 
ectopic pregnancy: serologic and histologic correlates. " J. Infect. Dis. 165: 1076-1081. 
Buendia, A., Sanchez, J., Martinez, M. et al. (1998), " Kenetics of infection and effects 
on placental cell populations in a murine model of Chlamydia psittaci-induced abortion. " 
Infect. Immun. 66: 2128-2134. 
Byrne, G., and Moulder, J. (1978), " Parasite-specified phagocytosis of Chlamydia 
psittaci and Chlamydia trachomatis by L and HeLa cells. " Infect. Immun. 12: 598-606. 
Byrne, G., Stephens, R., Ada, G. et al. (1993), " Workshop on in-vitro neutralization of 
Chlamydia trachomatis- summary of proceedings. " J. infect. Dis. 168: 415-425. 
Cabrera, M., Shaw, M., Sharples, C. et al. (1995) " Polymorphisms in Tumor Necrosis 
Factor genes associated with mucocutaneous Leishmaniasis. " J. Exp. Med. 182: 1255- 
1264. 
Caldwell, H., and Hitchcock, P. (1984), " Monoclonal antibody against a genus-specific 
antigen of Chlamydia species: location of the epitope on chlamydial lipopolysaccharide. " 
Infect. Immun. 44: 306-314. 
234 
Caldwell, H., and Judd, R. (1982c), " Structural analysis of chlamydial outer membrane 
protein of Chlamydia spp. " Infect. Immun. 28: 960-968. 
Caldwell, H., and Perry, L. (1982b), " Neutralization of Chlamydia trachomatis 
infectivity with antibodies to the major outer membrane protein. " Infect. Immun. R: 745- 
754. 
Caldwell, H., and Schachter, J. (1982a), " Antigenic analysis of the major outer 
membrane of Chlamydia spp. " Infect. Immun. 35: 1024-103 1. 
Caldwell, H., Kromhout, J., and Schachter, J. (1981), " Purification and partial 
characterization of the major outer membrane protein of Chlamydia trachomatis. " Infect. 
Immun. 31: 1161-1176. 
Campbell, L., Kuo, C., and Grayston, J. (1990), " Structural and antigenic analysis of 
Chlamydia pneumoniae. " Infect. Immun. 28: 1261-1264. 
Campbell, L., Kuo, C., Grayston, J. (1987), " Characterization of the new Chlamydia 
agent, TWAR, as a unique organism by restriction endonuclease analysis and DNA-DNA 
hybridization. " J. Clin. Microbiol. 25: 1911-1916. 
Campbell, L., O'Brien, E., Cappuccio, A. et al. (1995), " Detection of Chlamydia 
pneumoniae (TWAR) in human coronary atherectomy tissues. " J. Infect. Dis. 172: 585- 
588. 
Campbell, L., Patton, D., Moore, D. et al. (1993), " Detection of Chlamydia trachomatis 
deoxyribonucleic acid in women with tubal infertility. " Fertil. Steril. 2: 45-50. 
Campbell, S., Richmond, P., Yates, P. et al. (1994), " Lipopolysaccharide in cells 
infected with Chlamydia trachomatis. " Microbiol. 140: 1995-2002. 
Campos, M., Pal, S., O'Brien, T. et al. (1995), "A chlamydial outer membrane protein 
extract as a trachoma vaccine candidate. " Invest. Ophthalmol. Vis. Sci. 26: 1477-1491. 
Cappuccio, A., Patton, D., Kuo, C. et al. (1994), " Detection of Chlamydia trachomatis 
deoxyribonucleic acid in monkey models (Macaca nemestrina) of salpingitis by in situ 
hybridization: implications for pathogenesis. " Am. J. Obstet. Gynecol. 171: 102-110. 
Carter, M., Al-Mahdawi, S., Giles, I. et al. (1991), "Nucleotide sequences and 
taxonomic value of the major outer membrane protein gene of Chlamydia pneumoniae 
IOL-207. " J. Gen. Microbiol. 
, 
137: 465-475. 
Cates, W., and Wasserheit, J. (1991), " Genital chlamydial infections: epidemiology and 
reproductive sequalae. " Am. J. Obstet. Gynaecol. 164: 1771-1781. 
Cates, W., Joessef, M., and Goldman, M. (1993), " Atypical pelvic inflammatory 
disease: can we identify clinical predictors. " Am. J. Obstet. Gynecol. 116: 341-346. 
Centers for Disease Control (CDC) and Prevention. (1991), " False-positive results with 
the use of chlamydial tests in the evaluation of suspected abuse. " Morbid. Mortal. Weekly 
Rep. 32: 932-935. 
Centers for Disease Control (CDC), (1992), Ectopic pregnancy in the uSA 1978-1989, 
CDC surveillance summaries. " Morbid. Mortal. Weekly Rep. 41: 591-594. 
Cevenini, R., Donati, M, and la Placa, M. (1988), " Effects of penicillin on the synthesis 
of membrane proteins of Chlamydia trachomatis LGV2 serovar. " FEMS Microbiol. Lett. 
56: 41-46. 
Chalmers, W., Simpson, J., Lee, S. et al. (1997), " Use of a live chlamydial vaccine to 
prevent ovine enzootic abortion. " Vet. Record 141: 63-67. 
235 
Chambers, B., Quigley, B., Weinbaum, S. et al. (1995), " Detection of Chlamydia 
trachomatis in male and female urine specimens using transcription mediated amplification 
(TMA). " In. Abstracts of the 95th Annual Meeting of the American Society for 
Microbiology. American Society for Microbiology, Washington. Abstr. C-488 
Chang, J., Leonard, K., and Zhang, Y. (1997), " Structural studies of the surface 
projections of Chlamydia trachomatis by electron microscopy. " J. Med. Microbiol. 46: 
1013-1018. 
Chaouat, G., Menu, E., Clark, D. et al. (1990), " Control of fetal survival in CBA 
DBA/2 mice by lymphokine therapy. " J. Reprod. Fertil. 89: 447-458. 
Chen, G., Wilson, R., Wang, S. et al. (1996), " Tumour necrosis factor-alpha (TNF-(X) 
gene polymorphism and expression in pre-eclampsia. " Clin. Exp. Immunol. , 
103: 154- 
159. 
Chen, J., and Stephens, R. (1994), " Trachoma and LGV biovars of Chlamydia 
trachomatis share the same glycosaminoglycan-dependent mechanism for infection of 
eukaryotic cells. " Mol. Microbiol. 11: 501-707. 
Chernesky, M., Castriciano, S., Sellors, J. et al. (1990), " Detection of Chlamydia 
trachomatis antigens in urine as an alternative to swabs and cultures. " J. Infect. Dis. 161: 
124-126. 
Chernesky, M., Jang, D., Lee, H. et al. (1994b), " Diagnosis of Chlamydia trachomatis 
infections in men and women by testing first-void urine by ligase chain reaction. " J. Clin. 
Microbiol. 12: 2682-2685. 
Chernesky, M., Jang, D., Luinstra, S. et al. (1994c), " Ability of ligase chain reaction 
and polymerase chain reaction to diagnose female lower genitourinary Chlamydia 
trachomatis infection by testing cervical swabs and first void urine. " In Chlamydial 
Infections. Orfila, J., Byrne, I., Chernesky, M et al. (Eds. ). Societa Editrice Esculapio, 
Bologna, Italy. pp. 326-329. 
Chernesky, M., Jang, D., Sellors, J. et al. (1995), " Detection of Chlamydia trachomatis 
antigens in male urethral swabs and urines with a microparticle enzyme assay. " Sex. 
Trans. Dis. 22: 55-59. 
Chernesky, M., Lee, H., Schachter, J. (1994a), " Diagnosis of Chlamydia trachomatis 
urethral infection in symptomatic and asymptomatic men by testing first void urine in 
ligase chain reaction assay. " J. Infect. 170: 1308-1311. 
Chernesky, M., Luinstra, K., Sellors, J. et al. (1998), " Can serology diagnose upper 
genital tract Chlamydia trachomatis infection? Studies on women with pelvic pain, with 
and without chlamydial plasmid DNA in endometrial biopsy tissue. " Sex. Trans. Dis. 25: 
14-19. 
Chout, R. T., Duvalviolton, D., Leguyaderdespres, P. et al. (1995), " Screening for 
Chlamydia trachomatis infection in pregnant women in Martinique. " Sex. Trans. Dis. 22: 
221-227. 
Chow, J., Yonekura, L., Richwald, G. et al. (1990), " The association between 
Chlamydia trachomatis and ectopic pregnancy. " JAMA 263: 3164-3167. 
Chow, W., Daling, J., Cates, W. et al. (1987), " Epidemiology of ectopic pregnancy. " 
Epidemiological Rev. 2: 70-94. 
Chrysostomou, M., Karafyllidi, P., Papadimitriou, V. et al. (1992), " Serum antibodies 
to Chlamydia trachomatis in women with ectopic pregnancy, normal pregnancy or 
salpingitis. Eur. J. Obstet. Gynecol. Reproduct. Biol. 44: 101-105. 
236 
Claas, H., Melchers, W., de Bruijn, I. et al. (1990) " Detection of Chlamydia trachomatis 
in clinical specimens by the polymerase chain reaction. " Eur. J. Clin. Microbiol. Infect. 
Dis. 2: 864-868. 
Claesson, B., Trollfors, B., Brolin, I. et al. (1989), " Etiology of community-acquired 
pneumonia in children based on antibody responses to bacterial and viral antigens. " 
Pediatr. Infect. Dis. 8: 856-862. 
Claman, P., Honey, L., Peeling, R., et al. (1997), " The presence of serum antibody to 
the chlamydial heat shock protein (CHSP60) as a diagnostic test for tubal factor 
infertility. " Fertil. Steril. 67: 501-504. 
Claman, P., Toye, B., Amimi, M. et al. (1996), " Does serological evidence of remote 
Chlamydia trachomatis infection and its heat shock protein (CHSP60) affect in vitro 
fertilization-embryo transfer outcome? " Fert. Steril. 65(1): 146-149. 
Clark, D. and Chaouat, G. (1989), " What do we know about spontaneous-abortion 
mechanisms? " Am. J. Reprod. Immunol. 19: 28-37. 
Cleary, R, and Jones, R. (1985), " Recovery of Chlamydia trachomatis from the 
endometrium in infertile women with serum antichlamydial antibodies. " Fertil. Steril. 44: 
233-235. 
CMO's Expert Advisory Group, (1998), " Chlamydia trachomatis. Summary and 
conclusions of CMO's Expert Advisory Group. " Dept. of Health, Health Promotion 
Division, London. 
Coles, A., Reynolds, D., Harper, A. et al. (1993), " Low-nutrient induction of abnormal 
chlamydial development- a novel component of chlamydial pathogenicity. " FEMS 
Microbiol. Lett. 106: 193-200. 
Collett, B., Newhall, W., Jersild, R. et al. (1989), " Detection of surface-exposed 
epitopes of Chlamydia trachomatis by immune electron microscopy. " J. Gen. Microbiol. 
135: 85-94. 
Comanducci, M., Ricci, S., Cevenini, R. et al. (1990), " Diversity of the Chlamydia 
trachomatis common plasmid in biovars with different pathogenicity. " Plasmid 23: 149- 
154. 
Conlan, J., Clarke, I., and Ward, M. (1988), " Epitope mapping with solid-phase 
peptides: identification of type-, subspecies-, species-, and genus-reactive antibody 
binding domains on the major outer membrane protein of Chlamydia trachomatis. " Mol. 
Microbiol. 2: 673-679. 
Conway, D., Caul, E., Hull, M. et al. (1984), " Chlamydial serology in fertile and 
infertile women. " Lancet 1: 191-193. 
Conway, D., Holland, M., Bailey, R. et al. (1997), " Scarring trachoma is associated 
with polymorphism in the tumor necrosis alpha (TNF-(x) gene promotor and with 
elevated TNF-a levels in tear fluid. " Infect. Immun. 65: 1003-1006. 
Conway, D., Holland, M., Campbell, A. et al. (1996), " HLA class I and II 
polymorphisms and trachomatous scarring in a Chlamydia trachomatis-endemic village. " 
J. Infect. Dis. 174: 643-646. 
Cook, P., Davies, P., Tunnicliffe, W. et al. (1998), " Chlamydia pneumoniae and 
asthma. " Thorax 5: 254-259. 
Corradi, G., Bucsek, M., Panovics. et al. (1996), " Detection of Chlamydia trachomatis 
in the prostate by in-situ hybridization and by transmission electron microscopy. " Int. J. 
Androl. 19: 109-112. 
237 
`; 
.; ý. ý; 
III 
Coste, J., Job-Spira, N., Aublet-Cuvelier, B. et al. (1994b), " Incidence of ectopic 
pregnancy. First results of a population-based register in France. " Hum. Reprod. 2: 742- 
745. 
Coste, J., Laumon, B., Bremond, A. et al. (1994a), " Sexually transmitted disease as 
major causes of ectopic pregnancy: results from a large case-control study in France. " 
Fertil. Steril. 62: 289-295. 
Costerton, J., Poffenroth, L., Wilt, J. et al. (1976), " Ultrastructural studies of the 
nucleoids of the pleomorphic forms of Chlamydia psittaci 6BC: a comparison with 
bacteria. " Can. J. Bacteriol. 22: 16-26. 
Cotter, T., Ramsey, K., Miranpuri, G. et al. (1997), "Dissemination of Chlamydia 
trachomatis chronic genital tract infection in gamma interferon gene knockout mice. " 
Infect. Immun. 65: 2145-2152. 
Cotton, E., Strampfer, M., and Cunha, B. (1987), " Legionella and Mycoplasma 
pneumonia- a community hospital experience with atypical pneumonias. " Clin. Chest. 
Med. 8: 441-453. 
Crotchfelt, K., Pare, B., Gaydos, C. et al. (1998), " Detection of Chlamydia trachomatis 
by the Gen-Probe AMPLIFIED Chlamydia trachomatis Assay (AMP CT) in urine 
specimens from men and women and endocervical specimens from women. " J. Clin. 
Microbiol. 36: 391-394. 
Crowley, T., Homer, P., Hughes, A. et al. (1997), " Hormonal factors and the 
laboratory detection of Chlamydia trachomatis in women: implications for screening. " Int. 
J. STD AIDS 8: 25-31. 
Csemiczky, G., Landgren, B., Fried, G. et al. (1996), " High tubal damage grade is 
associated with low pregnancy rate in women undergoing in-vitro fertilization treatment. " 
Hum. Reprod. 11: 2438-2440. 
Cunningham, A., Johnson, S., Julious, S. et al. (1998), " Chronic Chlamydia 
pneumoniae infection and asthma exacerabations in children. " Eur. Resp. J. 11: 345-349. 
Dabekausen, Y., Evers, Land, J. et al. (1994), " Chlamydia trachomatis antibody testing 
is more accurate hysterosalpingography in predicting tubal factor infertility. " Fertil. Steril. 
61: 833-837. 
Daniliton, S., Maclean, I., Peeling, R. et al. (1990), " The 75-kilodalton protein of 
Chlamydia trachomatis: a member of the heat shock protein 70 family? " Infect. Immun. 
58: 189-196. 
Darville, T., and Laffoon, K. (1996), " Examination of immune responses in Chlamydia- 
resistant and susceptible mouse strains reveals differential production of tumor necrosis 
alpha. " J. Invest. Med. 44: A72. 
Darville, T., Andrews, C., Laffoon, K. et al. (1997), " Mouse strain-dependent variation 
in the course and outcome of chlamydial genital tract infection is associated with 
differences in host response. " Infect. Immun. 65: 3065-3073. 
Darville, T., Lafoon, K., Kishen, L. et al. (1995), " Tumor necrosis factor-alpha activity 
in genital tract secretions of guinea pigs infected with chlamydiae. " Infect. Immun. 63: 
4675-4681. 
Dawkins, R., Leaver, P., Cameron, E. et al. (1989), " Some disease-associated ancestral 
haplotypes carry a polymorphism of TNF. " Hum. Immunol. 26: 91-97. 
238 
Dayer, J., Beutler, B, and Cerami, A. (1985), " Cachetin/tumor necrosis factor stimlates 
collagenase and prostaglandin E2 production by human synovial cells and dermal 
fibroblasts. " J. Exp. Med. 162: 2163-2168. 
de Kossodo, S., Critico, B., and Grau, G. (1994), " Modulation of the transcripts for 
tumor necrosis factor-a and its receptors in vivo. " Eur. J. Immunol. 24: 769-772. 
de la Maza, M., and de la Maza, L. (1995), "A new computer model for estimating the 
impact of vaccination protocols and its application to the study of Chlamydia trachomatis 
genital infection. " Vaccine 13: 119-127. 
Dean, D. (1994), " Molecular characterization of a new Chlamydia trachomatis 
serological varient from a trachoma endemic region of Africa. " In Orifila, J., Byrne, G., 
Chernesky, M. et al. (Eds. ), Chlamydial Infections. Societa Editrice Esculapio, Italy. pp. 
259-262. 
Dean, D., Schachter, J., Dawson, C. et al. (1992), " Comparison of the major outer 
membrane protein varient sequence regions of B, Ba isolates: a molecular epidemiologic 
approach approach to Chlamydia trachomatis infections. " J. Infect. Dis. 166: 383-392. 
Dept. of Health, London. (1996). New cases at genitourinary medicine clinics in 
England. Annual figures 1995, summary information from KC60. " 
Desai, K., and Robson, H. (1982), " Comparison of the Gram-stained urethral smear 
and first-voided urine sedimant in the diagnosis of nongonococcal urethritis. " Sex. Trans. 
Dis. 2: 21-25. 
Dhir, S., Hakomori, S., Kenny, G. et al. (1972), " Immunochemical studies on 
chlamydial group antigen (presence of a 2-keto-3-deoxycarbohydrate as immunodominant 
group). " J. Immunol. 109: 116-122. 
Dieterle, S., and Wollenhaupt, J. (1996), " Humoral immune response to the chlamydial 
heat shock proteins hsp60 and hsp70 in Chlamydia-associated chronic salpingitis with 
tubal occlusion. " Hum. Reprod. 11: 1352-1356. 
Doble, A., Taylor-Robinson, D., Thomas, B. et al. (1989a), " Acute epididymitis: a 
microbiological and ultrasonographic study. " Br. J. Urol. 141: 332-333. 
Doble, A., Thomas, B., Walker, M. et al. (1989b), "A search for infectious agents in 
chronic abacterial prostatitis using ultra-sound biopsy. " J. Urol. 63: 90-94. 
Douglas, C. (1963), " Tubal ectopic pregnancy. " Br. Med. J. 64: 297-301. 
Dowe, G., King, S, Smikle, M. et al. (1998), " Prevalence of viral and bacterial sexually 
transmitted pathogens in Jamacian pregnant women. " West Ind. Med. J. 41: 23-25. 
Driscoll, G., Dodd, J., Tyler, J. et al. (1991), " Positive chlamydial serology and its 
effect on factors influencing outcome of IVF treatment. " Aust. NZ. J. Obstet. Gynaecol. 
31: 145-147. 
Duke-Elder, S. (1965), " System of ophthalmology. " London, Kimpton. Vol. 8. pp. 260. 
Dunlop, E., Jones, B., and Al-Hussaini, M. (1964), " Genital infection in association 
with TRIC virus infection of the eye. Clinical and other findings. Preliminary report. " 
Br. J. Ven. Dis. 40: 33-42. 
Duthil, B., Bebear, C., Rodriquez, P. et al. (1989), " Specific amplification of a DNA 
sequence common to all Chlamydia trachomatis serovars using the polymerase chain 
reaction. " Res. Microbiol. 140: 7-16. 
239 
Dwyer, R., Treharne, J., Jones, B. et al. (1972), " Chlamydial infections: results of 
micro-immunofluorescence tests for the detection of type specific antibody to certain 
chlamydial infections. " Br. J. Ven. Dis. 48: 452-459. 
Dymock, I., Lawson, J., MacLennan, W. et al. (1971), " Myocarditis associated with 
psittacosis. " Br. J. Clin. Practice 25: 240-242. 
Eckert, L., Hawes, S., Wolner-Hanssen, P. et al. (1997), " Prevalence and correlates of 
antibody to chlamydial heat shock protein in women attending sexually transmitted 
disease clinics and women with confirmed pelvic inflammatory disease. " J. Infect. Dis. 
175: 1453-1458. 
Edwards, R., Fishel, S., Cohen, J. et al. (1984), "Factors influencing the sucess of in 
vitro fertilization for alleviating human infertility. " J. In Vitro Fert. Embryo Transfer 1: 3- 
23. 
Ekman, M., Leinonen, M., Syrjala, H. et al. (1993), " Evaluation of serlogical methods 
in the diagnosis of Chlamydia pneumoniae pneumonia during an epidemic in Finland. " 
Eur. J. Clin. Microbiol. Infect. Dis. 12: 756-760. 
Elias, J., Krol, R., Freundlich, B. et al. (1988), " Regulation of human lung fibroblast 
glycosaminoglycan production by recombinant interferons, tumor necrosis factor, and 
lymphotoxin. " J. Clin. Invest. 81: 325-333. 
Englert, Y., Vekemans, M., Lejeune, B. et al. (1987), " Higher pregnancy rates after in 
vitro fertilization and embryo transfer in cases with sperm defects. " Fertil. Steril. 48: 254- 
257. 
Erbengi, T. (1993), " Ultrastructural observations on the entry of Chlamydia trachomatis 
into human spermatozoa. " Hum. Reprod. 8: 416-421. 
Erntell, M., Ljunggren, K., Gadd, T. et al. (1989), " Eithema nodosuma manifestation 
of Chlamydia pneumoniae (strain TWAR) infection. " Scand. J. Infect. Dis. 21: 693-996. 
Evans, R., and Taylor-Robinson, D. (1982), " Development and evaluation of an enzyme 
linked immunosorbent assay (ELISA), using chlamydial group antigen, to determine 
antibodies to Chlamydia trachomatis. " J. Clin. Pathol. 35: 1122-1128. 
Fan, J., and Stephens, R. (1997), " Antigen conformation dependence of Chlamydia 
trachomatis infectivity neutralization. " J. Infect. Dis. 176: 713-721. 
Farencena, A., Commanducci, M., Donati, M. et al. (1997), " Characterization of a new 
isolate of Chlamydia trachomatis which lacks the common plasmid and has properties of 
the biovar trachoma. " Infect. Immun. 65: 2965-2969. 
Fiers, W. (1991), " Tumor-necrosis-factor- Charactrization at the molecular, cellular and 
in vivo level. " FEBS Lett. 285: 199-212. 
Fish, A., Fairweather, D., Oriel, J. et al. (1989), " Chlamydia trachomatis infection in a 
gynaecology clinic population: identification of high-risk groups and the value of contact 
tracing. " Eur. J. Obstet. Gynecol. Reprod. Biol. 31: 67-74. 
Fitch, W., Peterson, E., and de la Maza, L. (1993), " Phylogenetic analysis of the outer- 
membrane genes of Chlamydiae, and its implication for vaccine development. " Mol. Biol. 
Evol. 10: 892-913. 
FIVNAT. (1992), " Infecondites inexpliquees bilan FIVNAT 1986-1991. " Contracept. 
Fertil. Sex. 20: 821-823. 
Foggie, A. (1973), " Preparation of vaccines against enzootic abortion of ewes. A review 
of the research work at the Moredun Institute. " Vet. Bull. 43: 587-590. 
240 
Forssner, H. (1907), " Adnexitis gonorrhoica. " Arch. Gynekol. 83: 447-451. 
Friedank, H., Clad, A., Herr, A. et al. (1995), " Immune responses to Chlamydia 
trachomatis heat shock protein in infertile female patients and the influence of Chlamydia 
pneumoinae antibodies. " Eur. J. Clin. Microbiol. Infect. Dis. 14: 1063-1069. 
Fritsch, H., Hofstatter, A., and Lindner, K. (1910), " Experimentelle studien zur 
Trachomfrage. " Graefe's Archiv. fur Ophthalmologie. 76: 547. 
Frost, E., Deslanders, S., Velleux, S., et al. (1991), " Typing of Chlamydia trachomatis 
by detection of restriction length polymorphism in the gene encoding the major outer 
membrane. " J. Infect. Dis. 163: 1103-1107. 
Fugger, L., Morling, L., Ryder, P. et al. (1989), " Ncol restriction fragment 
polymorphism (RFLP) of the tumor necrosis factor (TNF-a) region in primary biliary 
cirrhosis and in healthy Danes. " Scand. J. Immunol. 30: 185-189. 
Fukushi, H., and Hirai K. (1992), " Proposal of Chlamydia pecorum sp. nov. for 
chlamydia strains derived from ruminants. " Int. J. Syst. Bacteriol. 42: 306-308. 
Fukushi, H., and Hirai K. (1993), " Chlamydia pecorum-the fourth species of genus 
Chlamydia. " Microbiol. Immunol. 37: 515-522. 
Gall, J. G, and Pardue, M. L. (1969), " Formation and detection of RNA-DNA hybrid 
molecules in cytological preparations. " Proc. Natl. Sci. USA. 63: 378-383. 
Gaydos, C. A., Palmer, L., Quinn, T. C. et al. (1993), " Phylogenetic relationship of 
Chlamydia pneumoniae to Chlamydia psittaci and Chlamydia trachomatis as determined 
by analysis of 16S ribosomal DNA sequences. " Int. J. Syst. Bacteriol. 43: 610-612. 
Gencay, M., Puolakkainen, M., Wahlstrom, T. et al. (1997), " Chlamydia trachomatis 
detected in human placenta. " J. Clin. Pathol. 50: 852-855. 
Ghirardini, C., Ghinosi, P., Raisi, O. et al. (1991), " Detection of Chlamydia 
trachomatis in papanicolaou-stained cervical smears: control study by in situ 
hybridization. " Diag. Cytopathol. 7: 211-214. 
Gibson, J., Egerer, R., and Wiedbraul D. (1993), " Improved isolation of Chlamydia 
trachomatis from a low prevalence population by using polyethylene glycol. " J. Clin. 
Microbiol. 31: 292-295. 
Gordon, F., and Quan, A. (1965), " Isolation of trachoma agent in cell culture. " Proc. 
Soc. Exp. Biol. Med. 118: 354-359. 
Grayston, J. (1992), " Infections caused by Chlamydia pneumoniae strain TWAR. " Clin. 
Infect. Dis. 15: 757-763. 
Grayston, J., and Wang, S. (1975), " New knowledge of Chlamydiae and the diseases 
they cause. " J. Infect. Dis. 132: 87-105. 
Grayston, J., Campbell, L., Kuo, C. et al. (1990), "A new respirtaory tract pathogen: 
Chlamydia pneumoniae strain TWAR. " J. Infect. Dis. 161: 618-625. 
Grayston, J., Kuo, C., Campbell, L. et al. (1989), " Chlamydia pneumoniae sp. nov. for 
Chlamydia sp. strain TWAR. " Int. J. Syst. Bacteriol. 39: 88-90. 
Grayston, J., Kuo, C., Coulson, A. et al. (1995), " Chlamydia pneumoniae (TWAR) in 
atherosclerosis of the carotid artery. " Circulation 92: 3397-4000. 
Grayston, J., Kuo, C., Wang, S. et al. (1986), "A new Chlamydia psittaci strain 
TWAR, isolated in acute respiratory tract infection. " N. Eng. J. Med. 315: 161-168. 
24 
Grayston, J., Wang, S., Yeh, S. et al. (1985), " Importance of reinfection in the 
pathogenesis of trachoma. " Rev. Infect. Dis. Z: 717-725. 
Gregory, W., Gardner, M., Byrne, G. et al. (1979), " Arrays of hemispheric surface 
projections on Chlamydia psittaci and Chlamydia trachomatis observed by scanning 
electron microscopy. " J. Bacteriol. 138: 241-244. 
Griffais, R., and Thibon, M. (1989), " Detection of Chlamydia trachomatis by the 
polymerase chain reaction. " Res. Microbiol. 2: 139-141. 
Grifo, J., Jeremias, J., Ledger, W. et al. (1989), " Interferon-yin the diagnosis and 
pathogenesis of pelvic inflammatory disease. " Am. J. Obstet. Gynecol. 160: 26-31. 
Gump, G., Gibson, M., and Ashikaga, T. (1983), " Evidence of prior pelvic 
inflammatory disease and its relationship to Chlamydia trachomatis antibody and 
intrauterine contraception device use in infertile women. " Am. J. Obstet. Gynecol. 146: 
153-159. 
Guo, H., Liu, G., Zhang, Q. et al. (1997), " Detection of Chlamydia trachomatis by 
polymerase chain reaction assay in nonbacterial prostatitis. " Chin. Med. J. 110: 177-179. 
Hackstadt, T., Baehr, W., and Ying, Y. (1991), " Chlamydia trachomatis 
developmentally regulated protein is homologous to eukaryotic histone H1. " Proc. Natl. 
Acad. sci. USA 88: 3937-3941. 
Hackstadt, T., Fischer, E., Scidmore, M. et al. (1997), " Origins and function of the 
chlamydial inclusion. " Trends Microbiol. 5,: 288-293. 
Hackstadt, T., Scidmore, M., and Rocky, D. (1995), " Lipid metabolism in Chlamydia 
trachomatis-infected cells: direct trafficking of Golgi-derived sphingolipids to the 
chlamydial inclusion. " Proc. Natl. Acad. sci. USA 92: 4877-4881. 
Hackstadt, T., Todd, W., and Caldwell, H. (1985), " Disulfide-mediated interactions of 
the chlamydial major outer membrane protein: a role in differentiation of chlamydiae. " J. 
Bacteriol. 161: 25-31. 
Hahn, D. (1992), " Chlamydia pneumoniae infection and asthma. " Lancet 339: 1173- 
1174. 
Hahn, D., Anttila, T., and Saikku, P. (1996), " Association of Chlamydia pneumoniae 
IgA antibodies with recently symptomatic asthma. " Epidemiol. Infect. 11: 513-517. 
Hahn, D., Dodge, R., and Golubjantnikov, R. (1991), " Association of Chlamydia 
pneumoniae (strain TWAR) infection with wheezing, asthmatic bronchitis, and adult 
onset asthma. " JAMA 266: 225-230. 
Haidl, S., Ivarsson, S., Bjerre, I. et al. (1992), " Guillain-Barre syndrome after 
Chlamydia pneumoniae-coronary artery disease association. " New Eng. J. Med. 326: 
576-577. 
Haimovici, F., Hill, J. and Anderson, D. (1991), " The effects of soluble products of 
activated lymphocytes and macrophages on blastocyst implantation events in vitro. " Biol. 
Reprod. 44: 69-75. 
Halbertstaedter, L., and von Prowazek. (1907), " Uber zelleinschlussr parasitarer 
naturbeim trachoma. " Arbeiten aus dem Kaiserlichen Gesundheitsamke 26: 44-47. 
Halbertstaedter, L., and von Prowazek. (1909), " Uber Chlamydozoenbefunde bei 
blenorrhea neonatorum non gonorrhoica. " Klin. Wochenschr. 46: 1839-1840. 
242 
Hamilton, C., Evers, J., and Hoogland, H. (1986), "Ovulatory disorders and 
inflammatory adnexal damage: a neglected cause of the failure of fertility microsurgery. " 
Br. J. Obstet. Gynaecol. 93: 282-284. 
Hammer, M., Nettelnbreker, E., Hopf, S. et al. (1992), " Chlamydial rRNA in the joints 
of patients with Chlamydia trachomatis induced arthritis and undifferentiated arthritis. " 
Pediatr. Infect. Dis. 1: 395-401. 
Hammerschlag, M., Cummings, P., Roblin, P. et al. (1989), " Efficacy of neonatal 
ocular prophylaxis for the prevention of chlamydial and gonococcal conjunctivitis. " N. 
Eng. J. Med. 20: 769-772. 
Han, J., Brown, T., and Beutler, B. (1990), " Endotoxin-responsive sequences control 
cachectin/tumor necrosis factor biosynthesis at the translational level. " J. Exp. Med. 
171: 465-475. 
Hanna, L., Kerlan, R., Senyk, G. et al. (1982), " Immune responses to chlamydial 
antigens in humans. " Med. Microbiol. Immunol. 171: 1-10. 
Hanna, L., Schmidt, L., Sharp, M. et al. (1979), " Human cell mediated immune 
responses to chlamydial antigens. " Infect. Immun. 23: 412-417. 
Hashigucci, K., Ogawa, H., Suzuki, T. et al. (1992), " Isolation of Chlamydia 
pneumoniae from the maxillary sinus of a patient with purulent sinusitis. " Clin. Infect. 
Dis. 15: 570-571. 
Hatch, T., Miceli, M., and Sublett, J. (1986), " Synthesis of disulfide-bonded outer 
membrane proteins during the developmental cycle of Chlamydia psittaci and Chlamydia 
pneumoniae. " J. Bacteriol. 165: 379-385. 
Hatch, T., Vance, D., and Al-Hossainy, E. (1981), " Identification of a major envelope 
protein in Chlamydia spp. " J. Bacteriol. 146: 426-429. 
Hatt, C., Ward, M., and Clarke, I. (1988), " Analysis of the entire nucleotide-sequence 
of the cryptic plasmid of Chlamydia trachomatis serovar L1-evidence for involvement in 
DNA replication. " Nucleic Acid Res. 16: 4053-4067. 
Heinemann, M., Susa, M., Simnacher, U. et al. (1996), " Growth of Chlamydia 
pneumoniae induces cytokine production and expression of CD 14 in a human monocytic 
cell line. " Infect. Immun. 64: 4872-4875. 
Hellerstrom, S., and Western, E. (1930), " Meningo-enzephalitische veranderungen bei 
affen nach intracerebraler impfung mit Lymphogranuloma inguinale. " Proceedings 
Septieme Congress International de Dermatologie et de Syphiligraphie, Copenhagen. 
pp. 1147-1151. 
Henry-Suchet, J., Askienazy-Elbhar, M., Thibon, M., et al. (1994), " Post-therapeutic 
evolution of serum chlamydial antiody titers in women with acute salpingitis and tubal 
infertility. Fertil. Steril. 62: 296-304. 
Henry-Suchet, J., Catalan, F., Laffredo, V. et al. (1981), " Chlamydia trachomatis 
associated with chronic inflammation in abdominal specimens from women selected for 
tuboplasty. " Fertil. Steril. 36: 599-605. 
Henry-Suchet, J., Utzmann, C., de Brux, J. et al. (1987), " Microbiological study of 
chronic inflammation associated with tubal factor infertility: role of Chlamydia 
trachomatis. " Fertil. Steril. 47: 274-277. 
Herring, A., Anderson, I., McClenaghan, M. et al. (1987), " Restriction endonuclease 
analysis of DNA from two isolates of Chlamydia psittaci obtained from human abortion. " 
Br. Med. J. 295: 1239. 
243 
Heymann, B. (1910), " Uber die fundorte der powazetz'schen korperchen. " Berliner 
Klinische Wochenschrift 47: 663-666. 
Hill, J. (1991). In Cellular and Molecular Biology of the Maternal-Fetal Relationship. 
Edited by Chaouat, G. and Mowbray, J. pp. 269-275. 
Hilton, A., Richmond, S., Milne, J. et al. (1974), " Chlamydia in the female genital 
tract. " Br. J. Ven. Dis. 50: 1-9. 
Holland, S., Hudson, A., Bobo, L. et al. (1992), " Demonstration of chlamydial RNA 
and DNA during a culture-negative state. " Infect. Immun. 60: 2040-2047. 
Holt., S., Pedersen, A., Wane, S. et al. (1967), " Isolation of TRIC agents and 
mycoplasma from the genito-urinary tracts of patients of a venereal disease clinic. " Am. 
J. Ophthalmol. 63: 1057-1064. 
Hopwood, J., Mallinson, H., and Agnew, E. (1990), " Chlamydia screening-should it 
be offered as routine? " Br. J. Fam. Plan. 16: 59-67. 
Hori, S., and Tsutsumi, Y. (1995), " Histological differentiation between chlamydial and 
bacteria epididymitis: nondestructive and proliferative versus destructive and abscess 
forming-immunohistochemical and clinicopathological findings. " Hum. Pathol. 26: 402- 
407. 
Horn, J., Hammer, M., Falkow, S. et al. (1986), " Detection of Chlamydia trachomatis 
in tissue culture and cervical scrapings by in situ hybridization. " J. Infect. Dis. 163: 
1155-1159. 
Horn, J., Kappus, E., Falkow, S. et al. (1988), " Diagnosis of Chlamydia trachomatis in 
biopsied tissue specimens by using in situ hybridization. " J. Infect. Dis. 157: 1249-1253. 
Homer, P., Crowley, T., Leece, J. et al. (1998), " Chlamydia trachomatis detection and 
the menstral cycle. " Lancet 351: 341-342. 
Homer, P., May, P., Thomas, B. et al. (1995), " The role of Chlamydia trachomatis in 
urethritis and urethral symptoms in women. " Int. J. STD. AIDS. 6: 31-34. 
Hosein, I., Kaunitz, A., and Craft, S. (1992), " Detection of cervical Chlamydia 
trachomatis and Neisseria gonorrhoeae with deoxyribonucleic acid probe assays in 
obstetric patients. " Am. J. Obstet. Gynecol. 167: 588-591. 
Howard, C., Friedman, J., Leete, J. et al. (1991), " Correlation of the percent of positive 
Chlamydia trachomatis direct fluorescent antibody detection tests with the adequacy of 
specimen colletion. " Diagn. Microbiol. Infect. Dis. 14: 233-237. 
Howard, L. (1975), " Neutralization of Chlamydia trachomatis in cell culture. " Infect. 
Immun. 11: 698-703. 
Hsai, R., Pannekoek, Y., Ingerowski, E. et al. (1997), " Type III secretion genes 
identify a putative virulence locus of Chlamydia. " Mol. Microbiol. 25: 351-359. 
Hsia, R., Ohayon, H., Gounon, A. et al. (1996), " Phage infection of Chlamydia 
psittaci GPIC. " In Chlamydial Infections. Proceedings of the International Symposium. 
Orifila, J., Byrne, G., Chernesky, M. et al. (Eds. ). Societa Editrice Esculapio, Italy. pp. 
48. 
Hsia, R., Ohayon, H., Gounon, A. et al. (1998), " Altered development and lytic cycle 
activities induced by phage infection of Chlamydia psittaci. " In Chlamydia Infections. 
Stephens, R., Byrne, G. et al. (Eds. ). International Chlamydia Symposium, San 
Francisco, CA. pp. 131-134. 
244 
Hugall, A., Timms, P., Girjes, A. et al. (1989), " Conserved DNA sequences in 
chlamydial plasmids. " Plasmid 22: 91-98. 
Hull , M., Eddowes, H., Fahy, U. et al. (1992), " Expectations of assisted conception for infertility. " Br. Med. 304: 1465-1469. 
Igietseme, J., Perry, L., Ananba, G. et al. (1998), " Chlamydial infection in inducible 
nitric oxide synthase knockout mice. " Infect. Immun. 66: 1282-1286. 
Igietseme, J., Uriri, I., Chow, M. et al. (1997), " Inhibition of intracellular multiplication 
of human strains of Chlamydia trachomatis by nitric oxide. " Biochem. Biophys. Res. 
Commun. 232: 595-601. 
Ingails, R., Rice, P., Qureshi, N. et al. (1995), " The inflammatory cytokine response to 
Chlamydia trachomatis infection is endotoxin mediated. " Infect. Immun. 63: 3125-3130. 
Janier, M., Lassau, F., Casin, I. et al. (1995), " Male urethritis with and without 
discharge: a clinical and microbiological study. " Sex. Trans. Dis. 22: 244-252. 
Jannach, J. (1958), " Myocarditis in infancy with inclusion characteristics of psittacosis. " 
Am. J. Dis. Children 26: 734-740. 
Jantos, C., Heck, S., Roggendorf, R. et al. (1997), " Antigenic and molecular analyes of 
different Chlamydia pneumoniae strains. " J. Clin. Microbiol. 35: 620-623. 
Jenkins, J., Davies, D., Devonport, H. et al. (1991), " Comparison or 'poor' responders 
with 'good' responders using standard buserelin/human menopausal gonadotrophin 
regime for in-vitro fertilization. " Hum. Reprod. 6: 918-912. 
Jensen, S., Orsum, R., Dohn, S. et al. (1993), " Mycoplasma genitalium: a cause of 
male urethritis? " Genitourin Med. 69: 265-269. 
Johansson, M., Schon, K., Ward, M. et al. (1997), " Genital infection with Chlamydia 
trachomatis fails to induce protective immunity in gamma interferon receptor-deficient 
mice despite a strong local immunoglobulin A response. " Infect. Immun. 65: 1032-1044. 
John, H. A., Birnstiel, M. L. et al. (1969), " RNA-DNA hybrids at the cytological 
level. " Nature 223: 582-587. 
Jones , R., Ardery, B., Hui, S. et al. (1982), " Correlation between serum 
antichlamydial antibodies and tubal factor as a cause of infertility. " Fertil. Steril. 38: 553- 
558. 
Jones, B., Collier, L., and Smith, C. (1959), " Isolation of virus from inclusion 
blennorrhoea. " Lancet 1: 902-905. 
Jones, R. (1964), " Ocular syndromes of TRIC virus infection and their possible genital 
significance. " Br. J. Ven. Dis. 40: 3-18. 
Jones, R., and Van der Pol, B. (1994), " Lack of correlation between acquisition of 
infection and ability of serum to neutralize chlamydial infectivity in vitro. " In Orifila, J., 
Byrne, G., Chernesky, M. et al. (Eds. ), Chlamydial Infections. Societa Editrice 
Esculapio, Italy. pp. 95-98. 
Jones, R., Katz, B., VanderPol, B. et al. (1986a), " Effect of blind passage and multiple 
sampling on the recovery of Chlamydia trachomatis from urogenital specimens. " J. Clin. 
Microbiol. 24: 1029-1033. 
Jones, R., Mammel, J., Shepard, M et al. (1986b), " Recovery of Chlamydia trachomatis 
from the endometrium of women at risk for chlamydial infection. " Am. J. Obstet. 
Gynecol. 155: 35-39. 
245 
Joseph, T., and Bose, S. (1991), "A heat-labile protein of Chlamydia trachomatis binds 
to HeLa cells and inhibits the adherence of chlamydiae. " Proc. Natl. Acad. Sci. USA 88: 
4054-4058. 
Kahane, S., Gonen, R., Sayada, C., et al. (1993), " Description and partial 
characterization of a new chlamydia-like microorganism. " FEMS Microbiol. Lett. 
109: 329-334. 
Kahane, S., Metzer, E., and Friedman, M. G. (1995), " Evidence that the novel 
microorganism "Z" may belong to a new genus in the family Chlamydiaceae. " FEMS 
Microbiol. Lett. 126: 203-208. 
Kalayoglu, M., and Byrne, G. (1998), " Induction of macrophage foam cell formation by 
Chlamydia pneumoniae. " J. Infect. Dis. 177: 725-729. 
Kaltenboeck, B., Kousoulas, K., and Storz, J. (1993), " Structures of and allelic 
diversity and relationships among the major outer membrane (ompA) genes of the four 
chlamydial species. " J. Bacteriol. 175: 487-502. 
Kaltenboek, B., Kousouls, K., and Storz, J. (1992), " Two step PCR and restriction 
endonuclease analysis detects and differentiates ompA DNA of Chlamydia species. " J. 
Clin. Microbiol. 30: 1098-1104. 
Karimi, S., Schloemer, R., and Wilde, C. (1989), " Accumulation of lipopolysaccharide 
antigen in the plasma membrane of infected cells. " Infect. Immun. 57: 1780-1785. 
Keat, A., Dixey, J., Sonnex, C. et at (1987), " Chlamydia trachomatis and reactive 
arthritis: the missing link. " Lancet 8524: 72-74. 
Keay, S., Barlow, R., Eley., A. et al. (1998), " The relationship between 
immunoglobulin G antibodies to Chlamydia trachomatis and the poor ovarian response to 
gonadotropin stimulation before in vitro fertilization. " Fert. Steril. 70: 214-218. 
Keay, S., Liversage, N., Mathur, R. et al. (1997), " Assisted conception following poor 
ovarian response to gonadotrophin stimulation. " Br. J. Obstet. Gynaecol. 104: 521-527. 
Kellock, D., Barlow, R., Eley, A. et al. (1997), " Lymphogranuloma venereum: biopsy, 
serology and molecular biology. " Genitourin. Med. 73: 399-410. 
Kellogg, J., Seiple, J., and Hick, M. (1992), " Cross-reaction of clinical isolates of 
bacteria and yeasts with the chlamydiazyme test for chlamydial antigen before and after 
use of a blocking agent. " Am. J. Clin. Pathol. 37: 309-312. 
Kellogg, J., Seiple, J., Klinedinst, J. et al. (1991), " Impact of endocervical specimen 
quality on apparent prevalence of Chlamydia trachomatis infections using an enzyme- 
linked immunosorbent assay method. " Arch. Pathol. Lab. Med. 115: 1223-1227. 
Kellogg, J., Seiple, J., Klinedinst, J. et al. (1995), "Impact of endocervical specimen 
quality on apparent prevalence of Chlamydia trachomatis infections diagnosed by 
polymerase chain reaction. " In Abstract of the 95th General Meeting of the American 
Society for Microbiology. American Society for Microbiology, Washington, D. C. Abst. 
C-494, pp. 86. 
Kelly, K., Robinson, E., and Rank, R. (1996), " Initial route of antigen administration 
alters the T-cell cytokine profile produced in response to the mouse pneumonitis biovar of 
Chlamydia trachomatis following genital infection. " Infect. Immun. 64: 4976-4983. 
Kendrick, J., Atrash, H., Strauss, L. et al. (1997), " Vaginal douching and the risk of 
ectopic pregnancy among black women. " Am. J. Obstet. Gynecol. 176: 991-997. 
246 
Kimani, J., Maclean, I, Bwayo, J et al. (1996), " Risk factors for Chlamydia trachomatis 
pelvic inflammatory disease among sex workers in Nairobi, Kenya. " J. Infect. 173: 
1437-1444. 
Kingsbury, D., and Weiss, E. (1968), " Lack of deoxyribonucleic acid homology 
between species of the genus Chlamydia. " J. Bacteriol. 26: 1421-1423. 
Kiviat, N., Paavonen, J., Wolner-Hanssen, P. et al. (1990), " Histopathology of 
endocervical infection caused by Chlamydia trachomatis, herpes simplex virus, 
Trichomonas vaginalis, and Neisseria gonorrhoeae. " Hum. Pathol. 21: 831-837. 
Kramer, M., and Gordon, F. (1971), " Ultrastructure analysis of the effects of penicillin 
and chlortetracycline on the development of a genital tract Chlamydia. " Infect. Immun. 2: 
333-341. 
Krech, T., Bleckmann, M., and Paatz, R. (1989), " Comparison of Buffalo Geen 
Monkey cells and McCoy cells for isolation of Chlamydia trachomatis in a microtiter 
system. " J. Clin. Microbiol. 27: 2364-2365. 
Krieger, J., Riley, D., Roberts, M. et al. (1996), " Prokaryotic DNA sequences in 
patients with chronic idiopathic prostatitis. " J. Clin. Microbiol. 34: 3120-3128. 
Kroner, T. (1884), " Zur aetiologie der ophthalmoblennorrhea neonatorum. " Zentralblatt 
fur Gynakologie 8: 643. 
Kuo, C. Takahashi, A., Swanson, T. et al. (1996), " An N-linked high mannose type 
oligosaccharide, expressed at the major outer membrane protein of Chlamydia 
trachomatis, mediates attachment and infectivity of the microorganism to HeLa cells. " J. 
Clin. Invest. 988: 2813-2818. 
Kuo, C., and Chi, E. (1987), " Ultrastructural study of Chlamydia trachomatis surface 
antigens by inununogold staining with monoclonal antibodies. " Infect. Immun. 55: 1324- 
1328. 
Kuo, C., Chen, H., Wang, S. et al. (1986), " Characterisation of TWAR strains, a new 
group of Chlamydia psittaci. " In Chlamydial Infections. Oriel, J., Ridgway, G. et al. 
(Eds. ). Cambridge University Press, Cambridge. pp. 321-324. 
Kuo, C., Grayston, J., Campbell, L. et al. (1995), " Chlamydia pneumoniae (TWAR) in 
coronary arteries of young (15 to 35 year) adults. " Proc. Natl. Acad. Sci. USA 222: 6911- 
6914. 
Kuo, C., Shor, A., Campbell, D. et al. (1993), " Demonstration of Chlamydia 
pneumoniae in atherosclerotic lesions of coronary arteries. " J. Infect. Dis. 167: 841-849. 
Kuo, C., Wang, S., Wentworth, B. et al. (1972), " Primary isolation of TRIC organisms 
in HeLa 229 cells treated with DEAE-dextran. " J. Infect. Dis. 125: 665-668. 
Kutteh, W., Blackwell, R., Gore, H. et al. (1990), " Secretory immune system in normal 
and infected fallopian tube: A light and electronmicroscopic study. " Int. J. Gynecol. 
Pathol. 13: 175-180. 
Kwok, S., and Higuchi, R. (1989), " Avoiding false positives with PCR. " Nature M: 
237-238. 
Ladany, S., Black, C., Farshy, C. et al. (1989), " Enzyme immunoassay to determine 
exposure to Chlamydia pneumoniae (strain TWAR). " J. Clin. Microbiol. 22: 2778-2783. 
Laitinen, K., Laurila, A., Pyhala, L. et al. (1997), " Chlamydia pneumoniae infection 
induces inflammatory changes in the aortas of rabbits. " Infect. Immun. 65: 4832-4835. 
247 
Lamaury, I., Sotto, A., le Quellec, A. et al. (1993), " Chlamydia psittaci as a cause of 
lethal bacterial endocarditis. " Clin. Infect. Dis. 17: 821-822. 
Lampe, M., Suchland, R., and Stamm, W. (1993), " Nucleotide sequence of the variable 
domains within the major outer membrane protein gene from serovarients of Chlamydia 
trachomatis. " Infect. Immun. 61: 213-219. 
Lampe, M., Wong, K., Kuehl, L. et al. (1997), Chlamydia trachomatis major outer 
membrane protein varients escape neutralization by both monoclonal antibodies and 
human immune sera. " Infect. Immun. 65: 317-319. 
Lan, J., Ossewaarde, J., Walboomers, J. et al. (1994) " Improved PCR sensitivity for 
direct genotyping of Chlamydia trachomatis servars by using nested PCR. " J. Clin. 
Microbiol. 32: 528-530. 
Lan, J., van den Brule, A., Hemrika, D. et al. (1995) "Chlamydia trachomatis and 
ectopic pregnancy: retrospective analysis of salpingectomy specimens, endometrial 
biosies, and cervical smears. J. Clin. Pathol. 48: 815-819. 
Lan, J., Walboomers, J. M., Roosendaal, R. et al. (1993) " Direct detection and 
genotyping of Chlamydia trachomatis in cervical scrapes by using polymerase chain 
reaction and restriction fragment length polymorphism analysis. " J. Clin. Microbiol. 
31: 1060-1065. 
Lansford, B., Hass, G., de Bault, L. et al. (1990), " Effect of sperm associated 
antibodies on the acrosomal Staus of human sperm. " J. Androl. 11: 532-538. 
Lee, H., Chernesky, M., Schachter, J. et al. (1995), " Diagnosis of Chlamydia 
trachomatis genitourinary infection in women by ligase chain reaction assay of urine. " 
Lancet 345: 213-216. 
Lessey, B., Castelbaum, A., Riben, M. et al. (1994), " Effect of hydrosalpinges on 
markers of uterine receptivity and success in IVF. " (Abstract) The American Fertility 
Society 50th Annual Meeting, San Antonio, TX, USA. pp. 45. 
Lewis, V., Thacker, W., and Mitchell, S. (1977), " Enzyme-linked immosorbent assay 
for chlamydial antibodies. " J. Clin. Microbiol. 6: 507-510. 
Licciardi, F., Grifo, J., Rosenwaks, Z. et al. (1992), " Relationship between antibodies 
to Chlamydia trachomatis and spontaneous abortion following in vitro fertilization. " J. 
Assist. Reprod. Genet. 9: 207-209. 
Lichtenwalner, A., Patton, D., Cosgrove-Sweeney, Y. et al. (1997), " Evidence of 
genetic susceptibility to Chlamydia trachomatis-induced pelvic inflammatory disease in 
the pig-tailed macaque. " Infect. Immun. 65: 2250-2253. 
Lieberman, D., Kahane, S., Lieberman, D., et al. (1997), " Pneumonia with serological 
evidence of acute infection with the chlamydia-like microorganism "Z". Am. J. Crit. Care 
Med. 156: 578-582. 
Limberger, R., Biega, J., Evancoe, A. et al. (1992), "Evaluation of culture and the Gen- 
Probe PACE 2 assay for detection of Neisseria gonorrhoeae and Chlamydia trachomatis 
in endocervical specimens transported to a state health laboratory. " J. Clin. Microbiol. 30: 
1162-1166. 
Lin, J., Jones, W., Yan, L. et al. (1992), " Underdiagnosis of Chlamydia trachomatis 
infcetion. Diagnostic limitations in patients with low level infection. " Sex. Trans. Dis. 12: 
259-265. 
Lindner, K. (1910), " Uebertragungsversuche von gonokokkenfreinen Blenorrhoea 
neonatorum auf affen. " Wiener Klinische Wochenschrift 22: 1554-1659. 
248 
Loeffelholz, M., Lewinski, C., Silver, S. et al. (1992), " Detection of Chlamydia 
trachomatis in endocervical specimens by polymerase chain reaction. " J. Clin. Microbiol. 
30: 2847-2851. 
Lovett, M., Kuo, C., Holmes, K. et al. (1980), "Plasmids of the genus Chlamydia. " In 
Current Chemotherapy and Infectious Disease. Nelson, J and Grassi, C. American 
Society for Microbiology. Washington, DC. Vol 2, pp. 1250-1252. 
Lucero, M., and Kuo, C. (1985), " Neutralization of Chlamydia trachomatis cell culture 
infection by serovar-specific monoclonal antibodies. " Infect. Immun. 50: 595-597. 
Lukacova, M., Baumann, M., Brade, L. et al. (1994), " Lipopolysaccharide smooth- 
rough phase variation in bacteria of the genus Chlamydia. " Infect. Immun. 63: 516-521. 
Lusher, M., Storey, C., and Richmond, S. (1991), " Extra-chromosomal elements of the 
genus Chlamydia. " Adv. Gene Technol. 2: 261-285. 
Mabey, D., Bailey, R., Ward, M. et al. (1992), "A longitudinal study of trachoma in a 
Gambian village: implications concerning the pathogenesis of chlamydial infection. " 
Epidemiol. Infect. 108: 343-351. 
Magee, J. (1998), " Could Chlamydia pneumoniae be an asthma villain? " Lancet 351: 344. 
Mahadevan, M., Wiseman, D., Leader, A., and Taylor, P. (1985), " The effects of 
ovarian adhesive disease upon follicular development in cycles of controlled stimulation 
for in vitro fertilization. " Fertil. Steril. 44: 489-492. 
Mahony, J., and Chernesky, M. (1985), " Effect of swab type and storage temperature 
on the isolation of Chlamydia trachomatis from clinical specimens. " J. Clin. Microbiol. 22: 865-867. 
Mahony, J., Chernesky, M., Bromberg, K. et al. (1986), " Accuracy of immunoglobulin M immunoassay for diagnosis of chlamydial infections in infants and adults. " J. Clin. 
Microbiol. 24: 731-735. 
Mahony, J., Luinstra, K., Jang, D. et al. (1992), " Chlamydia trachomatis confirmatory 
testing of PCR-positive genitourinary specimens using a second set of plasmid primers. " 
Mol. Cell. Probes 6: 381-388. 
Mahony, J., Luinstra, K., Sellors, J. et al. (1994), " Role of confirmatory PCRs in determining performance of Chlamydia Amplicor PCR with endocervical specimens from 
women with a low prevalence of infection. " J. Clin. Microbiol. 22: 2490-2493. 
Makinen, J. (1993), " Is the epidemic of ectopic pregnancy over? " In Proceedings of the 
10th Meeting of the International Society for STD Research, Helsinki, Finland. 29 
August-1 September. pp. 71-79. 
Marana, R., Lucisano, A., Leone, F. et al. (1990), " High prevalence of silent 
chlamydial colonization of the tubal mucosa in infertile women. " Fertil. Steril. L3: 354- 
356. 
Marana, R., Rizzi, M., Muzii, L. et al. (1995), " Correlation between the American 
Fertility Society classifications of adnexal adhesions and distal tubal occlusion, 
salpingoscopy, and reproductive outcome in tubal surgery. " Fertil. Steril. 64: 924-929. 
Mardh, P., Lind, I., Svensson, L. et al. (1981), " Antibodies to Chlamydia trachomatis, 
Mycoplasma hominis and Neisseria gonorrhoea in sera from patients with acute 
salpingitis. " Br. J. Ven. Dis. 57: 125-129. 
249 
Mardh, P., Paavonen, J., Puolakkainen, M. (Eds. ). (1989), " Genital and associated 
infections in the male. In Chlamydia. New York and London, Plenum. pp. 137-150. 
Mardh, P., Ripa, K., Colleen, S. et al. (1978), " Role of Chlamydia trachomatis in non- 
acute prostatitis. " Br. J. Vener. Dis. 54: 330-334. 
Mardh, P., Ripa, T., Svensson, L. et al. (1977), " Chlamydia trachomatis infections in 
patients with acute salpingitis. " New Eng. J. Med. 2.96: 1377-1379. 
Marotta, C., Forget, B., Weissman, S. et al. (1974), " Nucleotide sequences of the 
human globin messenger RNA. " Proc. Natl. Acad. Sci. USA 71: 2300-2304. 
Matsumoto, A. (1981), " Isolation and electron microscopic observations of 
intracytoplasmic inclusions containing Chlamydia psittaci. " J. Bacteriol. 14 : 605-612. 
Matsumoto, A. (1982), " Electron microscopic observations of surface projections on 
Chlamydia psittaci reticulate bodies. " J. Bacteriol. 150: 358-364. 
Matsumoto, A. (1988), " Structural characteristics of chlamydial bodies. " In 
Microbiology of Chlamydia. Barron, A. (Ed. ), CRC Press Inc., Boca, Raton, Fla. pp. 
21-45. 
Matsumoto, A., and Manire, G. (1970), " Electron microscopic observations on the 
effects of penicillin on the morphology of Chlamydia psittaci. " J. Bacteriol. 101: 278. 
McComb, P., and Delbeke, L. (1984), " Decreasing the number of ovulations in the 
rabbit with surgical division of the blood vessels between the fallopian tube and ovary. " 
J. Reprod. Med. 29: 827-829. 
McCormack, W. (1994), " Pelvic inflammatory disease. " N. Eng. J. 330: 115-119. 
McEwen, A., Stamp, J., and Littlejohn, A. (1951), " Enzootic abortion of ewes II. 
Immunization and infection experiments. " Vet. Res. 63: 197-201. 
Melgosa, M., Kuo, C., and Campbell, L. (1991), " Sequence analysis of the major outer 
membrane protein gene of Chlamydia pneumoniae. " Infect. Immun. 2: 2195-2199. 
Menkin, M., and Rock, J. (1948), " In vitro fertilization and cleavage of human ovarian 
eggs. " Am J Obstet Gynecol 55: 440. 
Messer, G., Spengler, U., Jung, M. et al. (1991), " Polymorphic structure of the tumor 
necrosis factor (TNF) locus: an Ncol polymorphism in the first intron of the human 
TNF-ß gene correlates with a variant amino acid in position 26 and a reduced level of 
TNF-ß production. " J. Exp. Med. 173: 209-219. 
Meyer, K., and Eddie, B. (1933), " Latent psittacosis infection in shell parakeets. " Proc. 
Soc. Exp. Biol. Med. 30: 483-488. 
Miettinen, A., Heinonen, P., Teisala, K. et al. (1990), " Antigen specific serum antibody 
response to Chlamydia trachomatis in patients with acute pelvic inflammatory disease. " J. 
Clin. Pathol. 43: 758-761. 
Miyashita, N., Kubota, Y., Nakajima, M. et al. (1998), " Chlamydia pneumoniae and 
exacerabations of asthma in adults. " Ann. Allergy Asthma Immunol. 80: 405-409. 
Moazed, T., Kuo, C., and Grayston, J. (1997), " Murine models of Chlamydia 
pneumoniae infection and atherosclerosis. " J. Infect. 175: 883-890. 
Mohammed, N., and Hillary, I. (1985), " Improved method for isolation and growth of 
Chlamydia trachomatis in McCoy cells treated with cycloheximide using polyethylene 
glycol. " J. Clin. Pathol. 3: 1052-1054.250 
Mol, B., Dijkman, B., Wertheim, P. et al. (1997), " The accuracy of serum chlamydial 
antibodies in the diagnosis of tubal pathology: a meta-analysis. " Fertil. Steril. 2.: 1031- 
1037. 
Moller, B., Westrom, L., Ahrons, S. et al. (1979), " Chlamydia trachomatis infection of 
the Fallopian tubes, histological findings in two patients. " Br. J. Ven. Dis. 5ý: 422-428. 
Molloy, D., Martin, M., Speirs, A. et al. (1987), " Performance of patients with a 
'frozen pelvis' in an in vitro fertilization program. " Fertil. Steril. 47: 450-455. 
Moncada, J., Schachter, J., Bolan, G. et al. (1990), " Confirmatory assay increases 
specificity in the Chlamydiazyme test for Chlamydia trachomatis infection in the cervix. " 
J. Clin. Microbiol. 28: 1770-1773. 
Money, D., Hawes, S., Eschenbach, D. et al. (1997), " Antibodies to the chlamydial 
60kD heat-shock protein are associated with laparoscopically confirmed perhepatitis. " 
Am. J. Obstet. 176: 870-877. 
Moore, D., Foy, H., Daling, J. et al. (1982), " Increased frequency of serum antibodies 
to Chlamydia trachomatis in infertility due to distal tubal disease. " Lancet 2: 574-578. 
Morre, S., Sillekens, P., Jacobs, M. et al. (1996), " RNA amplification by nucleic acid 
sequence-based amplification with an internal standard enables reliable detection of 
Chlamydia trachomatis in cervical scrapings and urine samples. " J. Clin. Microbiol. 24: 
3108-3114. 
Morrison, R., Belland, P., Lyng, K. et al. (1989a), " Chlamydia disease pathogenesis: 
the 57kDa chlamydial hypersensitivity antigen is a stress response antigen. " J. Exp. Med. 
170: 1271-1283. 
Morrison, R., Lyng, K., and Caldwell, H. (1989b), " Chlamydia disease pathogenesis: 
ocular hyersensitivity elicited by a genus-specific 57-kD protein. " J. Grp. Med. i: 663- 
675. 
Morrison, R., Manning, D., and Caldwell, H. (1992), " Immunology of Chlamydia 
trachomatis infections: immunoprotective and immunopathogenic responses. " In Sexually 
Transmitted Disease. Quinn, T. (Ed. ), Raven Press, New York, N. Y. pp. 57-84. 
Morrison, R., Su, H., Lyng, K. et al. (1990), " The Chlamydia trachomatis hyp operon 
is homologous to the groE stress response operon of Escherichia coli. " Infect. Immun. 
58: 2701-2705. 
Moss, T., Dargougar, S., Woodland, R. et al. (1993), " Antibodies to Chlamydia species 
in patients attending a GUM clinic and the impact of antibodies to Chlamydia pneumoniae 
and Chlamydia psittaci on the sensitivity and specificity of Chlamydia trachomatis 
serology. " Sex. Trans. Dis. 20: 61-65. 
Moulder, J. (1991), " Interaction of chlamydiae and host cells in vitro. " Microbiol. Rev. 
5: 143-190. 
Moulder, J. (1993), " Why is Chlamydia sensitive to penicillin in the absence of 
peptidiglycan? " Infect. Agents Dis. 2: 87-99. 
Moulder, J. W., Hatch, J. P., Kuo, C. C. et al. (1984), " Genus Chlamydia. " In Bergey's 
Manuel of Systemic Bacteriology, vol. 1. N. R. Krieg (Ed. ), Williams and Wilkins, 
Baltimore, MD. pp. 729. 
Munday, P. (1985), " Persistent and recurrent non-gonococcal urethritis. " In Clinical 
problems in sexually transmitted disease. Taylor-Robinson, D (Ed. ). Dordrecht: Martinus 
Nijhoff. pp. 15-35. 
251 
Munday, P., and Taylor-Robinson, D. (1983), " Chlamydial infection in proctitis and 
Crohn's disease. " Br. Med. Bull. 22: 155-158. 
Munday, P., Johnson, A., Thomas, B. et al. (1981), " Chlamydia trachomatis proctitis. " 
N. Eng. J. Med. 305: 1158. 
Munoz, M., and Witkin, S. (1995), " Autoimmunity to speratozoa, asymptomatic 
Chlamydia trachomatis genital tract infection and gamma-delta T-lymphocytes in seminal 
fluid from the male partners of couples with unexplained infertility. " Hum. Reprod. 5: 
1070-1074. 
Munoz, M., Jeremias, J., and Witkin, S. (1996), " The 60kDa heat shock protein in 
human semen: relationship with antibodies to spermatozoa and Chlamydia trachomatis. " 
Hum. Reprod. 11: 2600-2603. 
Nackley, A., and Muasher, S. (1998), " The significance of hydrosalpinx in in vitro 
fertilization. " Fert. Steril. 67: 373-384. 
Naher, H., Petzoldt, D., and Sethi, K. (1988), " Evaluation of non-radioactive in situ 
hybridization method to detect Chlamydia trachomatis in cell culture. " Genitourin. Med. 
64: 162-164. 
Naz, R., and Menge, A. (1994), " Antisperm antibodies: origin, regulation, and sperm 
reactivity in human infertility. " Fertil. Steril. 61: 1001-1013. 
Nedwin, G., Naylor, S., Sakagucho, A. et al. (1985), " Human lymphotoxon and tumor 
necrosis factor genes: structure, homology and chromosomal localization. " Nucleic Acid 
Res. 13: 1487-1492. 
Neisser, A. (1879), "Über eine der Gonorrhoe eigentümliche Micro-coccusform. " 
Zentralbl. Med. Wissen. 17: 497-500. 
Neuer, A., Lam, K., Kiesel, L., and Witkin, S. (1997), " Humoral immune response to 
membrane components of Chlamydia trachomatis and expression of human 60kDa heat 
shock protein in follicular fluid of in-vitro fertilization patients. " Hum. Reprod. 12: 925- 
929. 
Newhall, W., and Jones, R. (1983), " Disulfide-linked oligomers of the major outer 
membrane protein of Chlamydiae. " J. Bacteriol. 154: 998-1001. 
Newhall, W., DeLisle, S., Fine, D. et al. (1994), " Head-to-head evaluation of five 
different nonculture chlamydia tests relative to a quality-assured culture standard. " Sex. 
Trans. Dis. 21: S165-S166 (Abstr. ). 
Newhall, W., Terho, P., Wilde, C. et al. (1986), " Serovar determination of Chlamydia 
trachomatis isolates by using type specific monoclonal antibodies. " J. Clin. Microbiol. 
23: 333-338. 
Ngeow, Y. (1996), " Limitations of serodiagnosis in chlamydial genital tract infections. " 
Ann. Acad. Med. Singapore 25: 300-04. 
Nichols, B., Setzer, P., Pang, F., and Dawson, C. (1985), " New view of the surface 
projections of Chlamydia trachomatis. " J. Bacteriol. 164: 344-349. 
Nikkanen, V., Gronoos, M., Suominen, J., and Multamaki, S. (1979), " Silent 
infections in male accessory genital organs and male infertility. " Andrologia 11: 236-241. 
Noeggerath, E. (1877), " Latent gonorrhoea, especially with regard to its influence on 
fertility in women. " Trans. Am. Gynecol. Soc. 1: 268-300. 
252 
Nurminen, M., Rietschel, E., and Brade, H. (1985), " Chemical characterization of 
Chlamydia trachomatis lipopolysaccharide. " Infect. Immun. 48: 573-575. 
O'Connell, C., and Anthony, M. (1998), " Introduction of foreign DNA into chlamydia 
and stable expression of chloramphenicol resistance. " In Chlamydial Infections. 
Stephens, R., Byrne, G., Christiansen, G et al. (Eds. ). International Chlamydia 
Symposium, San Francisco, CA. pp. 519-522. 
Ogawa, H., Fujisawa, T., and Kazuyama, Y. (1990), " Isolation of Chlamydia 
pneumoniae from middle ear aspirates of otitis media with effusion: a case report. " J. 
Infect. Dis. 162: 1000-1001. 
Ong, G., Thomas, B., Mansfield, O. et al. (1996), " Detection and widespread 
distribution of Chlamydia pneumoniae in the vascular system and its possible 
implications. " J. Clin. Pathol. 49: 102-106. 
Oriel, D. (1994), " The Scars of Venus. The History of Venereology. " Springer Verlag, 
London. 
Oriel, J., and Ridgeway, J. (1982). " Genital infections. Chlamydia trachomatis. " 
London: Edward Arnold. 
Osser, S., and Persson, K. (1992), " Chlamydial antibodies and deoxyribonucleic acid in 
patients with ectopic pregnancy. " Fertil. Steril. 57: 578-582. 
Osser, S., and Persson, K. (1996), " Chlamydial antibodies in women who suffer 
miscarriage. " Br. J. Obstet. Gynaecol. 103: 137-141. 
Ossewaarde, J., de Vries, A., van den Hoek, J., and van Loon, A. (1994b), "Enzyme 
immunoassay with enhanced specificity for detection of antibodies to Chlamydia 
trachomatis. " J. Clin. Microbiol. 32: 1419-1426 
Ossewaarde, J., Manten, J., and Hekker, A. (1989), " An enzyme immunoassay to 
detect specific antibodies to protein and lipopolysaccaride antigens of Chlamydia 
trachomatis. " J. Immunol. Methods 123: 293-298. 
Ossewaarde, J., Rieffe, M., de Vries, A. et al. (1994a), " Comparison of two panels of 
monoclonal antibodies for the determination of Chlamydia trachomatis serovars. " J. Clin. 
Microbiol. 22: 2968-2974. 
Paavonen, J. (1992), " Genital Chlamydial trachomatis infection in the female. " J. 
Infect. 25 (Si): 39-45. 
Paavonen, J., Aine, R., Teisala, K. et al. (1985b), " Chlamydial endometritis. " J. Clin. 
Pathol. 38: 726-732. 
Paavonen, J., and Lehtinen, M. (1994), " Immunopathogenesis of chlamydial pelvic 
inflammatory disease: the role of heat-shock proteins. " Infect. Dis. Obstet. Gynecol. 2: 
105-110. 
Paavonen, J., Kiviat, N., Brunham, R. et al. (1985a), " Prevalence and manifestations of 
endometritis among women with cervicitis. " Am. J. Obstet. Gynecol. 152: 280-286. 
Paavonen, J., Teisala, K., Heinonen, P. et al. (1987), " Microbiological and 
histopathological findings in acute pelvic inflammatory disease. " Br. J. Obstet. Gynaecol. 
944: 454-460. 
Pal, S., Peterson, E., and de la Maza, L. (1996), " Intranasal immunization induces long- 
term protection in mice against a Chlamydia trachomatis genital challenge. " Infect. 
Immun. 65: 5341-5348. 
253 
: ý9 
Palmer, L., and Falkow, S. (1986), "A common plasmid of Chlamydia trachomatis. " 
Plasmid 16: 52-62. 
Pastemack, R., Vuorinen, P., and Miettinen, A. (1997), " Evaluation of the Gen-Probe 
Chlamydia trachomatis transcription-mediated amplified assay with urine specimens from 
women. " J. Clin. Microbiol. 35: 676-678. 
Patton, D., and Kuo, C. (1989a), " Histopathology of Chlamydia trachomatis salpingitis 
after primary and repeated reinfections in the monkey subcutaneous pocket model. " , 
85: 
647-656. 
Patton, D., Askienazy-Elbhar, M., Henry-Suchet, J. et al. (1994b), " Detection of 
Chlamydia trachomatis in Fallopian tube tissue in women with post-infectious tubal 
infertility. " Am. J. Obstet. Gynecol. 171: 95-101. 
Patton, D., Cosgrove-Sweeny, Y., Bohannon, N. et al. (1997), " Effects of doxycycline 
and antiinflammatory agents on experimentally induced chlamydial upper genital tract 
infection in female macaques. " J. Infect. Dis. 175: 648-654. 
Patton, D., Halbert, S., and Wang, S. (1982), " Experimental salpingitis in rabbits 
provoked by Chlamydia trachomatis. " Fertil. Steril. 37: 691-700. 
Patton, D., Kuo, C., Wang, S. et al. (1987), " Distal tubal obstruction induced by 
repeated Chlamydia trachomatis salpingeal infection in the pig-tailed macaques. " J. Infect. 
Dis. 155: 1292-1299. 
Patton, D., Landers, D., and Schachter, J. (1989b), " Experimental Chlamydia 
trachomatis salpingitis in mice: initial studies on the characterization of the leukocyte 
response to chlamydial infection. " J. Infect. Dis. 159: 1105-1110. 
Patton, D., Sweeny, Y., and Kuo, C. (1994a), " Demonstration of delayed 
hypersensitivity in Chlamydia trachomatis salpingitis in monkeys: a pathogenic 
mechanism of tubal damage. " J. Infect. Dis. 169: 680-683. 
Paul, N., and Ruddle, N. (1988), " Lymphotoxin. " Annu Rev Immunol 6: 407-438. 
Peeling, R., Bailey, R., Conway, D. et al. (1998), " Antibody response to the 60kDa 
chlamydial heat-shock protein is associated with scarring trachoma. " J. Infect. Dis.: 
256-259. 
Peeling, R., Kimani, J., Plummer, F. et al. (1997), " Antibody to chlamydial hsp60 
predicts an increased risk for chlamydial pelvic inflammatory disease. " J. Infect. Dis. 
175: 1153-1158. 
Peeling, R., Maclean, I., and Brunham, R. (1984), " In vitro neutralization of Chlamydia 
trachomatis with monoclonal antibodies to an epitope on the major outer membrane 
protein. " Infect. Immun. 46: 484-489. 
Perara, E., Ganem, D., and Engel, J. (1992), "A developmentally regulated chlamydial 
gene with apparent homology to eukaryotic histone H1. " Proc. Natl. Acad. Sci. USA 82: 
2125-2129. 
Perara, E., Yen, T., and Ganem, D. (1990), " Growth of Chlamydia trachomatis in 
enucleated cells. " Infect. Immun. 58: 3816-3818. 
Perez-Melgosa, M., Kuo, C. C., and Campbell, L. (1991), " Sequence analysis of the 
MOMP gene of Chlamydia pneumoniae. " Infect. Immun. 59: 2195-2199. 
Perine, P., and Osoba, A. (1990), " Lymphogranuloma venereum. " In Sexually 
Transmitted Diseases. Holmes, K., Mardh, P., Sparling, P. et al. (Eds). McGraw Hill 
Book Co., New York, N. Y. pp. 195-204. 
254 
. "`ýý 
Perry, L., Feilzer, K., and Caldwell, H. (1997), " Immunity to Chlamydia trachomatis is 
mediated by T helper 1 cells through IFN-y dependent pathways. " J. Immunol. 158: 
3344-3352. 
Pesanti, E., and Smith, I. (1979), " Infective endocarditis with negative blood cultures. " 
Am. J. Med. 66: 43-50. 
Peters, A., and Coulam, C. (1992), " Review: sperm antibodies. " Am. J. Reprod. 
Immunol. 27: 156-162. 
Peterson, E., and de la Maza, L. (1988), " Restriction endonuclease analysis of DNA 
from Chlamydia trachomatis biovars. " J. Clin. Microbiol. 26: 625-629. 
Peterson, E., Cheng, X., Pal, S. et al. (1993), " Effects of antibody isotype and host cell 
type on in vitro neutralization of Chlamydia trachomatis. " Infect. Immun. 61: 498-503. 
Peterson, E., Markoff, B., Schachter, J. et al. (1990), " The 7.5kb plasmid present in 
Chlamydia trachomatis is not essential for growth of this microorganism.: Plasmid 23: 
144-148. 
Peterson, E., Zhong, G., Carlson, E. et al. (1988), " Protective role of magnesium in the 
neutralization by antibodies of Chlamydia trachomatis infectivity. " Infect. Immun. 56: 
885-891. 
Pettersson, B., Andersson, A., Leitner, T., et al. (1997), " Evolutionary relationships 
among members of the genus Chlamydia based on 16S ribosomal DNA analysis. " J. 
Bacteriol. 179: 4195-4205. 
Philips, R., Hanff, P., Kauffman, R. et al. (1987), " Use of a direct fluorescent antibody 
test for detecting Chlamydia trachomatis cervical infection in women seeking routine 
gynecological care. " J. Infect. Dis. 156: 575-581. 
Pociot, F., Briant, L., Jongeneel, C. et al. (1993), " Association of tumor necrosis factor 
(TNF) and class II major histocompatibility complex alleles with the secretion of TNFa 
and TNF f by human mononuclear cells: a possible link to insulin-dependent diabetes 
mellitus. " Eur. J. Immunol. 23: 224-231. 
Pollard, D., Tyler, S., et al. (1989), "A polymerase chain reaction (PCR) protocol for 
the specific detection of Chlamydia spp. " Mol. Cell. Probes 3: 383-389. 
Preece, P., Anderson, J., and Thompson, R. (1989), " Chlamydia trachomatis infection 
in infants: a prospective study. " Arch. Dis. Child. 64: 525-529. 
Pudjiatmoko, Fukushi, H., Ochiai, 0., et al. (1997), " Phylogenetic analysis of the 
genus Chlamydia based on 16S rRNA gene sequences. " Int. J. Syst. Bacteriol. 42: 425- 
431. 
Punnonen, R., Terrho, P., Nikkanen, V. et al. (1979), " Chlamydial serology in infertile 
women by immunofluorescence. " Fertil. Steril. 3: 656-659. 
Puolakkainen, M., Saikku, P., Leinomen, M. et al. (1984), " Chlamydial pneumonitis 
and serodiagnosis in infants. " J. Infect. Dis. 149: 598-604. 
Radouani, F., Takourt, B., Benomar, H. et al. (1997), " Chlamydia infection and female 
hypofertility in Morocco. " Pathologie Biologie 45: 491-495. 
Rahman, M., Cheema, M., Schumacher, H. et al. (1992), Molecular evidence for the 
presence of chlamydia in the synovium of patients with Reiter's syndrome. " Arthrit. 
Rheum. 3: 521-529. 
255 
9% 
Ramsey, K., Miranpuri, G., Poulsen, C. et al. (1998), " Inducible nitric oxide synthase 
does not affect resolution of murine chlamydial genital tract infection or eradication of 
chlamydiae in primary murine cell culture. " Infect. Immun. 66: 835-838. 
Rank, R., and Sanders, M. (1992b), " Pathogenesis of endometritis and salpingitis in a 
guinea pig model of chlamydial genital infection. " Am. J. Pathol. 140: 927-936. 
Rank, R., Dascher, C., Bowlin, A. et al. (1995b), " Systemic immunization with HSP60 
alters the development of chlamydial ocular disease. " Investig. Ophthalmol. Vis. Sci. L6: 
1344-1351. 
Rank, R., Ramsey, K., Pack, E. et al. (1992a), " Effect of gamma interferon on 
resolution of murine chlamydial genital infection. " Infect. Immun. 60: 4427-4429. 
Rank, R., Sanders, M., and Patton, D. (1995a), " Increased incidence of oviduct 
pathology in the guinea pig after repeated vaginal inoculation with the chlamydial agent of 
guinea pig inclusion conjunctivitis. " Sex. Trans. Dis. 22: 48-54. 
Rasmussen, S., Eckmann, L., Lagoff, M. (1996), " The mechanism of IL-8 induction in 
infected epithelial cells differs between C. trachomatis and C. psittaci. " In Proceedings of 
the Third Meeting of the European Society for Chlamydial Research. Stary, A. (Ed. ), 
Bologna, Societa Editrice Esculapio. pp. 63. 
Rasmussen, S., Eckmann, L., Quayle, A. et al. (1997), " Secretion of proinflammatory 
cytokines by epithelial cells in response to Chlamydia infection suggests a central role for 
epithelial cells in chlamydial pathogenesis. " J. Clin. Invest. 99: 77-87. 
Raulston, J. (1997), " Response of Chlamydia trachomatis serovar E to iron restriction in 
vitro and evidence for iron-regulated chlamydial proteins. " Infect. Immun. 65: 4539- 
4547. 
Raulston, J., Davis, C., Schmiel, D. et al. (1993), " Molecular characterization and outer 
membrane association of a Chlamydia trachomatis protein related to the hsp70 family of 
proteins. " J. Biol. Chem. 268: 23139-23147. 
Raulston, J., Davis, C., Terry, P. et al. (1998a), " Heat shock protein 70kDa and the 
chlamydial envelope: an entry level position? " In Chlamydia Infections. Stephens, R., 
Byrne, G. et al. (Eds. ). International Chlamydia Symposium, San Francisco, CA. pp. 
83-86. 
Raulston, J., Paul, T., Knight, S. et al. (1998b), " Localization of Chlamydia 
trachomatis heat shock proteins 60 and 70 during infection of a human endometrial 
epithelial cell line in vitro. " Infect. Immun. 66: 2323-2329. 
Reeve, P., Owen, J., and Oriel, J. (1975), " Laboratory procedures for the isolation of 
Chlamydia trachomatis from the human genital tract. " J. Clin. Pathol. 28: 910-914. 
Regan, R., Dathan, J., and Treharne, J. (1979), " Infective endocarditis with 
glomerulonephritis associated with cat Chlamydia (C. psittaci) infection. " Br. Heart J. 42: 
349-352. 
Richmond, S., and Sterling, P. (1981), " Localization of chlamydial group antigen in 
McCoy cell monlayers infected with Chlamydia trachomatis and C. psittaci. " Infect. 
Immun. 34: 561-570. 
Richmond, S., and Sterling, P. (1982), " Virus infecting the reticulate bodies of an avain 
strain of Chlamydia psittaci. " FEMS 14: 31-36. 
Richmond, S., Paul, I., and Taylor, P. (1980), " Feasibility of screening women 
attending STD clinics for cervical chlamydial inferctions. " Br. J. Ven. Dis. 56: 92-95. 
256 
it, 
Ridgway, G. (1996), " Azithromycin in the management of Chlamydia trachomatis 
infections. " Int. J. STD AIDS. 2 (Suppl. 1): 5-8. 
Ripa, K., and Mardh, P. (1977), " Cultivation of Chlamydia trachomatis in 
cycloheximide. " J. Clin. Microbiol. 6: 328-331. 
Robinson, A., Grant, J., Spencer, R. et al. (1990), " Acute epididymitis: why patient and 
consort must be investigated. " Br. J. Urol. 66: 642-645. 
Rocky, D., Heinzen, R., and Hackstadt, T. (1995), " Cloning and characterization of a 
Chlamydia psittaci gene coding for a protein localized in the inclusion membrane of 
infected cells. " Mol. Microbiol. 15: 617-626. 
Rodolakis, A., and Bernard, F. (1984), " Vaccination with temperature-sensitive mutant 
of Chlamydia psittaci against enzootic abortion of ewes. " Vet. Res. 114: 193-194. 
Rodriguez, P., Vekris, A., de barbeyrac, B. et al. (1993), " Typing of Chlamydia 
trachomatis by restriction endonuclease analysis of the amplified major outer membrane 
protein gene. " J. Clin. Microbiol. 22: 1132-1136. 
Rota, T., and Nichols, R. (1971), " Infection of cell culture by trachoma agent. 
Enhancement by DEAE-dextran. " J. Infect. Dis. 124: 419-421. 
Rowland, G., Forsey, T., Moss, T. et al. (1985), " Failure of in vitro fertilization and 
embryo replacement with Chlamydia trachomatis. " J. In Vitro Fertil. Embryo Transfer 2: 
151-155. 
Saiki, R. K., Scharf, S., Faloona, F. et al. (1985) " Enzymatic amplification of ß-globin 
genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. " 
Science 230: 1350-1354. 
Saikku, P., Wang, S., Kleemola, M. et al. (1985), " An epidemic of mild pneumonia due 
to an unusual strain of Chlamydia psittaci. " J. Infect. Dis. 151: 832-839. 
Salmon, V., Kenyon, B., Overall, J. et al. (1994), " Use of a universal transport media 
in a commercial polymerase chain reaction assay for Chlamydia trachomatis. " In 
Abstracts of the 10th Annual Clearwater Virology symposium. Abstr. S7, pp. 33. 
Sardinia, L., Segal, E., and Ganem, D. (1988), " Developmental regulation of the cystein 
rich outer membrane proteins of murine Chlamydia trachomatis. " J. Gen. Microbiol. , 
134: 
997-1004. 
Sariban, E., Imamura, R., Leubbers, R. et al. (1988), " Transcriptional and 
posttranscriptional regulation of tumor necrosis factor gene expression in human 
monocytes. " J. Clin. Invest. 81: 1506-1510. 
Sarker, G., and Sommer, S. (1990), " Shedding light on PCR contamination. " Nature 
343: 27. 
Sarov, I., and Becker, Y. (1971), " Deoxyribonucleic acid-dependant ribonucleic acid 
polymerase activity in purified trachoma elementary bodies: effect of sodium chloride on 
ribonucleic acid transcription. " J. Bacteriol. 107: 593-597. 
Schachter, J., and Dawson, C. (1978), " Human chlamydial infections. " PSG Publishing 
Company, Inc., Littleton, Mass., USA. 
Schachter, J., Banks, J., Sung, M. et al. (1982), " Hydrosalpinx as a consequence of 
chlamydial salpingitis in the guinea pig. " In Mardh, P., Holmes, K., Oriel, J., Piot, P., 
Schatchter, J (Eds. ) Chlamydial Infections. New York: Elsevier Biomedical Press. pp. 
371-374. 
257 
Schachter, J., Moncada, J., Dawson, C. et al. (1988), " Nonculture methods for 
diagnosing chlamydial infection in patients with trachoma: a clue to the pathogenesis of 
the disease. " J. Infect. Dis. 158: 1347-1352. 
Schenk, L., Ramey, J., Taylor, S. et al. (1996), " Embryotoxicity of hydrosalpinx 
fluid. " Presented at the 43rd Annual Meeting of the Society of Gynecological 
Investigators. J. Soc. Gynecol. Invest: 88A. 
Schmiel, D., Knight, S., Raulston, J. et al. (1991), " Recombinant Escherichia coli 
clones expressing Chlamydia trachomatis gene products attach to human endometrial 
epithelial cells. " Infect. Immun. 52: 4001-4012. 
Schmiel, D., Raulston, J., Fox, E. et al. (1996), " Characterization, expression and 
envelope association of Chlamydia trachomatis 28kDa protein. " Microb. Pathogen. 19: 
227-236. 
Schoenwald, E., Schidt, B., Steinmetz, G. et al. (1988), " Diagnosis of Chlamydia 
trachomatis infection-culture versus serology. " Eur. J. Epidemiol. 4: 75-82. 
Scholes, D., Stergachis, A., Ichikawa, L. et al. (1998), " Vaginal douching as a risk 
factor for cervical Chlamydia trachomatis infection. " Obstet. Gynecol. 911: 993-997. 
Schwebke, J., Stamm, W., and Handsfield, H. (1990), " Use of sequential enzyme 
immunoassay and direct immunofluorescent antibody tests for detection of Chlamydia 
trachomatis infections in women. " J. Clin. Microbiol. 28: 2473-2476. 
Scidmore, N., and Wyrick, P. (1996), " Vesicular interactions of the Chlamydia 
trachomatis inclusion are determined by chlamydial early protein synthesis rather that the 
route of entry. " Infect. Immun. 64: 5366-5372. 
Shah, J., Liu, J., Smith, J. et al. (1994), " Novel, ultrasensitive, Q-beta replicase- 
amplified hybridization assay for detection of Chlamydia trachomatis. " J. Clin. 
Microbiol. 32: 2718-2724. 
Shahmanesh, M. (1994), " Problems with non-gonococcal urethritis. " Int. J. STD. 
AIDS. 5: 390-399. 
Shamanesh, M., Stedronska, J., and Hendry, W. (1986), " Antisperm antibodies in men 
with urethritis. " Fertil. Steril. 46: 451-457. 
Sharara, F., Scott, R., Marut, E. et al. (1996), " In-vitro fertilization outcome in women 
with hydosalpinx. " Hum. Reprod. 11: 526-530. 
Shemer-Avni, Y., Wallach, Y., and Sarov, I. (1988), " Inhibition of Chlamydia 
trachomatis growth by recombinant tumor necrosis factor. " Infect. Immun. 56: 2503- 
2506. 
Shepard, M., and Jones, R. (1989), " Recovery of Chlamydia trachomatis from 
endometrial and fallopian tube biopsies in women with infertility of tubal origin. " Fertil. 
Steril. 52: 232-238. 
Shor, A., Kuo, C., and Patton, D. (1992), " Detection of Chlamydia pneumoniae in 
coronary arterial fatty streaks and athermatous plaques. " S. Afr. Med. J. 82: 158-161. 
Smith, T., Brown, S., and Weed, L. (1982), " Diagnosis of Chlamydia trachomatis 
infections by cell cultures and serology. " Lab. Med. 13: 92-100. 
Soffer, Y., Ron-El,. R., Golan, A. et al. (1990), " Male genital mycoplasmas and 
Chlamydia trachomatis culture: its relationship with accessory gland function, sperm 
quality, and autoimmunity. " Fertil. Steril. 53: 331-336. 
258 
41. 
  
Sowa, S., Sowa, J., Collier, L. et al. (1969), " Trachoma vaccine field trials in the 
Gambia. " J. Hyg. Camb. 2.: 699-717. 
Spengler, U., Moller, A., Jung, M. et al. (1992), " Lymphocyte-T cells from patients 
with primary bilary-cirrhosis produce reduced amounts of lymphotoxin, tumor necrosis 
factor and interferon upon mitogen stimulation. " J. Hepatology 15: 129-135. 
Stacey, C., Munday, P., Thomas, B. et al. (1990), " Chlamydia trachomatis in the 
fallopian tubes of women without laparoscopic evidence of salpingitis. " Lancet 336: 960- 
963. 
Stamm, W. (1988), " Diagnosis of Chlamydia trachomatis genitourinary infections. " 
Ann. Intern. Med.. 108: 163-165. 
Stamm, W., Kautsky, L., Benedetti, J. et al. (1984), " Chlamydia trachomatis urethral 
infections in men. " Ann. Int. Med. 100: 47-51. 
Stamm, W., Peeling, R., and Money, D. (1994), " Prevalence and correlates of antibody 
to chlamydial HSP60 in Chlamydia trachomatis infected women. " In Chlamydial 
Infections. Orifila, J., Byrne, G., Chernesky, M. et al. (Eds. ). Societa Editrice 
Esculapio, Italy. pp. 614-617. 
Stamm, W., Tam, M., Koester, M. et al. (1983), " Detection of Chlamydia trachomatis 
inclusions in McCoy cell cultures with fluorescein-conjugated monoclonal antibodies. " J. 
Clin. Microbiol. 17: 666-668. 
Stamm, W., Wager, K,. Amsel, R. et al. (1980), " Causes of acute urethral syndrome in 
women. " N. Eng. J. Med. 303: 409-415. 
Stargardt, K. (1909), " Epithelzellveranderungen beim Trachom und anderen 
conjunktivalerkrankungen. " Arch. Ophth. 67: 525-542. 
Stary, A., Chouieri, B., and Lee, H. (1995), " Implications of sensitive molecular 
diagnosis of Chlamydia trachomatis in non-invasive sample types. " In Abstracts of the 
11th Meeting of the International Society for STD Research. Abstr. 041. 
Stary, A., Teodorowicz, L., Horting-Vitouch, I. et al. (1994), " Evaluation of the Gen- 
Probe PACE 2 and Microtrak enzyme immunoassay for the diagnosis of Chlamydia 
trachomatis in urogenital samples. " Sex. Trans. Dis. 21: 26-30. 
Stephen, E., and Chandra, A. (1998), " Update projections of infertility in the United 
States: 1995-2025. " Fertil. Steril. 70: 30-34. 
Stephens, R. (1988), " Chlamydial genetics. " In Barron, A (Ed. ), Microbiology of 
Chlamydia. CRC Press, Boca Raton, FL. 
Stephens, R. (1992), " Challenge of Chlamydia research. " Infect. Agents Dis. l: 279- 
293. 
Stephens, R. (1993), " Challenge of chlamydia research. " Infect. Agents Dis..!: 279- 
293. 
Stephens, R. (1994a), " Cell biology of chlamydial infection. " In Proceedings of the 8th 
International Symposium on Human Chlammydial Infections. Societa Editrice Esculapio, 
Bologna, Italy. pp. 377-386. 
Stephens, R. (1994b), " Molecular mimicry and Chamydia trachomatis infection in 
eukaryotic cells. " Trends Microbiol. 2: 99-101. 
259 
Stephens, R., Kalman, S., Lammel, C. et al. (1998), " Genome sequences of an 
obligate intracellular pathogen of humans: Chlamydia trachomatis. " Sciences 282: 638- 
639. 
Stephens, R., Kuo, C., and Tam, M. (1982), " Sensitivity of immunofluorscence with 
monoclonal antibodies for detection of Chlamydia trachomatis inclusions in cell culture. " 
J. Clin. Microbiol. 16: 4-7. 
Stephens, R., Kuo, C., Newport, G. et al. (1985), " Molecular cloning and expression 
of Chlamydia trachomatis outer membrane protein antigens in Escherichia coli. " Infect. 
Immun. 47: 713-718. 
Stephens, R., Mullenbach, G., Sanchez-Pescador, R. et al. (1986), " Sequence analysis 
of the major outer membrane protein gene from Chlamydia trachomatis serovar L2. " J. 
B acteri ol. 168: 1277-1282. 
Stephens, R., Sanchez-Pescador, R., Wager, E. et al. (1987), " Diversity of Chlamydia 
trachomatis major outer membrane protein genes. " J. Bacteriol. 116: 3879-3885. 
Stephens, R., Wager, E., and Schoolnik, G. (1988), " High-resolution mapping of 
serovar-specific and common antigenic determinants of the major outer membrane protein 
of Chlamydia trachomatis. " J. Exp. 167: 817-831. 
Steptoe, P., and Edwards, R. (1978), " Birth after reimplantation of a human embryo. " 
Lancet 2: 366. 
Strandell, A., Waldenstrom, U., Nilsson, L. et al. (1994), " Hydrosalpinx reduces in- 
vitro fertilization/embryo transfer pregnancy rates. " Hum. Reprod. 9: 1935-1938. 
Su, H., and Caldwell, H. (1991), " In vitro neutralization of Chlamydia trachomatis by 
monovalent Fab antibody specific to the major outer membrane protein. " Infect. Immun. 
59: 2843-2845. 
Su, H., Feilzer, K., Caldwell, H., and Morrison, R. (1997), " Chlamydia trachomatis 
genital tract infection of antibody-deficient gene knockout mice. " Infect. Immun. 65: 
1993-1999. 
Su, H., Parnell, M., and Caldwell, H. (1995), " Protective efficacy of a parenterally 
administered MOMP-derived synthetic oligopeptide vaccine in a murine model of 
Chlamydia trachomatis genital tract infection: serum neutralizing IgG antibodies do not 
protect against chlamydial genital infection. " Vaccine 13: 1023-1232. 
Su, H., Raymond, L., Rockey, D. et al. (1996), "A recombinant Chlamydia trachomatis 
outer membrane protein binds to heparan sulphate receptors on epithelial cells. " Proc. 
Natl. Acad. Sci. USA 93: 11143-11148. 
Su, H., Watkins, N., Zhang, Y. et al. (1990), " Chlamydia trachomatis-host cell 
interactions: role of the chlamydial outer membrane protein as an adhesin. " Infect. 
Immun. f: 1017-1025. 
Su, H., Zhang, X., Barrera, 0. et al. (1988), " Differential effects of trypsin on 
infectivity of chlamydia trachomatis- loss of infectivity requires cleavage of major outer 
membrane variable domain II and IV. " Infect. Immun. 56: 2094-2100. 
Suffrys, P., Beyaert, R., Van, R. et al. (1989), " TNF in combination with interferon- 
gamma is cyto-toxic to normal, untransformed mouse and rat embryo fibroblast-like 
cells. " Anticancer Res. 2: 167-17 1. 
Sutton, G., Morrissey, R., Tobin, J. et al. (1967), " Pericardial and myocardial disease 
associated with serological evidence of infection by agents of the psittacosis- 
lymphogranuloma venereum group (Chlamydiaceae). " Circulation 26: 830-838. 
260 
Svensson, L., Mardh, P., and Westrom, L. (1983), " Infertility after acute salpingitis 
with special reference to Chlamydia trachomatis. " Fertil. Steril. 40: 322-329. 
Swanson, A., and Kuo, C. (1991), " Evidence that the major outer membrane protein of 
Chlamydia trachomatis is glycosylated. " Infect. Immun. 52: 2120-2125. 
Swanson, J., Eschenbach, D., Alexander, E. et al. (1975), " Light-electron microscopic 
study of Chlamydia trachomatis infection of the uterine cervix. " J. Infect. Dis. 1: 678- 
687. 
Swartz, S., Kraus, S., Herrman, K. et al. (1978), " Diagnosis and aetiology of non- 
gonococcal urethritis. " J. Infect. Dis. 138: 445-450. 
Sweet, R., Banks, J., Sung, M. et al. (1980), " Experimental chlamydial salpingits. " 
Am. J. Obstet. Gynecol. 138: 952-956. 
Sziller, I., Witkin, S., Ziegert, M. et al. (1998), " Serological responses of patients with 
ectopic pregnancy to epitopes of the Chlamydia trachomatis 60kDa heat shock protein. " 
Hum. Reprod. 1: 1088-1093. 
T'ang, F., Chang, H., Huang, Y. et al. (1957), " Studies on the aetiology of trachoma 
with special reference to isolation of the virus in the chick embryo. " Chin. Med. J. Z: 
429-447. 
Tam, J., Davis, C., and Wyrick, P. (1994), " Expression of recombinant DNA 
introduced into Chlamydial trachomatis by electroporation. " Can. J. Microbiol. 40: 583- 
591. 
Tan, M., Wong, B., and Engel. J. (1996), " Transcriptional organization and regulation 
of the dnaK and groE operons of Chlamydia trachomatis. " J. Bacteriol. m: 6983-6990. 
Tanikawa, M., Harada, T., Katagiri, C. et al. (1996), " Chlamydia trachomatis antibody 
titres by enzyme-linked immunosorbent assay are useful in predicting severity of adnexal 
adhesions. " Hum. Reprod. 11: 2418-2421. 
Taraska, T., Ward, D., Ajioka, R. et al. (1996), " The late chlamydial inclusion 
membrane is not derived from the endocytic pathway and is relatively deficient in host 
proteins. " Infect. Immun. 64: 3713-3727. 
Taylor, H., Johnson, S., Schachter, J. et al. (1987), " Pathogenesis of trachoma: the 
stimulus for inflammation. " J. Immunol. 1: 3023-3027. 
Taylor, H., Maclean, I., Brunham, R. et al. (1990), " Chlamydial heat shock proteins 
and trachoma. " Infect. Immun. 58: 3061-3063. 
Taylor-Robinson, D. (1991b), " Genital chlamydial infections: clinical aspects, 
diagnosis, treatment and prevention. " In Recent Advances in Sexually Transmitted 
Diseases and AIDS. Harris, J., Forsters, S. (Eds. ), Edinburgh, Churchill Livingstone. 
Taylor-Robinson, D. (1996), " The history of non-gonococcal urethritis. " Sex. Trans. 
Dis. 23: 86-91. 
Taylor-Robinson, D., and Thomas, B. (1991a), " Laboratory techniques for the 
diagnosis of chlamydial infections. " Genitourin. Med. 67: 256-266. 
Taylor-Robinson, D., Gilroy, C., Thomas, B. et al. (1992), " Detection of Chlamydia 
trachomatis DNA in the joints of reactive arthritis patients by polymerase chain reaction. " 
Lancet 340: 81-82. 
Taylor-Robinson, D., Thomas, B., Pierpoint, T. et al. (1998), " Ligase chain reaction 
assay for Chlamydia trachomatis during the menstrual cycle. " Lancet 251: 1290. 
261 
m 
Thejls, H., Gnarpe, J., Lundvist, O. et al. (1991), " Diagnosis and prevalence of 
persistant Chlamydia infection in infertile women: tissue culture, direct antigen detection 
and serology. " Fertil. Steril. 55: 304-310. 
Thorpe, E., Stamm, W., Hook, E. et al. (1996), " Chlamydial cervicitis and urethritis: 
single dose treatment compared with doxycycline for seven days in community based 
practises. " Genitourin. Med. Z: 93-97. 
Timms, P., Eaves, F., Hugall, A. et al. (1988), " Plasmids of Chlamydia psittaci - 
cloning and comparison of isolates by Southern hybridization. " FEMS Microbiol. Lett. 
51: 119-123. 
Ting, L., Hsia, R., Haidaris, C. et al. (1995), " Interaction of outer envelope proteins of 
Chlamydia psittaci GPIC with the HeLa cell surface. " Infect. Immun. 0: 3600-3608. 
Torode, H., Wheeler, P., Saunders, D. et al. (1987), " The role of chlamydial antibodies 
in an in vitro fertilization program. " Fertil. Steril. 48: 987-990. 
Toth, M., Jeremias, J., Ledger, W. et al. (1992), " In vivo tumor-necrosis-factor 
production in women with salpingitis. " Surg. Gynecol. 174: 359-362. 
Toye, B., Laferriere, C., Clanman, P. et al. (1993), " Association between antibody to 
chlamydial heat-shock protein and tubal infertility. " J. Infect. Dis. 168: 1236-1240. 
Tuffrey, M., Alexander, F., and Taylor-Robinson, D. (1990), " Severity of salpingitis in 
mice after primary and repeated inoculations with a human strain of Chlamydia 
trachomatis. " J. Exp. Pathol. 71: 403-410. 
Tuffrey, M., Alexander, F., Woods, F. et al. (1992a), " Genetic susceptibility to 
chlamydial salpingitis and subsequent infertility in mice. " J. Rep. Fertil. 25: 31-38. 
Tuffrey, M., et al. (1992b), " Heterotypic protection of mice against chlamydial 
salpingitis and colonization of the lower genital tract with the human serovar F isolate of 
Chlamydia trachomatis by prior immunization with recombinant serovar L1 major outer- 
membrane protein. " J. Gen. Microbiol. 138: 1707-171. 
Turner, V., West, S., Munoz, B. et al. (1993), " Risk factors for trichiasis in women in 
Kongwa, Tanzania: a case-control study. " J. Epidemiol. 22: 341-347. 
Ulstein, M., Capell, P., Holmes, K. et al. (1976), " Non-symptomatic genital tract 
infection and male infertility. " In Hafez, E. (Ed. ), Human Semen and Fertility Regulation 
in men. CVMosbey, St. Louis, MO. pp. 355. 
van der Laar, M., Lan, J., van Duynhoven, Y et al. (1991), " Differences in clinical 
manifestations of genital chlamydial infections related to serovars. " Genitourin. Med. 72: 
261-265. 
van Prooijen-Knegt, A., Raap, A. et al. (1983), " Spreading and staining of human 
metaphase chromosomes on aminoalkylsilane-treated slides. " Histochem. J. 14: 333-334. 
van Voorhis, W., Barret, L., Cosgrove-Sweeney, Y. et al. (1997), " Repeated 
Chlamydia trachomatis infection of Macaca nemestrina fallopian tube produces a Thl-like 
cytokine response assocaited with fibrosis and scarring. " Infect. Immun. §J: 2175-2182. 
van Voorhis, W., Barrett, L., Cosgrove-Sweeney, Y. et al. (1996), " Analysis of 
lymphocyte phenotype and cytokine activity in the inflammatory infiltrates of the upper 
genital tract of female macaques infected with Chlamydia trachomatis. " J. Infect. Dis. 
174: 647-650. 
Vassalli, P. (1992), " The pathophysiology of tumor necrosis factors. " Annu. Rev. 
Immunol. 10: 411-452. 
262 
Verhoest, P., Sevestre, E., Bissac, E. et al. (1997), " Use of an experimental model of 
chlamydial salpingitis in mice for the evaluation of activity of antibiotics and ant- 
inflammatory drugs on fertility. " J. Obstet. Gynecol. 1: 476-478. 
Verkooyen, R., Luijendijk, A., Goessens, W. et al. (1995), "A one-tube quantitative 
HIV-1 RNA NASBA nucleic acid amplification assay using electrochemiluminescent 
(ECL) labelled probes. " In Program and Abstracts of the 35th Interscience Conference on 
Antimicrobial Agents and Chemotherapy. American Society for Microbiology. 
Washington DC. Abstr. D104. pp. 84. 
Vilcek, J., and Lee, T. (1991), " Tumor-necrosis-factor-New insights into the molecular 
mechanisms of its multiple actions. " J Biol. Chem. 266: 7313-7316. 
Villegas, H., Pinon, M., Shor, V. et al. (1991), " Electron microscopy of Chlamydia 
trachomatis infection of the male genital tract. " Arch. Androl. 27: 117-126. 
Voisin, G. and Raghupathy, R. (1995), " In Immunology of Human Reproduction. 
Edited by Kurpisz, M. and Fernandez, N. Bios Scientific Publishers. pp. 335-353. 
Wager, E., and Stephens, R. (1988), " Developmental-form-specific DNA-binding 
proteins in Chlamydia spp. " Infect. Immun. 56: 1678-1684. 
Wager, E., Schachter, J., Bavoil, P. et al. (1990), " Differential human serological 
response to two 60,000 molecular weight Chlamydia trachomatis antigens. " J. Infect. 
Dis. 162: 922-927. 
Wang, S., and Grayston, J. (1970), ' Immunological relationship between genital TRIC, 
lymphogranuloma venereum, and related organisms in a new microtitre indirect 
immunofluorescence test. " J. Infect. Dis. 152: 791-800. 
Wang, S., Grayston, J., and Alexander, E. (1967), " Trachoma vaccine studies in 
monkeys. " Am. J. Ophthalmol. 63: 1615-1630. 
Wang, S., Kuo, C., Barnes, R. et al. (1985), " Immunotyping of Chlamydia trachomatis 
with monoclonal antibodies. " J. Infect. Dis. 152: 791-800. 
Watford, A., Carter, T., Levy, R. et al. (1985), " Comparison of sonicated and non- 
sonicated specimens for the isolation of Chlamydia trachomatis. " J. Clin. Pathol. 83: 
625-629. 
Watkins, N., Hadlow, W., Moos, A. et al. (1986), " Ocular delayed hypersensitivity: a 
pathogenic mechanism of chlamydial conjunctivitis in guinea pigs. " Proc. Natl. Acad. 
Sci. USA 83: 7480-7484. 
Wegmann, T. G., Lin, H., Guilbert, L. et al. (1993), " Bidirectional cytokine 
interactions in the maternal-fetal relationship-is successful pregnancy a Th2 
phenomenon. " Immunol. Today 14: 353-356. 
Weidner, W., Floren, E., Zimmerman, O. et al. (1996), " Chlamydial antibodies in 
semen-search for silent chlamydial infections in aspmtomatic andrological patients. " 
Infection 24: 309-313. 
Weidner, W., Schiefer, H., Krauss, H. et al. (1991), " Chronic prostactitis: a thorough 
search for etiologically involved microorganism in 1461 patients. " Infect. 19 (Suppl. 3): 
119-125. 
Weisburg, W., Hatch, T., and Woese, C. (1986), " Eubacterial origin of chlamydiae. " J. 
Bacteriol 167: 570-574. 
263 
Weiss, E., Schramek, S., Wilson, N. et al. (1970), " Deoxyribonucleic acid 
heterogeneity between human and murine strains of Chlamydia trachomatis. " Infect. 
Immun. 2: 24-28. 
Weiss, S., Newcomb, W., and Beem, M. (1991), " Pulmonary assessment of children 
after chlamydial pneumonia of infancy. " J. Adolesc. Health 12: 326-329. 
Westrom, L. (1975), " Effect of acute pelvic inflammatory disease on fertility. " Am. J. 
Obstet. Gynecol. 121: 707-713. 
Westrom, L. (1980), " Incidence, prevalence, and trends of acute pelvic inflammatory 
disease and its consequences in industrialized countries. " Am. J. Obstet. Gynecol. 138: 
880-892. 
Westrom, L., Joesoef, G., Reynolds, A. et al. (1992), Pelvic inflammatory disease and 
fertility. Acohort study of 1,844 women with laparoscopically verified diease and 657 
control women with normal laproscopic results. " Sex. Trans. Dis. 12: 185-192. 
WHO. (1987), " Towards more objectivity in diagnosis and managment of male 
infertility. " Int. J. Androl. 2 (suppl): 1-53. 
Wiesenfeld, H., Heine, R., di Biasi, F. et al. (1995), " Self collection of vaginal introitus 
specimens: a novel approach to Chlamydia trachomatis testing in women. " In Abstracts of 
the 11th Meeting of the International Society for STD Research. Abstr. 040. pp. 42. 
Wilcox, L., and Mosher, W. (1993), " Use of infertility services in the United States. " 
Obstet. Gynecol. 82: 122-127. 
Wilde, C., Karimi, S., and Haak, R. (1986), " Cell surface alterations during chlamydial 
infection. " In Microbiology. Leive, L., Bonventre, J. et al. (Eds. ), American Society for 
Microbiology, Washington DC. pp. 96-98. 
Williams, D., Bonewald, L., Roodman, G. et al. (1989), " Tumor necrosis factor alpha 
is a cytotoxin induced by murine Chlamydia trachomatis infection. " Infect. Immun. 2: 
1351-1355. 
Williams, D., Grubbs, B., Pack, E. et al. (1997), " Humoral and cellular immunity in 
secondary infection due to murine Chlamydia trachomatis. " Infect. Immun. 65: 2876- 
2882. 
Williams, D., Grubbs, B., Schachter, J. et al. (1993), " Gamma interferon levels during 
Chlamydia trachomatis pneumonia in mice. " Infect. Immun. 61: 3556-3558. 
Williams, D., Magee, D., Bonewald, L. et al. (1990), A role in vivo for tumor necrosis 
factor alpha in host defense against Chlamydia trachomatis. " Infect. Immun. 58: 1572- 
1576. 
Wilson, A., di Giovine, F., Blackemore, A. et al. (1993), " Single base polymorphism in 
the human tumor necrosis factor alpha (TNF(x) gene detectable by Nco 1 restriction of 
PCR product. " Hum. Mol. Genet. 1: 353. 
Wilson, A., Symons, J., McDowell, T. et al. (1994), " Effects of a tumor necrosis factor 
(TNF-alpha) promotor base transition on transcritpional activity. " Br. J. Rheumatol. 22: 
89. 
Witkin, S, and Ledger, W. (1992), " Antibodies to Chlamydia trachomatis in sera of 
women with recurrent spontaneous abortions. " Am. J. Obstet. Gynecol. 1-61: 135-139. 
Witkin, S., and Toth, A. (1983), " Relationship between genital tract infections, sperm 
antibodies in seminal fluid, and infertility. " Fertil. Steril. 40: 805-808. 
264 
Witkin, S., Askienazy-Elbhar, M., Henry-Suchet, J. et al. (1998), " Circulating 
antibodies to a conserved epitope of the Chlamydia trachomatis 60kDa heat shock protein 
(hsp60) in infertile couples and its relationship to antibodies to C. trachomatis surface 
antigens and the Escherichia coli and human HSP60. " Hum. Reprod. 11: 1175-1179. 
Witkin, S., Jeremias, J., Grifo, J. et al. (1993b), " Detection of Chlamydia trachomatis 
in semen by polymerase chain reaction in male members of infertile couples. " Am. J. 
Obstet. Gynecol. 168: 1457-1462. 
Witkin, S., Jeremias, J., Toth, M. et al. (1993a), " Cell-mediated immune response to 
the recombinat 57-kDa heat-shock protein of Chlamydia trachomatis in women with 
salpingitis. " J. Infect. Dis. 167: 1379-1383. 
Witkin, S., Kligman, I., and Bongiovanni, A. (1995a), " Relationship between an 
asyptomatic male genital tract exposure to Chlamydia trachomatis and an autoimmune 
response to spermatozoa. " Hum. Reprod. 10: 2952-2955. 
Witkin, S., Kligman, I., Grifo, J. et al. (1995b), " Chlamydia trachomatis detected by 
polymerase chain reaction in cervices of culture-negative women correlates with adverse 
in vitro fertilization outcome. " J. Infect. Dis. 171: 1657-1659. 
Witkin, S., Sultan, K., Neal, G. et al. (1994), " Unsuspected Chlamydia trachomatis 
infection and in vitro fertilization outcome. " Am. J. Obstet. Gynecol. jJ 1: 1208-1214. 
Wollenhaupt, J. (1996), " Is there a role for chlamydial serology in the diagnosis and 
follow-up of chlamydia induced reactive arthritis. " In Proceedings: Third Meeting of the 
European Society for Chlamydia Research. Stary, A. (Ed. ) pp. 356. 
Wolner-Hansen, P., and Mardh, P. (1984), " In vitro tests of adherence of Chlamydia 
trachomatis to human spermatozoa. " Fertil. Steril. 42: 102-107. 
Woolridge, R., Grayston, J., Chang, I. et al. (1967), " Field trial of a monovalent and of 
a bivalent mineral oil adjuvant trachoma vaccine in Taiwan school children. " Am. J. 
Ophthalmol. 63: 1615-1630. 
Worm, A., and Osterlind, A. (1995), " Azithromycin levels in cervical mucuc and plasma 
after a single 1. Og oral dose for chlamydial cervicitis. " Genitourin. Med. 71: 244-246. 
Wyrick, P., and Brownridge, E. (1978b), " Growth of Chlamydia psittaci in 
macrophages. " Infect. Immun. 19: 1054-1060. 
Wyrick, P., Brownridge, E., and Ivins, B. (1978a), " Interaction of Chlamydia psittaci 
with mouse peritoneal macrophages. " Infect. Immun. 19: 1061-1067. 
Wyrick, P., Choong, J., Knight, D. et al. (1994), " Chlamydia trachomatis antigens on 
the surface of infected human endometrial epithelial cells. " Immunol. Infect. Dis. 4: 131- 
141. 
Wyrick, P., Davis, C., Knoght, S. et al. (1993), " In vitro activity of azithromycin on 
Chlamydia trachomatis infected, polarized human endometrial epithelial cells. " J. 
Antimicrob. Chemother. 31: 139-150. 
Yaun, Y., Zhang, Y., Watkins, N. et al. (1989), " Nucleotide and deduced amino acid 
sequences for the four variable domains of the major outer membrane proteins of 15 
Chlamydia trachomatis serovars. " Infect. Immun. 57: 1040-1049. 
Yi, Y., Zhong, G., and Brunham, R. (1993), " Continuous B-cell epitopes in Chlamydia 
trachomatis heat shock protein 60. " Infect. Immun. 61: 1117. 
Yoder, B., Stamm, W., Koester, C. et al. (1981), " Microtest procedure for isolation of 
Chlamydia trachomatis. " J. Clin. microbiol. , 
113: 1036-1039. 
265 
Yoshida, K., Kobayashi, N., and Negishi, T. (1994), " Chlamydia trachomatis infection 
in the semen of asymptomatic infertile men: detection of the antigen by in situ 
hydridization. " Urol. Int. 53: 217-221. 
Yuan, Y., Zhang, Y., Watkins, N. et al. (1989), " Nucleotide and deduced amino acid 
sequences for the four variable domains of the major outer membrane proteins of the 15 
Chlamydia trachomatis serovars. " Infect. Immun. 57: 1040-1049. 
Yui, J., Garcia-Lloret, M., Wegmann, T. et al. (1994), " Functional long-term cultures of 
human term trophoblasts purified by column-elimination of CD9 expressing cells. " 
Placenta 15: 819-827. 
Zhang, J., and Stephens, R. (1992), " Mechanism of Chlamydia trachomatis attachment 
to eukaryotic host cells. " Cell 69: 861-869. 
Zhang, Y., Morrison, S., Caldwell, H. et al. (1989b), " Cloning and sequence analysis 
of the major outer membrane genes of two Chlamydia psittaci strains. Infect. Immun. 57: 
1621-1625. 
Zhang, Y., Stewart, S., and Caldwell, H. (1989a), " Protective monoclonal antibodies to 
Chlamydia trachomatis serovar- and serogroup-specific major outer membrane protein 
determinants. " Infect. Immun. 57: 636-638. 
Zhang, Y., Stewart, S., Joseph, T. et al. (1987), " Protective monoclonal antibodies 
recognize epitopes located on the major outer membrane protein of Chlamydia 
trachomatis. " J. Immunol. 138: 575-581. 
Zhong, G., Reid., R., and Brunham, R. (1990), " Mapping antigenic sites on the major 
outer membrane protein of Chlamydia trachomatis with synthetic peptides. " Infect. 
Immun. 58: 1450-1455. 
Zouari, R., de Almeida, M., Rodrigues, D. et al. (1993), " Localization of antibodies on 
spermatozoa and sperm movement characteristics are good predictors of in-vitro 
fertilization sucess in cases of male autoimmune infertility. " Fertil. Steril. 59: 606-612. 
266 
